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Abstract
Troglitazone was introduced as an anti-diabetic drug in the late 1990s, and 
represented the first of the thiazolidinedione (TZD) class of drugs to be marketed. 
Troglitazone works by activating the peroxisome proliferator-activated receptor y (PPARy), 
reducing blood glucose levels by enhancing insulin sensitivity, primarily in the adipose and 
skeletal muscle tissues. Due to increasing concerns of troglitazone-linked hepatotoxicity, 
troglitazone was withdrawn from the U.K. market in 1997 and U.S.A. in 2000. A 
considerable effort to elucidate the mechanisms of troglitazone-induced hepatotoxicity has 
been made, resulting in a variety of proposed mechanisms; formation and accumulation of 
toxic metabolites, oxidative stress, mitochondrial dysfunction, and inhibition of bile salts 
excretory protein leading to cholestasis. The purpose of this study was to investigate whether 
a metabolomics approach can be used to further elucidate the mechanism of toxicity of 
troglitazone. Furthermore, metabolomic profiling was undertaken to determine if this 
approach can distinguish between TZDs with hepatotoxic potential (i.e. troglitazone) and 
those with none (i.e. rosiglitazone and pioglitazone).
Conventional MTT assay revealed that troglitazone was a more potent toxin to the 
HuH-7 hepatoma cell line compared to rosiglitazone and pioglitazone, with an IC50 value of
25.9 ± 1.8, > 168.9 ± 30.0, and > 79.4 ± 13.5 pM, respectively. A comparison between the 
IC50 values obtained by the MTT versus LDH assays (25.9 ±1.8 versus > 42.7 ± 3.6 pM) 
suggests that troglitazone affected the reductive capacity of mitochondria at lower level 
before causing the cells to rupture and release their intracellular contents.
An untargeted and a targeted metabolomics approach revealed that troglitazone 
decreased the levels of intracellular glutamate, malate, energy production, GSH, and 
nicotinamide at concentrations that are non-toxic by the MTT assay. These observations 
demonstrate the discriminative ability of a metabolomics approach for the assessment of drug 
toxicity. The findings also suggest that troglitazone affects the tricarboxylic acid (TCA) 
cycle, interrupting the anaplerotic and cataplerotic balance of the TCA cycle, leading to 
oxidative stress and reduced energy level.
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Chapter 1: Introduction
In the recent years, there has been a rapid revolution in scientific and technological 
innovations, with huge progress in the development of high-throughput and high-content 
analytical approaches. The scientific perspective has also shifted from the reductionist 
approach of meticulously analysing a single component of a biological system to the holistic 
approach of examining the global interactions of elements in the entire biological organism. 
Metabolomics is an emerging “omic” science aiming to quantify cellular metabolites and 
decipher the metabolic profile in complex systems through the combination of sophisticated 
high-throughput data-rich analytical techniques that requires only a minimal amount of 
biological materials and the application of statistical and multi-variant methods for 
information extraction and data interpretation. Metabolomics is a useful application for the 
understanding of the biology of an organism in response to internal and external 
environmental stimuli or genetic perturbation. Comparison of profiles from different 
phenotypes is used to identify specific metabolic changes leading to the understanding of 
biochemical pathways, complex biomarker combinations, toxic effects, and disease 
progression (Roessner and Bowne, 2009; Fontana et al, 2012).
Metabolites are defined as chemical entities that are transformed during metabolism. 
In comparison to the epigenetic and posttranslational modifications that exist to control 
nucleic acid and protein function, respectively, metabolites change faster in response to 
biochemical reactions. As such, they provide a functional readout of the cellular state that is 
both global and highly responsive, and this means that metabolites are ideal to serve as direct 
signatures of biological activity with good correlates to phenotype (Patti et a l, 2012). Within 
the current work, a metabolomics approach will be used to increase understanding of the 
mode(s) of toxicity of troglitazone.
1.1 Glucose metabolism
Glucose metabolism is one of the central metabolic processes, acting to provide 
energy for the body in the form of adenosine triphosphate (ATP). This generation of ATP 
from glucose metabolism involves three main, inter-linked, metabolic pathways (Figure 1.1). 
Firstly, glucose is oxidised to two molecules of pyruvate through the glycolytic pathway, a 
process that occurs in the cytosol of the cell. Secondly, the generated pyruvate molecules are 
transported into the mitochondria and enter the tricarboxylic acid cycle (TCA cycle), also
known as citric acid cycle or Krebs cycle. In the TCA cycle, pyruvate is completely oxidised 
to form three molecules of carbon dioxide while hydrogen carriers NAD"  ^ (nicotinamide 
adenine dinucleotide) and FAD (flavin adenine dinucleotide) are reduced to NADH + H^ and 
FADH], respectively. The third pathway within this energy generation network occurs when 
NADH + H^ and FADH2 enter the respiratory chain; they pass through the coupled processes 
of electron transport and oxidative phosphorylation to form water and ATP. Hydrolysis of 
ATP can then be used to release energy required for a multitude of biological activities, such 
as muscle contraction, protein synthesis, and conduction of nerve impulses (Salway, 2004).
In addition to this major route for ATP generation, the metabolism of glucose can 
proceed along several alternative pathways, depending on the conditions within the cell and 
the body’s need. Under anaerobic conditions, pyruvate is converted to lactate instead of 
entering the TCA cycle. While this process is less efficient for energy generation, releasing a 
comparatively small amount of usable energy, it is important during strenuous exercise when 
ATP is required rapidly, but local oxygen supply can be limiting especially in working 
muscles. Lactate produced through this process can diffuse out of the cells into the systemic 
circulation; from here it can be taken up by the liver and oxidised to pyruvate when oxygen is 
available, which in turn can then be converted back to glucose. While the muscle cells are 
traditionally thought of as the major site of anaerobic glycolysis due to the high energy 
demand and lowered limiting local oxygen concentrations achieved during intense exercise, it 
should be noted that other tissues also rely on this mechanism of energy generation. For 
example, anaerobic glycolysis is the sole source of energy for erythrocytes because they do 
not contain mitochondria. In addition, the retina and kidney medulla also rely mostly on 
anaerobic glycolysis for the production of ATP, even in the presence of oxygen (Salway, 
2004; Gropper et al, 2009).
During periods when there is surplus glucose, and the requirement for energy 
generation is limited, then glucose metabolism is directed towards glycogenesis. This process 
converts excess glucose to glycogen for storage of an energy-rich precursor. When the need 
for energy generation is increased, and glucose reserves begin to fall, glycogenolysis occurs, 
resulting in the breakdown of glycogen to reform glucose. In addition, under these conditions, 
glucose can also be formed from non-carbohydrate precursors (e.g. amino acids or glycerol) 
through the process of gluconeogenesis (Salway, 2004; Gropper et a l, 2009). Figure 1.2 
shows an integrated overview of pathways related to glucose metabolism.
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Figure 1.1: Metabolism of glucose to give energy. Glycolysis, the TCA cycle, and the respiratory 
chain are the three major pathways involved in glucose metabolism to produce energy in the form 
of ATP, shown by the red arrows. Reproduced from Salway (2004).
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Figure 1.2: Integrated pathways related to glucose metabolism. The metabolic pathways of 
glucose consist of glycogenesis (conversion of glucose to glycogen), glycogenolysis (conversion of 
glycogen to glucose), glycolysis (oxidation of glucose to pyruvate) followed by the TCA cycle, and 
gluconeogenesis (conversion of non-carbohydarate precursors to glucose). Pyruvate can be 
converted to lactate during anaerobic metabolism and lactate is transported through the general 
circulation to the liver to be converted back to glucose via gluconeogenesis. Pyruvate is also linked 
to the synthesis of fatty acids through acetyl-CoA. The pentose phosphate pathway uses glucose to 
produce 5-carbon monosaccharides and NADPH. Intermediary metabolites of fructose enter 
glycolysis while galactose is metabolised to glucose or gets incorporated into glycogen. Adapted 
from Gropper et al. (2009).
Furthermore, glueose can enter the pentose phosphate pathway, also known as hexose 
monophosphate shunt or the phosphogluconate pathway. This pathway is important for the 
generation of NADPH + H^, the reducing power that is essential for the synthesis of fatty 
acids and cholesterol, as well as the reduction of oxidised glutathione (GSSG) to reduced 
glutathione (GSH). It also generates ribose 5-phosphate, the pentose sugar for nucleotide and 
nucleic acid synthesis (Salway, 2004; Gropper et a l, 2009).
Other metabolic pathways (e.g. lipid and protein metabolism) are also capable of 
feeding into the reactions that occur during glueose metabolism. For example, lipogenesis 
(conversion of excess glueose to stored fat, i.e. triaeylglycerol) encompasses the pentose 
phosphate pathway, which is a temporary diversion from the glycolytic pathway because of 
the inhibition of phosphofructokinsase. The metabolites may enter the glycolytic pathway as 
glyceraldehye 3-phosphate and ultimately the TCA cycle to form citrate. Citrate is diverted 
from the TCA cycle during well-fed state, diffuses into the cytosol and enters the fatty acid 
synthesis pathway. Citrate is broken down to oxaloacetate and aeetyl-CoA. Aeetyl-CoA 
forms malonyl-CoA, which combines with acyl carrier protein (ACP) to form malonyl ACP. 
Cyclical series of reactions with the successive additions of two carbon units build up fatty 
acids. Thereafter, estérification of fatty acids with glycerol results in the production of
triaeylglycerol. Lipolysis (breakdown of stored fat) involves hydrolysis of triaeylglycerol to 
fatty acids and glycerol. The fatty acids then undergo p-oxidation, forming acetyl-CoA, 
which enters the TCA cycle to yield energy in the form of ATP. Each P-oxidation cycle also 
produces FADH2 and NADH that can undergo oxidative phosphorylation to generate ATP. 
Synthesis of non-essential amino acids, catabolism of amino acids, and metabolism of protein 
to fat are also linked to pathways in glucose metabolism via cataplerosis and anaplerosis 
reactions (Salway, 2004; Mathews et a l, 2000).
1.2 Diseases of glucose metabolism: Insulin resistance
Insulin is a polypeptide hormone that is synthesised as an inactive prohormone. The 
biosynthesis involves two inactive precursors, i.e. preproinsulin and proinsulin. Insulin is 
activated prior to secretion into the systemic circulation by sequential cleavage of 
preproinsulin and proinsulin to form the active hormone and C-peptide. Insulin has many 
roles in metabolism, and impacts upon glucose, lipid, and amino acid/protein synthesis and 
storage. Generally, insulin acts to reduce the blood glucose level by increasing glucose 
uptake into cells. When insulin binds to the a-subunit insulin receptor on a cell surface, a 
series of signal transduction cascade is initiated, resulting in a number of actions including 
the translocation of glucose transporter type 4 (GLUT-4) to the plasma membrane, which is 
an insulin-sensitive glucose transporter. This transporter then increases the specific uptake of 
glucose from the systemic circulation into the cells. Insulin also increases the expression or 
activity of a number of enzymes that catalyse the synthesis of glycogen in the liver and 
muscle, while inhibiting hepatic production of glucose through inhibition of glycogenolysis 
and gluconeogenesis (Champe et a l, 2008; Gropper et al, 2009; Silverthom, 2010).
In addition, insulin also affects the metabolism of lipid. It reduces the circulatory fatty 
acids by in decreasing triaeylglycerol degradation through inhibition of hormone-sensitive 
lipase activity in the adipose tissue, and promoting triaeylglycerol synthesis via increasing 
lipoprotein lipase synthesis, so that the enzyme can provide fatty acids for estérification. 
Insulin also stimulates the uptake of amino acids into cells for anabolic reactions. In the 
fasting state, when insulin levels are low, the balance is pushed towards the opposite direction 
where glucose production, triaeylglycerol and protein degradation are increased (Champe et 
a/., 2008; Gropper e/ a/., 2009; Silverthom, 2010). Together, these effects act to reduce 
system glucose concentration, and convert the cellular glucose into the metabolites storage.
Given the critical role of insulin in co-ordinating body responses to glucose 
challenged, it is not surprising that loss of this function is associated with pathogenesis. 
Insulin resistance is a condition in which there is reduced sensitivity towards insulin, such 
that a subnormal biological response is produced in response to a raised blood glucose level. 
The results of insulin resistance are reduced glucose uptake into muscle and fat cells, 
impaired hepatic glycogen synthesis, and failure to suppress hepatic glucose production, 
which all contribute to high blood glucose level (hyperglycaemia) (Evans and Krentz, 2001; 
Champe et al, 2008).
The majority of insulin-resistant individuals are able to maintain a normal or 
near-normal glucose tolerance by releasing more insulin. Therefore, insulin-resistant 
individuals normally display high levels of blood insulin (hyperinsulinaemia). However, this 
process of hyperinsulinaemia is associated with a further increase in insulin resistance, until 
individuals are unable to maintain the compensatory hyperinsulinaemia needed to overcome 
the defect of insulin action. At this point, significant hyperglycaemia develops, with the 
majority of individuals progressing to type 2 diabetes mellitus, with its associated increased 
morbidity and mortality rates (Reaven, 2005b).
One example of this increased morbidity is the fact that insulin resistance may 
increase the frequency of cardiovascular diseases. Insulin plays a role in lipid metabolism by 
promoting fat storage and restraining fat mobilisation. Deficiency of insulin results in an 
elevated level of hydrolysis of stored triacylglycerols, and mobilisation of fat cells. This 
results in high blood levels of triglycerides, very-low-density lipoproteins (VLDL), free fatty 
acids, and low levels of high-density lipoproteins (HDL); the net result of this is an elevated 
blood pressure, an increased incidence of cardiovascular diseases (Evans and Krentz, 2001; 
Reaven, 2005b; Reaven, 2005a).
1.3 Diabetes mellitus
The World Health Organisation, WHO (1999) described diabetes mellitus as “a 
metabolic disorder of multiple aetiology characterised by chronic hyperglycaemia with 
disturbance to carbohydrate, fat, and protein metabolism due to defects in insulin secretion, 
insulin action, or both”. It is estimated that 345 million people worldwide have diabetes and
3.4 million people died from the consequences of high blood glucose level in 2004 (WHO, 
2011). In the U.K., there are approximately 2.9 million people diagnosed with diabetes
mellitus, although this is likely to be underestimate of the real number of sufferers due to 
under-diagnosis; it is estimated that up to 1 million additional individuals in the U.K. suffer 
from the condition, but are currently unaware (Diabetes U.K., 2012).
There are two major classes of diabetes mellitus, namely type 1 and type 2: Type 1 
diabetes mellitus is primarily due to pancreatic p-cell destruction and individuals are prone to 
ketoacidosis; type 2 diabetes mellitus is the major form of diabetes, with over two million 
people in the U.K. diagnosed with the disease. In type 2 diabetes mellitus, defects in insulin 
secretion and almost always with the underlying cause, with a major contribution from 
insulin resistance. WHO diagnostic criteria for diabetes is fasting plasma glucose of more 
than 7.0 mmol/1 (126 mg/dl) or the 2-hour plasma glucose (after ingestion of 75 g oral 
glucose load) is more than 11.1 mmol/1 (200 mg/dl). Other minor categories of diabetes or 
related impairments include gestation diabetes, impaired glucose tolerance (IGT), and 
impaired fasting glycaemia (IFG). Gestation diabetes is a condition in which women 
experience the onset of hyperglycaemia during pregnancy. Impaired glucose tolerance and 
impaired fasting glycaemia are intermediate conditions in the transition between normality 
and diabetes. The diagnostic of impaired glucose tolerance is fasting plasma glucose of less 
than 7.0 mmol/1 (126 mg/dl) and the 2-hour plasma glucose of 7.8 mmol/1 (140 mg/dl) to
11.1 mmol/1 (200 mg/dl). Impaired fasting glucose is diagnosed when the fasting plasma 
glucose is between 6.1 mmol/1 (110 mg/dl) to 6.9 mmol/1 (125 mg/dl) and the 2-hour plasma 
glucose is less than 7.8 mmol/1 (140 mg/dl). Both impaired glucose tolerance and impaired 
fasting glucose are risks for future development of diabetes (WHO, 1999; WHO, 2006; 
WHO, 2011; Diabetes U.K., 2012).
The therapy and management of diabetes mellitus is varied, ranging from lifestyle 
interventions such as increased exercise and healthy eating adviee to help sufferers maintain a 
healthy weight, through to pharmacologieal interventions that directly impact upon glucose 
metabolism. It is well established that diet and exercise can improve glycaemic control, 
especially in individuals with type 2 diabetes that are insulin resistant (Reaven, 2005b), and 
this is the first line of treatment for the majority of individuals. The target glycaemic control 
recommended by National Institute for Health and Clinical Excellence (NICE) is between 
48 mmoEmol -  58 mmoEmol of glycosylated haemoglobin A% (HbAic), i.e. 6.5 -  7.5% 
(NICE, 2011). HbAic is considered the gold-standard marker of glycaemic control because 
unlike direct measurement of blood glucose that give a series of snapshots of the current
8condition, HbAic provides an approximation of a patient’s average blood glucose levels over 
the past 2 - 3  months (Woo et al, 2008).
When the response to such lifestyle interventions is insufficient, appropriate 
pharmacotherapy is introduced, with the aim of safe glycaemic control. There is a wide range 
of pharmacological agents that have been developed to reduce hyperglycaemia, and these fall 
into a number of general classes. Firstly, the secretion of insulin can be stimulated through 
the use of sulphonylureas and meglitinides (e.g. glimepiride and glybenclamide; nateglinide 
and repaglinide). Secondly, biguanides (e.g. metformin) is used to decrease hepatic glucose 
production and increases liver and muscle insulin sensitivity. Thirdly, therapies may be 
targeted against intestinal glucose absorption (a-glucosidase inhibitors, e.g. acarbose). 
Fourthly, thiazolidinedione class of compounds (e.g. rosiglitazone and pioglitazone) increases 
adipose and muscle insulin sensitivity (Cheng and Fantus, 2005).
When lifestyle and pharmacological therapies have failed to adequately control the 
diabetes mellitus, insulin injection may be used to directly increase systemic insulin levels 
post-prandially, or (rarely) pancreatic (3-cells transplantation can be used, especially for type 
for type 1 diabetes patients, to increase insulin production (Fry, 2012; McCall and James 
Shapiro, 2012; Bose et al., 2012).
1.4 Thiazolidinediones (TZDs): Their action as insulin sensitisers
The thiazolidinediones (TZDs) are a class of drugs used for the treatment of type 2 
diabetes mellitus. They are also known as glitazones and their development has been 
suggested to be the most significant breakthrough in type 2 diabetes treatment, after the 
discovery of insulin. These oral antidiabetic agents lower blood glucose level by improving 
insulin resistance, one of the key features in the aetiology of type 2 diabetes and, hence, they 
are described under the general class of insulin sensitisers. TZDs are agonists of peroxisome 
proliferator-activated receptor-y (PPARy), which is a nuclear receptor (Bradley, 2002; Patlak, 
2002; Yki-Jarvinen, 2004).
1.4.1 Nuclear receptors
Nuclear receptors are ligand-activated transcription factors that have roles in a wide 
range of biological functions, ranging from reproduction and development to xenobiotic 
metabolism. The human genome sequencing has identified 48 genes that encode nuclear
receptors, making them a superfamily (Chen, 2008; Chawla et al, 2001). Work by Bookout 
and colleagues (Bookout et al, 2006) examined the tissue localisation of the nuclear 
receptors, creating a functional phylogeny. They proposed a classification of nuclear 
receptors based upon this physiological functioning, including sub-divisions for 
steroidogenesis; reproduction and development, CNS, circadian and basal metabolism; lipid 
metabolism and energy homeostasis; and bile acid and xenobiotic metabolism.
All nuclear receptors share a common structural feature, a single polypeptide chain 
with a conserved N-terminal DNA-binding domain (DBD) and a C-terminal ligand-binding 
domain (LBD) (Figure 1.3). DBD contains two highly conserved zinc fingers that target the 
receptors to the highly specific DNA sequences known as hormone-response elements. The 
LBD is responsible for recognising specific ligands and co-factor (co-activator and 
co-repressor) interaction, and also mediates dimérisation. A second dimérisation domain 
exists in the DBD and is required for heterodimerisation of receptors on response elements. 
Separating the DBD and LBD is a region that acts as a hinge, allowing receptor to bend and 
undergo conformation changes in response to ligand binding. In addition to DBD, LBD and 
the hinge, nuclear receptors also have two transactivation domains known as AF-1 and AF-2. 
AF-2 is a ligand-dependent activation function 2 within the LBD and some nuclear receptors 
have a ligand-independent activation 1 located at the N-terminal (Chen, 2008; Olefsky, 2001; 
Chawla et al, 2001; Moore et al, 2006; Lopez-Velazquez et al, 2012; Bourguet et al, 2000; 
Plant and Aouabdi, 2009).
The general concept of nuclear receptor signalling is that nuclear receptor is often 
associated with a co-repressor complex during the absenee of a ligand, resulting in an 
inhibition of basal transcription activity. When ligand binds to a nuclear receptor, 
conformational changes take place leading to the release of the co-repressor complex and 
recruitment of a co-activator complex. Recruitment of the co-activator complex contributes to 
chromatin remodelling and transcriptional activation (Moore et a l, 2006; Chen, 2008; Lopez- 
Velazquez et al, 2012). Besides the direct transcriptional activation of target genes, several 
nuclear receptors can also indirectly affect the transcription of target genes by negatively 
interfering with the transcriptional responses mediated by other classes of transcription 
factors, especially those involved in inflammation such as nuclear factor-xB (NF-kB). This 
indirect association of nuclear receptor with target genes is referred to as transrepression 
(Glass and Saijo, 2010; Yki-Jarvinen, 2004).
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Figure 1.3: Schematic representation of a typical nuclear receptor. Nuclear receptor can be 
divided into six regions (A, B, C, D, E, and F). Region A/B is the N-terminal region that contains 
ligand-independent transcription activator function 1 (AF-1). Region C is the highly conserved 
DNA-binding domain and mediates heterodimerisation. Region D is the hinge domain. Region E is 
the less conserved ligand-binding domain (LBD) also responsible for dimérisation and ligand- 
dependent transactivation function 2 (AF-2). Region F is not present in all nuclear receptors and its 
function is poorly understood. Adapted from Bourguet et al. (2000) and Plant and Aouabdi (2009).
1.4.2 Peroxisome proliferator-activated receptors (PPARs)
Peroxisome proliferator-activator receptors (PPARs) are a subfamily of the 
48-member nuclear receptor superfamily, which regulate gene expression in response to 
ligand binding. The PPAR subfamily is classified within the lipid metabolism and energy 
homeostasis clade, which also includes the glucocorticoid and thyroid receptors, amongst 
others. There are three known PPARs isotypes, namely PPARa , PPARô (also referred to as 
PPARp), and PPARy (Yki-Jarvinen, 2004; Berger and Moller, 2002; Bookout et a l, 2006).
The functional roles of PPARs are consistent with their distribution. PPARa that is 
expressed in high levels in the liver, kidney, heart, and muscle (organs carrying out 
catabolism of fatty acids) is master regulator of fatty acid oxidation and lipoprotein 
metabolism, as well as having anti-inflammatory effects too. PPARô has the broadest tissue 
expression and is reflective of a wide biological function. PPARÔ is expressed in most 
tissues, markedly in the skin, brain, and adipose tissue and impacts on energy homeostasis; 
cell proliferation, survival, and differentiation (cellular growth and organ development); and 
is also involved in wound healing. PPARy, which is localised mainly in the adipose tissue, 
plays a critical role in adipocytes differentiation (adipogenesis) and in energy conservation 
(lipogenesis). fri addition, PPARy also act to limit inflammation (Yki-Jarvinen, 2004; Feige et 
al, 2006; Michalik et a l, 2006; Yu and Reddy, 2007; Zoete et al, 2007; Sutinen, 2009). 
Interestingly, anti-inflammatory effect of PPARs is most likely not mediated through the 
traditional direct, transcriptional activity of the receptors; instead, transrepression of
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inflammatory pathways occurs through direct interaction with NFkB, limiting the 
pro-inflammatory action of this molecule (Venteclef et al, 2011).
Because PPARs act as lipid sensors that translate the changes in lipid levels into 
metabolic activity, various fatty acids serve as endogenous ligands to PPARs in general, and 
PPARy specifically. PPARa and PPARô are activated by saturated and unsaturated fatty 
acids while PPARy prefers polyunsaturated fatty acids. In addition to their large number of 
endogenous ligands, PPARs are also the primary target of numerous classes of synthetic 
compounds due to their vast metabolic and therapeutic action. Perhaps the best known of 
these are PPARa agonists the fibrates (e.g. gemofibrozil, bezafibrate), which act as lipid- 
lowering drugs and the TZDs as agonists against PPARy, for their insulin sensitising activity 
(Michalik et al, 2006; Yki-Jarvinen, 2004; Feige et al, 2006; Zoete et al, 2007; Berger and 
Moller, 2002). The TZDs are highly selective and potent agonists of PPARy (Mudaliar and 
Henry, 2001), with affinity values in the range of 40-200 nM (Reginato and Lazar, 1999). In 
contrast, most natural ligands bind with relatively weak affinity, in the micromolar range 
(Feige et al, 2006).
1.4.3 Physiological consequence of PPARy activation
As suggested by the class name, PPARy is located within the nucleus of the cell even 
in the absence of exogenous ligand. Upon activation, it forms a heterodimer with another 
nuclear receptors, the retinoid X receptor (RXR), and this heterodimer recognises specific 
DNA sequences in the promoter region of target genes called PPAR response elements 
(PPRE). The consensus sequence of a PPRE is AGGTCANAGGTCA, often referred to as 
direct repeat 1 (DRl) due to the spacing of the repeats by a single nucleotide. Ligand binding 
(such as with TZD) induces specific confirmational changes that both increase the affinity of 
the nuclear receptor for DNA, but also allow recruitment of co-activators. Interaction 
between co-activators and nuclear receptor heterodimer is responsible for transcription of a 
set of genes controlling a series of biochemical reactions involved in lipid and carbohydrate 
metabolism, such as lipoprotein lipase, fatty acid transporter protein, fatty acid binding 
protein, acyl-CoA synthase, glycerol kinase, malic enzyme, glucokinase, phosphoenol 
pyruvate carboxykinase, pg-adrenergic receptor, cytokines leptin, and tumour necrosis factor 
a  (TNFa). The end result is improvement of symptoms of insulin resistance (Reginato and
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Lazar, 1999; Picard and Auwerx, 2002; Yki-Jarvinen, 2004; Bailey, 2007). Figure 1.4 shows 
a diagrammatic representation of the activation of PPARy by TZD.
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Figure 1.4: The mechanism of action of TZD at a molecular level. PPARy binds to a specific 
DNA sequence in the target genes as a heterodimer with RXR. After activation with TZD, 
co-activator complexes are recmited, resulting in an increase of transcription activity. Adapted 
from Yki-Jarvinen (2004).
1.4.4 Mechanism of TZD action
TZDs lower blood glucose levels by aetivating PPARy (Reginato and Lazar, 1999; 
Mudaliar and Henry, 2001; Patlak, 2002; Yki-Jarvinen, 2004; Lite and Blickle, 2007). The 
mechanism by which TZDs promote insulin action and, indeed, the site at which this 
mechanism occurs within the body are still unclear. It is generally agreed that the primary site 
of TZD action is at the level of skeletal muscle, but as PPARy is expressed abundantly in the 
adipose tissue it eannot be ignored that the insulin-sensitising mechanism could be explained 
through the direet effect on the adipocytes (Yki-Jarvinen, 2004; Cheng and Fantus, 2005; 
Mankovsky and Kurashvili, 2007).
As previously detailed, PPARy is important for adipocytes differentiation and 
lipogenesis. Activation of PPARy by TZDs therefore, increases fatty acid uptake and storage
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in adipocytes, and this in turn leads to an increase in adipose tissue mass and body weight 
(Picard and Auwerx, 2002; Yki-Jarvinen, 2004). Studies have shown that TZDs treatment 
inereases the number of small adipoeytes and the subcutaneous adipose tissue mass (Okuno 
et al, 1998; Mori et al, 1999; Miyazaki et al, 2002). This aetion to increase lipogenesis and 
storage, together with reduced lipolysis leads to a decrease in eirculatory free fatty acid 
levels. Reduced cireulatory free fatty aeid levels has been shown to enhanee insulin 
sensitivity of tissues sueh as the skeletal musele, liver, and panereatie p-cells (Yki-Jarvinen, 
2004; Bailey, 2007), while high concentrations of free fatty aeids have deleterious effects on 
these tissues and ean lead to insulin resistanee (Kusminski et al, 2009). Enhaneed sensitivity 
of the liver towards insulin, suppresses hepatie glueose produetion, resulting in lower blood 
glucose and insulin levels (Yki-Jarvinen, 2004).
Adipokines are a specific sub-group of the cytokines, being speeifieally seereted from 
adipose tissue. Altered adipokine release, ineluding adiponeetin, TNFa, leptin, resistin, and 
llp-hydroxysteroid dehydrogenase 1 is another mechanism by which insulin sensitivity 
could be modulated. Weyer and eolleagues demonstrated that low levels of cireulatory 
adiponeetin are strongly assoeiated with the progression of insulin resistanee (Weyer et al, 
2001), while the aetivation of PPARy by TZDs has been demonstrated to markedly increase 
plasma adiponeetin levels, enhancing insulin sensitivity (Maeda et al, 2001; Yamauchi et al, 
2001; Yang et al, 2002; Majuri et al, 2007).
In addition to these potential positive aetions of PPARy ligands such as TZDs, they 
have also been shown to potentially impact on glycaemic control through a repressive mode 
of action. The eytokine TNFa has been shown to reduee insulin-stimulated glueose uptake 
and is found in high coneentrations in obese and insulin-resistant individuals (Hotamisligil et 
al, 1993; Hotamisligil et al, 1995). Moreover, a number of other moleeules have also been 
shown to increase insulin resistanee, including leptin, resistin, and llp-hydroxysteroid 
dehydrogenase 1. The expression of these molecules is repressed by PPARy ligands sueh as 
TZDs, thereby improving glyeaemic eontrol, although whether this is via a direet or 
trans-repressive mechnisms is not clear in all cases (Pieard and Auwerx, 2002; Yki-Jarvinen, 
2004; Bailey, 2007; Majuri et a l, 2007).
In summary, multiple meehanisms have been presented to explain the insulin 
sensitising nature of the TZDs class of PPARy agonists. These effects are mediated 
predominantly through direet effect on the adipoeytes, although indirect effects on other
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tissues have also been suggested. It is likely that the observed biological effects of these 
drugs are due to a combination of these mechanisms, rather than any single one.
1.4.5 Members of TZD group of drugs
All members of the TZDs have a core thiazolidine-2-4-dione structure, from which 
the class derives its name, which is a thiazole ring with two keto-oxygen (Figure 1.5 A). 
TZDs differ from each other in their side chains, which alter the pharmacodynamics and 
pharmacokinetic properties of the individual TZDS, as described in detail subsequently 
(Taylor, 2003). The major TZDs, either historically or currently, are ciglitazone, troglitazone, 
rosiglitazone, and pioglitazone, with the main features of each described below.
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Figure 1.5; The molecular structure of (A) thiazolidine-2,4-dione and (B) troglitazone.
Ciglitazone (ADD-3878) is a clofrbrate analogue developed by Takeda Chemical 
Industries Ltd. in Japan in the early 1980s (Table 1.1). It was initially screened as a potential 
lipid-lowering agent, but was found to have blood glucose-lowering effects without an 
increase in insulin secretion in type 2 diabetic animals. However, ciglitazone was not 
prescribed clinically due to the marked hepatotoxicity that was observed in pre-clinical 
testing, but was considered as a prototypical compound for the development of other TZDs 
(Hulin et al, 1996; Gale, 2001; Parker, 2002; Avom, 2004).
Troglitazone (CS-045) was developed by Daiichi Sankyo Co. Ltd. through the 
combination of ciglitazone with a substructure of the a-tocopherol molecule (Figure 1.5 B 
and Table 1.1), with the aim of combining glucose lowering potential with the ability to 
inhibit lipid peroxidation in a single molecule (Hulin et a l, 1996; Parker, 2002). Troglitazone 
was the first TZD to be marketed and was launched in the U.S.A. in 1997, under the brand 
name Rezulin (manufacturer: Warner-Lambert) and in Europe under the brand name 
Romozin. By the year 2000, trogliatzone was seen as an important clinical tool for treatment 
of type 2 diabetes mellitus, and sales of troglitazone in the U.S.A. alone generated over $2
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billion. However, it was implicated in at least 90 cases of idiosyncratic liver failure, of which 
70 resulted in death or liver transplantation. On the basis of this adverse risk profile, 
troglitazone was withdrawn in the U.S.A. in March 2000, having aheady been withdrawn 
from the U.K. market nearly three years previously (Gale, 2001; Avom, 2004).
Rosiglitazone was designed by researchers at SmithKline Beecham and designated 
the code number BRL-46953 (Table 1.1). The lipophilic tail of ciglitazone was replaced with 
an amino pyridine, which gave a 300-fold increase in hypoglycaemic activity relative to 
ciglitazone (Hulin et a l, 1996). Rosiglitazone was released into the market in the U.S.A. in 
May 1999, and in Europe in March 2000 by GlaxoSmithKline pic, as both a single and 
combination therapy. Avandia was the trade name for the single chemical formulation, whilst 
combinations with metformin and glimepiride were sold as Avandamet and Avandaryl/ 
Avaglim, respectively. At that time, the use was limited as second-line therapy in 
combination with other oral antidiabetic dmgs (Bailey, 2007; Gale, 2001; Nissen and Wolski, 
2007). The association of rosiglitazone with hepatotoxicity was rare (Scheen, 2001; Nagasaka 
et aï., 2002; Yokoi, 2010), but it has been linked to severe cardiovascular side effects in the 
recent years, including heart attack and stroke (Loke et al., 2011; Nissen and Wolski, 2010; 
Juurlink et ah, 2009). In September 2010, rosiglitazone was removed from the European 
market but it is still available in the U.S. subject to strict restriction (Mayor, 2010; Cohen, 
2010b; Cohen, 2010a; Blind et al, 2011).
Pioglitazone (AD-4833) is another modification of ciglitazone backbone, and 
produced by Takeda Pharmaceuticals Co. Ltd. through the substitution of the lipophilic tail of 
ciglitazone with a 5-ethylpyridyl moiety (Table 1.1) (Hulin et al, 1996). Pioglitazone came 
into the market in July 1999, a few months later than rosiglitazone, and is marketed under the 
trademarks of Actos in the U.S.A., Canada, U.K., and Germany, Glustin in other parts of 
Europe, and Zactos in Mexico. Similar to rosiglitazone, the association of pioglitazone with 
hepatotoxicity is rare (Scheen, 2001; Nagasaka et al, 2002; Yokoi, 2010), and any 
association with cardiovascular events with pioglitazone treatment is significantly weaker 
than rosiglitazone (Juurlink et al, 2009; Loke et a l, 2011). However, recent evidence has 
focussed on a potential association between pioglitazone usage and an increased risk of 
bladder cancer (Azoulay et al, 2012; Voelker, 2012; Colmers et al, 2012), leading to the 
benefit-risk review of pioglitazone by the European Medicines Agency (EMA). In July 2011, 
EMA concluded that the benefits of pioglitazone continue to outweigh the risks for patients 
who responded to the treatment and in whom there was no identified risk factors for bladder
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cancer (European Medicines Agency, 2011), making pioglitazone the only remaining TZD 
still available in the market. However, in a unilateral action, French and German regulatory 
bodies have decided to suspend pioglitazone (Ryder, 2011).
A number of other manufacturers have developed TZD molecules, but the use of 
these is minor in comparison to rosiglitazone (historically) and pioglitazone (historically and 
currently). These compounds include englitazone, darglitazone, isaglitazone, and 
rivoglitazone (Table 1.1). Englitazone (CP-68722) and darglitazone (CP-86325) were 
developed by Pfizer Inc. but the development of these drugs was abandoned before they 
reached the clinic (Parker, 2002). Netoglitazone, also referred to as isaglitazone or MCC-555, 
was developed by Mitsubishi-Tokyo Pharmaceuticals Inc., and has a higher antidiabetic 
potency than rosiglitazone (Reginato et a l, 1998). It contains a naphthalene moiety (Rahman, 
2009) and is a dual PPAR-a/y agonist (Imran et al, 2007). Netoglitazone entered Phase III 
clinical trials in April 2005 (Diabetes digest.com, 2010). Rivoglitazone (CS-011) is a PPARy 
agonist developed by Daiichi Sankyo Co. Ltd. (Kanda et a l, 2009; Schimke and Davis, 
2007). It has a benzimidazolyl tail group and is more potent than rosiglitazone and 
pioglitazone (Rahman, 2009; Kanda et al, 2009). Rivoglitazone has completed several 
clinical trial phases and is currently still under development process (Levien and Baker, 2009; 
Schimke and Davis, 2007; Kong et al, 2011; Rohatagi et al, 2008; Truitt et a l, 2010).
Cl,
T 3
m
4=1
00 y
în  t-'' ^
l l ï IIII
H <N
H «A
(N
(N
z  1
ü  z
t
en
m
(N
z ;
illi! oCNenen
en
DX)
N
(N
(N
(N
t
19
1.5 General characteristics of drug metabolism
Drug metabolism is the enzyme-catalysed process by which a drug is broken down 
into different biochemical components, called metabolites. These biochemical modifications 
alter the activity of the drug, leading to activation or termination of pharmacological action, 
and are an important step in the clearance of drugs from the body, preventing overdose and 
toxicity. It is worth noting that the phrase ‘drug metabolism’ is a catch-all, and the same 
processes are used to metabolise non-drug xenobiotics (e.g. food additives, environmental 
contaminants, etc.), as well as endogenous chemicals (e.g. steroids, bile acids, etc.). Drug 
metabolism takes place mainly in the liver, but it can occur in any parts of the body such as 
kidney, gastrointestinal tract and flora, lungs, blood plasma, brain, placenta, and skin. Drug 
metabolism is divided into phase 1 and 2 reactions (Boden et al, 2007; Gibson and Skett, 
2001), the overall aim of which is to lead to polar and less toxic metabolites that can be 
cleared from the body via the aqueous excretion routes (urine and faeces). However, as 
described in more detail below, during drug metabolism it is also possible to generate 
reactive metabolites that, if not rapidly detoxified can elicit various types of cellular damage 
(Testa and Mayer, 1998).
1.5.1 Phase 1 metabolism
For efficient absorption of a drug, lipophilic properties are generally favoured. 
However, this is problematic for subsequent clearance of the drug, as excretion routes are 
aqueous in nature. During phase 1 metabolism, the basic structure of the drug is altered, 
creating or revealing a reactive centre that can be used in subsequent Phase II metabolic 
processes. These functional groups include hydroxyl (-0H), sulfhydrl (-SH), amino (-NH2), 
or carboxyl (-COOH) moieties, and are introduced via a range of processes, including 
oxidation, reduction, hydrolysis and hydration, (Gibson and Skett, 2001). The introduction of 
the functional group normally increases hydrophilicity and these metabolites may be readily 
excreted at this point if they are sufficiently polar (Boden et al, 2007; Gibson and Skett, 
2001). However, many phase 1 products are not readily excreted and serve as substrates for 
phase 2 reactions (Gibson and Skett, 2001).
The predominant catalysts of phase 1 metabolism are members of the cytochrome 
P450s (CYPs) superfamily of proteins, a group of haem-containing enzymes found in the 
endoplasmic reticulum of cells (Gibson and Skett, 2001). Cytochrome P450s are encoded by
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a gene superfamily members of which are found in all species from archaebacteria to man; 
humans possess 57 cytochrome P450 genes. Approximately 15 of the cytochrome P450 
enzymes in humans mediate 70% -  80% of all phase 1 drug metabolism, and are members of 
the CYPl, CYP2, and CYP3 families (Table 1.2 and 1.3) (Boden et a l, 2007). The other 
cytochrome P450s enzymes belong to other families such as CYP4, CYP5, CYP7, CYPll, 
CYPl7, CYPl9, CYP21, CYP24 and CYP27, and are involved in a variety of specialised 
endogenous functions, such as cholesterol and steroid synthesis and fatty acid metabolism 
(Boden et al, 2007; Gibson and Skett, 2001).
Table 1.2: Functions of cytochrome P450 families
P450 family Function
CYPl —
CYP2 -  Drug, xenobiotic, and steroid metabolism
CYP3
—
CYP4 Fatty acid, prostaglandin, leukotriene metabolism
CYP5 Thromboxane synthesis
CYP7 Cholesterol 7 a-hydroxylation
CYPll Cholesterol side change cleavage + steroid l ip  hydrolase
CYP17 Steroid 7 a-hydroxylation
CYP19 Aromatisation of steroids
CYP21 Steroid 21-hydroxylase
CYP24 Vitamin D hydroxylation
CYP27 Cholesterol 27-hydroxylase
Adapted from Gibson and Skett, 2011
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Table 1.3: Isoenzymes in the CYPl, CYP2, CYP3 sub-families
P450 family Member
CYPl CYPlAl
CYP1A2
CYP2 CYP2A6
CYP2A13
CYP2B6
CYP2C8
CYP2C9
CYP2C18
CYP2C19
CYP2D6
CYP2E1
CYP2F1
CYP2J2
CYP3 CYP3A4
CYP3A5
CYP3A7*
"Expressed in foetal liver and uterine endometrium.
Adapted from Boden et al., 2002.
Cytochrome P450s function as monooxygenases, inserting one atom of oxygen into 
the substrate molecule, producing a hydroxylated metabolite. Reactions catalysed by the 
cytochrome P450s require the reducing source NADPH, plus oxygen, which is reduced to the 
level of water during the catalytic cycle (Gibson and Skett, 2001). NADPH-cytochrome P450 
reductase is the redox partner of cytochrome P450s. It is a flavin-containing enzyme 
consisting of one molecule of flavin mononucleotide (FMN) and a flavin adenine nucleotide 
(FAD). NADPH-cytochrome P450 reductase acts as a transducer by accepting electrons from 
NADPH and transferring them sequentially to cytochrome P450 (Laursen et a l, 2011; 
Gibson and Skett, 2001). The cytochrome P450s catalyse a wide variety of reactions 
including aromatic and aliphatic hydroxylation, epoxidation, and N-, S-, and O-dealkylation, 
oxidative deamination, N- and ^'-oxidation, phosphothionate oxidation, dehalogenation, and 
alcohol oxidation (Gibson and Skett, 2001).
Given that the total number of cytochrome P450 enzymes in any given species is 
relatively small (10s to low 100s) compared to the number of chemicals that are required to 
be substrates (high 1000s), it is perhaps not surprising that cytochrome P450s do not obey the 
normal “lock and key” paradigm for enzymes. Instead cytochrome P450s generally possess a 
broad substrate specificity, allowing each enzyme to accept multiple different substrates all at 
relatively low affinity (Kd ~ pM). Due to this, there is high potential for drug-drug
22
interactions, either through direct competition for the enzyme (e.g. competitive inhibition), 
allosteric interaction (e.g. non-competitive inhibition) or transcriptional effects (e.g. 
induction/inhibition of cytochrome P450 production (Gibson and Skett, 2001). Their effects 
can lead to an altered expression level and/or activity of the relevant enzyme, in a response to 
the “perpetrator” drug. This then leads to altered metabolism and clearance of 
co-administered “victim” drugs, potentially resulting in loss of efficacy or increased toxicity 
(Pelkonen et al, 1998; Boden et al, 2007). Arguably the most important cytochrome P450 
enzyme affected by such drug-drug interactions is CYP3A4, for the simple reason that this 
enzyme is the most abundant cytochrome P450 in the human body, the potential magnitude 
of its induction, and the vast array of drugs metabolised by CYP3A4 (Boden et al, 2007). 
Inhibition of drug metabolism decreases the amount or activity of drug metabolising 
enzymes, which can result in increased bioavailability of parent compound or decreased the 
active form of prodrugs, leading to toxicity or lack of efficacy (Pelkonen et al, 2008). Simple 
competition between drugs for the access of catalytic pocket of relevant drug metabolising 
enzyme is the most common inhibition mechanism. Another mechanism involves formation 
of catalytically inactive, covalently bond complex between drug substrate and cytochrome 
P450 enzymes (Boden et al, 2007).
Besides the cytochrome P450 enzymes, flavin-containing monooxygenases (FMOs) 
are the second most abundant family of enzymes involved in phase 1 metabolism. FMO is a 
fiavoprotein that contains one molecule of FAD at its core. It is located in the endoplasmic 
reticulum of the cell, and is found in many tissues, with the highest expression in the 
microsomal fi*action of the liver (Krueger and Williams, 2005; Gibson and Skett, 2001). It 
should be noted that while FMOs also constitute a multi-gene family, this is much smaller 
than the cytochrome P450s, with only 5 functional families, each with a single member in 
man (FMOl -  FM05) (Krueger and Williams, 2005; Cashman and Zhang, 2006; Gibson and 
Skett, 2001).
FMO oxygenates nucleophilic nitrogen and sulphur compounds (Krueger and 
Williams, 2005; Cashman, 2005; Gibson and Skett, 2001). The catalytic cycle for 
FMO-mediated reactions is remarkably similar to that of the cytochrome P450s, with both 
utilising the reducing of NADPH to reduce one atom of molecular oxygen to water while the 
other oxygen atom is used to oxidise the substrate (Krueger and Williams, 2005). However, 
FMO can also use NADH as a source of reducing power but NADPH is the preferred 
cofactor (Gibson and Skett, 2001). FMO does not require a reductase to transfer electrons
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from NADPH and the catalytic cycle is different from that of the cytochrome P450s. The 
major difference between the two catalytic cycles is that no real substrate binding takes place 
during FMO catalytic activity. The flavin-hydroperoxide (FAD-OOH), formed from the 
reduction of FAD, followed by reaction with oxygen, reacts with any suitable nucleophilic 
gaining access to the active site without requiring substrate binding. Furthermore, electrons 
are transferred in a single 2-electron step (Krueger and Williams, 2005). It is interesting to 
note that FMOs have overlapping substrate specificities with cytochrome P450s, they often 
yield distinct metabolites (Krueger and Williams, 2005). As noted above, the cytochrome 
P450 family of enzymes is subject to drug-drug interactions, and this is an important 
consideration during polypharmacy. Another distinction between these two families of Phase 
I catalytic enzymes is that FMOs, generally, are not subject to same degree of induction and 
inhibition by xenobiotics compared to cytochrome P450s (Krueger and Williams, 2005; 
Cashman, 2005). As such, FMO-mediated drug-drug interactions are considerably less 
common.
Another important enzyme in phase 1 metabolism is prostaglandin synthetase. It is 
an enzyme located primarily in the endoplasmic reticulum and found in most mammalian 
cells, with greatest levels in respiratory tissues such as the lung. Prostaglandin synthetase 
catalyses the oxidation of archidonic acid to prostaglandin H2 , which is an important 
precursor in the formation of prostaglandins, thromboxanes, and prostacyclins. Prostaglandin 
H2 has two distinct catalytic functions: a fatty acid cyclooxygenase activity that forms 
prostaglandin G2 as an intermediate, and a hydroperoxidase activity that reduces 
prostaglandin G2 to prostaglandin H2 . During the second step, i.e. the reduction of 
prostaglandin G2 to prostaglandin H2 , drugs and xenobiotics can be co-oxidised (Rose and 
Hodgson, 2004; Gibson and Skett, 2001). Paracetamol is an example of drug which 
undergoes this co-oxidation reaction, although it should be noted that cytochrome 
P450-mediated metabolism of paracetamol is the major phase 1 fate (Gibson and Skett, 
2001). Other enzymes responsible for phase 1 metabolism include alcohol dehydrogenase, 
aldehyde dehydrogenase, xanthine oxidase, amine oxidases, aromatases, alkylhydrazine 
oxidase, esterases and amidases, epoxide hydrolase, and molybdenum hydroxylases, which 
catalyse oxidation, reduction, hydrolysis, hydration, and many other reactions (Rose and 
Hodgson, 2004; Gibson and Skett, 2001).
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1.5.2 Phase 2 metabolism
While phase 1 metabolism creates or reveals a reactive centre within substrates, the 
resulting metabolite does not generally possess significantly increased hydrophilicity. 
Products of phase 1 metabolism are usually conjugated with endogenous metabolites in 
phase 2 metabolism. Endogenous metabolites include sugars, sulphate, glutathione, amino 
acids, and fatty acids. The conjugation markedly increases the hydrophilicity of the chemical, 
making it more readily excreted via the bile or urine. Some drugs may be readily cleared 
following phase 1 metabolism only, if this significantly increases their hydrophilicity, or may 
directly enter into phase 2 metabolism if they already possess a suitable reactive centre; 
however, for the majority of drugs metabolism occurs sequentially through phase 1 and 
phase 2 (Rose and Hodgson, 2004; Gibson and Skett, 2001). As noted above, phase 1 
reactions act to increase the reactivity of a chemical (bioactivation), which results in an 
increased potential for toxicity. In contrast, as phase 2 reactions markedly increase the 
clearance of chemical, they are, generally seen as detoxifying. Enzymes that catalyse phase 2 
metabolism are known as “transferases” because they catalyse the transfer of a moiety from a 
donor molecule to the drug recipient (Boden et al, 2007).
Glucuronidation, which is conjugation with sugar, is the most widespread of the 
conjugation reactions (Gibson and Skett, 2001). Drugs and xenobiotics that have hydroxyl 
(-0H), carboxyl (-COOH), amino (-NH2), and sulfydryl (-SH) functional groups can be 
subject to glucuronidation reactions with sugar derivatives, most commonly UDP-glucuronic 
acid (UDPGA) (Rose and Hodgson, 2004; Gibson and Skett, 2001). The enzymes responsible 
for glucuronidation are the UDP-glucuronosyltransferases (UGTs), catalysing the transfer of 
a glucuronic acid moiety from UDPGA to a substrate molecule forming a glucuronide 
(Boden et al, 2007; Rose and Hodgson, 2004; Gibson and Skett, 2001). UGTs are membrane 
bound in the endoplasmic reticulum of many tissues, and have a significant expression level 
in the liver (Rose and Hodgson, 2004; Gibson and Skett, 2001). The UGT enzymes are 
subdivided into two large superfamilies: the UGTl family has nine human isoenzymes, 
while the UGT2 comprises six members (Rose and Hodgson, 2004). UGTs have wide 
substrate specificities, with the majority of drugs (or their metabolites) being substrates for at 
least one UGT. The resulting conjugates may be excreted in the bile or urine, depending upon 
the final size of the metabolite. The conjugates are also subject to enterohepatic recirculation, 
a process where glucuronide conjugates excreted in the intestine are cleaved by 
P-glucuronidase (mainly in the gut flora), reforming the free drug, which may be reabsorbed
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from the intestine, effectively extending the half-life of the drug (Gibson and Skett, 2001). 
Conjugation with glucuronic acid is the most important of sugar conjugation in most species 
but conjugation with UDP-glucose yielding glucosides can also occur, although this is 
generally restricted to insects and plants, being uncommon in mammals. Conjugation can also 
occur with UDP-xylose or UDP-ribose forming xyloside or riboside (Gibson and Skett, 
2001).
Sulphation is another phase 2 conjugation pathway for phenols, alcohols, amines, and 
to a lesser extent thiols (Gibson and Skett, 2001). The conjugate donor is 
3 ’-phosphoadenosine-5 ’-phosphosulphate (PAPS). Inorganic sulphate is relatively inert and 
must first be activated by ATP to PAPS in a two-stage reaction. Conjugation of drugs and 
xenobiotics with PAPS is catalysed by sulphotransferases (SULTs), a family of cytosolic 
enzymes, which produce water-soluble sulphate esters that are often readily eliminated (Rose 
and Hodgson, 2004; Gibson and Skett, 2001). The phenol, alcohol, and arylamine SULTs are 
fairly non-specific and will metabolise a wide range of drugs and xenobiotics, but the steroid 
SULTs tend to exhibit specificity for a single, or limited number, of steroids of a particular 
type (Gibson and Skett, 2001). SULTs are also classified into gene families, similar to the 
cytochrome P450s and UGTs. There are five mammalian SULT families (SULTl -  5) that 
are sub-divided into sub-families, e.g. SULTl has five (A -  E) and SULT2 has two (A, B) 
sub-families (Gibson and Skett, 2001). Sulphation reactions are not as widespread as 
glucuronidation, although there is a good overlap between substrates. In general, sulphate 
conjugation predominates at low substrate concentration, but is succeeded by glucuronidation 
as substrate concentration rises due to the differential kinetics of the two reactions and limited 
bioavailability of PAPS in the cells compared to UDPGA (Gibson and Skett, 2001).
Both glucoronidation and sulphation are categorised as type 1 reactions, meaning that 
they are usually targeted towards substrates with limited chemical reactivity (e.g carboxylic 
acids, esters, etc.), and thus require an activated (high energy conjugate). However, for 
chemical that are highly reactive, it is not necessary to utilise a high energy conjugate, and 
these type 2 reactions utilise low energy conjugates, such as conjugation to the tripeptide 
glutathione. Hence, drugs that are metabolised into highly electrophilic metabolites in phase 1 
metabolism are conjugated with glutathione to form non-toxic conjugates. Compounds that 
are conjugated to glutathione include epoxides, haloalkanes, nitroalkanes, alkenes, and 
aromatic halo- and nitro-compounds. The conjugation is catalysed by the glutathione-*S- 
transferase (GST) family of enzymes, which are ubiquitously expressed in the body, but with
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particularly high expression levels in the liver, kidney and gut (Gibson and Skett, 2001). 
GSTs belong to a large gene family with microsomal (membrane-bound) and cytosolic 
enzymes, thus ensuring that they are correctly localised to rapidly metabolise any reactive 
metabolites regardless of their subcellular localisation. The majority of GSTs are found in the 
cytosol, with members of this group divided into six families, i.e. a (alpha), k  (kappa), 
\i (mu), Tc (pi), a  (sigma), and 0 (theta) (Rose and Hodgson, 2004; Gibson and Skett, 2001). 
Glutathione conjugates may be excreted directly in the urine or bile, but are, generally, 
further metabolised to cysteinyl-sulphur substituted V-acetylcysteines (mercapturic acids). 
This further metabolism involves the removal of glutamate and glycine portions from the 
glutathione conjugate by y-glutamyltranspeptidase and a peptidase, respectively, to yield the 
cysteine conjugate. The cysteine conjugate is then TV-acetylated to form an 7V-acetylcysteine 
conjugate, which is an excretion product (Rose and Hodgson, 2004; Sheweita, 2000; Gibson 
and Skett, 2001).
Another phase 2 conjugation reaction is méthylation. Méthylation predominantly 
metabolises endogenous compound but certain drugs may also be methylated (Gibson and 
Skett, 2001). The enzymes responsible for méthylation are methyltransferases, utilising the 
high-energy conjugate S'-adenosylmethionine (SAM), which is produced from L-methionine 
and ATP reactions by L-methionine adenosyltransferase (Rose and Hodgson, 2004; Gibson 
and Skett, 2001). Unusually, méthylation leads to less polar metabolites than the parent 
compound and hinders excretion of the compound (Gibson and Skett, 2001). However, 
méthylation is generally regarded as a detoxification reaction, while it does not necessarily 
produce more polar metabolites, it does function to terminate biological activity (Rose and 
Hodgson, 2004).
Acétylation reactions are common for aromatic amines and sulphonamides. The 
reaction is not widespread for endogenous compounds, and is undertaken by the 
A-acetyltransferases, located in the cytosol (Rose and Hodgson, 2004). The acétylation donor 
is acetyl-CoA, a major product of glycolysis and p-oxidation, or obtained from direct 
interaction of acetate and coenzyme A (Gibson and Skett, 2001). Similar to méthylation, 
acétylation also produces less polar metabolites than the parent compound, and instead acts to 
terminate pharmacodynamic effects (Erhardt, 2009).
Finally, phase 2 metabolism can also takes place via amino acid and fatty acid 
conjugation. Amino acid conjugation occurs with drugs that contains carboxylic acids and
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fatty acid conjugation occurs with substrates that contain hydroxyl (-0H) functional group 
(Gibson and Skett, 2001). Table 1.4 shows the reactions of phase 2 metabolism and the 
respective enzymes, conjugation donors, and substrates involved.
Table 1.4: Summary of phase 2 metabolism
Reaction Enzyme Conjugation donor Substrate
Glucuronidation UDP-Glucuronosyltransferases
(UGTs)
Glucuronic acid -OH
-COOH
-NH2
-SH
Sulphation Sulphotransferases (SULTs) 3 ’-phosphoadenosine- 
5 ’-phosphosulphate
-NH2
-SO2NH2
-OH
Glutathione
conjugation
Glutathione-5'-transferases
(GSTs)
Glutathione Epoxide 
Organic halide
Méthylation Methyltransferases *S'-adenosylmethionine -OH
-NH2
Acétylation Acetyltransferases Acetyl-CoA -NH2
-SO2NH2
-OH
Amino acid 
conjugation
Glycine, glutamine, 
ornithine, arginine, 
taurine
-COOH
Fatty acid 
conjugation
Stearic and palmitic 
acid
-OH
Adapted from Gibson and Skett (2001).
1.6 Metabolism of TZDs
1.6.1 Metabolism of troglitazone
General vharmacokinetics parameters o f troslitazone
Pharmacokinetic studies reveal that troglitazone is rapidly absorbed with an absolute 
bioavailability of between 40% -  50%; concomitant food intake generally increases 
absorption, and results in a bioavailability of 30% -  80% (Loi et al, 1999b; Physician’s Desk 
Reference, 1999). The steady-state plasma concentration for troglitazone was achieved by 
day 7 of troglitazone administration, with a maximum plasma concentration of 2.0, 3.5, and 
6.4 pM when human subjects are treated with 200, 400, and 600 mg of troglitazone, 
respectively. The time to achieve the maximum plasma concentration was between 2.7 -
2.9 hours (after administration on day 7) (Loi et al, 1999a). The mean plasma elimination 
half-life ranges from 7.6 -  24 hours for a once daily administration (Loi et a l, 1999b). The
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major route of excretion for troglitazone is in the faeces (Kostrubsky et a l, 2000; Coleman, 
2010; Smith, 2003), with approximately 85% of radioactivity recovered in faeces and only 
3% in urine following oral administration of [^"^C]-labelled troglitazone; the plasma 
elimination half-life of [^ "^ C] troglitazone is between 1 6 - 3 4  hours (Physician's Desk 
Reference, 1999). Troglitazone binds strongly to plasma protein with a protein bound fraction 
of 99.9% (Shibukawa et al, 1995). High uptake of troglitazone by the liver is seen in rats and 
mice (Kawai et al, 1997), while in isolated perfused livers and cultured hepatocytes, 
troglitazone is absorbed within minutes (Preininger et al, 1999; Haskins et a l, 2001). In rats, 
the concentration of troglitazone is 10- to 12-fold higher in liver tissues compared to plasma 
(Sahi et al, 2000), but there is no evidence that troglitazone accumulates in human liver in 
the same manner (Yokoi, 2010).
Metabolism o f troglitazone
Troglitazone is metabolised by sulphation, glucuronidation, and oxidation reaction to 
form sulphate conjugate, glucuronide conjugate, and quinone metabolites, respectively (Loi 
et al, 1999b; Physician's Desk Reference, 1999). The predominant metabolic route is 
sulphation, which accounts for approximately 70% of the metabolites detected in human 
plasma (Loi et al, 1999b; Loi et al, 1999a; Physician's Desk Reference, 1999). This 
sulphation is catalysed by SULTl A3 (a phenol sulphotransferase) and to a lesser extent, 
SULT1E4 (an oestrogen sulphotransferase) (Honma et al, 2002; Coleman, 2010; Yokoi,
2010). Troglitazone sulphate undergoes enterohepatic circulation after biliary excretion 
resulting in a long half-life (Yokoi, 2010; Smith, 2003).
The chromane ring in the troglitazone molecule can be oxidised to a quinone 
metabolite (Yokoi, 2010; Smith, 2003), with approximately 10% of these metabolites 
detected in the plasma (Loi et al, 1999b; Loi et al, 1999a; Physician's Desk Reference,
1999). CYP3A4 and CYP2C8 are the major cytochrome P450 enzymes responsible for the 
oxidation of troglitazone to troglitazone quinone, with CYP3A4 having greatest input due to 
its high expression levels in human liver (Yamazaki et al, 1999; He et a l, 2001). The 
quinone metabolite can be further reduced to its diol or hydroquinone form, which are subject 
to further metabolism and excretion as sulphate or glucuronide conjugates (Tettey et al, 
2001). This reductive metabolism is postulated to be catalysed by NAD(P)H:quinone 
oxidoreductase 1 (NQOl) although there is no robust proof of this in the literature (Smith,
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2003). The troglitazone quinone may undergo epoxidation to form a quinone epoxide 
(Yamamoto, 2002). Conjugation with glutathione has also been observed, involving TZD 
ring scission of troglitazone or troglitazone quinone (Kassahun et a l, 2001; Dixit and 
Bharatam, 2011; Madsen et a l, 2008; Smith, 2003; Prabhu et al, 2002; He et a l, 2004).
Troglitazone has been shown to induce CYP3A4 at clinical doses in human and rat 
hepatocytes (Ramachandran et al, 1999; Sahi et al, 2000; Sahi et al, 2003), which suggests 
that troglitazone exposure could induce the formation of the quinone metabolites (Smith, 
2003; Yokoi, 2010; Physician's Desk Reference, 1999). In addition to the inductive effect, 
troglitazone is also a potent inhibitor of certain cytochrome P450s, such as CYP2C8 and 
CYP2C9, and to a certain degree CYP2C19 and CYP3A4 (Sahi et al, 2003; Yamazaki et al,
2000). Nevertheless, troglitazone was reported that it does not inhibit any of the major 
cytochrome P450 enzymes at clinically relevant concentrations (Physician’s Desk Reference, 
1999).
Conjugation of troglitazone to a glucuronide metabolite is considered a minor 
pathway in comparison to troglitazone sulphate and troglitazone quinone formation. 
Troglitazone glucuronide present only in negligible amounts in the plasma (Loi et a l, 1999b; 
Physician’s Desk Reference, 1999). Multiple UGTs are involved in troglitazone 
glucuronidation (Yoshigae et al, 2000). In human intestine, glucuronidation of troglitazone is 
threefold higher than in the liver, with the reaction in the liver mediated by UGTlAl while in 
the intestine, it is mediated by UGT1A8 and UGTIAIO (Watanabe et al, 2002). Troglitazone 
glucuronide is also excreted in the bile and may undergo enterohepatic circulation (Smith, 
2003). Figure 1.6 shows the known metabolic pathways of troglitazone.
Pharmacokinetic studies in healthy and diabetic subjects revealed no difference in 
troglitazone metabolism, suggesting that diabetic patients, in general, are not metabolically 
predisposed to troglitazone toxicity (Kostrubsky et al, 2000; Loi et a l, 1997). However, 
patients with hepatic impairment exhibited higher plasma concentrations of troglitazone, 
troglitazone sulphate, and troglitazone quinone relative to healthy subjects, consistent with 
the known alterations that would occur in an individual with hepatic impairment (Loi et a l, 
1999b; on  et al, 1998).
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Figure 1.6: Metabolism pathways of troglitazone. Troglitazone (TGZ) is metabolised to 
troglitazone sulphate, troglitazone glucuronide, and troglitazone quinone. Troglitazone quinone can 
undergo epoxidation to form troglitazone quinone epoxide or be reduced to troglitazone 
hydroquinone, which is then sulphated or glucuronidated. Troglitazone can also be metabolised to 
reactive metabolites, which are subsequently eliminated by glutathione (GSH) conjugation. 
PST1A3: Phenol sulphotransferase 1A3 (SULTlA3); UGT: UDP-glucuronyltransferase; P450: 
Cytochrome P450; P4503A4: Cytochrome P450 3A4 (CYP3A4); P4502C8: Cytochrome P450 2C8 
(CYP2C8); NQOl: NAD(P)H:quinone oxidoreductase 1. Reproduced from Smith (2003).
Understanding the molecular mechanism of troglitazone toxicity has been 
complicated by the fact that there are species differences in troglitazone metabolism. 
Sulphation and glucuronidation are the major metabolism pathways for troglitazone in rats 
and mice (Kawai et al, 1997; Izumi et a l, 1997). In contrast, in vitro studies using human 
hepatocytes showed that troglitazone was metabolised equally to the sulphate and quinone 
metabolites, while very little glucuronide conjugate was formed (Kostrubsky et a l, 2000). 
Coleman (2010) suggested that animal species such as rats and mice that do not have the 
same high sulphation capacity as humans tend to eliminate drugs as glueuronides (Coleman, 
2010).
31
1.6.2 Metabolism of rosiglitazone
General vharmacokinetics varameters o f rosiglitazone
The absolute bioavailability of rosiglitazone was estimated to be approximately 99% 
after oral tablet dosing (Cox et a l, 2000; Avandia (rosiglitazone) package insert, 2008). 
Unlike troglitazone, administration of rosiglitazone with food does not have a clinically 
significant effect on the overall exposure, meaning that rosiglitazone may be administered 
with or without food (Avandia (rosiglitazone) package insert, 2008). Rosiglitazone is rapidly 
absorbed into the systemic circulation with a maximum plasma concentration of 
approximately 1.7 pM after 0.75 -  1.0 hours for an 8 mg oral tablet dose (Cox et a l, 2000; 
Avandia (rosiglitazone) package insert, 2008). Rosiglitazone is rapidly cleared from the 
plasma, with an elimination half-life of 3 -  4 hours (Cox et al, 2000; Avandia (rosiglitazone) 
package insert, 2008), with quantifiable levels only present up to 24 hours after dosing (Cox 
et a l, 2000). However, patients with hepatie impairment displayed a 2-fold increase of 
maximum plasma concentration of rosiglitazone and the elimination half-life was about 
2 hours longer than healthy subjects (Cox et al, 2000). Oral and intravenous administration 
of [^"^C]-labelled rosiglitazone showed that the radioactivity was excreted primarily via the 
urine (about 64%) and only about 23% was detected in the faeces (Cox et al, 2000), which is 
significantly different fi*om the drug fate observed with troglitazone (Avandia (rosiglitazone) 
package insert, 2008). The plasma half-life of [^ "^ C] rosiglitazone ranged from 103 -  
158 hours and it is approximately 99.8% bound to plasma proteins, primarily albumin 
(Avandia (rosiglitazone) package insert, 2008).
Metabolism o f rosislitazone
Rosiglitazone is extensively metabolised with no unchanged drug excreted in urine 
(Avandia (rosiglitazone) package insert, 2008). The major route of metabolism for 
rosiglitazone is via 7V-demethylation and hydroxylation of the pyridine ring, followed by 
sulphation and glucuronidation (Figure 1.7) (Cox et al, 2000; Baldwin et a l, 1999; Avandia 
(rosiglitazone) package insert, 2008). Hydroxylation is more dominant than A-demethylation 
and the formation of or//zo-hydroxy rosiglitazone was only a minor route in comparison to 
para-hyàvoxy and A-desmethyl rosiglitazone (Baldwin et al, 1999; Cox et a l, 2000). 
Oxidative removal of the pyridinylamino group to yield the phenoxyaeetie acid derivative 
was observed in the rat and dog (Bolton et al, 1996), but is only a minor pathway in humans
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(Cox et al, 2000). Rosiglitazone is the major circulating component at early times (about 
1 hour postdose) but sulphate conjugates of phase 1 metabolites became predominant at later 
times (from 4 hours onwards), indicating that high percentage of the phase 1 metabolites are 
conjugated (Bolton et a l, 1996; Cox et al, 2000). Only uneonjugated metabolites are 
detected in the faeces, suggesting that the conjugated metabolites in bile are hydrolysed by 
intestinal microflora through enterhepatic recirculation (Cox et al, 2000). CYP2C8 is mainly 
responsible for the hydroxylation and A-demethylation of rosiglitazone, while CYP2C9 
contributes as a minor pathway (Baldwin et al, 1999; Avandia (rosiglitazone) package insert,
2008). Figure 1.7 shows the metabolism pathways of rosiglitazone.
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Figure 1.7: Metabolism pathways of rosiglitazone. Rosiglitazone is metabolised predominantly 
via P450-mediated A-demethylation and hydroxylation, followed by conjugation with sulphate or 
glucuronide. The cleavage of the pyridinylamino to give Ml 6 and Ml metabolites are minor routes 
of elimination in humans.
Ml: Phenoxyaeetie acid derivative; M2 and Ml5: A-desmethyl glucuronide; M3: Ortho-0- 
glucuronide; M4: A-desmethyl-/7ara-(9-sulphate; M5: Para-G-glucuronide; M6: A-desmethyl- 
or//zo-0-sulphate; M7: A-desmethyl-/>ara-hydroxy; M8: (9r//zo-0-sulphate; M9: A-desmethyl- 
or^Ao-hydroxy; MIO: Para-(9-glucuronide; Mil: Ortho-hydvoxy, Ml2: Adesmethyl; M13: Para- 
hydroxy; M14: Rosiglitazone; and M16: A-despyridinyl. Reproduced from Cox et al (2000).
There are no reports on the inducibility of CYP2C8 by rosiglitazone. However, 
rosiglitazone does induce CYP3A4 and CYP2B6 at coneentrations of 10 pM and 50 pM, 
respectively (Sahi et al, 2003). Rosiglitazone is an inhibitor of CYP2C8 and to a certain 
degree, CYP2C9, CYP2D6, and CYP3A4 (Sahi et al, 2003; Yamazaki et a l, 2000; Walsky
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et a l, 2005) although the rosiglitazone package information states that it does not inhibit any 
of the major cytochrome P450 enzymes at clinieally relevant concentrations (Avandia 
(rosiglitazone) package insert, 2008).
Besides the common metabolic pathways shown in Figure 1.7, rosiglitazone can also 
produce reactive intermediates that are subsequently conjugated with glutathione (Soglia et 
al, 2004; Alvarez-Sanehez et al, 2006; Uchiyama et al, 2010b). However, unlike 
troglitazone, the formation of reactive intermediates is only detected at high concentrations of 
rosiglitazone (above 100 pM). It is postulated that rosiglitazone undergoes the same 
metabolic activation on the TZD ring as troglitazone, i.e. via TZD ring opening to generate 
a-ketoisocyanate and sulphenic acid intermediates (Alvarez-Sanehez et a l, 2006). A more 
recent study using freshly isolated human, rat, and monkey hepatocytes proposed that 
rosiglitazone can also be metabolised via (1) A-glucuronidation on the TZD ring, followed by 
hydrolysis, which opens the TZD ring and is methylated in the presence of SAM to form 
TZD ring-opened methylmereapto carboxylic acid or (2) the sequential TZD ring opening 
will ultimately lead to méthylation of the mercapto group of the TZD ring-opened mercapto 
amide, forming TZD ring-opened methylmereapto amide (Uchiyama et a l, 2010b).
1.6.3 Metabolism of pioglitazone
General pharmacokinetics varameters o f vioslitazone
Pioglitazone is rapidly absorbed with an absolute bioavailability of 83% and, like 
rosiglitazone absorption is not influenced by food intake. The maximum plasma 
concentration of unchanged pioglitazone was reported to be 2.6 pM (Jaakkola et a l, 2006a) 
and achieved 1.5 hours after administration, with the steady-state achieved after 4 - 7  days of 
dosing (Eckland and Danhof, 2000; Actos (pioglitazone) package insert, 2009). Pioglitazone 
and its metabolites are also extensively bound to plasma protein (approximately 98%), 
primarily to albumin (Eckland and Danhof, 2000; Actos (pioglitazone) package insert, 2009). 
The mean plasma elimination half-life for pioglitazone and its total active metabolites is 5 -  
6 hours and 1 6 - 2 3  hours, respectively (Actos (pioglitazone) package insert, 2009). 
Pioglitazone is excreted by two routes following oral administration, with 55% and 45% 
recovery of radiolabelled pioglitazone in the faeces and urine, respectively (Actos 
(pioglitazone) package insert, 2009). The pharmacokinetics of pioglitazone is not affected by 
age, gender, and race and does not differ between healthy volunteers or type 2 diabetics
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(Eckland and Danhof, 2000; Budde et al, 2003; Actos (pioglitazone) package insert, 2009). 
In contrast to both troglitazone and rosiglitazone, the total plasma concentration of 
pioglitazone is not different between healthy individuals and those with hepatie impairment; 
however, there is an increased volume of distribution and therefore reduced intrinsic 
clearance, coupled with a higher unbound fraction of pioglitazone (Actos (pioglitazone) 
package insert, 2009).
Metabolism ofpioslitazone
Pioglitazone undergoes extensive hepatic metabolism via hydroxylation of the 
aliphatic methylene groups, followed by sulphation, glucuronidation, and unusually, taurine 
conjugation (Alvarez-Sanehez et al, 2006; Actos (pioglitazone) package insert, 2009). Six 
metabolites of pioglitazone have been identified in humans (M-I -  M-VI), of which three 
metabolites are pharmacologically active (M-II, M-III, and M-IV) (Figure 1.8) (Jaakkola,
2007). Metabolite M-III is equipotent with the parent compound, while metabolite M-IV is 
approximately three-fold more potent than pioglitazone, metabolite M-II minimally active 
(Actos (pioglitazone) package insert, 2009). Another metabolite designated as metabolite 
M-XI (dihydroxypioglitazone) was detected in human urine and was postulated to be 
generated through further rounds of hydroxylation of M-II or M-IV, although this has not 
been clearly demonstrated (Figure 1.8) (Jaakkola et al, 2006a). Four other metabolites of 
pioglitazone were identified in in vitro and animal studies (M-VII -  M-X) (Shen et al, 2003), 
but are minor metabolites formed in low concentrations (Jaakkola, 2007).
CYP2C8 and CYP3A4 are the main cytochrome P450 enzymes catalysing the 
metabolism of pioglitazone (Scheen, 2007), with CYP2C8 being the predominant enzyme 
(Jaakkola et al, 2006b; Actos (pioglitazone) package insert, 2009). In vitro studies have 
shown that CYP3A4 and CYP2B6 are induced by pioglitazone at 10 pM and 50 pM 
concentrations, respectively (Sahi et al, 2003), while CYP2C8, CYP2C9, and CYP3A4 are 
also subject to inhibition as well (Sahi et al, 2003; Yamazaki et al, 2000; Walsky et al, 
2005).
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Figure 1.8: Metabolism pathways of pioglitazone. Pioglitazone is metabolised in humans by 
hydroxylation and oxidation to five primary metabolites (M-I, M-II, M-IV, M-V, and M-VI) and a 
fiirther oxidation of metabolite M-IV produces metabolite M-III. Metabolite M-II, M-III, and M-IV 
are pharmacologically active in animal models. Metabolite M-XI is a dihydroxypioglitazone found 
in human urine from the hydroxylation of M-II and M-IV. Metabolite M-VII -  M-X are minor 
metabolites of pioglitazone identified in vitro and in animal studies. Adapted from Jaakkola (2007).
Pioglitazone is also capable of generating reactive metabolites, which are then 
conjugated with glutathione (Baughman et al, 2005; Alvarez-Sanehez et al, 2006; Soglia et 
al, 2004). This bioactivation pathway involves TZD ring cleavage, forming sulphenic acid 
and a-ketoisocyanate (Alvarez-Sanehez et al, 2006; Baughman et al, 2005; Uchiyama et al, 
2010a). An A-glucuronidation of the TZD ring of pioglitazone followed by sequential 
ring-opening pathway has also been reported in the metabolism of pioglitazone (Uchiyama et 
al, 2010a).
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1.7 Troglitazone hepatotoxicity
Troglitazone represents a model compound for the study of idiosyncratic 
hepatotoxicity. Idiosyncratic toxicity is a term applied towards drug toxicity that occurs at 
low frequency and is often unpredictable on the basis of dose or time of exposure (Peters, 
2005). In general, an adverse effect level of less than one in every 5,000 patients taking a 
particular drug (0.02%) is observed with idiosyncratic toxins, meaning they are unlikely to be 
detected in clinical trials (Li, 2002). The adverse reactions are not related to the known 
pharmacological properties of the drug and are undetected during preclinieal testing or 
clinical trials. Due to these properties, idiosyncratic toxins are often only detected after the 
drug has gained broad exposure in a large population of patients (i.e. post-marketing), and 
usually leads to recall from the market, such as in the case of troglitazone (Ulrich, 2007).
Troglitazone was launched in 1997 and within a year there were reports of acute liver 
failure associated with the drug (Watkins, 2005). Troglitazone was withdrawn from the U.K. 
market in late 1997, i.e. only a few weeks after its launch, followed by abandonment of the 
overall approval process and all clinical trials in Europe. In the U.S. and Japan, a series of 
labelling changes were first introduced, recommending the close monitoring of liver enzyme 
levels and signs of clinical liver dysfunction (Scheen, 2001). However, these were 
determined to provide insufficient safety and troglitazone was withdrawn from the U.S.A. 
and Japan markets in March 2000 (Scheen, 2001; Yokoi, 2010). At that point, 61 reports of 
fatal hepatotoxicity associated with troglitazone and 7 cases requiring liver transplantation 
had been reported in the U.S.A. while in Japan 153 cases of severe hepatitis and 8 deaths 
were reported (Scheen, 2001).
The “signature” of troglitazone hepatotoxicity was that classical liver chemistries 
remained normal during the first few weeks or months of treatment, with that liver injury 
being subsequently indicated by elevation of serum alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) levels. Rising serum bilirubin occurred after these 
transaminase elevations, with jaundice typically appearing weeks after the onset of 
transaminase elevations. Elevation in serum alkaline phosphatase (ALP) was generally mild 
or negligible, and only evidences as a relatively late phenomenon. Such a continuous rise of 
serum bilirubin and fall of serum aminotransferases is a typical indicator for acute liver 
failure due to hepatocellular injury and reflects the loss of viable liver tissue (Watkins, 2005).
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In contrast, neither rosiglitazone nor pioglitazone, which were introduced in 1999, 
exhibited the hepatotoxic effects of troglitazone, or at least the association was very rare 
(Scheen, 2001; Nagasaka et al, 2002; Yokoi, 2010). The recommended dose for troglitazone, 
rosiglitazone, and pioglitazone was 200 -  600 mg/day, 4 - 8  mg/day, and 1 5 - 4 5  mg/day, 
respectively (Physician's Desk Reference, 1999; Avandia (rosiglitazone) package insert, 
2008; Actos (pioglitazone) package insert, 2009), and is reflective of their relative affinity for 
PPARy (Parker, 2002). The higher dosage required for therapeutic efficacy of troglitazone 
could attribute towards the hepatotoxic potential, but numerous toxicological tests, both in 
vivo and in vitro, have failed to conclusively demonstrate a direct mechanism of toxicity 
(Yokoi, 2010). This is perhaps not surprising given that idiosyncratic toxicity is perhaps one 
of the least understood issues in drug safety. It is driven by a mixture of factors that are both 
drug-related and also unique to the patient. Drug-related risk factors include metabolism, 
bioactivation, covalent binding, and inhibition of key cell functions, while patient-related risk 
factors include disease, age, gender, eo-medication, nutritional status, activation of innate 
immune system, physical activity, and genetic predisposition (Ulrich, 2007). Many factors 
contributing to the idiosyncratic hepatotoxicity of troglitazone have been proposed in an 
attempt to understand the mechanism of toxicity, but there is no direct evidence indicating a 
precise mechanism of toxicity (Yokoi, 2010). Some of the proposed mechanisms include 
formation of reactive metabolites, oxidative stress, mitochondrial dysfunction, and inhibition 
of bile salt transporters leading to cholestasis (Yokoi, 2010; Masubuchi, 2006; Smith, 2003; 
Chojkier, 2005).
1.7.1 Formation of reactive metabolites by troglitazone
To understand why troglitazone demonstrates idiosyncratic toxicity, whereas its sister 
chemicals rosiglitazone and pioglitazone do not, one approach is to examine the differences 
in molecular structure. A unique feature of troglitazone compared to other TZDs is the 
chromane ring of the vitamin E moiety. This structure provides antioxidant activity, with the 
desired effect of preventing diabetic vascular complications (Inoue et a l, 1997). However, 
the chromane structure has the potential to undergo oxidation reactions, leading to the 
potential formation of quinone metabolites that can be further metabolised to troglitazone 
epoxide (Yamamoto et al, 2002) or troglitazone o-quinone methide (Dixit and Bharatam, 
2011; Kassahun et al, 2001; Madsen et al, 2008), which are potent electrophiles (Yokoi, 
2010; Smith, 2003). Electrophilic intermediates are toxicologically active because they can
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interact with intracellular macromolcculcs and nucleophiles, giving rise to toxicity and 
carcinogenesis (Sheweita, 2000). Furthermore, the TZD ring of troglitazone and troglitazone 
quinone can also undergo oxidative metabolism, generating highly eleetrophilie 
a-ketoisocyanate and sulphenic acid intermediates (Kassahun et al, 2001; Alvarez-Sanchez 
et al, 2006; Walgren et a l, 2005; Smith, 2003). The oxidation of the chromane ring to form 
reactive epoxide and o-quinone methide, and also the scission of the TZD ring is catalysed by 
CYP3A4 (Yamazaki et a l, 1999; He et al, 2001; Kassahun et a l, 2001). Because 
troglitazone is both the substrate and inducer of CYP3A4 (Ramaehandran et al, 1999; Sahi et 
al, 2000; Sahi et al, 2003), troglitazone has the potential to increase the production of its 
own reactive metabolites.
Although the formation of reactive metabolites from troglitazone had been 
demonstrated by many studies (Madsen et al, 2008; He et al, 2004; Kassahun et a l, 2001; 
Alvarez-Sanchez et al, 2006; He et al, 2001; Yamazaki et al, 1999; Dixit and Bharatam,
2011), the role of these reactive metabolites in troglitazone toxicity is still controversial 
(Smith, 2003; Yokoi, 2010). Primary cultures of rat hepatocytes, which are considered to 
have active drug-metabolising enzymes, appear to be less sensitive to troglitazone toxicity 
than HepG2 cells that express lower cytochrome P450 enzyme levels (Tettey et a l, 2001). 
Moreover, there is no specific correlation of phase 1 (CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, 
3 A4) and phase 2 (phenol SULT and UGT) metabolising enzyme levels with troglitazone 
cytotoxicity in human hepatocytes (Hewitt et al, 2002). However, in the same study, a 
negative correlation was observed between troglitazone cytotoxicity and the sum of CYP3A4 
and UGT activities relative to phenol SULT activities, which led to the hypothesis that 
troglitazone and troglitazone sulphate are the direct toxicants of troglitazone, whereas 
oxidation via CYP3A4 and glucuronidation are part of the detoxification pathway (Hewitt et 
al, 2002). Porcine hepatocytes, which are deficient in troglitazone sulphation capability, are 
more resistant to troglitazone toxicity than human hepatocytes, and the decreased toxicity has 
been suggested to be due to the compensation of sulphation with glucuronidation (Kostrubsky 
et al, 2000). However, in the same study, when human hepatocytes were exposed to a 
combination of troglitazone and inhibitors of sulphation (2,4-dichloro-4-nitrophenol, DCNP, 
or pentachlorophenol, PCP), the cytotoxicity was not attenuated. Formation of troglitazone 
sulphate was reduced by 90%, but there was no effect on the formation of the quinone 
metabolite, and a 4-fold increase of unmetabolised troglitazone was observed; thus, it was 
suggested that troglitazone-induced cytotoxicity resulted from an increased exposure to the
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parent drug (Kostrubsky et al, 2000). Exposure of HepG2 cells and rat hepatocytes to 
troglitazone sulphate did not produce any significant cytotoxic effect (Yamamoto et a l, 2001; 
Haskins et a l, 2001). Similarly, exposure of HepG2 cells to troglitazone glucuronide did not 
show any cytotoxic effect (Yamamoto et a l, 2001). Although the exposure to troglitazone 
quinone demonstrated a slight reduction in the viability of HepG2 and rat hepatocytes, but it 
was less cytotoxic than troglitazone (Yamamoto et al, 2001; Yamamoto et a l, 2002; Haskins 
et al, 2001; Tettey et a l, 2001). AU these findings support the idea that troglitazone is more 
cytotoxic than its three main metabolites (troglitazone sulphate, troglitazone quinone, and 
troglitazone glucuronide), but do not directly support any specific mechanism of toxicity. 
This may suggest that alternative (potentially minor) metabolic pathways may be responsible 
for the toxicity of troglitazone.
In agreement with this, the use of chemical inhibitors of the major drug metabolising 
enzymes responsible for metabolism of troglitazone, such as ketoconazole (an inhibitor of 
CYP3A4), quercetin (an inhibitor of CYP2C8), and SKF-525A (a non-selective cytochrome 
P450 inhibitor) did not protect HepG2 cells against troglitazone-induced cell death, which 
suggests that metabolism by cytochrome P450 is not required for troglitazone toxicity 
(Yamamoto et al, 2001; Tirmenstein et al, 2002). However, the strength of this finding 
should be tempered by the fact that the HepG2 cell line contains low levels of drug 
metabolising enzymes in general and, hence, the cytotoxicity data requires careful 
interpretation to avoid misleading conclusions (Yokoi, 2010). In contrast, when HepG2 cells 
were incubated with microsomes containing cDNA-expressed CYP3A4, or HepG2 cells were 
transfected with CYP3A4, co-incubation with CYP3A4 inhibitor, ketoconazole, protected the 
cells against troglitazone toxicity, suggesting that increased toxicity is mediated by CYP3A4- 
dependent formation of reactive metabolites (Vignati et al, 2005). The apparent disparity in 
metabolism-dependent toxicity data was addressed by Masubuchi (2006), who suggested that 
there might be some cytotoxic metabolites generated by CYP3A4 but not those derived from 
troglitazone quinone, and the contribution of these metabolites to the overall toxicity is 
relatively low because they would not generate and accumulate in the cells enough to exert 
their toxic effects.
Besides the formation of reactive intermediates via the chromane ring, troglitazone 
can also generate reactive metabolites via reactions through its TZD ring. However, if 
activation of the TZD ring was the cause of troglitazone hepatotoxicity, then rosiglitazone 
and pioglitazone would be expected to be similarly hepatotoxie since both drugs contain the
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same TZD ring (Table 1.1). Interestingly, the incidenee of rosiglitazone and pioglitazone- 
associated hepatotoxicity is rare (Scheen, 2001; Nagasaka et a l, 2002; Yokoi, 2010), even 
though the potential for these compounds to generate reactive metabolites has been 
demonstrated (Alvarez-Sanchez et al, 2006; Uchiyama et al, 2010b; Uchiyama et al, 2010a; 
Baughman et al, 2005; Soglia et al, 2004). One potential explanation could be the lower 
clinical dosage recommended for rosiglitazone (15 -  45 mg/day) or pioglitazone (4 -  
8 mg/kg) in comparison to troglitazone (200 -  600 mg/kg) (Physician's Desk Reference, 
1999; Avandia (rosiglitazone) package insert, 2008; Actos (pioglitazone) package insert,
2009). Additional support for the lack of association between TZD ring scission and the 
hepatotoxie potential of troglitazone was provided by Alvarez-Sanchez et al (2006). They 
observed that the predominant glutathione adduct of troglitazone in rat and human liver 
microsomes contained all the positions of the TZD moiety, while there were less glutathione 
adducts derived from TZD ring scission. Smith (2003) suggests that bioactivation of 
troglitazone may play a role in troglitazone hepatotoxicity, but it cannot be the primary 
mechanism of troglitazone toxicity.
1.7.2 Oxidative stress and troglitazone toxicity
There is little information available about enzymatic detoxification of the reactive 
metabolites generated from troglitazone (Yokoi, 2010; Masubuchi, 2006). It has been 
speculated that these reactive metabolites will form covalent adducts to hepatic proteins, 
which would be deleterious to the liver (Kassahun et al, 2001). Quinone metabolites are also 
known to undergo redox cycling with molecular oxygen to produce superoxide radicals, 
which subsequently leads to oxidative stress, and this represent another potential mechanism 
of toxicity (Yokoi, 2010).
Troglitazone has been shown to induce membrane peroxidation, and decrease reduced 
glutathione (GSH) content in the Novikoff rat hepatoma cell line (NISI); similar effects were 
also observed with troglitazone quinone (although at a higher concentration), but not with 
rosiglitazone or thiazolidinedione-phenoxyaeetie acid. This suggests that the chromane ring is 
responsible for inducing oxidative stress since rosiglitazone does not have a chromane ring 
and thiazolidinedione-phenoxyacetic acid is the product of hydroxylation of the pyridinyl 
ring of rosiglitazone (Narayanan et al, 2003). In the same study, troglitazone also increased 
intracellular superoxide anion (O2 ) levels, and this process was inhibited by the addition of 
superoxide dismutase (SOD) mimetic scavenger, Mn(III)tetrakis(4-benzoic acid-)porphyric
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choloride (MnTBAP). The generation of superoxide anion by troglitazone quinone was 
minimal (Narayanan et a l, 2003). In another study using the THLE-2 cell line (a normal 
human hepatocyte), troglitazone sulphate was demonstrated to deplete more GSH than 
troglitazone, suggesting that troglitazone sulphate produces greater oxidative stress than 
troglitazone (Saha et a l, 2010). A higher protein carbonyl content was also detected in 
THLE-2 cells ineubated with troglitazone sulphate, supportive of the hypothesis that this 
metabolite generates greater oxidation of cellular proteins than the parent drug (Saha et al,
2010). It can be concluded from all these findings that there is likely to be an occurrence of 
oxidative stress following troglitazone exposure, although whether it is a direct or indirect 
action of troglitazone is not clear at present.
A study in rats treated with troglitazone demonstrated that induction of hepatic 
CYP3As by dexamethasone (DEX) not only increased the concentration of troglitazone 
quinone but also resulted in a 2 -  5-fold increase of glutathione conjugates (Tettey et al,
2001). Administraton of troglitazone quinone after pre-treatment with DEX also generated 
troglitazone-glutathione thioester, glutathione adduct of troglitazone quinone hydroquinone, 
and troglitazone quinol glucuronide, which suggests that the conjugate formation via 
glutathione represents a deactivation process of troglitazone and troglitazone quinone (Tettey 
et al, 2001). The proposed bioactivation and bioinactivation of troglitazone and troglitazone 
quinone is shown in Figure 1.9.
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Figure 1.9: Pathways of bioactivation and bioinactivation of troglitazone and troglitazone 
quinone proposed by Tettey et al (2001). Bioactivation of troglitazone and troglitazone quinone 
to reactive metabolites is bioinactivated by glutathione conjugation. Troglitazone and troglitazone 
quinone can also be directly inactivated by sulphation and glucuronidation.
The depletion of GSH has been thought to be an important factor in troglitazone 
toxicity. Studies using human hepatocytes detected that troglitazone was biotransformed to 
two glutathione conjugates in addition to the main metabolites, glucuronide and sulphate 
conjugates. The interesting finding is that the formation of troglitazone glutathione 
conjugates and glueuronides was significantly lower in hepatocytes from troglitazone-toxicity
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sensitive donors. These findings suggest that inter-individual metabolic variability may play 
an important role in the susceptibility towards troglitazone hepatotoxicity, and the inability to 
form glutathione conjugates may be linked to troglitazone toxicity (Prabhu et al, 2002). 
Furthermore, genetic polymorphic analysis found that there was strong correlation between 
elevation of transaminase (ALT and AST) and glutathione ^transferase theta 1 (GSTTl) and 
glutathione ^'-transferase mu 1 (GSTMl) null genotypes, indicating that the double null 
mutation of GSTTl and GSTMl might cause one to be more susceptible to a troglitazone- 
associated abnormal increase of liver enzymes (Watanabe et al, 2003). The double null 
genotype GSTTl and GSTMl are a general risk factor for drug-induced liver injury, 
regardless of the type of drug involved (Lucena et al, 2008). Therefore, individuals with 
double null genotype of GSTTl and GSTMl have lower glutathione conjugation capacity, 
suggesting that troglitazone-induced hepatotoxicity resides in the decreased process of 
scavenging the chemically reactive metabolites and not in the process of producing the 
reactive metabolites (Ikeda, 2011).
1.7.3 Mitochondria-mediated toxicity of troglitazone
The potential mechanism of action for toxicity of troglitazone has often been 
suggested as mitochondrial dysfunction. In cells treated with troglitazone, a decrease in cell 
viability as measured by the MTT assay, which measures mitochondrial enzyme function, 
and decreased ATP content were observed (Tirmenstein et al, 2002; Haskins et a l, 2001; 
Tettey et al, 2001; Rachek et al, 2009; Lloyd et a l, 2002). This reveals that troglitazone 
induces certain degree of mitochondria injury, however such studies do not demonstrate if 
these effects are causative or consequential of troglitazone-induced cell death. Studies on the 
effects that troglitazone has on mitochondria showed that troglitazone decreased 
mitochondrial membrane potential and altered mitochondrial morphology preceding HepG2 
cell death (Tirmenstein et al, 2002). When HepG2 cells were incubated with the 
mitochondrial permeability transition inhibitor, cyclosporine A, the cells were protected from 
troglitazone-induced cell death, suggesting that troglitazone toxicity may involve disruption 
of mitochondrial function, leading to mitochondrial permeability transition and cell death 
(Tirmenstein et al, 2002). Other studies also support this hypothesis: Haskin et al (2001) 
observed that the disruption of mitochondrial activity was followed by increase membrane 
permeability, calcium influx, and nuclear condensation in human and rat hepatocytes treated 
with troglitazone, and that there was a subsequent leakage of hepatic enzymes, reduced
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reductive metabolism, and depletion of ATP; Bova et al (2005) observed that the pattern of 
troglitazone-induced cytotoxicity involved a rapid loss of mitochondrial membrane potential 
prior to the changes in cell permeability and cell count. Increased intracellular calcium was 
also detected subsequent to the drop of mitochondrial membrane potential, and this could be 
blocked by ethylene glycol tetraacetic acid (EGTA) or inhibitors of the NaVCa^^ exchanger 
such as bepridil (Bova et a l, 2005). Investigations using the liver mitochondrial fraction 
isolated from male CD-I mice showed that troglitazone induced mitochondrial swelling (an 
indicator of mitochondrial permeability transition) could be partially inhibited by 
cyclosporine A, leading to decreased mitochondrial membrane potential and mitochondrial 
calcium accumulation, demonstrating that troglitazone induces opening of the membrane 
permeability transition pore. All these findings are supportive of an action of troglitazone in 
causing mitochondrial dysfunction.
The main function of mitochondria is to produce energy for the cells in the form of 
ATP, as described in Section 1.1, ATP generation is coupled to the transfer of electrons to 
oxygen by the electron transport system, which is located on the inner membrane of 
mitochondria. The inner membrane is highly impermeable and specific protein carriers are 
required to translocate molecules across it, while the outer membrane is freely permeable to a 
wide range of substrates and metabolites. In the matrix, where the TCA cycle takes place, 
electrons are sequentially removed and these reducing equivalents (NADH and FADH2) 
cascade down the electron transport system consisting of four redox active respiratory 
complexes. The energy released during this process pumps protons across the inner 
membrane into the intramembrane compartment, resulting in an inside-out negative 
membrane potential that is used to phosphorylate ADP to ATP. When cells are exposed to 
excessive calcium loading or reactive oxygen species (ROS), mitoehondria can undergo an 
irreversible collapse of membrane potential and the opening of membrane permeability 
transition pore. This leads to the rupture of the outer membrane and the release of cytoehrome 
c into the cytosol. Cytochrome c is a component of the electron transport chain that is loosely 
associated with the inner membrane and its release is assoeiated with the activation of 
caspases, leading to cell death via apoptosis (Boelsterli and Lim, 2007; Dykens and Will, 
2007; Labbe et al, 2008). Treatment of HepG2 with troglitazone has been reported to 
increase caspase 3 activity and apoptosis, and this was blocked by pre-treatment of the cells 
with the caspase inhibitor Z-Vad FMK (Bova et a l, 2005).
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Dissipating mitochondrial membrane potential and inducing mitochondrial 
permeability transition are not the only way to inhibit mitochondrial function: Impairment of 
mitochondrial function can also occur through mechanisms such as depletion of hepatic 
mitochondrial DNA (mtDNA); direct impairment of mitochondrial respiratory chain; and 
generation of superoxide anion or other reactive oxygen species (ROS) (Labbe et al, 2008). 
Mitochondria contain their own DNA with the ability to replicate and express their genome, 
preventing mitochondrial replication will gradually reduce mitochondrial function (Dykens 
and Will, 2007). Damage of mtDNA has been suggested as the prime initiator of troglitazone- 
induced hepatocyte cell death (Rachek et al, 2009). Following the observation that 
troglitazone induced caspase-3 cleavage, cytochrome c release, and apoptosis in primary 
human hepatocytes, Rachek and colleagues targeted a DNA repair protein to mitochondria by 
protein transduction using a fusion protein containing the DNA repair enzyme Endonuclease 
III (EndoIII) from Escherichia coli, a mitochondrial translocation sequence (MTS), and the 
protein transduction domain (PTD) from HIV-1 TAT protein; this construct was able to 
proteet hepatocytes against troglitazone-induced toxicity, adding weight to previous in vitro 
observations on troglitazone-mediated apoptosis (Rachek et al, 2009).
Direet inhibition of the electron transport chain or uncoupling of electron transport 
from ATP synthesis by a number of toxins has been shown to dissipate mitochondrial 
membrane potential and diminish ATP production (Dykens and Will, 2007). This includes 
troglitazone, which has been shown to be a potent inhibitor of oxidative phosphorylation 
Complexes II + III, IV, and V (Nadanaciva et al, 2007). Furthermore, free radicals can 
directly inactivate several of the electron transport complexes (Dykens and Will, 2007), and 
as previously detailed, troglitazone has been shown to generate free radicals in vitro. In 
normal circumstance, the mitochondrial respiratory chain has several sites, most probably in 
complexes I and III, where eleetrons can generate a small amounts of superoxide anion 
radical by direct reaction with oxygen.
OUMS-29, a polarised human hepatocyte cell line, showed significant production of 
hydrogen peroxide when treated with troglitazone, and this was attenuated using V-aeetyl-L- 
cysteine, an antioxidant (Shishido et al, 2003). Besides the high oxidant level, treatment with 
troglitazone also caused a signifieant increase in the mitochondrial volume due to 
intramitochondrial electron-dense deposits that looked like myelin-like structures, an 
indieation of degraded membrane constituents. The mitoehondrial membrane potential per 
unit mitochondrial volume also declined without clear cell death, indicating that the
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overproduction of hydrogen peroxide deteriorates both the mitochondrial membrane structure 
and function, leading to a possible initiation of severe hepatoeyte toxicity (Shishido et al, 
2003). Narayanan et al (2003) showed that the generation of superoxide in NISI eells 
treated with troglitazone was markedly suppressed with cyclosporine A, a mitochondrial 
permeability transition inhibitor, suggesting that the troglitazone-induced superoxide 
generation may be mediated by mitochondrial membrane permeability. In addition, studies 
using heterozygous superoxide dismutase 2 (S0D2^ ') mice, a model partially deficient in 
S0D2, troglitazone increased ALT activity and caused mid-zonal hepatic necrosis and in 
isolated hepatie mitoehondrial, there were decreased activities of aeonitase, complex I of the 
mitoehondrial electron transport chain and increased protein carbonyl content, which are 
indicative of mitochondrial oxidant stress but there was no measurable mitochondrial 
dysfunction, oxidative stress, or liver injury observed in wild-type animals treated with 
troglitazone. The cultured hepatocytes from S0D2^ " animals also generated more superoxide 
in mitochondrial in response to in vitro troglitazone exposure. These observations correlate 
mitochondrial oxidant stress and partial loss of mitochondrial function with troglitazone- 
induced hepatotoxicity (Ong et al, 2007).
1.7.4 Inhibition of bile salt export pump (BSEP) leading to cholestasis
Another proposed mechanism of troglitazone toxicity is the inhibition of the bile salt 
export pump (BSEP), either by troglitazone directly or its metabolite troglitazone sulphate, 
ultimately leading to cholestasis (Smith, 2003; Masubuchi, 2006; Yokoi, 2010; Chojkier, 
2005). Formation of bile salts is essential for the excretion of eholesterol, both as a metabolic 
product and solubiliser of cholesterol (Champe et al, 2008). Bile consists of a watery mixture 
of phosphatidylcholine and bile salts. Bile acids are synthesised in the liver and they are 
conjugated with either glycine or taurine to produce bile salts before leaving the liver 
(Champe et al, 2008). Retention of bile aeids or bile salts in the hepatocytes may be toxic 
due to their detergent properties (Kubitz et al, 2012), with bile salts being more effective 
detergents than bile acids because of their enhanced amphipathic nature (Champe et al,
2008). Therefore, an effective transport system is required in the liver to ensure efficient 
excretion of bile salts. BSEP (encoded by the ABCBll gene) is the major protein that is 
responsible for the excretion of bile salts from hepatocytes, and is located at the canalicular 
(apical) membrane of hepatocytes (Kubitz et al, 2012; Smith, 2003). Others transporters 
involved in bile salts transport are the sodium-taurocholate cotransporting polypeptide
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(NTCP), organic anion transporting polypeptides (OATPs), organic solute transporters 
OSTa/OSTp, and the multidrug resistance associated protein 4 (MRP4). NTCP and OATPs 
mediate the uptake of bile salts from blood into hepatocytes while OSTa/OSTp and MRP4 
secrete bile salts from hepatocytes back into blood (Kubitz et al, 2012).
Troglitazone was demonstrated to affect hepatic bile secretion in isolated perfused rat 
liver. Addition of 3.15 pM of troglitazone rapidly decreased the secretion of bile by 
approximately two-thirds within 1 hour (Preininger et al, 1999). In isolated eanalicular rat 
liver plasma membrane preparations, troglitazone and troglitazone sulphate inhibited the 
ATP-dependent taurocholate transport mediated by BSEP, with the inhibition by troglitazone 
sulphate being 10-fold more potent than observed with troglitazone (IC50 values of 0.4 and
3.9 pM, respectively) (Funk et al, 2001a; Funk et al, 2001b). Furthermore, considering the 
readily achievable concentration of troglitazone in plasma of humans treated with 
troglitazone (maximum plasma coneentration of 2.0 -  6.5 pM) (Loi et a l, 1999a) and high 
aecumulation of troglitazone sulphate observed in rat liver tissue (Funk et al, 2001a; Funk et 
al, 2001b), the concentrations of these compounds required to significantly inhibit BSEP are 
most likely achievable in hepatocytes in vivo.
High intracellular bile salts can induce cell death through mitoehondrial dysfunction 
and apoptosis, a mechanism that is observed in troglitazone-mediated cell death, as 
previously described (Masubuehi, 2006; Jaeschke et al, 2002; Smith, 2003). An example of 
how multiple factors may help initiate toxicity is provided by the fact that, as BSEP-mediated 
excretion of bile salts is dependent on ATP, impaired ability of mitoehondrial to generate 
ATP will further disturb the functioning of BSEP (Masubuchi, 2006). Furthermore, 
mitochondria mediate death receptor signalling, and mitochondrial dysfunction can thus 
initiate apoptosis and contribute to oxidative damage (Arduini et al, 2012). Nevertheless, 
apoptosis involving Fas receptors appears to be the predominant pathway. Fas receptor is a 
death reeeptor expressed on the surface of cells leading to programmed cell death. Bile salts 
promote the translocation of cytoplasmic Fas to the plasma membrane where these receptors 
self-aggravate and trigger apoptosis (Masubuchi, 2006; Jaeschke et a l, 2002). Therefore, 
accumulation of bile salts from impaired BSEP will lead to cell death via apoptosis.
In summary, the troglitazone-associated hepatotoxicity involves multiple mechanisms 
that may not be driven by exclusively one mechanism but are interrelated. The genetic
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predisposition of an individual may also cause one to be more susceptible to the toxicity of 
troglitazone.
1.8 Metabolomics
1.8.1 Introduction to metabolomics
The word “metabolomics” was coined in 1998 and it refers to the study of the entire 
set of small molecules in a biological sample (Baker, 2011). The phrase “small molecules” 
denotes metabolites with chemical structures that are less than 1,000 Da in molecular mass, 
with the entire set of small molecules being known as metabolome (Roux et a/., 2011; Khoo 
and Al-Rubeai, 2007). Metabolites function as substrates and products in biochemical 
pathways and the analysis of these metabolites offers the closest measurement of a cell’s 
physiological activity (Khoo and Al-Rubeai, 2007).
Metabolomics belongs to the “omics” technique, together with genomics, 
transcriptomics, and proteomics, which are related to the analysis of the genome (DNA), 
transcriptome (RNA), and proteome (proteins), respeetively (Figure 1.10) (Roux et al, 2011). 
The ultimate goal of these techniques is to understand the biological system from the genetic 
blueprint right down to the metabolome and how the levels of “omes” relate to each other 
(Cubbon et al, 2010).
The term metabolomies and metabonomics are sometimes used interchangeably, but 
there are significant differences between them. Metabolomics refers to the measurement of 
the pool of cell metabolites whereas metabonomics describes the quantitative measurement of 
the dynamie multiparametric metabolic response of living systems to a pathophysological 
stimuli or genetic modification (Roux et al, 2011). Tang and Wang (2006) described the 
main difference between metabolomics and metabonomics as being that metabolomies is 
concerned with a “snap-shot” of the cellular metabolome at a given time whereas 
metabonomics looks at the dynamic changes within a system in response to some internal or 
external stimuli. Sometimes the two terms are differentiated based upon the analytical 
method used; metabolomics often utilises mass spectrometry (MS) techniques, whereas 
metabonomics utilises nuclear magnetic resonance (NMR)-based techniques. However, such 
as distinction is not absolute, with no prerequisite that metabolomics investigations must be 
performed on MS-based platforms or metabonomics must be conducted using NMR 
techniques (Cubbon et al, 2010; Robertson, 2005). There is also a debate as to whether
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metabolomics relates to plant and microbial systems whereas metabonomics relates to animal 
models (Tang and Wang, 2006). The differences between metabolomics and metabonomics 
are mainly philosophical rather than technical as the analytical and data-handling process are 
the same (Nicholson and Lindon, 2008). Metabolomics appears to be the favoured term 
currently used in the literature (Cubbon et al, 2010) and the term “metabolomics” is used in 
this thesis.
genomics
DNA
transcriptomics
mRNA
proteomics
protein
transcription
translation
metabolome
metabolomics
Figure 1.10: Schematic representation of the levels of “omics” technologies. The flow of 
information from genes to transcripts and proteins, and finally down to metabolites. Reproduced 
from Roux et al (2011).
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1.8.2 Analytical techniques used in metabolomics studies
Metabolites such sugars, nucleotides, amino acids, lipids, and also drug metabolites, 
exhibit a high chemical diversity. Due to these diverse chemical properties, there is no single 
and universal technique for the measurement of all metabolites in a biological sample (Roux 
et al, 2011; Khoo and Al-Rubeai, 2007). However, two main analytical platforms are, 
generally, used that can provide structural information relevant to metabolite identification: 
NMR spectroscopy and MS (Nicholson and Lindon, 2008; Roux et a/., 2011; Khoo and Al- 
Rubeai, 2007). Each tool provides complementary and sometimes redundant information 
(Roux et al, 2011).
NMR spectroseopy is a rapid, high-throughput and robust technique that produces 
highly informative struetural information. The advantage of NMR is that it does not require 
any physical or chemical treatment of samples prior to analysis. In essence, this means that it 
can analyse a rather crude sample, with little impact of the other components in the complex 
mixture (matrix) on the analysis. It is also non-destructive and this is particularly useful for 
studying metabolite levels in intact tissues such as biopsy samples, which can later be used in 
further experiments. However, NMR falls short in terms of resolution and sensitivity 
compared to MS, requires larger amounts of sample and the deconvolution of signals is not 
straight-forward (Nicholson and Lindon, 2008; Roux et a/., 2011; Cubbon et al, 2010; Khoo 
and Al-Rubeai, 2007).
MS is also a rapid, high-throughput, and robust technique, whieh funetions by 
measuring the mass of the metabolites. To achieve this, the teehnique disrupts the structure 
and interaction of molecular complexes and therefore samples are destroyed after the 
analysis. MS is usually more sensitive than NMR, although it usually requires a prior 
separation method (e.g. chromatographie separation) before the mass of the metabolite can be 
determined. Many metabolomics studies now utilise MS coupled to a separation teehnique 
such as chromatography or electrophoresis (Nicholson and Lindon, 2008; Roux et a/., 2011; 
Cubbon et al, 2010).
Gas chromatography (GC) coupled to MS (GC-MS) provides an efficient basis for the 
analysis of metabolites, but it is restricted to volatile samples or those that can be derivatised. 
GC-MS is a relatively low-eost method that provides high separation efficiencies 
(approximately 300 metabolites/run), and hence is applicable to the resolution of very 
complex biologieal mixtures. It offers good sensitivity (limits of detection in the magnitude
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of picomolar (pM) or nanomolar (nM)) and selectivity. However, GC-MS analysis is 
relatively time-consuming due to the long separation runs required by GC (Cubbon et al, 
2010; Roux et a/., 2011; Khoo and Al-Rubeai, 2007).
Capillary electrophoresis (CE) makes use of an electric field to move molecules 
towards a detector, similar to the principle of a gel eleetrophoresis. CE linked to an MS 
detector (CE-MS) is another technique that can be used to separate, identify, and quantify a 
variety of metabolites. CE-MS provides a high level of separation efficiency, as well as being 
able to eope with “dirty” samples that have a eomplex matrix, thus incorporating advantages 
fi*om both MS- and NMR-based analysis methodologies. However, CE-MS requires the 
analytes to be both water-soluble and chargeable, and therefore only a certain subset of 
analytes is effieiently separated. CE-MS also suffers fi"om technical difficulties and lack of 
robustness, meaning that it is of limited use for many applications (Cubbon et al, 2010; Khoo 
and Al-Rubeai, 2007; Lei et al, 2011).
Liquid chromatography (LC) is a common separation technique used in MS-based 
metabolomics. Liquid chromatography-mass spectrometry (LC-MS) analysis requires little or 
no preparation prior to sample injection onto the separation column. The introduction of 
ultra-performance liquid chromatography (UPLC) in LC-MS has increased column efficiency 
and the number of metabolites that can be detected by LC-MS. For example, high 
performance liquid chromatography-mass spectrometry (HPLC-MS) systems allow the 
deteetion of about 1,500 ions in 10 minutes, while UPLC-MS systems can detect over
5.000 ions in 5 minutes. UPLC systems operate at a high operating pressure (around
12.000 psi compared to 6,000 psi in standard HPLCs), and use smaller porous packing 
materials (sub 2 pm) compared to HPLC-based approaehes. A shift from standard HPLC to 
UPLC inereases resolution sensitivity and peak capaeity, and decreases the sample volume 
(2 pi versus 20 -  50 pi in HPLC) and mobile phase volume (around 500 pl/min eompared to 
1 ml/min in HPLC) required. UPLC also displays superior retention time reproducibility and 
signal-to-noise ratios over HPLC. Nevertheless, liquid phase techniques often display 
significant matrix effects due to the presence of non-volatile eompounds, which may reduce 
the evaporation of volatile ions during the electrospray ionisation process. This phenomenon 
is termed ion suppression, and can be redueed by decreasing the size of liquid droplets. The 
typical run times for LC-MS techniques can range fi*om 5 minutes to as long as 2 hours 
(Cubbon et al, 2010; Khoo and Al-Rubeai, 2007; Want et al, 2007).
51
1.8.3 LC-MS-based metabolomics
LC-MS analysis is a combination of physical separation capabilities using LC and the 
mass analysis capabilities using MS. The final outcome of the analysis is orientated towards 
detection of metabolites (qualitative and quantitative), as well as the potential identification 
of metabolites present in complex mixtures. Because metabolites differ greatly in their 
physical and chemical properties in terms of size, polarity/hydrophobicity, and charge, there 
is no single LC or MS method that is ideal for all classes of metabolites. There are many 
methods and instruments for LC-MS analysis (Lu et al, 2008; Hoffmann and Stroobant, 
2007).
A metabolomics experiment begins with an appropriate experimental design 
according to the research question, followed by collection of the samples. Samples collected 
undergo preparation before being injected into the LC-MS system for metabolite profiling. 
The acquired LC-MS data in the form of ion signals, which represent mass-to-charge ratios of 
metabolites, are then analysed using peak detection software and statistical tools. Finally, 
identification of the signals is undertaken by combining mass spectrum analysis, database 
consultation, and mathematics and informatics tools (Roux et al, 2011). Figure 1.11 shows a 
flow chart of MS-based metabolomics process.
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Figure 1.11: Flow chart of the LC-MS-based metabolomics. A metabolomics experiment 
involves sample preparation, metabolic profiling, data analysis and multivariate statistics, 
identification of the metabolites, confirmation, and quantification. Reproduced from Roux et al 
(2011).
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Sample preparation
An adequate method for sample preparation is important because metabolite levels 
reflect the final response of a biological system to a genetic or an environmental change. 
Beeause the levels of metabolite will continue to change with time, quenching is performed 
to stop all biochemical processes, ensuring that an accurate biological picture is obtained. 
Quenching is most commonly achieved through rapid changes in temperature or pH (Villas- 
Boas et al., 2005).
For metabolomics analysis by LC-MS, the sample needs to be in a de-proteinated 
suspension. In theory, any biological samples ean be used for metabolomics studies, 
including biofluids, tissues, cells, or whole organisms. Urine is rieh in metabolites and often 
only requires aqueous dilution before it is injected in the LC-MS system. Plasma, on the other 
hand, is rich in proteins and requires proeessing using organic solvents such as methanol or 
acetonitrile to remove the protein before these samples can be injected in to a LC-MS system 
(Roux et a/., 2011 ; Lu et al., 2008).
Besides quenching and removal of protein, metabolites must be released from the 
eells and extraeted for analysis. The appropriate means of extraction depends on sample type 
and the targeted metabolite(s) of interest (Lu et al, 2008). Cell samples are usually 
centrifuged to separate the extracellular content from the cells. The cell pellets are then 
re-suspended in water/cold organic solvent mixtures, followed by sonication or mechanical 
agitation to disrupt cell membranes. For tissue samples, they are normally rapidly colleeted 
and frozen in liquid nitrogen, which acts to quench the sample, followed by homogenisation 
in cold organic solvents such as methanol, and an extraction protocol to separate the polar 
fraction from insoluble lipids (Roux et al, 2011). Quenching and extraction are normally 
done in combination as quenching procedures results in partial extraction of the intraeellular 
metabolites because of disruption of the cell wall (Villas-Boas et al, 2005). Depending on 
the type of organic solvent used for metabolite extraction, samples are diluted in the mobile 
phase or centrifuged, evaporated to dryness and finally re-suspended in a compatible solvent 
to be injeeted into the LC-MS system (Roux et al, 2011).
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Liquid chromatoeraphv (LC) analysis
Metabolites in the samples are separated by LC. Various types of chromatographie 
separation can be performed for LC analysis. Reversed-phase liquid chromatography 
(RP-LC) is the most popular LC method. RP-LC uses a non-polar stationary phase (column) 
and a polar eluting solvent (mobile phase), resulting in the retention of non-polar metabolites 
with the most polar metabolites eluted near the void volume. Void volume is the volume not 
retained by the eolumn and is eluted at the beginning of the LC runs, with metabolites eluted 
at/near the void volume being poorly analysed. Normal-phase liquid chromatography 
(NP-LC) is the opposite of RP-LC. The stationary phase is more polar than the eluting 
solvent, resulting in increased retention for polar metabolites. However, the mobile phase of 
NP-LC typically contains hydrophobic non-aqueous solvents with low solubility for polar 
metabolites. Hydrophilic interaction liquid chromatography (HILIC) is a more recent 
approach, similar to NP-LC except that the non-aqueous solvents (e.g. heptane, hexane, 
pentane, and cyclohexane) used as the mobile phase in NP-LC is replaced with an eluent 
containing high content of water-miscible organic solvent sueh as acetonitrile in water or 
volatile buffer, which promotes hydrophilic (polar) interactions between the analytes and a 
water-enriched hydrophilic stationary phase to enhance retention of polar metabolites. HILIC 
is well suited for analysis of polar compounds, which are not retained very well in RP-LC, 
and when NP-LC cannot be used due to poor solubilisation of samples in the high organic 
solvent mobile phase used in NP-LC (Lu et al, 2008; Dejaegher and Vander, 2010; Cubbon 
et al, 2010).
Mass spectrometry (MS) analysis
Onee the samples are chromatographically separated, MS analysis can be performed 
to detect the metabolites. A mass spectrometer always contains a sample inlet to introduce the 
sample to be analysed, an ionisation source for the production of ions from the sample, one or 
several analysers to separate the various ions, a detector to “count” the ions emerging from 
the last analyser, and lastly a data processing system that produces the mass spectrum in a 
suitable form. Figure 1.12 shows a basic diagram of a mass spectrometer (Hoffinann and 
Stroobant, 2007).
Samples eluting from the chromatographic column are channelled via the sample inlet 
into the mass speetrometer. Direet MS analysis without chromatographic separation is also
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possible, although this approach is less informative but useful for certain applications such as 
screening of large mutant populations, or with instruments that are capable of high resolution 
and accurate mass measurements (Lei et al.,2Çil\).
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Figure 1.12: Basic diagram for a mass spectrometer. A mass spectrometer with two analysers 
and feedback control carried out by a data system. Reproduced from Hoffmann and Stroobant 
(2007).___________________________________________________________________________
On entry into the mass spectrometer, the samples are ionised in the ion source 
compartment. There are a variety of ionisation techniques: Electron ionisation (El) and 
chemical ionisation (Cl) are only suitable for gas-based samples and therefore mostly used in 
GC-MS. In El ionisation, a heated filament releases electrons that are accelerated towards an 
anode and collide with gaseous-sample molecules to produce ions. El induces extensive 
fragmentation and the molecular ions are not always observed. Cl produces ions through 
collision of sample molecules with ions of a reagent gas that are present in the source. This 
technique produces little excess energy and there is less fragmentation of the molecular ion; 
therefore, it is a form of soft ionisation technique (Hoffmann and Stroobant, 2007; Want et 
a/., 2007).
For LC-MS analysis, electrospray ionisation (ESI) is most commonly used. ESI offers 
soft ionisation with excellent quantitative analysis and high sensitivity. Liquid samples are
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transformed into a gas-phase by the generation of ions. The ionisation process involves liquid 
samples leaving the chromatographic column and then being injected by a mechanical 
syringe pump through a metal capillary at low flow rate ( 1 - 2 0  pl/min.). The capillary is 
maintained at high voltage ( 3 - 5  kV) and this strong electric field nebulises the sample 
solution to form a fine spray of electrically-charged droplets. The aqueous solvent in the 
droplets is rapidly evaporated by the application of heat and nitrogen gas. Any residual 
electrical charges on the droplets are transferred to the analytes and the ionised analytes pass 
into the high vacuum analyser of the mass spectrometer via a series of small apertures and 
focusing voltage (Want et al, 2007; Pitt, 2009; Hoffinann and Stroobant, 2007).
Other alternatives for liquid-based samples ionisation strategies include nano-ESl, 
atmospheric pressure chemical ionisation (APCl), and atmospheric pressure photoionisation 
(APPl). Nano-ESl is a low flow-rate version of ESI (about 200 nl/min.) with smaller droplets, 
leading to less evaporation and increased sensitivity and greater dynamic range (Want et al, 
2007). APCl is a form of Cl which takes place at atmospheric pressure. Nebulised liquid 
sample is carried along a corona discharge electrode located near the tip of the capillary, 
initially ionising gas and solvent molecules present in the ion source and these ions then react 
with the analytes and ionise them via charge transfer. APPl uses photons to excite and ionise 
sample molecules after nébulisation. Because ESI, nano-ESl, APCl, and APPl take place 
under atmospheric pressure, they are also classified as atmospheric pressure ionisation (API) 
(Pitt, 2009; Hoffmann and Stroobant, 2007).
Besides the mentioned liquid-phase ion source, there are also ion sources for “solid 
solution”. This involves various preparation methods in which the analytes are deposited in a 
matrix that can either be a solid or a viscous fluid. The deposit is then irradiated by 
high-energy particles or photons that desorb ions near the surface of the deposit, and these 
ions are extracted by an electric field and focused towards the mass analyser. Matrix-assisted 
laser desorption ionisation (MALDl) is an example of this technique (Hoffmann and 
Stroobant, 2007).
Regardless of the process by which gas-phase ions are produced, the next step is 
separation of the ions according to their mass. The physical properties of the ions are 
measured as their mass-to-charge ratio (m/z) rather than their mass alone. This process takes 
place in the mass analyser, which is the core of a mass spectrometer. There are many types of 
mass analyser and the most common are quadrupole, time-of-flight, and ion-trap based
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analysers. Quadrupole analysers use the trajectory stability of ions in oscillating electric 
fields to separate them according to their m/z ratios. A quadrupole consists of a set of four 
circular metal rods arranged in parallel to each other. A combination of constant and varying 
(radio frequency) voltages allows the transmission of a narrow band of ions along the axis of 
the rods. Only ions with a certain m/z value will reach the detector for a given ratio of 
voltages, while other ions have unstable trajectories and will collide with the rods. By varying 
the voltages with time, it is possible to scan across a range of ions resulting in a mass 
spectrum. Time-of-Flight (ToF) analysers separate ions based on the velocity of the ions. ToF 
works by accelerating ions through a high voltage, and then measuring the time taken to 
travel down a flight tube to the detector, which is dependent on the ion’s m/z ratio. A ToF 
analyser can acquire mass speetra extremely quickly, with high sensitivity and high mass 
accuracy. In ion-trap analysers, the separation principle is based on resonance frequency, 
whereby three hyperbolic electrodes trap ions in a three-dimensional space using static and 
radio fi-equency voltages. The ions are then sequentially ejected from the trap on the basis of 
their m/z values to create a mass spectrum. One advantage of ion-trap analysers is that they 
are capable of performing multiple-stage tandem MS (MS^): In this technique, a specific ion 
can be isolated in the trap by application of an exciting voltage while other ions are ejected. 
Introduction of an inert gas into the trap then induces fi-agmentation. The fi*agmentation and 
isolation of ions several times in succession before the final mass spectrum is obtained 
produces MS" data (Pitt, 2009; Hoffmann and Stroobant, 2007).
Tandem MS (MS/MS) can also be performed using a tandem mass spectrometer such 
as triple quadrupole analyser, which is quadrupole analyser but arranged in a series of three. 
The first (Qi) and third quadrupoles (Qg) function as mass filters while the middle quadrupole 
(qi) serves as a collision cell. The q% is a radio frequency (RF)-only quadrupole that does not 
filter mass. The Qi is set to monitor ions with a specific m/z value, which are allowed to pass 
through to q2 . The selected ions collide with a collision gas and the fragments are passed 
through to Qg where they may be filtered or scanned. This technique is useful for detection of 
targeted analytes because more detector time can be devoted to detecting specific ions instead 
of scanning across a wide range (Pitt, 2009; Hoffmann and Stroobant, 2007; Want et al, 
2007).
Combinations of different analysers are also available, known as hybrid analysers. For 
example, the Qg of a triple quadrupole can be replaced by a ToF analyser to produce a 
quadrupole time-of-flight (QToF). The Qg of a triple quarupole analyser can also be operated
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in a different mode in which ions are trapped and then sequentially ejected on the basis of 
their m/z values: This is known as linear ion-trap or QTrap. Finally, the end quadrupole can 
be switched between ion trap mode and conventional quadrupole mode so that the instrument 
has the combination feature of both triple quadrupole and ion trap analysers (Pitt, 2009; 
Hoffinann and Stroobant, 2007; Want et al, 2007).
In the final stage of physical analysis, ions that pass through the mass analyser are 
detected and transformed into electrical signals by a detector. The detector could be as simple 
as a Faraday Cup, in which ions that hit the metal cup, are neutralised, and the resulting 
current is measured. However, this method is only useful when the ion flux is relatively large. 
Generally, the number of ions leaving the mass analyser at a particular instant is quite small 
and a significant amplification is often necessary, meaning that a Faraday Cup does not 
provide sufficient sensitivity. A more advanced detector for the measurement of low ion flux 
is therefore commonly used; an electron multiplier. Ions fi*om the analyser are accelerated to 
a high velocity in order to enhance detection efficiency. Multichannel plate (MCP) detectors 
are closely related to electron multipliers and commonly used in modem commercial mass 
spectrometers (Hoffinann and Stroobant, 2007).
Signals fi*om the detector are processed and transmitted to a computer. Software 
converts the data into values of masses and peak intensities. Besides acquiring and processing 
data from the mass spectrometer, the software also ftinctions to control the mass spectrometer 
instmment and facilitates data interpretation (Hoffmann and Stroobant, 2007).
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1.9 Hypothesis, aims, and objectives
This research project was generated from the desire to find a sensitive and predictive 
method for toxicological assessment. The currently available toxicity testing methods have 
been predictive of human risk, but are time-consuming and resource-intensive. In order to 
meet the challenges of toxicology in the 21®^ century, it is essential to understand the 
metabolic pathways underlying a toxic effect. The “omics” related techniques utilise the 
state-of-the-art technology.
The hypothesis of this study is that a metabolomics approach can be used to 
understand troglitazone toxicity. Troglitazone was selected as model compound as it is an 
example of a drug that even though it went through a rigorous proeess of clinical trials but 
showed a high incidence of idiosyncratic hepatotoxicity. Drugs that induce idiosyncratie 
toxieity do not exhibit a harmful effect in most people, but it is likely that biochemical 
changes are precursors to idiosyncratic toxicity and individuals responded with tolerance or 
adaptation (Uetrecht, 2007). Monitoring the patterns of biochemical changes, i.e. metabolite 
levels, has potential as a tool to assess the possible occurrence of idiosyncratic drug toxicity. 
Therefore, the focus of this study was to develop a methodology using an untargeted and a 
targeted metabolomics approach to study troglitazone toxicity. The aims and objectives of the 
study are as follows:
Aim 1: Investigation of troglitazone toxicity by a conventional cell-based cytotoxicity assay. 
Objectives:
i. Determination of the toxic concentration of troglitazone and the non-hepatotoxic 
TZDs, based on the 50% inhibitory concentration (IC50).
ii. Identification of factors that induce troglitazone hepatotoxicity.
iii. Improvement of the cell-based assay system to be more sensitive towards 
mitochondrial toxicity by substituting glucose with galactose in the culture medium.
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Aim 2: Application of an untargeted and a targeted LC-MS-based metabolomics approach to
investigate troglitazone toxicity.
Objectives:
i. Set up of LC-MS method(s) for metabolomics studies.
ii. Characterisation of metabolites in cells treated with troglitazone and non-
hepatotoxic TZDs.
iii. Identification of metabolites correlated with troglitazone toxicity.
Aim 3: Towards a better understanding of the mechanism of troglitazone-induced 
hepatotoxicity.
Objectives:
i. Elucidation of the biochemical processes related to troglitazone toxicity.
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Chapter 2: Materials and Methods
2.1 Materials
Cell line and cell culture media and reasents
The human hepatocellular carcinoma cell line (HuH-7) was a kind gift from Dr. Steve 
Hood (GlaxoSmithKline, Ware, U.K.). Dulbecco’s Modified Eagle Medium (DMEM) 
(containing 25 mM glucose and 4 mM L-glutamine but without sodium pyruvate), 
Dulbecco’s Modified Eagle Medium without phenol red (DMEM PSP") (containing 25 mM 
glucose but without L-glutamine and sodium pyruvate), low glucose Dulbecco Modified 
Eagle Medium without phenol red (L-DMEM PSP ) (containing 5 mM glucose and 1 mM 
sodium pyruvate but without L-glutamine), Dulbecco’s Modified Eagle Medium without 
glucose (DMEM G") (containing 4 mM L-glutamine but without sodium pyruvate), heat 
inactivated foetal bovine serum (FBS), 10,000 U/ml penicillin/10 mg/ml streptomycin, MEM 
non-essential amino acids solution (NEAA) (10 mM), 0.5% trypsin-EDTA solution, sodium 
pyruvate MEM solution (100 mM), and L-glutamine solution (200 mM) were purchased from 
Invitrogen Ltd. (Paisley, U.K). Phosphate-buffered saline tablets (PBS) was obtained from 
Oxoid Ltd. (Basingstoke, U.K.). Tissue culture flasks, 6-well plates, 96-well plates, cryovials, 
and cell scrapers were provided by Nunclon Produets (Roskilde, Denmark).
Chemicals and reagents
Troglitazone (TGZ) and rosiglitazone (RGZ) were obtained from Cayman Chemical 
(Michigan, U.S.A.) whereas pioglitazone (PGZ) was from Alexis Biochemicals (Exeter, 
U.K.). Sigma-Aldrich Company Ltd. (Poole, U.K.) supplied paracetamol (PCM), 
D-galactosamine (GaIN), rifampicin (RIF), L-buthionine-sulfoximine (BSO), 
3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT), Hybri-Max™ 
dimethyl sulphoxide (DMSO), 0.4% trypan blue solution, vitamin C and E, D-(+)-glucose, 
D-(+)-galactose, and D-mannitol. Tritox X was made by Roche Diagnostics Ltd. (Burgess 
Hill, U.K.). The CytoTox 96® non-radioactive cytotoxicity assay from Promega U.K. 
(Southampton, U.K.) was used for LDH assay. Nylon membrane filter (0.2 pm) was 
purchased from Millipore (Watford, U.K.).
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Chemical standards for LC-MS analysis were purchased from Sigma-Aldrich 
Company Ltd. (Poole, U.K.): leucine enkephaline, sodium pyruvate, sodium L-lactate, citric 
acid, a-ketoglutaric acid potassium salt, succinic acid, fumaric acid, malic acid, oxaloacetic 
acid, glucose 6-phosphate dipotassium salt hydrate, adenosine 5’-triphosphate disodium salt 
hydrate, D-valine (Val), D-methionine (Met), D-phenyalanine (Phe), D-leucine (Leu), 
D-tryptophan (Trp), L-glutamine (Gin), L-glutamic aeid (Glu), L-glutathione reduced (GSH), 
L-glutathione oxidised (GSSG), p-nicotinamide adenine dinucleotide (NAD^, 
p-nicotinamide adenine dinucleotide reduced dipotassium salt (NADH), p-nicotinamide 
adenine dinucleotide phosphate hydrate (NADP^, p-nicotinamide adenine dinucleotide 
2’-phosphate reduced tetrasodium salt hydrate (NADPH), nicotinamide, nicotinuric acid, 
nicotinic acid, riboflavin, and pyridoxal hydrochloride. Metabolomics MS systems test mix 
was obtained from Waters Ltd. (Hertfordshire, U.K.).
Fisher Scientific U.K. Ltd. (Loughborough, U.K.) provided water (LC-MS grade), 
acetonitrile (LC-MS grade), methanol (HP-LC grade), formic acid (Aristar grade), 
chloroform, sodium hydroxide, DMSO, and reserpine while Romil Ltd. (Cambridge, U.K.) 
supplied ultra gradient methanol. LC-MS vials and LC-MS vial caps were purchased from 
Chromacol Ltd. (Herts, U.K.).
2.2 Methods
2.2.1 Cell culture
The HuH-7 cell line is a human hepatocellular carcinoma cell line (Cell Line 
No. JCRB0403, Japanese Collection of Research Bioresources -  Cell Bank, Osaka, Japan), 
and is used in this study as a hepatocyte model. HuH-7 cells have an infinite life span, and 
present an epithelial-like morphology. The HuH-7 cells were originally derived from a well- 
differentiated hepatocellular carcinoma of a 57-year-old Japanese male in 1982. The cell line 
was established by Nakabayashi and Sato (Nakabayashi et al, 1982).
HuH-7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 25 mM glucose, 4 mM L-glutamine, and phenol red. Medium was routinely 
supplemented with 1% penicillin/streptomycin (final concentration of 100 U/ml 
penicillin/100 pg/ml streptomycin), 10% foetal bovine serum (FBS), and 1% non-essential 
amino acids (NEAA) (Table 2.1). The cells were maintained in a 37°C cell culture incubator
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with atmospheric condition of 5% C02/95% air. They were sub-cultured to approximately 
80-90% confluence and then passaged. The cells were used only until passage number 20 to 
ensure phenotypic consistency (ATCC, 2007).
Table 2.1: The major components of culture media
Culture medium Basal medium Supplements Function
Complete
medium
DMEM 
+ 25 mM glucose 
+ 4 mM L-glutamine 
+ phenol red 
-  sodium pyruvate
10% FBS, 
1%NEAA,
1% penicillin / 
streptomycin
For growing cells
Serum-free
medium
DMEM PSP'
+ 25 mM glucose
-  L-glutamine
-  phenol red
-  sodium pyruvate
1%NEAA,
1% penicillin / 
streptomycin 
4 mM L-glutamine
For treatments
Low glucose,
serum-free
medium
L-DMEM PSP'
+ 5 mM glucose
-  L-glutamine
-  phenol red
+ 1 mM sodium pyruvate
1%NEAA,
1% penicillin / 
streptomycin 
4 mM L-glutamine
For treatments 
(as alternative to the 
high glucose, serum- 
free medium)
Freezing medium - 10% DMSO, 
90% FBS (v/v)
For cryopreservation
2.2.1.1 Passage of cells
When the cells were 80 -  90% confluent, they were plated into new passages. Routine 
culture was undertaken in T75 culture flasks (surface area of 75 cm^), and all volumes reflect 
this. First, spent culture medium was aspirated from the cells. Next, cells were washed with 
10 ml of sterile phosphate-buffered saline (PBS), which was aspirated and replaced with with
0.05% trypsin-EDTA (~ 3 ml). Excess trypsin-EDTA was removed by aspiration, and the 
cells incubated at 37°C for 3 -  5 minutes. When the cells were detached, fresh complete 
culture medium was added to inhibit trypsin action through neutralising pH, dilution and 
serum inhibition. Gentle pipetting action was used to facilitate dispersal and dissociate small 
clumps of cells into single cells. The cell suspension was then divided to a suitable ratio, e.g. 
1:5 (cell suspension: fresh medium) and plated in new culture flasks. The newly passaged 
cells were returned to the cell culture incubator. If the cells have been growing well for a few 
days but not yet confluent (e.g. due to high split ratio such as 1:10), the culture medium was 
refreshed every 2 - 3  days, 15 ml per flask (~ 0.2 -  0.5 ml/cm^ area) (Freshney, 2010).
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2.2.1.2 Cryopreservation
HuH-7 cells were cryopreserved to ensure sufficient availability. Cells growing well 
and in the log phase (70 -  80% confluent) were detached with trypsin (as described in 
Section 2.2.1.1). The detached cell suspension was centrifuged at 500 x g for 5 minutes with 
AccuSpin 400 (Fisher Scientific) and the supernatant discarded. The cell pellet was 
re-suspended to 1%10^ cells/ml in freezing medium (10% DMSO, 90% FBS, v/v) and 
transferred into cryovials (1 ml/vial). The cryovials were maintained on ice for 30 minutes, 
then moved to a Nalgene® Cryo 1°C Freezing Container containing alcohol and kept in a 
-80°C freezer for 24 hours to slowly freeze the cells at the rate of ~l°C/minute before 
long-term storage in liquid nitrogen (Freshney, 2010).
2.2.1.3 Recovery cells from frozen stock
A frozen ampoule of cells was thawed rapidly in a 37°C water bath. The contents 
were transferred to a universal tube and 10 -  20 ml of pre-warmed DMEM (basal medium) 
was added slowly. The cell suspension was centrifuged at 500 x g for 3 -  5 minutes, 
supernatant discarded and the cell pellet re-suspended in 10 ml of complete culture medium 
(Table 2.1). The cell suspension was then transferred to a T25 tissue culture flask (culture 
area 25 cm^) and incubated 37°C, 5% C02/95% air. After 24 hours, the culture medium was 
refreshed (Freshney, 2010).
2.2.1.4 Estimation of cell number
The number of cells was estimated by counting using a Neubauer haemocytometer. 
Briefly, a coverslip was placed over the counting chamber of a clean haemocytometer with 
the edge of the coverslip dampened to hold it in place. The coverslip was then gently and 
firmly pressed over the grooves of the counting area. Appearance of Newton rings (a series of 
alternating circular bright and dark rings) was an indicator that the coverslip has 
formed a tight seal and ensured the depth of the chamber was 0.1 mm. A homogenous 
mixture (8 -1 0  pi) of cell suspension with 0.4% trypan blue solution (at a ratio of 1:1, v/v) 
was placed at the edge of the coverslip and allowed to be drawn into the chamber by capillary 
action. Care was taken not to overfill or underfill the chamber. The number of viable cells 
(unstained) and dead cells (stained) were counted in all five regions of the chamber 
(Figure 2.1). Each region corresponded to 1 mm^ area. Both sides of the chambers were
64
utilised. The concentration of viable cells in the cell suspension and percentage of cell 
viability were calculated with the following formulas (Freshney, 2010):
c = (n X df) /  V with c = concentration of viable cells (cells/ml)
n = average number of unstained cells / mm^ area 
df = dilution factor 
V = volume counted
(volume of 1 mm^ area = 0.1 mm  ^or ICf^  ml)
Cells viability (%) = Total viable cells (unstained)_____
Total cells count (stained and unstained)
X 100%
(A) Sample introduction point
Counting cham bers
V
Cover glass
Cover glass m ounting support
0.1 mm sam ple depth
(C)
(B)
1 mm
corner
square
1 mm
middle
square
(
— L K  
)
( :
1-------(
Figure 2.1: Estimation of cell number using haemocytometer. (A) View of the haemocytometer. 
(B) View of one chamber under ICQx magnifications (IQx ocular and IQx objective). Cells in the 
numbered regions were counted. (C) In each region, cells touching the middle line on the top and 
left borders were counted (O) but not those on the bottom and right borders (0).
2.2.1.5 Seeding of cells for experimental purposes
HuH-7 cells were seeded in 6-well plates at a density of 3 x lo^ cells/well in 
5 ml/well of complete culture medium. Following an overnight incubation to allow cell 
attaehment, the eulture medium was removed and the eells were washed with 3 ml of 
serum-free medium (DMEM containing 25 mM glucose but without phenol red and 
L-glutamine (DMEM PSP'); supplemented with 1% penieillin/streptomycin, 1% NEAA, and
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4 mM L-glutamine) (Table 2.1). The cells were then treated with the compound of interest at 
the desired concentration(s) in a total volume of 5 ml/well of serum-free medium (unless 
otherwise stated) and incubated for the desired duration. After the treatment incubation 
period, cells were harvested for various assays.
2.2.2 Cell viability
The number of viable cells was assessed by either the MTT (3-(4, 5- 
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) or lactate dehydrogenase (LDH) 
assay.
2.2.2.1 MTT assay
The MTT assay was based on the method described by (Mosmann, 1983). The 
principle of this assay is that water-soluble yellow MTT is actively absorbed into cells. The 
mitochondrial succinate dehydrogenase system then cleaves the tétrazolium ring to form a 
water-insoluble purple formazan crystal that cannot pass the cell membrane. Addition of 
DMSO or other suitable solvent solubilises and releases the formazan from the intracellular 
compartment, and this is quantified spectrometrically at 570 nm. The reduction of MTT is 
dependent on functional mitochondria and therefore the intensity of the solubilised purple 
formazan is proportional to the number of viable cells (Roche Diagnostics GmbH, 2008).
The first step of the protocol was aspiration of the spent medium after the treatment 
period. Cells were then washed with PBS (5 ml/well) to remove all traces of the test 
compounds. Fresh serum-free medium containing MTT (0.5 mg/ml, 3 ml/well) was added to 
each well and incubated at 37°C for 150 minutes. After the incubation time, medium 
containing MTT was removed and the formazan crystals formed were dissolved with 3 ml of 
DMSO. Absorbance was measured at 570 nm with a spectrophotomer (Lambda 25, Perkin 
Elmer, Cambridgeshire, U.K.). When the absorbance reading was more than 1, the dissolved 
formazan was diluted 1:10 times, which produced more reproducible readings.
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MTT Formazan
NADH NH
■CH3 NAD CH3
CH3CH3
Figure 2.2: The reaction of MTT assay. Metabolic active cells convert MTT to formazan, which 
can be measured spectrometrically. Adapted from Roche Diagnostics GmbH (2008).
2,2.2.1,1 Determination of 50% Inhibitory Concentration (IC50)
HuH-7 cells were seeded in 6-well plates (as described in Section 2.2.1.5) and 
exposed to various concentrations of test chemical or vehicle control in 5 ml/well of 
serum-free culture medium for 24 hours. Solvents and concentration ranges used for each 
chemical are supplied in Table 2.2. The MTT assay was used to determine the toxic effect of 
these eompounds on HuH-7 eells. Dose-response curves for each compound were plotted and 
the IC50 value of each compound determined by non-linear regression using a variable slope 
model (GraphPad Prism 5, GraphPad Software Inc., California, U.S.A).
Table 2.2: Compositions of the test compounds for the determination of the IC5 0  values
Test compound Stock concentration 
of test compound
Final concentration 
of test compound
Final concentration 
of DMSO
Troglitazone 56.6 mM in DMSO 0 -  100 pM 0.5%
Rosiglitazone 69.9 mM in DMSO 0 -  350 pM 0.5%
Pioglitazone 14.0 mM in DMSO 0 -7 0  pM 0.5%
Rifampicin 300 mM in DMSO 0 -  1,500 pM 0.5%
BSO 10 mM in serum-free 
culture medium
0 -  10,000 pM N/A
Paracetamol 70 mM in serum-free 
culture medium
0 -  70,000 pM N/A
Galactosamine 100 mM in serum-free 
culture medium
0 -  80,000 pM N/A
Components of the serum-free culture medium are stated in Table 2.1. N/A: Not applicable.
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2.2.2.L2 Co-incubation and pre-incubation of troglitazone with rifampicin, BSO, 
paracetamol, and galactosamine
HuH-7 cells were simultaneously treated with troglitazone and rifampicin, BSO, 
paracetamol, or galactosamine for 24 hours. All compounds were tested at non-toxic levels,
i.e. O.lx of their respeetive IC50 values except for rifampicin and BSO. Rifampicin was used 
at a final coneentration of 10 pM and BSO at 100 pM. The control samples were treated with 
0.1% DMSO. The experiment was performed in 6-well plates as previously described. The 
total volume in each well was 5 ml/well of serum-free culture medium but the final 
concentration of DMSO was only 0.1% (v/v). The MTT assay was used to test the toxic 
effect of these compounds towards HuH-7 cells.
In the pre-incubation experiment, HuH-7 cells were pre-incubated with troglitazone, 
rifampicin, BSO, paracetamol, and galaetosamine, separately, for 24 hours before exposing 
them simultaneously as in the co-incubation experiment. All compounds were also tested at 
non-toxic levels and the MTT assay was used as the end point detection assay. The conditions 
of the experiment were similar to the co-incubation experiment.
2.2.2,13 Incubating HuH-7 cells in galactose medium
Substituting glucose with galactose in the culture medium was performed based to the 
method deseribed by Marroquin et al. (2007). HuH-7 cells cultured under the standard 
conditions (Section 2.2.1) were seeded in 6-well plates at a density of 3 x 10^  cells/well, as 
four different treatment groups. Each treatment group was seeded in 5 ml/well of culture 
medium containing glucose or galactose, with/without sodium pyruvate as indicated in 
Table 2.2. After an overnight incubation to allow cell attachment, seeding medium was 
removed and the cells were washed with 3 ml of their respective culture medium (but 
deprived of serum). In every treatment group, cells were then exposed to Ox, O.lx, or 0.5x 
IC50 of troglitazone for 24 hours in 5 ml/well of their respective culture medium. The 
eoncentration of DMSO was maintained at 0.5%. Cell viability was assessed by the MTT 
assay.
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i
Remove tre a tm e n t m edium and wash with PBS (5 ml/well)
I
Add MTT (0.5 m g/m l in serum -free culture m edium ; 3 ml/well) and incubate for 150 min.
Remove culture medium  containing MTT
i
Solubilise th e  form azan with DMSO (3 ml/well) and m easure absorbance a t 570 nm
Figure 2.3: Diagrammatic representation of the experimental procedures in 2.2.2.1.1 and
2.2.2.I.2. Determination of (1) the IC50 values of some compounds of interest and (2) the effects of 
co-incubation and pre-incubation of troglitazone (TGZ) with rifampicin (RIF), BSO, paracetamol 
(PCM), or galactosamine (GaIN) on HuH-7 cells.________
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Table 2.2: Culture media composition for incubating HuH-7 cells in galactose
Treatment group Glucose Galactose Na pyruvate TGZ treatment
1: Glucose 25 mM Ox IC50 
O.IXIC50 
0.5 X IC50
2: Glucose + 
Na pyruvate
25 mM 1 mM Ox IC50 
O.lxICso 
0 .5X  I C 5 0
3: Galactose 25 mM Ox IC50 
O.IXIC50 
0.5 X IC50
4: Galactose + 
Na pyruvate
25 mM 1 mM Ox IC50 
O.lxICso 
0.5X IC50
• Basal medium; DIV 
4 mM L-glutamine
• All culture media \ 
and 2 mM L-gluta 
during treatment.
• O.lx IC50 — 2.4 pM
EM G (deprived of glucose and sodium pyruvate (Na pyruvate); contained 
and phenol red).
vere supplemented with 10% FBS, 1% penicillin/streptomycin, 1% NEAA, 
mine (final concentration was 6  mM). FBS was excluded from the media
of TGZ; 0 . 5 X  IC50 = 12 pM of TGZ.
The MTT assay protocol used was similar to Section 2.2.2.1 but with a small 
modification (Figure 2.4). After treating the cells with troglitazone for 24 hours, the culture 
medium was removed, cells washed (5 ml/well of PBS), refreshed with culture medium 
containing MTT (0.5 mg/ml in DMEM G‘ supplemented with 1% penicillin/streptomycin, 
1% NEAA, and 2 mM L-glutamine (final concentration was 6 mM); 1.5 ml/well), and 
incubated at 37°C for 150 minutes. DMSO (1.5 ml/well) was then added to solubilise the 
formazan. The medium containing MTT was not removed beforehand as in Section 2.2.2.1 
because it was observed that some formazan was floating and aspiration of the medium might 
remove the formazan as well. The solubilised formazan was centrifuged to separate lipid-like 
precipitate caused by the addition of DMSO to the culture medium, at 10,000 x g for 
5 minutes (5424 Microcentrifuge, Eppendorf Ltd., Cambridge, U.K.). The absorbance of the 
supernatant was measured photometrically at 570 nm and percentage of viability calculated.
The same experimental procedures were repeated with cells that have been passaged 
2 and 4 times in culture medium containing glucose or galactose, with/without sodium 
pyruvate (Figure 2.5).
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After th e  t r e a tm e n t  incubation period, rem ove t r e a tm e n t  m ediumT
W ash with PBS (5 ml/well)
Add MTT (0.5 m g/m l in DMEM G 's u p p le m e n te d  with 1% penicillin/streptomycin, 1% NEAA, and 
2 mM L-glutamine (final concerfrration w as 6 mM); 1.5 ml/well)
Incubate  for  150 min.
Add DMSO (1.5 ml/well) to  solubilise th e  form azan
Centrifuge a t  10,000 x g for  5 min.
M easure  th e  abso rbance  of th e  s u p e rn a ta n t  a t  570 nm
Figure 2.4: Schematic representation of the modified MTT assay for the viability 
measurement of cells incubated in galactose medium. (The basal composition of DMEM G was 
Dulbecco’s Modified Eagle Medium without glucose and sodium pyruvate but contained 4 mM 
L-glutamine.)
Standard  culture
Passage 1
!
Seed 
Treat 
MTT assay
Cells grown in glucose o r  galactose 
m edium  w ith /w ith o u t  sodium  pyruvate
Passage 2
I
Passage 3
Seed 
Treat 
MTT assay
?
Passage 4
!
Seed 
Treat 
MTT assay
Figure 2.5: The experimental design of growing HuH-7 cells in galactose medium. Cells were 
grown in glucose/galactose medium with/without sodium pyruvate. At passage number 1, 2, and 4, 
the cells were treated with troglitazone and viability was assessed by the MTT assay.
2.2.2.2 Lactate dehydrogenase (LDH) assay
Lactate dehydrogenase (LDH) is a stable cytosolic enzyme present in all cell types. It 
is rapidly released into the culture medium when the plasma membrane is damaged (Roche 
Diagnostics GmbH, 2008). Release of LDH is widely used as a marker of cell 
damaged/cytotoxicity, and the CytoTox 96® non-radioactive cytotoxicity assay kit from 
Promega (Southampton, U.K.) was used in this study. The kit involves a 30-minute coupled 
enzymatic assay, resulting in the conversion of tétrazolium salt (INT) into a red formazan 
product, which is measured at visible wavelength (e.g. 490 nm). The colour formed is 
proportional to the number of damaged cells. The principle of the assay is shown in 
Figure 2.6.
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1®^ enzymatic reaction
Pyruvate
COO-
C ^ = 0
ICH3
2”^ enzymatic reaction
o a
Cl-
LDH
NADNADH + m
Catalyst
(Diaphorase)
Cl-
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Tétrazolium  salt, IN T (pale yellow)
NO2
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Figure 2.6: The reaction of LDH assay. In the first enzymatic reaction, LDH reduces NAD'*' to 
NADH -flL by the oxidation of lactate to pyruvate. The second enzymatic reaction transfers H/H  ^
from NADH + H^  to the tétrazolium salt (iodonitrotetrazolium (INT)), which is then reduced to 
formazan by diaphorase, leading to colour change from pale yellow to red. Adapted from Roche 
Diagnostics GmbH (2008).
HuH-7 cells cultured under standard conditions (Section 2.2.1.1.) were seeded in 
6-well plates (3 x IQ^  cells/well in 5 ml/well of complete culture medium). After an overnight 
incubation (37°C), the cells were treated with various concentrations of troglitazone in low 
glucose, serum-free medium (5 ml/well) for 24 hours. The final concentration of DMSO was 
maintained at 0.5% (v/v), with vehicle alone used to represent 100% alive; triton XlOO 
(1%, v/v) was used as the positive control to produce 100% cell death. Wells containing 
untreated cells were included as the negative control (100% live cells), and wells containing 
culture medium only (without cells) were used as the background control.
The LDH assay was performed according to the manufacturer’s instruction (Promega 
U.K.). Briefly, incubated culture medium from each well of a 6-well plate (50 pi) was 
transferred into a 96-well flat-bottom plate and 50 pi of Reconstituted Substrate Mix added (a 
bottle of Substrate Mix was reconstituted by adding 12 ml of Assay Buffer equilibrated to 
room temperature; both components were provided by the manufacturer). The plate was 
covered with foil to protect it from light and incubated at room temperature for 30 minutes to 
allow enzymatic reaction to proceed. Stop Solution (50 pl/well) was added at the end of the 
reaction, and absorbance (490 nm) read with a Victor^™ 1420 Multilabel Counter (Perkin 
Elmer, Cambridgeshire, U.K.) within one hour after the addition of the Stop Solution.
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Seed HuH-7 cells: 3 x 10^ cells/well; 
ml/well of com plete culture medium
Incubate overnight tcA llow  cell a ttachm ent
Remove seeding m edium  and w ash with low glucose, serum -free culture medium  (3 ml/well)
Add te s t com pounds in 5 ml/well of low glucose, serum -free culture medium
Test com pounds
TGZ: 0 - 1 6 0  pM (final concentration  of DMSO: 0.5%) 
Positive control: Triton X (1%, v/v)
Negative control: U ntreated  cells 
Background control: M edium only, w ithout cells
Incubate 24 h
Transfer 50 pi of th e  incubated culture m edium  into a 96-well flat-bottom  plate 
Add Reconstituted Substrate Mix (50 pl/well)
Incubate 30 min. a t room  tem p era tu re  (pro tect from  light)
Add Stop Solution (50 pl/well)
Read absorbance a t 490 nm
Figure 2.7: The experimental design for the determination of troglitazone (TGZ) IC50 value 
measured via LDH release assay. Troglitazone dose-response curve was plotted and the I C 5 0  
value was determined using non-linear regression
2.2.3 Metabolomics analysis
2.2.3.1 Sample preparation
Samples for LC-MS analysis consisted of the culture medium of treated cells and the 
cells themselves. The cells were seeded and treated as described in Section 2.2.1.5, and then 
prepared by one of two methods, as described below and in Figure 2.8.
2.23.1.1 Method 1: Lyophilised samples (extraction with freeze-drying process)
Following incubation of the cells with the test compound(s), 750 pi of the treated
culture medium was collected from each well into a fresh tube. The cells were washed with 
PBS (5 ml/well) to remove all traces of culture medium and/or the test compound(s) before 
being suspended in PBS (1 ml/well). Cells were then collected by scraping and 750 pi of the 
cell suspension was transferred into a fresh tube.
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Collected culture media and cell samples were homogenised using a hand-held 
homogeniser (Kimble® Kontes Microtube Pellet Pestle Rods with Motor). Ice-cold 
acetonitrile (LC-MS grade) was added to the samples (1:1, v/v) for protein precipitation. The 
contents were mixed with a vortex mixer for 30 seconds (Jencons-PLS VXlOO Vortex Mixer, 
Jencons, East Grinstead, U.K.). Samples were then incubated on ice for 30 minutes, vortexed 
(30 seconds), and centrifuged at 10,000 x g for 10 minutes at 4°C (Heraeus Biofuge Fresco 
Microcentrifuge, Thermo Scientific, Loughborough, U.K.). The supernatants 
(1000 p 1/sample) were collected, frozen at -80°C, and lyophilised (Edwards Modulyo Freeze- 
dryer Modulyo).
When samples were required for LC-MS analysis, each lyophilised sample was 
re-suspended in 200 pi of water (LC-MS grade). Samples were vortexed for 30 seconds, 
incubated on ice for 30 minutes before being vortexed again (30 seconds), and then 
centrifuged at 10,000 x g for 10 minutes at 4°C. The supernatant (180 pl/sample) was 
transferred to a LC-MS vial and ready for LC-MS analysis.
2.2.3.L2 Method 2: Non-lyophilised samples (extraction without freeze-drying process)
Method 2 was a slight modification to Method 1, producing non-lyophilised samples. 
PBS was replaced with LC-MS grade ice-cold water and the ffeeze-drying step was omitted. 
Briefly, after treating the cells with the test compound(s) for the desired time, the culture 
medium was removed and the cells were washed with 3 ml/well of ice-cold water. Each well 
was suspended in 500 pi of ice-cold water, the cells were scraped and transferred into a fresh 
tube (~ 500 pl/well). Ice-cold acetonitrile (LC-MS grade) was added to the same well, 
scraped again to remove residual cells, and transferred to the same tube (~ 500 pl/well). The 
contents were homogenised, vortexed (30 seconds), and incubated on ice for 30 minutes to 
allow time for protein precipitation. Then, the cell suspension was vortexed again 
(30 seconds) before centrifugation at 10,000 x g for 10 minutes at 4°C. The supernatant 
(900 pi) was transferred into a LC-MS vial. This method of sample preparation was 
performed only on samples from the cells (culture medium samples excluded).
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LC-MS analysis LC-MS analysis
Figure 2.8: Comparison of the two different sample preparation methods for LC-MS 
analysis. The main difference was (1) exclusion of the freeze-drying process and (2) replacing PBS 
with water. LC- MS grade water and acetonitrile (ACN) were used in the preparation process.
2.2.3.2 LC-MS analysis of the cell and culture medium extracts
2.2.3.2.1 Instrumentation
An Acquity UPLC® System (Waters Ltd., Hertfordshire, U.K.) coupled to 
Micromass® Quadrupole Time-of-Flight Premier™ mass spectrometer (UPLC-QToF MS) 
(Waters Micromass, Manchester, U.K.) was used for LC-MS analysis. Waters Reagent 
Manager (Waters Ltd., Hertfordshire, U.K.) was used to deliver post-column lock mass.
Three different columns were used for chromatographic separation in the course of 
this project. (1) Acquity UPLC™ BEH Cig column, (2) Luna® 3pm NHi 100 A, and 
(3) Synergi™ 2.5 pm Polar-RP 100 A. Detailed description of the columns are presented in 
Table 2.4.
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Table 2.4: Description of the columns used for chromatographic separation
Acquity UPLC™ BEH 
CIS
Luna® 3pm  
NH2 100 Â
Synergi™ 2.5 pm 
Polar-RP 100 A
Stationary phase Trifunctional octadecyl 
carbon (Cl8) chain, fully 
encapped and bonded to 
Ethylene Bridged Hyrid 
(BEH) substrate
Amino Ethyl-linked phenyl 
with hydrophilic 
encapping
Dimension 2.1 X 100 mm 2.0 X 100 mm 2.0 X 100 mm
Particle size 1.7 pm 3.0 pm 2.5 pm
Pore size 130Â 100 A 100 A
Catalogue
number
186002352 00D-4377-B0 00D-4371-B0
Manufacturer Waters Corp., 
Hertfordshire, U.K.
Phenomenex, Inc., 
Cheshire, U.K.
Phenomenex, Inc., 
Cheshire, U.K.
A column guard was attached to each column to protect its lifespan. An Acquity 
UPLC® BEH Ci8 1.7 pM VanGuard™ Pre-column (2.1 x 5 mm) from Waters (catalogue 
number: 186003975) was attached to the Acquity UPLC™ BEH Cis column while 
SecurityGuard Guard Cartridge Kit (catalogue number: KJO-4282) with a NHi Cartridge 
(catalogue number: AJO-4301) and Polar-RP Cartridge (catalogue number: AJO-6075) from 
Phenomenex (both 4 x 2.0 mm) used for the Luna® 3pm NH2 100 Â and Synergi™ 2.5 pm 
Polar-RP 100 A columns, respectively.
2.23.2,2 Chromatographic separation setup (Acquity UPLC® system)
Different chromatographic separation conditions (e.g. mobile phase and wash 
solutions, gradient and run time) were used for different types of column.
Acquity UPLC BEH Cm column
The method used for the Acquity UPLC™ BEH Cig column was based on Ma ct ah 
(2008) with a slight modification. Metabolites separation was carried out under reversed- 
phase conditions using LC-MS grade water containing 0.1% formic acid as mobile phase A 
and ultra-gradient methanol containing 0.1% formic acid as mobile phase B. The linear 
gradient used was as follows: 100% mobile phase A for the first 2 minutes, changing to 95% 
B within 8 minutes, holding at 95% B for 2 minutes, changing back to 100% A in 
0.5 minutes, and holding at 100%A for 3.5 minutes. The total run time was 14 minutes, and 
the flow rate was 0.4 ml/min. Summary of the chromatographic conditions used are presented 
in Figure 2.9 and Table 2.5.
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Luna® Sum NHy 100 Â column
The chromatographic separation conditions for the Luna® 3 pm NH2 100 Â column 
were based on the methods of Lewis et al. (2008) and Yang et al. (2009) with modification to 
suit the Acquity UPLC® system and research requirements. The mobile phase A consisted of 
5 mM ammonium acetate + 0.05% (v/v) ammonium hydroxide (28%) in water/acetonitrile 
(95:5, v/v), pH 8.50 while mobile phase B was acetonitrile (both water and acetonitrile were 
LC-MS grade) (Table 2.5). A 35 minutes cycle run time was used, starting with 85% B 
increasing linearly to 100% A in 15 minutes, holding for 4 minutes at 100% A, increasing 
back to 85% B in 1 minute, and holding at 85% B till the end of the run (Figure 2.9). The 
flow rate was 0.15 ml/min.
Svnersi™2.5 jum Polar-RP 100 Â column
The chromatographic separation conditions used for the Synergi™ 2.5 pm Polar-RP 
100 Â column was according to the method described by Lewis ct al. (2008) and Wei ct al. 
(2010) with slight modification. The mobile phase A for Synergi Polar-RP column was 
20 mM ammonium acetate in water/acetonitrile (95:5, v/v), pH 4.00, and the mobile phase B 
was acetonitrile (both water and acetonitrile were LC-MS grade) (Table 2.5). The cycle 
began with 95% B holding for 1 minute, then a linear increase of 95% A over 15 minutes, 
holding at 95% A for 4 minutes, and finally back to 95% B in 1 minute and holding for 
15 minutes. The total run time was 35 minute at 0.15 ml/min. (Figure 2.9).
LC-MS grade (or equivalent) water and solvents were used to maintain the efficiency 
of the Acquity UPLC® system and to obtain accurate and reproducible chromatograms. When 
salt was added to the mobile phase (e.g. mobile phase containing ammonium acetate), the 
solution was filtered through a 0.2 pm nylon membrane filter. All mobile phase and wash 
solutions were degassed with a sonicator for 10 minutes to remove dissolved air before being 
fed to the pump. Mobile phase and wash solutions that contained 100% water were freshly 
prepared to avoid bacteria growth.
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Figure 2.9: The mobile phase gradients for (A) Acquity UPLC™ BEH Cis column, (B) Luna® 
3pm NH2 100 Â column, and (C) Synergi™ 2.5 pm Polar-RP 100 Â column. Reversed-phase 
gradient starting with 100% water was used for (A) while aqueous normal-phase gradient starting 
with 85% ACN and 95% ACN were used for (B) and (C), respectively.
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Table 2.5: Mobile phase and wash solvents for the different types of columns
Mobile phase and 
wash solutions
Acquity UPLC™ 
BEH Cis
Luna® 3pm 
NH2 IOOÂ
Synergi™ 2.5 pm  
Polar-RP 100 Â
Mobile phase A Water + 
0.1% formic acid
5 mM ammonium acetate 
+ 0.05% (v/v) ammonium 
hydroxide (28%) in 
water/acetonitrile 
(95:5, v/v), pH 8.50
20 mM ammonium 
acetate in 
water/acetonitrile 
(95:5, v/v), pH 4.00
Mobile phase B MeOH + 
0.1% formic acid
ACN ACN
Weak wash Water + 
0.1% formic acid
Water 95% Acetonitrile
Strong wash MeOH + 
0.1% formic acid
Acetonitrile Water
Seal wash 10% ACN 10% ACN 10% ACN
Storage solution 50%/50%
MeOH/water
Isopropanol 65%/35%
ACN/water
Water and solvents were of the highest grac 
methanol.
e commercially available. ACN: acetonitrile; MeOH:
To prepare the Acquity UPLC® system for operation, the seal wash was primed for 
2 minutes, followed by the binary solvent manager for 5 minutes and 5 cycles (Figure 2.10). 
The system was “wet primed” whenever preparing for a new set of runs, the system had been 
in an idle state for more than 4 hours, or when changing to different solvents. After priming 
the system, the column was conditioned to the chromatographic separation method. The flow 
rate was equilibrated to the method by slowly increasing at 0.1 ml/min. steps. Then, the 
mobile phase was equilibrated to the correct percentage of starting mobile phase by switching 
over gradually at 10% steps.
The column temperature was set at 40°C and the autosampler temperature at 4°C. 
Sample injection volume was 10 pi, full loop, unless otherwise stated. Volume of the weak 
and strong wash was 1500 and 500 pi, respectively. The duration of the seal wash was 
4 minutes.
79
(A) To p r im e  t h e  seal w a sh ,  go  to  ACQUITY UPLC S ys tem  > C ontro l > Prim e seal w a sh .  Select  
"Yes" as  s h o w n  on  t h e  s c re e n  be low . P rim e t h e  seal w a sh  fo r  2 m in u te s .  To s to p  t h e  seal 
w a sh ,  r e p e a t  t h e  c o m m a n d  ACQUITY UPLC sy s te m  > C ontrol > P rim e seal w ash .  Ensure  t h a t  
t h e  o u t l e t  tu b in g  is ch a n n e l le d  to  t h e  w a s t e  a n d  n o t  in to  t h e  m a ss  s p e c t r o m e te r .
Prime Seal Wash
s ta rt priming seal wash?
Yes No
(B) To " w e t  p r im e"  sy s tem ,  go to  ACQUITY UPLC S ystem  > C ontro l > S ta r t  up  sy s te m .  S e lec t  t h e  
m ob ile  p h a s e  a n d  w a sh  so lu t io n s  to  b e  p r im e d  as  s h o w n  on  t h e  s c re e n  be low . Set t h e  
d u ra t io n  fo r  5 m in u te s  a n d  5 cycles. In t h e  Equilib ra te  to  M e th o d  ta b ,  s e t  t h e  c o lu m n  s t a r t  up  
co n d i t ions ,  no rm ally  s ta r t in g  a t  100%  B (solvent)  a t  0 .1  m l/m in .  Select  "S ta r t"  to  beg in  th e  
" w e t  p r im e" .  The  f low  r a te  fo r  ea ch  p u m p  is 4  m l/m in .
P r i m e  S o l v e n t s  | Equilibrate to  M ethod | Optional: C haracterize  Volume | Prime Solvents E q u i l i b r a t e  t o  M e t h o d 1 O ptional; C haracterize  Volume | I
A  / B  S o l v e n t s
Q  Prime A l Q  Prime B1 0  Seal w ash
M e t h o d  I n i t i a l  F l o w
Column: 4 0 .0  ° C
0  Prime A2 0  Prime B2 0  Strong  w ash  |s 2 1  cycles 0 .1 0 0  mL/min
Sample: 4 i  ° C
Duration of prime:
0  Weak w ash A2 M .  %
| l0 .0  1 min 0  Sample syringe B2 100 .0  7o Lamp; O ff
1 Set Defaults I 1 Start 1 1 Cancel ) 1 S et D efaults j 1 Start 1 1 C ancel j
1 1
(C) G radual ly  bring t h e  f low  o f  so lv e n t  up  to  t h e  c o r re c t  f low  r a te  acco rd in g  t o  t h e  m e th o d ,  a t  
0 .1  m l/m in .  inc reas ing  s te p s .  Next, g radua lly  sw itch  o v e r  to  t h e  c o r r e c t  s ta r t in g  p e r c e n ta g e  
o f  t h e  m ob ile  p h a s e  (b ase d  on  t h e  m e th o d )  in 10% inc reas ing  s t e p s  a n d  c o n d i t io n e d  th e  
co lu m n .
S e t  Flow
Flow:
0.000 mL/min
S o lv e n t A: S o lv e n t B:
0.0 % 100.0 %
B2
Figure 2.10: Steps in (A) priming the seal wash, (B) “wet prime” the Acquity UPLC 
system, and (C) equilibrating the flow rate and percentage of mobile phase. The outlet tubing 
must be channelled to the waste and not into the mass spectrometer throughout this whole process.
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2.23.2.S Reagent Manager setup
The Reagent Manager is a single-piston, pulse-dampened pump that delivers post­
column lock mass. The lock mass was used to accurately correct mass drift, which could be 
caused by temperature variations in the environment. Leucine enkephaline was used as the 
lock mass. It was prepared at a concentration of 1 ng/pl in 50% aqueous acetonitrile with 
0.1% formic acid and delivered at the rate of 0.04 ml/min. The leucine enkephaline solution 
was sonicated for 20 minutes to remove dissolved air before being fed to the Reagent 
Manager.
To setup the Reagent Manager, it was primed by opening the “Prime/Purge” valve 
and selecting the “Prime” button. It was primed until there was no visible air bubble seen in 
the tubing. The “Prime/Purge” valve was then closed and the Reagent Manager was set to run 
at high flow rate (1.00 ml/min.) for 2 minutes before reducing to 0.04 ml/min. The Reagent 
Manager was allowed to run for approximately an hour to stabilise the flow before it was 
ready for the real LC-MS runs. The outlet tubing of the Reagent Manager was channelled to 
the waste instead of the mass spectrometer while stabilising the flow.
2.2.3.2.4 Mass spectrometer setup
The QToF Premier MassLynx and tune page were always left on even when the 
instrument was not in use because it can take up to two hours for the voltages to stabilise. 
Figure 2.11 shows the view of the MassLynx main screen and tune page.
Cleanin2 o f the Samvlins Cone
Before beginning each set of runs, the Sampling Cone needs to be cleaned to remove 
and chemical build-up from previous runs: Build-up on the Cone will reduce the detection 
intensity/sensitivity. To clean the Cone, the “Shutdown” tune page was opened and this was 
the only time when the instrument was set to the Standby mode. Flow of solvents and gases 
(atmospheric pressure ionisation (API) and collision gases) were turned off. The system was 
allowed to cool (source temperature < 40°C) and the voltages were cheeked to have been 
turned off before proceeding. Gloves must be worn to handle the instrument. The gas and 
electronic connections from the side-plate were disconnected. The “door” was dropped down 
and the four locking nuts were unscrewed. The reflector was removed. Later, the reflector 
must be returned to the same position. The vacuum on Cone was shut off by turning the lever 
90°. Gas line connected to the outer cover of the Cone was disconnected. The Cone and its
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outer cover were removed by unscrewing two Allen screws. The Cone was separated from its 
outer cover and the O ring (washer) and placed in a safe place (never put Cone down nose- 
down).
The Cone outer cover and reflector were cleaned with fine polishing paste (but not the 
Cone itself). The Cone, its outer cover, and the reflector were then sonicated in chloroform 
for 20 minutes, followed by methanol for another 20 minutes. If there were stubborn build­
ups on the Cone, it can be sonicated in formic acid, followed by water, chloroform, and 
methanol to remove such stubborn deposits. When all the three parts have been cleaned and 
dried, they were reassembled following the steps above in reversed order. The vacuum valve 
was opened and all connections were reconnected. Finally, the QToF Premier was switched 
back to the Operate mode and all gases were turned on.
Settinss o f the OToF Premier: Tune pa2e method
The setting conditions used for the QToF Premier were based on the recommended 
settings by the manufacturer Operator’s Guide (Waters Micromass, 2005) and modified 
according to the methods described by Ma et al. (2008) and Pandher et al. (2009). It was 
operated in the V-mode in both the negative (ESI ) and positive (ESI^) electrospray ionisation 
modes. The capillary and cone voltages were set to 2.6 kV and 15V for the ESI' mode and
3.2 kV and 30 V for the ESI^ mode, respectively (unless otherwise stated). The source and 
desolvation temperature were set at 120°C and 350°C, respectively. Nitrogen was applied as 
the desolvation gas at 600 1/h. Argon was used as the collision gas at 0.30 ml/min. with 
collision energy of 5 V. The cone and ion guide gas flow were set to zero. The QToF Premier 
resolution was set to 4.7 for the low resolution mass filter and 15 for the high resolution mass 
filter. The detector was set to 1900 V. Table 2.6 shows the major settings for the QToF 
Premier.
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Figure 2.11: Main screen of the MassLynx and Tuge page. (A) View of the Sample List; 
(B) Tune page: (1) positive ionisation mode, (2) negative ionisation mode, (3) V optics mode, 
(4) W optics mode, (5) API gas, (6 ) collision gas, (7) start run, (8 ) start injection, (9) display of 
ions-per-push; (C) indicator of instrument in operate or standby mode.
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Table 2.6: QToF Premier setting parameters
Parameters E s r ESI^
Ion optics V-mode V-mode
Capillary voltage 2.6 kV 3.2 kV
Sampling cone voltage 15 V 30 V
Extraction cone voltage 4.5 V 4.7 V
Ion guide voltage l.OV 1.3 V
Source temperature 120°C 120°C
Desolvation temperature 350°C 350°C
Cone gas flow 0 0
Desolvation gas flow 600 1/h 600 1/h
LM resolution 4.7 4.7
HM resolution 15.0 15.0
Ion energy l.OV 2.8 V
Pre-filter 2.0 V 10.0 V
Collision energy 5.0 V 5.0 V
Cell entrance 2.0 V 2.0 V
Cell exit -10.0 V -10.0 V
Collision cell gas flow 0.30 ml/min. 0.35 ml/min.
Ion guide gas flow 0 0
Detector 1900 V 1900 V
Acceleration 1 80 V 80 V
Acceleration 2 200 V 200 V
Aperture 2 70 V 6 6  V
Transport 1 70 V 69 V
Transport 2 70 V 70 V
Steering OV -0.41 V
Tube lens 73 V 80 V
Pusher 920 V 920 V
Pusher off set -0.70 V -1.11 V
Puller 677 V 681V
Note: The capillary voltage used for the Acquity UPLC™ BEH Cig column in the ESC mode 
was 2.9 kV.
Calibration o f OToF Premier
The QToF Premier was calibrated using sodium formate (4.5 ml of isopropanol, 
0.25 ml of O.IM sodium hydroxide, and 0.25 ml of 10% formic acid). To calibrate the 
instrument, the appropriate tune page that will be used for the LC-MS run was loaded. The 
correct ionisation (ESL or ESI^) and V or W modes were then selected. The detector voltage 
was set similar to the method that will be used. The Lock Spray display was selected for 
“Analyte”. For calibration, the source and desolvation temperature were set to 80°C and 
180°C, respectively. The scan time, inter scan delay, and mass range in the tuning setup were
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set to be identical with the method that will be used, in this case, scan time: 0.3 seconds, inter 
scan delay: 0.02 seconds, start mass: 50, and end mass: 950. The data format was set to as 
centroid. Next, the uncalibrated file was loaded (Tune page > Calibrate TOF > File > Open > 
Uncal).
The Hamilton syringe and the PEEK (polyether ether ketone) tubing for delivering the 
calibration solution into the mass spectrometer were washed with acetonitrile (three times the 
full syringe volume) before being filled with sodium formate. The calibration solution was 
infused to the QToF Premier via the analyte source at a flow of 10 pl/min. Detection intensity 
in the ESI^ mode was normally higher than in the ESF and therefore the flow rate of 5 pl/min 
was used when calibrating in the ESI^ mode. The ions-per-push (IPP) value for the peaks was 
ensured to be below 0.1 by dropping the capillary voltage (IPP value of 0.09 was the best). 
When the infusion of sodium formate was stabled, the spectra were acquired for 3 minutes 
with the scan rate of 0.3 seconds, inter scan time of 0.02 seconds, and in the continuum 
format. Once acquisition was completed, the syringe pump was stopped immediately. 
Figure 2.12 shows some of the displays of acquiring scans for sodium formate.
All the scans acquired were summed, and background subtracted. These were then 
smoothed, centred, and the spectra saved (Figure 2.13). Then, the correct reference in the 
uncalibrated file was selected, i.e. ESI NaFormate Neg or ESI NaFormate Pos. The 
instrument was calibrated by selecting Tune page > Calibrate TOF > Calibrate > Create 
calibration. The acquired data file was highlighted and the last smoothed and centred 
spectrum in the History was selected. Calibration was accepted if the RMS residual has a 
value of < 2e-4 amu (Finished > Accept calibration > Save file as > Rename the file).
The tune page that will be used for the samples analysis was loaded and checked that 
the newly created calibration file was selected. Once the calibration was completed, the 
PEEK tubing and the syringe was disconnected and washed three times with acetonitrile.
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Figure 2.13 cont: Steps in calibrating QToF Premier using the acquired sodium formate 
scans. (A) Sum all scans, (B) subtract background, (C) smooth, (D) centre, and (E) save spectra. 
(F) Set the correct reference in the uncalibrated file. (G) Highlight the acquired data file and (H) 
select the last smoothed and centred spectra from the History. (I) Accept calibration if the RMS 
residual has a value of less than 2e-4 amu.
Inlet and MS method files setup
Mass chromatograms and mass spectra were acquired by MassLynx™ software 
version 4.1 (Waters) in centroid format at the rate of 0.3 sec./scan with an interscan delay of 
0.02 seconds. The scan range was between 50 -  950 m/z.
Intermittent injection of lock mass, leucine enkaphaline [(M -  H)' 554.2615 m/z, 
(M + H)^ 556.2771 m/z], was used in real tiiue to maintain mass accuracy. The scan time was 
1 second with 10 seconds frequency. The mass window was set to ± 0.5 Da with the scan 
average to 10. The collision energy used was 5 V for both ionisation modes and the sampling 
energy for EST mode was 28V and 40 V for the ESI^ mode.
The autosampler syringe draw rate was 100 pl/min. and the full loop overfill factor 
was 2 times. Other conditions and settings for the inlet and MS method files were as
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mentioned earlier (Section 2.23.2.2). Examples of the inlet and MS method files are shown 
in Supplementary Figures SI and S2.
2.2.3.2.5 Starting the LC-MS run
The mobile phase and lock mass flow was stopped temporarily to connect the outlet tubing of 
the Acquity UPLC® system and Reagent Manager to the QToF Premier via the analyte and 
reference source, respectively. The flow was re-established and the background noise of the mobile 
phase was checked to ensure that it was low. The lock mass signal was also checked to ensure that the 
correct mass was detected and the counts were approximately 700 counts.
The Sample List was created and all samples for the run highlighted. Automatic shutdown 
was enabled by checking the “Enable shutdown after batch” box (Figure 2.14). The LC-MS run was 
set off by selecting the “Play” symbol on the tune page.
ShutOownAM.acl - Shutdown
File Edit View Control List Shutdown Log
■  f  I
Help
Shutdown Auto Control Tasks ■
Batch Control 
□1
Enable shutdown
I Enable startup 
‘ before batch
after batch C: \fv1 assLynxSS hutdown\S hutD owrAf^ . acl
Browse.
Browse.
O  Shutdown if queue is in pause
Shutdown Time Shutdown On Error
Shutdown time after batch or error [mins): 1 00 Configure error shutdown.
Optimization 
O  Optimize
E-mail on Error Shutdown 
O  E-mail recipient
Figure 2.14: How to enable automatic shutdown of the UPLC-QToF MS system once the runs 
are completed. Select the “Edit Shutdown or Startup” menu on the MassLynx main page and then 
checking the “Enable shutdown after batch” with the correct file loaded.
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2.2.3.2.6 S h ut down and column storage
Acquity UPLCf^ system
At the end of the run, if the mobile phase was still flowing, it was stopped manually,
and the analyte line connecting the Acquity UPLC® system to the QToF Premier
disconnected. The column was flushed at a low flow rate for 30 minutes or longer with the
mobile phase to remove residual samples. If buffer was used (e.g. for the Luna® 3pm NH2
100 A and Synergi™ 2.5 pm Polar-RP 100 A column), the mobile phase containing buffer
was replaced with water and the Acquity UPLC® system was “wet primed” and column
flushed to remove all traces of salts that might precipitate in the system when high organic
content solvents was introduced to the instrument/column for different LC-MS protocols.
After flushing the system and column to remove any residual salts or samples, the
recommended storage solution was flowed through the column (Table 2.5), i.e. 50%/50%
methanol/water for the Acquity UPLC™ BEH Cig column; isopropanol for Luna® 3pm NH2
100 A column; and 65%/35% acetonitrile/water for Synergi™ 2.5 pm Polar-RP 100 A
column. The column was removed and the nuts/caps were placed back on both ends to
prevent the column from drying up or contaminated. The temperature of the autosampler and
column was reset to the ambient temperature.
Reasent Manaser
In the Inlet method, the lock mass was set to automatically stopped once the LC-MS 
run was completed. If by the end of the LC-MS run the lock mass was still running, it was 
stopped manually. The outlet tubing of the Reagent Manager was then disconnected from the 
QToF Premier.
OToF Premier
When the QToF Premier was not in use, the “Shutdown” tune page was loaded and 
the collision gas was switched off. In the “Shutdown” tune page, the source and desolvation 
temperature were set to 40°C. The capillary, sampling cone, and extraction voltage and the 
cone and desolvation gas flow were set to either zero or minimal level (Figure 2.15).
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Figure 2.15: Settings of the “Shutdown” tune page. The temperature of the source and 
desolvation were 40 °C. The capillary, sampling cone, and extraction cone voltage and the cone 
and desolvation gas flow were set to either zero or at minimal level.
2.2.3.3 Analytical variability control and reproducibility
To monitor the performance of the instrument, a test mix containing paracetamol and 
reserpine were used. The test mix was included at the beginning, middle, and end of each set 
of runs. Paracetamol and reserpine were prepared at a concentration of 1 mM in water, with 
the exception of the Synergi™ 2.5 pm Polar-RP 100 Â column, where in 50% aqueous 
acetonitrile (500 pM) was used.
Waters commercially available Metabolomics MS systems test mix were also used for 
the LC-MS analysis utilising the Acquity UPLC™ BEH Cig column. The test mix contained 
theophylline (120 pg/ml), caffeine (120 pg/ml), hippuric acid (120 pg/ml), nortriptyline 
hydrochloride (45 pg/ml), and 4-nitrobenzoic acid (30 pg/ml) dissolved in water.
Standard compounds of the metabolites of interest were used to ascertain the mass 
detected were of the correct metabolites. For the LC-MS analysis using the Synergi™ 2.5 pm 
Polar-RP 100 Â column, some of the cell extract samples were spiked with the standard 
compounds (28 compounds in total) at a concentration of 5 pM. The samples were also used
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in a random sequence to ensure that there was no bias between the early runs and the late 
runs. The column was “conditioned” by running ten injections of 10 pi of cell extracts grown 
under normal condition without any form of treatments (not even DMSO) at the beginning of 
the run.
2.2.3.4 Data processing
Raw spectrometric data obtained from the UPLC-QToF MS system in MassLynx™ 
software version 4.1 (Waters) were processed to generate multivariate data matrix using 
MarkerLynx™ application manager software version 4.1 (Waters). MarkerLynx performed 
extraction by peak finding for each sample and alignment using mass and retention time 
windows for the peaks. However, different columns produced different chromatographic 
profiles, e.g. signal-to-noise levels, peak-shape, and peak-width. Therefore, the MarkerLynx 
method parameters based on Michopoulos et al. (2009) and Pandher et al. (2009) were 
adjusted according to the chromatographic profiles obtained in this study to find the best 
detection and collection of chromatographic peaks and markers. Table 2.7 shows the 
parameters used to generate MarkerLynx data matrix.
Table 2.7: MarkerLynx method parameters
Parameters Acquity UPLC™ 
BEH Ci8
Luna® 3pm  
NH2 100 Â
Synergi™ 2.5 pm 
Polar-RP 100 Â
Initial retention time (min.) 0.00 0.00 0.50
Final retention time (min.) 14.00 35.00 14.00
Low mass 50.00 50.00 50.00
High mass 950.00 950.00 950.00
Mass tolerance (Da) 0.08 0.10 0.05
Use relative retention time No No No
Peak width at 5% height (sec.) Automatic 60.00 20.00
Peak-to-peak baseline noise Automatic Automatic Automatic
Apply smoothing No Yes Yes
Intensity threshold (counts) 100 5 5
Mass window 0.08 0.05 0.05
Retention time window 0.20 0.50 0.30
Noise elimination level 8.00 No No
Deisotope data No Yes No
The metabolites present in the samples were also quantified using QuanLynx™, 
another application manager within the MassLynx™ software suite. The quantification was 
based on the theoretical m/z value and predicted retention time obtained from chromatograms 
of standard compounds. The mass window was set to 0.02 Da and 10 ppm while the retention
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time window was set to 0.25 minutes. QuanLynx software was selected to integrate samples, 
providing an output in the form of peak area to represent the relative intensity/concentration 
of the metabolites. Figure 2.16 shows an example of the method created to quantify 
glutamate.
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2.2.4 Statistical Analysis
2.2.4.1 Descriptive statistics
The absorbance measured from the MTT and LDH assay was reported as percentage 
of viability relative to the control.
Percentage of viability (%) = Absorbance of sample x 100%
Absorbance of control
The intensity of the detected metabolites in the metabolomics studies was represented 
by the area under curve (AUC) of the peaks in the chromatograms. The monoisotopic mass 
was used for the calculation of the theoretical m/z value. The accuracy of the detected 
metabolites was expressed as ppm.
Accuracy (ppm) = [Measured m/z -  Theoretical m/z| x 10^
Theoretical m/z
All the data generated were summarised and expressed as mean ± S.E.M. (n > 3 
biological replicates) except for the standard compounds in the metabolomics studies, in 
which sometimes only a single run was performed.
2.2.4.2 Inferential statistics
The 50% inhibitory concentration (IC50) was determined by non-linear regression 
with a variable slope model using GraphPad Prism 5 (GraphPad Software Inc., California, 
U.S.A).
Comparison of means was performed by one-way analysis of variance (ANOVA) 
followed by a Bonferroni post-hoc test. When more than two test variables were present, such 
as in the case of the pre-incubation experiment in Section 2.2.2.1.2, two-way ANOVA was 
conducted followed by a Bonferroni post-hoc test. Statistical significance was accepted at 
p < 0.05 level (Overholser and Sowinski, 2007) . The statistical tests were performed using 
GraphPad Prism 5.
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2.2.4.3 Multivariate data analysis
Multivariate data matrix obtained from MarkerLynx was further analysed using 
SIMCA-P+ software version 12 (Umetrics, Berkshire, U.K.). Principal components analysis 
(PCA) and partial least squares for discriminant analysis (PLS-DA) were used to discriminate 
between treatments (Eriksson et al, 2006).
The MarkerLynx data matrix was pre-treated with pareto-scaling before the PCA and 
PLS-DA analyses. The “cleaned” data were than used to generate the PCA and PLS-DA 
models. Both models were fitted with the two first components. The scores scatter plot 
(tl vs. t2, i.e. component 1 vs. component 2) for the PCA and PLS-DA models were 
generated to evaluate the clustering of different treatments, tl was selected for the x-axis and 
t2 for the series (Figure 2.17 A). To better visualise the contribution of the metabolites in the 
separation of the treatments, the loadings 5"-plot for the PLS-DA model was examined. The 
6"-plot (w*c (contribution) vs. p(corr) (realiability/correlation)) was generated by selecting 
“Observations and loadings” data type, w*c for the x-axis, and p(corr) for the series 
(Figure 2.17 B) (Umetrics, 2005).
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Figure 2.17: Plotting of the (A) scores scatter plot and (B) loadings 5-plot. To plot the scatter 
plot, select tl for the x-axis and t2 for the series. To plot the 5'-plot, select observations and 
loadings for the data type. Select p(corr) for the item, w*c for the x-axis and p(corr) for the series.
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Chapter 3: Assessment of Troglitazone Toxicity using a Cell Viability
Assay
The function of a drug is to modify biological processes, resulting in a therapeutic 
benefit (pharmacodynamics, i.e. the effects of a drug on the body). In parallel with the 
positive pharmacodynamic actions of the drug, there will always be some degree of risk of 
negative pharmacodynamic actions, resulting in toxicity. Understanding the toxicology 
profile of a drug is therefore an important key in the drug development process. Indeed, as 
drug discovery and development is a time consuming and expensive process, if a potential 
drug candidate can be eliminated in the early phase of the drug discovery process due to a 
negative balance between positive and negative pharmacodynamic actions, then the 
remaining resources can be used more effectively (Dorato and Buckley, 2006).
The liver is the main site of biotransformation of unwanted chemicals in the body. 
This is due to a number of factors: First, its anatomical position between the gastro-intestinal 
tract and the systemic circulation allows the liver to receive large amounts of nutrients and 
harmful substances via intestinal uptake and portal vein flow, allowing first pass metabolism 
of drugs before they enter the systemic circulation. Second, as the liver has a large blood 
flow, drugs in the systemic circulation are efficiently distributed to it. Third, the liver’s 
metabolic properties enable it to play an important role in the metabolism of exogenous 
substances. All these factors make the liver a crucial site for the metabolism of drugs, and 
hence an important site for the study of drug-induced toxicity (Guillouzo, 1998; Groneberg et 
al, 2002).
There are three major in vitro models to study the effects of hepatotoxins: isolated 
organs, liver slices, and cells. The isolated perfused liver is closest to the in vivo condition, 
preserving the 3-dimensional organ structure and cell-to-cell interactions. However, the 
viability of ex vivo perfiised organs is only short-term ( 2 - 4  hours) and the experimental 
setup is complex. There are also ethical concerns over the large animal usage in this model, 
and the study of human liver metabolism is absolutely impractical in this manner (Groneberg 
et al, 2002; Guillouzo, 1998). In contrast, precision-cut liver slices model can be obtained 
from all species, including humans, using tissues removed during surgery or biopsies. The 
lobular structure is partially preserved, maintaining tissue organisation and cell-to-cell matrix 
interactions. However, the main limitations of this model are the short viability ( 1 - 2  days), 
and missing bile flow (Groneberg et al, 2002; Guillouzo, 1998). Isolated liver cells are the
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most frequently used in vitro liver model and have been widely used to examine the effects of 
drugs on the cellular level (Groneberg et a l, 2002; Guillouzo, 1998; Davila et a l, 1998). 
Cultured liver cell systems are well-established, with a variety of isolation, culture, and 
cryopreservation methods available. The absence of organ-specific cell-to-cell interactions is 
probably the main disadvantage of using isolated hepatocytes in culture, but more recently, 
3D-liver culture models have become available to mimic the in vivo environment (Meng, 
2010). In addition, the application of stem cells in toxicology is also increasing due to their 
undifferentiated characteristics that can give rise to more specialised cells (Davila et al, 
2004).
Primary human hepatocytes are the “gold standard” of cultured liver cells. They retain 
much of the biotransformation capacity of the liver, which is important in toxicological 
studies. However, it should be noted that the activity of specific systems such as cytochrome 
P450 is generally much lower compared to in vivo system, which is a potentially limiting 
factor. Perhaps a more important limiting factor is that healthy primary hepatocytes are scarce 
and not readily available to all investigators. In addition, samples from different donors have 
huge variations in expression and functions of drug-metabolising enzymes, which is due to 
varying donors’ genetics, and this can complicate data analysis. Finally, primary hepatocytes 
culture has limited longevity, lasting approximately 1 week in culture. On the other hand, 
immortalised hepatoma cell lines have indefinite proliferative capacity, and can be grown 
easily in vitro. Even though these cells typically exhibit significantly reduced hepatocyte 
functions, such as low levels of liver-specific drug-metabolising enzymes and transcription 
factors, they could still potentially serve as the basis of more practical alternative 
experimental systems (Guillouzo, 1998; Donato et a l, 2008; Guguen-Guillouzo and 
Guillouzo, 2010).
In this study, HuH-7 cells were used as a model system to study the toxicity of 
troglitazone. Although HuH-7 has low drug/xenobiotic metabolic capacity and is a form of 
cancer cells, it is still a good hepatocyte model, especially for the study of the toxicity effect 
of parent drug. In addition, the cell line is stable and the metabolic capacity is inducible (Choi 
et al, 2009). As discussed in the introduction, troglitazone was selected for this study 
because it is a well-known hepatotoxicant, whilst other drugs from the same class of TZDs 
such as rosiglitazone and pioglitazone, do not exhibit the same toxic effect. Specific 
experiments were carried out to determine the following objectives:
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Objective 1: Determination of the IC50 values of troglitazone, rosiglitazone, and 
pioglitazone by MTT assay.
Objective 2: Investigation of the factors contributing to troglitazone-induced hepatotoxicity.
Objective 3: Assessment of replacing glucose with galactose in the culture medium to 
enhance the sensitivity of MTT assay in detecting troglitazone toxicity.
Objective 4: Determination of troglitazone IC50 value by LDH assay.
3.1 Optimisation of the MTT assay
The MTT assay is an indirect measure of cell viability, reflecting mitochondrial 
activity within cells. Before the effects of TZDs on HuH-7 cells were assessed, a method 
optimisation experiment was carried out to determine (1) the optimum incubation time for the 
MTT solution and (2) the relationship between seeded cell number and MTT absorbance. 
Cells were seeded for 24 hours before the MTT assay was carried out. As shown in Figure
3.1 A, increasing the incubation time longer than 150 minutes did not increase the measured 
absorbance, and this was independent of the original seeding density; on this basis 
150 minutes incubation with MTT was selected for future experiments. Figure 3.1 B shows 
the MTT absorbance at 150 minutes resulting from various initial cell seeding densities. From 
the graph, it can be deduced that the optimum number of cells for seeding in a 6-well plate 
was 3x10^ cells/well. At higher density, the absorbance of the MTT assay was not linear and 
had begun to plateau. Therefore, the MTT incubation time was set at 150 minutes while the 
seeding density for HuH-7 cells in a 6-well plate was set at 3 x 10^  cells/well.
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Figure 3.1: Optimisation of the MTT assay. Effects of (A) MTT solution incubation time and 
(B) cell seeding density on MTT absorbance. HuH-7 cells were seeded at various densities in 
6-well plates prior to the MTT assay 24 h later. (A) MTT solution was incubated with the cells for 
90, 150, and 240 min. and (B) 150 min. Plotted absorbance values were corrected for dilution 
factor. Linear regression was used to fit the data in (B). Data shown as mean ± S.E.M. (n = 3 
independent experiments).
3.2 Effects of TZDs on HuH-7 cells: Assessed by the MTT assay
The cytotoxicity of three different TZDs drugs (troglitazone, rosiglitazone, and 
pioglitazone) was evaluated with HuH-7 cells. MTT assay, which measures cellular 
metabolic activity, was used as a predictor of cytotoxicity. The dose-response curves were 
employed as the basis to determine the IC50 value of each drug. Drugs with lower IC50 values 
indicate a more potent cytototoxin and vice versa.
Using the optimum MTT incubation time and cell seeding density derived from 
Section 3.1 the dose-response relationship between TZDs and HuH-7 cells after 24 hours of 
exposure was evaluated. All the three TZDs showed a dose-dependent cytotoxic effect 
towards HuH-7 cells (Figure 3.2 A -  C). The dose-response curves for these three drugs 
were, however, very different from each other. Troglitazone was the most toxic, being able to
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kill approximately 100% of the cells at a concentration of 50 pM. On the other hand, 
rosiglitazone was the least toxic, with nearly 100% of HuH-7 cells still viable at a 
concentration of 50 pM. Even at a concentration of 350 pM, rosiglitazone only produced 
approximately 50% toxicity of HuH-7 cells. The toxicity of pioglitazone was in between 
troglitazone and rosiglitazone, with approximately 35% cell kill at a concentration of 50 pM, 
and approximately 40% cytotoxicity observed at the maximal concentration used (70 pM).
Based on the dose-response curves, the 50% inhibitory concentration (IC50) of the 
three drugs were determined by non-linear regression. Table 3.1 shows the IC50 values of the 
TZDs. Using this measurement, troglitazone was the most potent cytotoxin, followed by 
pioglitazone, and then rosiglitazone.
Table 3.1: IC50 values of TZDs
TZDs ICsoCpM)
Troglitazone 22.1 ±1.5"
Rosiglitazone >124.7 ±6.5'=
Pioglitazone >29.7 ±8.1 “
I C 5 0  values were calculated by non-linear regression, based on the respective dose-response curves. 
Constraints were set as top =100 and bottom > 0. The mean ± S.E.M. are shown (n > 3 independent 
experiments). Data were analysed by one-way ANOVA followed by Bonferroni post-test. Different 
superscript letters denote significant differences {p < 0.001).
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Figure 3.2: Dose-response curves of (A) troglitazone (TGZ), (B) rosiglitazone (RGZ), and 
(C) pioglitazone (PGZ). HuH-7 cells were seeded in 6-well plates (3x10^ cells/well; 5 ml/well of 
culture medium). After an overnight incubation, they were exposed to the drugs at various 
concentrations for 24 h. DMSO was maintained at 0.5% (v/v) and cytotoxicity was assessed by the 
MTT assay. Percentage of viability was calculated relative to the untreated control. Non-linear 
regression was used to fit the data. Data shown as mean ± S.E.M. (n > 3 independent experiments).
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3.3 Co-exposure of HuH-7 cells with troglitazone and rifampicin, L-buthionine-
sulfoximine (BSO), paracetamol, or galactosamine
Troglitazone has been withdrawn from the market for more than a decade, but till 
now, there is compelling scientific evidence for the molecular mechanism that underlies 
troglitazone hepatotoxicity. However, several hypotheses have been postulated, including the 
formation of reactive metabolites, mitochondrial dysfunction, oxidative stress, apoptosis and 
PPARy-dependent steatosis, and inhibition of bile salt export pump leading to cholestasis 
(Masubuchi, 2006; Chojkier, 2005). Troglitazone associated hepatotoxicity was defined as an 
example of idiosyncratic toxicity, due to its rarity in the population (less than 1 in every 
10,000 patients treated) (Chojkier, 2005). Because of this rarity, it has been hypothesised that 
troglitazone hepatotoxicity may be due to low-level perturbation of endogenous metabolic 
pathways, which only results in overt toxicity in a small number of patients due to 
stochasticity.
The aim of this experiment was to investigate the factors contributing to troglitazone 
toxicity, using cytotoxicity as an indirect measurement. HuH-7 cells were simultaneously 
treated with troglitazone and (1) rifampicin, a compound that will increase liver metabolising 
enzyme activities, potentially increasing bioactivation of troglitazone; (2) BSO, a compound 
that will deplete glutathione synthesis, causing reduced protection from oxidative damage; 
and (3) paracetamol and (4) galactosamine, i.e. classic hepatotoxicants, to evaluate the effect 
of interaction with other hepatotoxicants.
Initially, the effects of rifampicin, BSO, paracetamol, and galactosamine on HuH-7 
cells alone were evaluated by the MTT assay. Figure 3.3 shows the dose-response curves of 
the four compounds, with derived IC50 values presented in Table 3.2. Rifampicin was the 
most potent toxin with an IC50 value of 200.0 ± 35.1 pM. Galactosamine was the second most 
potent toxin, followed by paracetamol. The IC50 values for galactosamine and paracetamol 
were in the millimolar range. On the contrary, BSO did not have any cytotoxic effect on 
HuH-7 cells over the concentration range tested (Figure 3.3 B), and thus the IC50 value is 
expressed as > 10 mM.
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Figure 3.3: Dose-response curves of (A) rifampicin (RIF), (B) BSO, (C) paracetamol (PCM), 
and (D) galactosamine (GaIN). An overnight pre-seeded HuH-7 cells (3 x 10^  cells/well; 
5 ml/well of culture medium) were treated with various concentrations of the test compounds for 
24 h and viability determined by the MTT assay. Rifampicin was dissolved in DMSO (0.5%, v/v) 
while the rest were dissolved in culture medium. Percentage of viability was calculated relative to 
the untreated control. Non-linear regression was used to fit the data. Data shown as mean ± S.E.M. 
(n > 3 independent experiments).
Table 3.2: IC5 0  values of rifampicin, BSO, paracetamol, and galactosamine
Compounds IC5 0
Rifampicin 200.0 ±35.1 pM"
BSO > 1 0  mM"'"
Paracetamol 23.8 ± 1.6 mM"
Galactosamine 14.5 ± 2.2 mM
IC50 values were calculated by non-linear regression, based on the respective dose-response curves. 
Constraints were set as top =100 and bottom > 0. The mean ± S.E.M. are shown (n > 3 independent 
experiments). Data were analysed by one-way ANOVA followed by Bonferroni post-test. Different 
superscript letters denote significant differences (p < 0 .0 1 ).
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For the co-exposure experiment, all compounds were tested at the non-toxic level, i.e. 
at, or less than, O.lx of their respective IC50 values: Hence, troglitazone was administered at
2.4 pM, paracetamol at 100 pM, and galactosamine at 2.9 mM. Rifampicin and BSO were 
used at concentrations less than O.lx of their IC50 values, but proven in the literature to be 
sufficient to induce CYP3A4 enzyme activity and depletion of glutathione levels, 
respectively: Rifampicin was used at the concentration of 10 pM while BSO at 100 pM 
(Paris et ah, 2009; Vignati et al, 2005; Ramachandran et al, 1999).
As expected, treatment with the indicated concentrations of each drug alone had a 
minimal impact on cell viability. However, cells treated with troglitazone and rifampicin 
simultaneously, showed a significant decrease in viability as compared to the control, which 
was treated with 0.1% DMSO (Figure 3.4). The decrease, however, was not significant when 
compared to cells treated with either troglitazone or rifampicin alone. Co-exposures of 
troglitazone with BSO, paracetamol, or galactosamine did not show any significant effect at 
the concentration investigated (Figure 3.4). Further investigation of the combined treatment 
of troglitazone with rifampicin at various concentrations revealed that there was no 
significant synergistic effect in the range tested (Figure 3.5).
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Figure 3.4: Effect of co-incubation of troglitazone (TGZ) with (1) rifampicin (RIF), (2) BSO, 
(3) paracetamol (PCM), or (4) galactosamine (GaIN) on HuH-7 cells for 24 h. The cells were 
treated with the non-toxic level of the compounds, i.e. approximately O.lx of their respective IC50 
values or less (troglitazone: 2.4 pM, rifampicin: 10 pM, BSO: 100 pM, paracetamol: 2.9 mM, and 
galactosamine: 1.4 mM). Viability was assessed by the MTT assay and DMSO concentration was 
maintained at 0.1% (v/v). Percentage of viability was calculated relative to the untreated control. 
The mean ± S.E.M. are shown (n = 3 independent experiments). Data were analysed using one-way 
ANOVA followed by Bonferroni post-test (*p < 0.05).
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Figure 3.5: Dose-response curves of HuH-7 cells treated with troglitazone (TGZ) plus 
rifampicin (RIF) for 24 h. The concentration of troglitazone ranges from 2.4 -  120 pM while 
rifampicin was 0, 10, and 50 pM. The MTT assay was used to determine cell viability. DMSO 
concentration was maintained at 0.3% (v/v). Percentage of viability was calculated relative to 
untreated control (without troglitazone and rifampicin). Non-linear regression was used to fit the 
data. The mean ± S.E.M. are shown (n = 3 independent experiments). Data were analysed using 
two-way ANOVA followed by Bonferroni post-test.
3.4 Pre-Incubation of HuH-7 cells with troglitazone, rifampicin, BSO, paracetamol,
or galactosamine
The aim of this experiment was to evaluate whether an initial chemical challenge 
resulting in increased bioactivation of drugs, reduced antioxidant level, and interaction with 
other hepatotoxicants, would cause the cells to become more vulnerable to troglitazone 
hepatotoxicity. Therefore, HuH-7 cells were pre-incubated with troglitazone, rifampicin, 
BSO, paracetamol, and galactosamine for 24 hours; and then another 24 hours with the 
combination treatments as in Section 3.3. Although the experimental duration was increased 
by 24 hours, the seeding density was maintained at 3 x 10^  cells/well to prevent the loss of 
cell-cell interaction and contact inhibition properties observed at lower seeding densities. All 
compounds were used at the non-toxic level, i.e. approximately 0 . 1  x IC50 value or less.
Figure 3.6 shows the viability of cells exposed for 24 hours to the vehicle control 
(DMSO), followed by a 24 hours exposure to the previously determined non-toxic 
concentrations of each drug. As expected, there was no significant difference between
105
treatments (Figure 3.6), confirming that 24-hours exposure to these five compounds at the 
non-toxic level did not affect cell viability.
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Figure 3.6: The controls of the “pre-incubation experiment”. HuH-7 cells were treated with 
DMSO for 24 h, followed by another 24 h of treatment with either DMSO, troglitazone (TGZ), 
rifampicin (RIF), BSO, paracetamol (PCM), or GaIN (galactosamine). MTT assay was used to 
assess cell viability. Treatment was conducted at the non-toxic level of each compound 
(troglitazone: 2.4 pM, rifampicin: 10 pM, BSO: 100 pM, paracetamol: 2.9 mM, and 
galactosamine: 1.4 mM). DMSO concentration was maintained at 0.1% (v/v). Percentage of 
viability was calculated relative to untreated control (i.e. treated with DMSO during pre-treatment 
and treatment). The mean ± S.E.M. are shown (n = 3 independent experiments). Data were 
analysed using one-way ANOVA followed by Bonferroni post-test.________________________
Following evaluation of the toxicity of each compound individually, the impact of 
pre-exposing HuH-7 cells to each compounds for 24 hours prior to 24 hours exposure to 
troglitazone was examined. As can be seen fi'om figure 3.7, pre-exposing cells to rifampicin 
or troglitazone, and then co-incubating these two compounds for another 24 hours also did 
not affect cell viability.
Incubating the cells with BSO for 24 hours prior to the combination treatment of 
troglitazone with BSO (TGZ + BSO) did not significantly reduced cell viability in 
comparison to cells that were also pre-incubated with BSO but treated with only DMSO or 
troglitazone for the second 24 hours (Figure 3.8). However, BSO treatment for a total 
duration of 48 hours markedly reduced cell viability. This reduction was significant when 
compared to the cells that were treated with either DMSO or troglitazone in the second 
24 hours, but it was not statistically significant against cells treated with troglitazone plus 
BSO. This result suggests that troglitazone protected the cells from 48 hours of BSO-induced 
oxidative stress. Pre-exposing the cells to troglitazone before the combination treatment 
reduced cell viability, but the effect seems to be an additive cytotoxic effect of troglitazone 
and BSO instead of the expected synergistic effect of the combined treatment.
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Figure 3.7: Pre-incubation with rifampicin and troglitazone. The survival of HuH-7 cells after 
pre-treatment with rifampicin (RIF) and troglitazone (TGZ) for 24 h, followed by another 24 h of 
treatment with the compounds in combination were determined by the MTT assay. Treatment was 
conducted at the non-toxic level of each compound (troglitazone: 2.4 pM, rifampicin: 10 pM). 
DMSO concentration was maintained at 0.1% (v/v). Percentage of viability was calculated relative 
to untreated control (i.e. treated with DMSO during pre-treatment and treatment). The 
mean ± S.E.M. are shown (n = 3 independent experiments). Data were analysed using two-way 
ANOVA followed by Bonferroni post-test.
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Figure 3.8: Pre-incubation with BSO and troglitazone. The survival of HuH-7 cells after pre­
treatment with BSO and troglitazone (TGZ) for 24 h, followed by another 24 h of treatment with 
the compounds in combination. The MTT assay was used to assess cell viability. Treatment was 
conducted at the non-toxic level of each compound (troglitazone: 2.4 pM, BSO: 100 pM). DMSO 
concentration was maintained at 0.1% (v/v). Percentage of viability was calculated relative to 
untreated control (i.e. treated with DMSO during pre-treatment and treatment). The mean ± S.E.M. 
are shown (n = 3 independent experiments). Data were analysed using two-way ANOVA followed 
by Bonferroni post-test (*/? < 0.05, **p < 0.01).
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To further examine the pre-incubation effect with BSO, cells were pre-incubated with 
various concentrations of BSO for 24 hours, followed by the combination treatment of 
troglitazone and BSO. These data confirmed that troglitazone exhibited a protective effect 
against BSO toxicity (Figure 3.9).
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Figure 3.9: Dose-response curves of HuH-7 cells pre-treated with BSO. Cells were treated with 
BSO for 24 h, followed by another 24 h of combined treatments of troglitazone (TGZ) and BSO. 
The concentration of BSO ranges from 0 .1 -5  mM while troglitazone was 0 and 2.4 pM. The 
MTT assay was used to determine cell viability. DMSO concentration was maintained at 
0.1% (v/v). Percentage of viability was calculated relative to the untreated control (without 
troglitazone and BSO treatment). The mean ± S.E.M. are shown (n = 4 independent experiments). 
Data were analysed using two-way ANOVA followed by Bonferroni post-test (***p < 0.001 vs. 0 
pM troglitazone, according to the respective BSO concentrations).
Incubation with paracetamol prior to the combination treatment (TGZ + PCM) did not 
affect cell viability (Figure 3.10). On the contrary, pre-incubating the cells with troglitazone, 
followed by the combination treatment or with paracetamol alone reduced cell viability 
significantly. This effect appeared to be due to the pre-incubation with troglitazone 
sensitising cells to the cytotoxic effect of paracetamol, as a second 24 hour exposure to 
troglitazone alone did not result in significant toxicity.
Pre-incubating the cells with galactosamine before the combination treatment (TGZ + 
GaIN) also did not have any effect on cell viability (Figure 3.11). When cells were pre­
treated with various concentrations of galactosamine before the co-treatment of troglitazone 
with galactosamine, there was also no significant synergistic effect (Figure 3.12). On the 
other hand, pre-incubating the cells with troglitazone before the combination treatment 
caused the cells to become more susceptible to the toxicity of galactosamine (Figure 3.11).
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Figure 3.10: Pre-incubation with paracetamol and troglitazone. The survival of HuH-7 cells 
after pre-treatment with paracetamol (PCM) and troglitazone (TGZ) for 24 h, followed by another 
24 h of treatment with the compounds in combination. The MTT assay was used to assess cell 
viability. Treatment was conducted at the non-toxic level of each compound (troglitazone: 2.4 pM, 
paracetamol: 2.9 mM). DMSO concentration was maintained at 0.1% (v/v). Percentage of viability 
was calculated relative to untreated control (i.e. treated with DMSO during pre-treatment and 
treatment). The mean ± S.E.M. are shown (n = 3 independent experiments). Data were analysed 
using two-way ANOVA followed by Bonferroni post-test (*p < 0.05, **p < 0.01).
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Figure 3.11: Pre-incubation with galactosamine and troglitazone. The survival of HuH-7 cells 
after pre-treatment with galactosamine (GaIN) and troglitazone (TGZ) for 24 h, followed by 
another 24 h of treatment with the compounds in combination. The MTT assay was used to assess 
cell viability. Treatment was conducted at the non-toxic level of each compound (troglitazone: 
2.4 pM, galactosamine: 1.4 mM). DMSO concentration was maintained at 0.1% (v/v). Percentage 
of viability was calculated relative to untreated control (i.e. treated with DMSO during pre­
treatment and treatment). The mean ± S.E.M. are shown (n = 3 independent experiments). Data 
were analysed using two-way ANOVA followed by Bonferroni post-test (**p < 0.01,
***p< 0.001).
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Figure 3.12: Dose-response curves of HuH-7 cells pre-treated with galactosamine. Cells were 
treated with galactosamine (GaIN) for 24 h, followed by another 24 h of combined treatments of 
troglitazone (TGZ) and galactosamine. The concentration of galactosamine ranges from 1.4- 
70 mM while troglitazone was 0 and 2.4 pM. The MTT assay was used to determine cell viability. 
DMSO concentration was maintained at 0.1% (v/v). Percentage of viability was calculated relative 
to the untreated control (without troglitazone and BSO treatment). Non-linear regression was used 
to fit the data. The mean ± S.E.M. are shown (n = 4 independent experiments). Data were analysed 
using two-way ANOVA followed by Bonferroni post-test (24 pM vs. 0 pM troglitazone, according 
to the respective BSO concentrations).
The protective effect displayed by troglitazone against BSO-induced cytotoxicity was 
further investigated to evaluate whether all TZDs display similar effects. Cells pre-treated 
with various concentrations of BSO for 24 hours were further exposed to BSO alone, BSO 
with the combination of vitamin C or E (positive controls for replaced antioxidant ability), or 
BSO with TZDs (troglitazone, rosiglitazone, and pioglitazone) for another 24 hours. Results 
showed that among the three TZDs, only troglitazone displayed a protective effect 
(Figure 3.13). This indicates that the protective effect of troglitazone against BSO was a 
compound-specific effect. Furthermore, the protective effect of troglitazone was similar to 
that of vitamin E and better than vitamin C at the doses tested (Figure 3.13).
110
150
o
L_
cou
o
1 0 00)
>
50
!5(0
>
0
2" 24 h treatment:
1®‘ 24 h treatment: D 0 .0  pM □  0.1  pM 1.0 pM BSO
Figure 3.13: The protective effect of troglitazone against oxidative stress. HuH-7 cells were 
pre-treated with 0, 0.1, and 1.0 mM of BSO for 24 h, followed another 24 h of combined treatments 
of BSO with vitamin C, E, troglitazone (TGZ), rosiglitazone (RGZ), or pioglitazone (PGZ). 
Vitamin C, E, troglitazone, rosiglitazone, and pioglitazone were tested at 50, 40, 2.4, 11.2, and 
2.7 pM, respectively. DMSO concentration was maintained at 0.5% (v/v). The MTT assay was 
used to determine cell viability. Percentage of viability was calculated relative to control (without 
BSO), according to individual treatment group. The mean ± S.E.M. are shown (n = 3 independent 
experiments). Data were analysed using two-way ANOVA followed by Bonferroni post-test 
(*p < 0.05, **p < 0.01 vs. untreated, according to the concentration of BSO treatment; §p < 0.05 
vs. 0 mM treatment of BSO, according to each treatment group).
3.5 Incubating HuH-7 cells in galactose culture medium
Most highly proliferative cells such as cancer eells produce ATP via the pyruvate- 
lactate pathway in glyeolysis, even when oxygen is plentiful (Vander Heiden et al, 2009). 
This may cause xenobiotics that damage mitochondria to go undetected in conventional cell- 
based assay system that uses cancer cells as model hepatocytes. HuH-7 cells originated from 
a liver tumour (Nakabayashi et al, 1982; Nakabayashi et al, 1982) while troglitazone has 
been shown to disrupt mitochondrial function (Tinnenstein et al, 2002), and thus it is 
possible that troglitazone-mediated mitochondrial toxicity may be poorly detected in this 
model. Substituting glucose with galactose in the culture medium as described by Marroquin 
et a l (2007) has been proposed to increase the detection sensitivity of cell-based assay 
systems towards mitoehondrial toxicants such as troglitazone. The following experiment was
I l l
undertaken to investigate whether culturing cells in galactose medium was an effective 
method to increase the sensitivity of MTT assay towards troglitazone toxicity.
HuH-7 cells cultured in culture medium where galactose had been substituted for 
glucose appeared to be more “fragile” than those cultured in high-glucose medium. They 
proliferate slower in comparison to the cells cultured under high-glucose medium and also 
detached easily from tissue culture plasticware. Furthermore, it was observed that after 
150 minutes of incubating the cells with MTT solution, cells cultured in galactose medium 
began to detach even though they were still viable, as indicated by the purple formazan 
crystals visible in the cells. The purple formazan crystals were the products of functional 
mitochondrial activity, i.e. converted from the water-soluble yellow MTT. One of the steps in 
the MTT assay was to remove medium-containing MTT prior to the solubilisation of the 
purple formazan with DMSO (Section 2.2.2.1). The MTT assay protocol had to be modified 
by omitting that particular step to avoid losing the formazan crystals in the detached cells. 
Instead, DMSO was added without removing the medium containing MTT. Detailed 
description of the modified MTT assay has been documented in Section 2.2.2.1.3.
Figure 3.14 shows the MTT results of cells cultured under either high-glucose or 
galactose media without troglitazone treatment. The results showed that cells cultured in 
galactose medium exhibited lower viability in comparison to those cultured in high-glucose 
medium. The viability of cells culture under galactose medium also reduced with increasing 
culturing time (passage number). Addition of 1 mM pyruvate as an alternative energy source 
did not have any effect on cell viability in either media.
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Figure 3.14: Effect of culturing cells in galactose culture medium. HuH-7 cells were seeded in 
6-well plates and cultured in either glucose or galactose medium, without/without pyruvate. After 
an overnight incubation, they were treated with 0.5% DMSO for 24 h. Cell viability was assessed 
by the MTT assay. Percentage of viability was calculated by nonnalising the absorbance against 
the absorbance of cells cultured in glucose medium, according to respective passage number. The 
mean ± S.E.M. are shown (n = 3 independent experiments). Data were analysed using two-way 
ANOVA followed by Bonferroni post-test. Effect of culture media: */? < 0.05, **p < 0.01, 
***p < 0.001; effect of passage number: §§p < 0.01, §§§p < 0.001).
Having determined that cells grown using galactose as the primary energy source 
present in the medium exhibited a lower viability under control conditions, we next examined 
the impact of troglitazone on cell viability. When the cells cultured in galactose for 1, 2, or 4 
passages were treated with troglitazone (2.4 and 12 pM) for 24 hours, the results did not 
indicate an increased sensitivity towards troglitazone compared to cells cultured in high 
glucose-containing medium.
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Figure 3.15: Effect of troglitazone on HuH-7 cells cultured in galactose culture medium.
HuH-7 cells cultured in glucose or galactose medium, without/without pyruvate were seeded in 
6-well plates and allowed to adhere overnight. They were then treated with 0, 2.4, and 12 pM of 
troglitazone (TGZ) for 24 h. The concentration of DMSO was maintained at 0.5%. MTT assay was 
performed to determine cell viability. Percentage of viability was calculated by nonnalising the 
absorbance against the absorbance of the untreated control (0 pM troglitazone), according to each 
types of culture medium. The mean ± S.E.M. are shown (n = 3 independent experiments). Data 
were analysed using two-way ANOVA followed by Bonferroni post-test (**/? < 0.01).
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3.6 Dose-response curves of TZDs using low-glucose culture medium
Growing cells in high-glucose conditions is the typical practice in tissue culture 
(Freshney, 2010). However, the concentration of glucose contained in such medium (25 mM) 
is fivefold higher than the physiological level (Marroquin et al, 2007). While such conditions 
promote good growth of cells under culture, it will also move cells away fi'om the normal 
balance of energy generation towards an increased dependence on aerobic glycolysis. Two 
methods are recommended to stop the dependence of cells on aerobic glycolysis: First, to 
substitute glucose with galactose in the medium, increasing the reliance on mitochondria 
oxidative phosphorylation (Marroquin et al, 2007); second, to use a low-glucose (5.5 mM) 
culture medium. The following experiment was conducted to evaluate whether changing the 
culture medium from high- to low-glucose affected the MTT dose-response curves of 
troglitazone, rosiglitazone, and pioglitazone.
The MTT dose-response curves of HuH-7cells exposed to troglitazone, rosiglitazone, 
or pioglitazone for 24 hours under low-glucose conditions (5.5 mM) are shown in 
Figure 3.16. The curves for all three TZDs under low-glucose conditions are consistent with 
those generated under high-glucose conditions. The generated IC50 values form these dose- 
response curves were not significantly different for troglitazone and rosiglitazone, but was 
significantly different for pioglitazone, although there was more uncertainty around the IC50 
determination for this chemical (Table 3.3).
Table 3.3: IC5 0  values of TZDs performed under high-glucose (25 mM) vs. low-glucose 
(5.5 mM) conditions
TZDs High-glucose conditions Low-glucose conditions
Troglitazone 22.1 ±1.5 pM" 25.9 ±1.8 pM^
Rosiglitazone > 124.7 ± 6.5 nM " > 168.9 ± 30.0 pM"
Pioglitazone >29.7 ±8.1 nM “ > 79.4 ± 13.5 n M '
IC50 values were calcu 
Constraints were set as 
experiments). Data wei 
superscript letters deno
ated by non-linear regression, based on the respective dose-response curves, 
top =100 and bottom > 0. The mean ± S.E.M. are shown (n > 3 independent 
•e analysed by two-way ANOVA followed by Bonferroni post-test. Different 
te significantly different versus glucose conditions and treatments {p < 0.05).
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Figure 3.16: Comparison of the dose-response curves of troglitazone, rosiglitazone, and 
pioglitazone performed under high- and low-glucose conditions. An overnight pre-seeded 
HuH-7 cells (3 x 10^  cells/well; 5 ml/well of culture medium) were treated with various 
concentrations of troglitazone (TGZ), rosiglitazone (RGZ), and pioglitazone (PGZ) for 24 h and 
viability determined by the MTT assay. DMSO was maintained at 0.5% (v/v). Percentage of 
viability was calculated relative to the untreated control. Data shown as mean ± S.E.M. (n > 3 
independent experiments).
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3.7 Lactate dehydrogenase (LDH) assay
The MTT assay is a marker of mitochondrial activity, and thus can represent altered 
cell number or mitochondrial inhibition. To complement this approach, levels of lactate 
dehydrogenase (LDH) were determined in the medium. The cytosolic enzyme LDH is 
released from cells that have a compromised plasma membrane. As such, the readout from 
these two assays can be used to evaluate whether troglitazone-exposure of HuH-7 cells 
causes cellular destruction or metabolic compromise.
Figure 3.17 shows the LDH dose-response curve of troglitazone, in comparison to the 
MTT assay. The dose-response curve measured by the LDH assay was shifted to the right, 
with an IC50 of > 42.7 ±3.6 pM, i.e. approximately two-fold higher than the MTT assay. This 
difference between the IC50 values was statistically significantly different. Furthermore, at the 
maximum concentration used (160 pM troglitazone), LDH assay detected only 70% cell 
death, while the MTT assay has already detected approximately 100% loss of mitochondrial 
activity by approximately 70 pM.
MTT: IC50 = 25.9 ± 1 .8  pM t
LDH: IC50 > 42.7 ± 3.6 pM
1.0 1.5
Log [TGZ] (pM)
o  LDH •  MTT
Figure 3.17: Comparison of the dose-response curves of troglitazone measured by the LDH 
vs. MTT assays, performed under low-glucose conditions. HuH-7 cells were seeded in 6 -well 
plates (3 x 1 0  ^cells/well; 5 ml/well of culture medium). After an overnight incubation, they were 
treated with various concentrations of troglitazone (TGZ) for 24 h. Viability was measured by LDH 
and MTT assays. DMSO was maintained at 0.5% (v/v). Percentage of viability was calculated 
relative to the untreated control. IC50 values were calculated using non-linear regression with the 
constraints set as top = 100 and bottom > 0 . The IC50 values were compared using t-test 
(*p < 0.05). Data shown as mean ± S.E.M. (n > 3 independent experiments).
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3.8 Discussion
The primary aim of the studies condueted in this chapter was to investigate the 
toxicity of troglitazone using a cell-based assay system, more precisely, the MTT assay. A 
secondary aim was to develop a cell culture system that could be used in the liquid 
chromatography-mass spectrometry (LC-MS) analysis (metabolomics approach) utilised in 
subsequent chapters.
The toxicity of troglitazone towards HuH-7 cells after 24 hours exposure generated an 
IC50 value of 22.1 ±1.5 pM. This value was comparable to the results of other researchers: 
Tettey et al. (2001) reported that 24 hours of exposure gave an IC50 value of 35 pM in rat 
hepatocytes and 20 pM in HepG2 (human liver carcinoma) cells. Other studies with different 
cell lines, incubation time, and viability assays have reported the IC50 to be between 1 1 -  
54 pM (Yamamoto et al, 2001; Guo et al, 2006), again consistent with the value obtained in 
this study.
The IC50 values for rosiglitazone and pioglitazone were calculated to be > 124.7 ± 6.5 
and > 29.7 ±8.1 pM, respectively. The expression “equal or more than (>)” was used to 
indicate uncertainty in the generated IC50 value. In this study, it was not possible to test the 
effect of rosiglitazone and pioglitazone at higher eoncentration than what was employed 
because of the need to maintain the concentration of DMSO (used to dissolve the drugs), or 
else the observed reduction in cell viability might be due to DMSO instead of the tested 
drugs. Hence, it is probable that the IC50 values would increase if a full dose-response curve 
could be generated. Although the IC50 value for pioglitazone was not statistically different 
from troglitazone, suggesting they both have similar toxieity, a close inspection of the dose- 
response curves showed that at 22 pM (i.e. the IC50 value of troglitazone), pioglitazone only 
caused approximately 20% cell death whereas troglitazone had redueed 50% of the cell 
viability (Figure 3.2), which is an indication that pioglitazone is actually less toxic than 
troglitazone. Furthermore, at IC50 concentraion of troglitazone (22 pM), cells treated with 
rosiglitazone were still 100% viable. Sueh a lack of toxicity with rosiglitazone is consistent 
with the published literature, where rosiglitazone has been reported to exert almost no 
inhibitory effect on HT-29 cells at eoncentrations below 30 pM, even after 72 hours of 
exposure (Zhang et al, 2007). Taken together, these data point to the fact that troglitazone 
was the most potent toxin of the three compounds tested, followed by pioglitazone and 
rosiglitazone, which is again consistent with the published literature (Yamamoto et a l, 2001; 
Guo et al, 2006; Lloyd et al, 2002).
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The overt hepatotoxicity associated with troglitazone is idiosyncratic (Chojkier, 
2005), suggesting that exposure to the drug itself is not predictive of an adverse event on its 
own, but is subject to a number of, as yet unidentified, risk factors. Three factors that could 
increase troglitazone toxicity were tested indireetly in this chapter, namely (1) bioactivation 
of troglitazone, (2) reduced antioxidant level, and (3) interaction of troglitazone with other 
hepatotoxicants. Bioactivation of troglitazone into reactive metabolites or intermediates has 
been proposed as one of the multiple mechanisms of troglitazone-induced hepatotoxicity 
(Peters, 2005; Alvarez-Sanchez et al, 2006). Troglitazone is metabolised by CYP3A4 
(Alvarez-Sanchez et al, 2006; Tarantino et al, 2009), the major isoform of cytochrome P450 
present in the liver (Gibson and Skett, 2001). As rifampicin is an effective inducer of 
CYP3A4 (Yamamoto et a l, 2002), cells were pre-treated with rifampicin to potentially 
increase the extent of troglitazone metabolism. The IC50 value for rifampicin with HuH-7 
cells was detected as 200.0 ± 35.1 pM, consistent with the high value reported in HepG2 cells 
of 510 pM (Tostmann et al, 2008). In this study the eoncentration of rifampicin used was 
only 10 pM, less than O.lx of its IC50 and therefore can be considered as non-toxic; however, 
10 pM, rifampicin has been shown elicit significant induction of CYP3A4 activity 
(Ramachandran et al, 1999; Paris et al, 2009; Paris et al, 2009). Any observed cell death 
can therefore be most likely attributed to enhanced bioactivation of troglitazone by CYP3A4, 
although it should be noted that the levels of reactive troglitazone metabolites and induction 
of CYP3A4 were not directly quantified.
The objective of co-incubating with rifampicin was the evaluation of its 
posttranslation effects while the pre-incubation experiment was done to evaluate its 
transeriptional effects. Simultaneous exposure of cells to troglitazone and rifampicin at 
concentrations that are non-toxic singly, elicited a significant decreased in cell viability 
(Figure 3.4); however, as the concentrations of troglitazone and rifampicin increased, no 
significant deviation from additivity was observed (Figure 3.5). Such a response could be 
explained by any synergistic effect occurring only at low concentrations of troglitazone, with 
higher concentrations of compounds demonstrating an additive effect. This is supported by 
the fact that the dose-response curve of rifampicin (Figure 3.3 A) demonstrates a cell viability 
of 74% at 50 pM, which is similar to the co-treatment experiment. Pre-incubation of HuH-7 
cells with rifampicin or troglitazone, followed by co-incubation of rifampicin and 
troglitazone also did not show any apparent synergistic toxic effect (Figure 3.7).
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As there was no observable synergistic toxic effect in the co-incubation and pre­
incubation experiments of troglitazone and rifampicin, this could imply that bioactivation of 
troglitazone does not play a major role in the observed toxieity. It should be noted, however, 
that HuH-7 cells have low expression levels of metabolising enzyme, and we cannot discount 
the possibility that rifampicin did not increase the amount of CYP3A4 sufficiently to increase 
troglitazone bioactivation. Although HuH-7 cells have been demonstrated to express low 
levels of drug-metabolising enzymes, but treatment with DMSO (1%) can dramatically 
increase these levels (Choi et al, 2009). Furthermore, the induction of CYP3A4 by 
rifampicin in HuH-7 cells is equivocal (Wang et a l, 2006), and many studies that use HuH-7 
cells for drug metabolism have incorporated heterologous expression systems containing the 
gene of interest (Faucette et al, 2004; Desai et al, 2002; Phillips et al, 2005).
There is substantial evidence that troglitazone is metabolised into reactive metabolites 
(Kassahun et al, 2001; Alvarez-Sanchez et al, 2006; Dixit and Bharatam, 2011; He et al, 
2001), but the role of these reactive metabolites in troglitazone toxicity remains controversial. 
Evidenee for the role of metabolism in troglitazone toxicity is provided by HepG2 eells 
incubated with microsomes containing cDNA-expressed CYP3A4 and HepG2 transiently 
transfected with CYP3A4 expression plasmids. These cells exhibited a decreased cell 
viability compared to naïve cells, suggesting that troglitazone metabolism was important in 
the toxicity; furthermore, in these studies, co-incubation with the cytochrome P450 inhibitor, 
ketoconazole, protected against the decrease in cell viability (Vignati et a l, 2005). However, 
there is much evidence that appears to contradict this study: For example, formation of 
epoxide- and quinone-type metabolites of troglitazone has been reported, but these showed 
weaker cytotoxic effect on HepG2 cells than the parent drug (Yamamoto et a l, 2001; 
Yamamoto et al, 2002). Furthermore, hepatocytes pre-treated with dexamethasone (another 
CYP3A inducer) only demonstrated marginal suseeptibility to troglitazone cytotoxicity 
(Tettey et al, 2001). Consistent with this finding, pre-incubation of HepG2 with P450 
inhibitors (SKF-525A, a non-selective cytochrome P450 inhibitor, and ketoconazole, a 
CYP3A4 inhibitor), did not protect the cells from troglitazone-induced cell death 
(Tirmenstein et al, 2002). Finally, inhibition of sulphation by 2,6-dichloro-4-nitrophenol 
(DCNP), the major metabolism pathway of troglitazone, increased the levels of 
unmetabolised troglitazone with no significant increase in formation of troglitazone quinone 
(the other metabolic pathway of troglitazone metabolism). The inhibition of sulphation 
resulted in increased cytotoxicity, suggesting that the toxicity may be due to accumulation of
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troglitazone itself rather than formation of a reactive metabolite, or that an presently 
unidentified minor reactive metabolite is responsible for the toxicity (Kostrubsky et al, 
2000).
The second factor that was assessed for its ability to mediate troglitazone-induced 
hepatotoxieity was reduced antioxidant levels. Cytotoxicity was used as an indirect 
measurement of decreased GSH levels. It has been previously demonstrated that an 
individual can be susceptible to hepatic damage if the capacity of the usual protective systems 
such as reduced glutathione (GSH) is decreased (Collins, 2002). BSO irreversibly inhibits 
y-glutamylcysteine synthetase (y-GCS) (Griffith, 1982), one of the two enzymes involved in 
the synthesis of GSH, thus reducing the capacity of this protective system. Treating cells with 
BSO has been previously used to lower the cellular GSH levels, producing a BSO model of 
oxidative stress (Griffith and Meister, 1979; Martensson and Meister, 1991; Tanaka et al, 
1998).
The cytotoxicity of BSO was evaluated prior to the co-incubation and pre-incubation 
experiments. The IC50 value for BSO could not be determined as the MTT assay showed no 
change in cell viability at < 10 mM BSO on HuH-7 cells. Thus, it was concluded that the IC50 
value of BSO is > 10 mM. Based on other research, BSO toxicity appears to be highly 
cell-line specific. For example, gastric adenocarcinoma (MKN 28 and MKN 45) and gastric 
cancer (KATO III) cell lines were less cytotoxic towards BSO (Saikawa et a l, 1993) whereas 
BSO has been shown to be cytotoxic towards a panel of human neuroblastoma cell lines with 
IC50 values ranging from 0.7-311 pM (Anderson et al, 1999).
Vignati et a l (2005) demonstrated that 100 pM BSO decreased GSH levels in HepG2 
cells by up to 98% after 48 hours of incubation. Therefore, the concentration of BSO used in 
the co-incubation and pre-incubation studies in this work was set at 100 pM, on the 
presumption that HepG2 and HuH-7 liver cells would respond in a similar fashion. Exposing 
HuH-7 cells to troglitazone and BSO simultaneously for 24 hours did not reduee cell viability 
(Figure 3.4), potentially due to a lack of time to sufficiently reduce GSH levels before 
troglitazone challenge. A pre-incubation with BSO for 24 hours, such that cells received a 
total of 48 hours of BSO exposure, decreased cell viability significantly in the absence of 
troglitazone. Interestingly, when cells were also exposed to O.lx IC50 troglitazone for the 
second 24 hours, there was an antagonistic effect, such that the cells were protected fi'om 
BSO-induced oxidative stress (Figure 3.8). Replacing troglitazone with rosiglitazone and
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pioglitazone did not protect the cells against BSO (Figure 3.9), suggesting that the protective 
effect was a unique property of troglitazone. Aoun et al. (2003) has previously observed a 
similar effect, whereby cultured retinal ganglion cells (RGC-5) exposed to troglitazone 
(<10 pM) were protected against BSO cytotoxicity. A plausible mechanism for this 
protection could be the a-tocopherol moiety in the troglitazone molecule exerted its 
antioxidant effect. Treating the cells with troglitazone prior to the combination treatment of 
troglitazone and BSO reduced cell viability (Figure 3.8) but the observed deerement appears 
to be an additive cytotoxic effect of troglitazone and BSO rather than an enhancement of 
troglitazone eytotoxicity due to lower antioxidant level. Hence, there is no evidence presented 
here to support depletion of GSH as a risk factor for troglitazone-mediated toxicity, with low- 
dose troglitazone even appearing to have some protective ability against such depletion, 
probably through free radical scavenging.
The interaction of troglitazone with other hepatotoxicants was the third form of risk 
factor that was tested. Potential interaction between paracetamol, a elassic model of 
hepatotoxicant that is widely used by the general public, was examined using both the 
co-incubation and pre-incubation experiments. Initially, the IC50 value of paracetamol in 
HuH-7 cells was determined as 23.8 ± 1.6 mM, which was similar to the values obtained in 
other studies using HepG2 cells (Wang et ah, 2002; Tuschl and Schwab, 2004).
The concentration of paracetamol used in the co-incubation and pre-incubation 
experiments was 2.9 mM, approximately O.lx IC50 value. Co-incubation of low-dose 
troglitazone and paracetamol for 24 hours did not affect the viability of HuH-7 cells, nor did 
pre-incubating the cells with paracetamol for 24 hours prior to the combination treatment. 
However, pre-incubating the cells with troglitazone before the combination treatment did 
have a significant impact on cell viability, a similar finding as when cells pre-treated with 
troglitazone were exposed to paracetamol alone. One possible explanation for this effect is 
that troglitazone itself is an inducer of CYP3A4 (Ramachandran et a l, 1999; Sahi et al, 
2000; Sahi et al, 2003; Yueh et al, 2005), and hence could increase the production of 
NAPQI from paracetamol. NAPQI is primarily responsible for the toxic effects of 
paracetamol. Such a hypothesis is consistent with the findings in rats, where administration of 
troglitazone alone has been reported to augment the CYP3A activity and in combination with 
paracetamol increase the paracetamol-induced hepatotoxicity (Li et al, 2002). However, this 
conclusion should be treated tentatively as no direct measure of CYP3A was made in the
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HuH-7 cells, and as noted previously, hepatoma cells have been previously shown to have a 
poor inductive capacity for CYP3A4.
Another chemical that was used examined for potential interaction with troglitazone 
the classic model hepatotoxicant galactosamine. It induces liver injury by interfering with the 
uridine pool in cells as a consequence of its metabolic conversions (Apte and Mehendale, 
2005). Galactosamine is metabolised by the enzymes of the galactose metabolism pathway, 
i.e. galactokinase and galactose-1-phosphate: UDP-glucose uridylyltransferase (Figure 3.18). 
Initially, galaetosamine is converted to galactosamine-1-phosphate. Then, UDP-glucose 
reacts with galactosamine-1-phosphate to form UDP-galactosamine, which is subsequently 
epimerised to UDP-glucosamine. UDP-glucosamine is then converted to glucosamine-1- 
phosphate and undergoes a cascade of reactions, forming UDP-A-acetyl-glucosamine. A 
minor route of galactosamine metabolism is the A-acetylation of galactosamine-1-phosphate 
to A-acetyl-galactosamine-1 -phosphate, which reacts with UTP to form UDP-A-acetyl- 
galactosamine. UDP-A-acetyl-glucosamine and UDP-7V-acetyl-galactosamine are utilised for 
glyeoproteins and glycolipids synthesis. The main event that caused galactosamine toxicity is 
the exhaustion of UDP-glucose, UTP, UDP, and UMP. Unlike in the metabolism of 
galactose, formation of UDP-galactose can serve as uridylate donors in the 
uridylyltransferase reaction but UDP-glucosamine cannot serve as uridylate donor, resulting 
in depletion of uridine nucleotide pool, which ultimately leads to the inhibition of protein and 
RNA synthesis (Coen, 2010; Coen et a l, 2007; Coen et al, 2009). Galactosamine has been 
widely used to induce hepatocyte injury in cultured cells (McMillan, 1999; Park et a l, 2009) 
and also animal models (Wilhelm et a l, 2009; Lin et a l, 2009). Treatment of primary 
cultured rat hepatocytes with 30 mM galactosamine for 24 hours has been shown to 
significantly induce LDH leakage (Park et al, 2009).
The IC50 value of galactosamine obtained in this study was 14.5 ± 2.2 mM, and 
therefore, a non-toxic O.lx IC50 concentration would be 1.4 mM. Co-incubating HuH-7 cells 
with low dose troglitazone and galactosamine for 24 hours did not affect cell viability, nor 
did pre-incubating HuH-7 cells with galactosamine prior to the combination treatment. 
However, statistically significant reduced viability was observed when the cells were pre­
incubated with troglitazone prior to the eombination treatment or with galactosamine alone 
(Figure 3.11). This observation is consistent with the work of Mercer, who examined the 
impact of increasing the incubation times, from 1 to 7 days. The dose-response curves shifted 
to the left as the time of exposure was prolonged, with IC50 values decreasing from
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approximatley 52.5 ± 2.2 pM to 15.3 ± 2.9 pM, indicating an increment in the toxicity of 
troglitazone when the exposure time was increased (E. Mercer 2011, pers. comm.).
U M P
6 lc  " G lc-6 -P
“  11 «
G c - l - P
A fP A D P  ATP AC
U D P -g a lac to se
G lycogen
G lu c u ro n id e s
H e te ro -P o ly s a c c h a r id e s
U D P-G Ic G Ic -l-P
A TPA D P GaIN J X Z  , GalN-l-P
/
U D P-G aiN  U D P-G lcN
A c-C oA
U D P-G lcN G fc N -l-P
II
/ F ru -6 -P  G lcN -G-P T = ±  G lcN  A c-CoA
G a lN A c -l-P  PPi
UTP ^  ^  U D P-G alN A c
11
CoA
G lcN A c-6-P  G lcN A c
II
ManNAc *“
P ro te o g ly c a n s
G lyco lip id s
U D P-G lcN A c
G lcN A c-l-P
UTP
Figure 3.18: Hepatic metabolism of galactosamine. GaIN: galactosamine; GalN-l-P: 
galactosamine-1-phosphate; UDP-GaIN: UDP-galactosamine; UDP-GalNAc: UDP-A-acetyl- 
galactosamine; GalNAc-l-P: A-acetyl-galactosamine-1-phosphate; GlcN: glucosamine; GlcN-l-P: 
glucosamine-1-phosphate; GlcN-6-P: glucosamine-6-phosphate; UDP-GlcN: UDP-glucosamine; 
GlcNAc: A-acetyl-glucosamine; GlcNAc-l-P: A-acetyl-glucosamine-1-phosphate; GlcNAc-6-P: 
A-acetyl-glucosamine-6-phosphate; UDP-GlcNAc: UDP-A-acetyl-glucosamine; Glc: glucose; 
Glc-l-P: glucose-1-phosphate; Glc-6-P: glucose-6-phosphate; UDP-Glc: UDP-glucose; Fru-6-P: 
fmctose-6-phosphate; Ac-CoA: acetyl-CoA. Key for enzymes: 1: galactokinase; 2: UDP-glucose 
pyrophosphoiylase; 3: UDP-glucose: galactose-1-phosphate uridylyltransferase; 4: UDP-glucose 
4-epimerase; 5: UDP-7V-acetylglucosamine pyrophosphorylase; 6: glucosamine-6-phosphate 
deaminase; 7: glucosamine-6-phosphate A-acetyltransferase; 8: phosphoglucomutase;
9: glucokinase; 10: glucose-6-phosphatase; 11: galactosamine-phosphotransferase;
12: galactosamine deaminase. Reproduced from Coen et al. (2010).
A noticeable observation of the “classical hepatotoxicants” is that they appear to be 
less toxic towards HuH-7 cells than troglitazone. The IC50 values were in the order of 
magnitude of millimolar while for troglitazone, the IC50 value was three orders of magnitude
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higher (i.e. micromolar). This probably reflects the low drug/xenobiotic metabolism capacity 
of HuH-7 cells as the toxicity of paracetamol is related to NAPQI, a byproduct of 
paracetamol metabolism. It also implies that troglitazone as the parent drug is very cytotoxic.
Having examined the potential role of other hepatoxicants on troglitazone-mediated 
toxicity, we next examined the theory that troglitazone impacts upon mitochondrial 
functioning. To achieve this, glucose in the culture medium was replaced with galactose: The 
rationale behind this approach was that the vast majority of immortalised cells used in the 
evaluation of drug toxicity are derived from cancerous cells and grown in supraphysiological 
glucose concentrations. Although these cells have competent mitochondria, energy in the 
form of ATP is derived almost exclusively via glycolysis and not through oxidative 
phosphorylation. Because the cells rely on glycolysis to generate ATP, xenobiotics that 
impair mitochondrial function will not show any effect on the cells and the cells appear to be 
resistant towards mitochondrial toxicants (Marroquin et al, 2007; Dykens and Will, 2007; 
Dykens et al, 2007)).
Mitochondrial impairment is increasingly implicated in the aetiology of drug-induced 
toxicity. Many drugs that were removed from the market or had their usage restricted have 
been documented to have mitochondrial liabilities that cause or aggravate toxicities 
(Boelsterli and Lim, 2007; Dykens and Will, 2007; Shishido et a l, 2003). Troglitazone is an 
example of mitochondrial toxicant. Haskins et a l (2001) observed disruption of 
mitochondrial activity, followed by increased membrane permeability, calcium influx, and 
nuclear condensation in rat and human hepatocytes following troglitazone exposure. 
Troglitazone has been observed to induce rapid decrease in mitochondrial membrane 
potentials, which preceded changes in cell permeability and cell count, accompanied by 
increased of intracellular Ca^  ^ in HepG2 cells (Bova et al, 2005; Tirmenstein et a l, 2002). 
Such findings have been replicated in vivo, with studies on liver mitochondria fractions 
showing that troglitazone induced mitochondrial permeability transition and mitochondrial 
Ca^  ^accumulation (Masubuchi, 2006). Troglitazone was also found to be potent inhibitors of 
Complex II + III (succinate-cytochrome c oxidoreductase), IV (cytochrome c oxidase), and V 
(FiFo-ATPase) of the oxidative phosphorylation complexes (Nadanaciva et a l, 2007). 
Troglitazone has also been shown to cause mitochondrial enlargement with 
intramitochondrial electron-dense deposits, resembling myelin-like bodies, indicating 
degraded membrane constituents. In addition, immunofluorescence confocal laser scanning
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microscopy for cytochrome c suggested there was lack of cristae structure within individual 
mitochondria (Shishido et a l, 2003; Masubuchi, 2006).
To generate cell models that are capable of detecting mitochondrial dysfunction, 
Marroquin et a l  (2007) recommended the replacement of glucose in the growth medium with 
galactose. During aerobic respiration, ATP is generated from glucose via three major 
metabolic pathways: glycolysis, tricarboxylic acid cycle (TCA), and oxidative
phosphorylation, which give rise to a net yield of 38 molecules of ATP (Table 3.4) (Salway, 
2004). In comparison, generating ATP via anaerobic glycolysis produces a net total of two 
molecules of ATP (Figure 3.19) (Champe et al, 2008). When galactose is used as the source 
of energy, it must be converted to glucose before it can feed into glycolysis (Figure 3.20), a 
process that requires two molecules of ATP (Mathews et al, 2000; Champe et al, 2008). As 
complete glycolysis to pyruvate (or lactate) yields only two molecules of ATP, the oxidation 
of galactose to pyruvate via glycolysis produces no net ATP, making this an ATP-neutral 
pathway (Marroquin et al, 2007). Under such circumstances, the cells must depend on 
mitochondrial oxidative phosphorylation to generate sufficient ATP for survival.
Table 3.4: Overall yield of ATP via glycolysis, TCA cycle, and oxidative 
phosphorylation (Salway, 2004)
From glycolysis
Substrate-level phosphorylation
Phosphoglycerate kinase 2 ATP
Pyruvate kinase 2 ATP
Oxidative phosphorylation
2 N A D H  + from glyceraldehydes 3-phosphate dehydrogenase 6 ATP
Total: 10 ATP
From TCA
Substrate-level phosphorylation
Succinyl CoA synthetase (via GTP) 2 ATP
Oxidative phosphorylation
8 N A D H  +  H ^ 24 ATP
2 F A D H 2 4 ATP
Total: 30 ATP
Two molecules of ATP were consumed by glucokinase/hexokinase and
phosphofructokinase reaction in the early stage of glycolysis. .’. 4 0 -2 = 38 ATP
Glucose
ATP
AD ?
Hexokinase
Glucokinase
Glucose 6-phosphate
lî Phosphoglucoseisnmerase
Fructose 6-phosphate
AT?
Phosphofructokinase-1
ADPAldose
Dihydroxyacetone phosphate  ^  ^ Fructose 1, 6-bis-phosphate
Triose phosphate ^  Aldose
isomerase
-► Glyceraldehyde 3-phosphate
2 Pi + 2 N A D ^    A Glyceraldehyde
3-phosphate
2 N AD H  + 2H -4 y  | dehydrogenase
2 (1,3-bis-Phosphoglycerate)
2 ADP I A Phosphoglycerate
2 ATP -4— I IdnaseP iî
2 (3-Phosphoglycerate)
lî Phosphoglyceratemutate
2 (2-Phosphoglycerate)
  Enolase
2 (Phosphoenolpyruvate)
2 A D P    I
j  I  Pyruvate 
2 ATP -4—  y  Idnase 
_  L^actate dehydrogenase
2 (Lactate) w Pyruvate
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2N AD + 2 N A D H  + 2H ^
Figure 3.19: Summary of the reactions involved in ATP generation via lactate. The
metabolism yields two moleeules of laetate and a net produetion of two molecules of ATP from 
each molecule of glucose. The thick arrows indicate irreversible reactions of glycolysis. Adapted 
from Champe et ah (2005).
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Figure 3.20: Metabolism of galactose. Galactose is first phosphorylated to galactose 1-phosphate. 
Galactose 1-phosphate must be converted to UDP-galactose in order to enter the glycolytic 
pathway. This is an exchange reaction in which UDP-glucose reacts with galactose 1-phosphate 
producing UDP-galactose and glucose 1-phosphate. For UDP-galactose to enter the mainstream of 
glucose metabolism, it must be converted to UDP-glucose. Then, this new UDP-glucose can 
participate in many biosynthetic reactions as well as being used in converting another molecule of 
galactose 1-phosphate into UDP-galactose, releasing glucose 1-phosphate whose carbon skeleton is 
of the original galactose. Adapted from Matthews et al. (2000) and Champe et al. (2005).
In this study, culturing HuH-7 cells in culture medium containing galactose were not 
more sensitive towards the toxic effects of troglitazone. However, these findings are 
confounded by the observation that the galactose-grown cells were very “fragile” and 
viability was low, even without any troglitazone challenge. According to Dykens, this 
fragility can be mitigated to some degree by replacing glucose with galactose gradually (J.A. 
Dykens 2011, pers. comm.). However, in this study, glucose was immediately replaced with 
galactose and the cells were probably in a “shocked” state due to the sudden lack of glucose 
for energy generation. By allowing the cells to adapt slowly to galactose as the new source of 
energy, this could prevent the vast number of observed cell death, and this is a potential 
pathway for future experiments.
An alternative approach to reduce the reliance of cells on ATP generation from 
aerobic glycolysis has been to switch from high-glucose medium to low-glucose medium. 
Marroquin et al. (2007) reported that treating cells grown under low-glucose conditions with 
the known mitochondrial toxicants such as rotenone, oligomycin, carbonyl cyanide 4- 
(trifluoromethoxy) phenylhydrazone (FCCP), and antimycin caused a significant decrease in
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cellular ATP generation when compared to similarly treated cells grown under high-glucose 
conditions. Pre-treatment with 2-deoxy-D-glucose, a glycolytic inhibitor, reduced further the 
ability of the cells to maintain cellular ATP. This is an indication that low-glucose medium 
decreased the ability of cells to maintain cellular ATP levels via aerobic glycolysis, with the 
emphasis switching towards mitochondrial oxidative phosphorylation.
The IC50 value of troglitazone generated under low-glucose conditions was not 
significantly different from the value generated under high-glucose conditions (Table 3.3), 
and the overall shape of the two dose-response curves were also highly similar. This result is 
perhaps surprising, given that troglitazone is thought to be a mitochondrial toxin, and there 
are several possibilities to explain this. One reason for this could be because low-glucose 
conditions were only used during the 24-hour treatment period. If the cells were maintained 
(grown) in low-glucose conditions for a longer period before being treated with troglitazone, 
this might allow the cells to switch to oxidative phosphorylation for ATP generation and 
become more sensitive towards troglitazone toxicity. In addition, the use of a positive model 
mitochondrial toxin, such as antimycin, would be useful to examine the degree to which ATP 
generation had been switched in this experiment. Interestingly, treating HuH-7 cells with 
rosiglitazone and pioglitazone under low-glucose conditions altered the calculated IC50 values 
from those calculated under high-glucose conditions, but was only significantly different for 
the case of pioglitazone (Table 3.3). The difference in the IC50 values could be because the 
highest concentration of rosiglitazone and pioglitazone used to generate the dose-response 
curves did not cause 100% cell death. Hence, a slight shift on the viability of the highest 
concentration will change the IC50 value quite dramatically since the IC50 was calculated 
based on the highest and lowest viability detected.
The LDH assay detected less toxicity in HuH-7 cells treated with troglitazone in 
comparison to the MTT assay (Figure 3.17). The result suggests that cells treated with 
troglitazone were metabolically compromised before cell damage occurred. As such, this is 
supportive that the model paradigm used did inhibit glycolytic ATP generation to some 
extent, although perhaps not sufficiently to produce a clear effect on the troglitazone IC50 
value.
In conclusion, troglitazone is more toxic to the human hepatoma cell line HuH-7 than 
rosiglitazone and pioglitazone based on the MTT assay. The toxicity is most likely due to 
decrease mitochondrial functionality, as suggested by the fact that MTT values decreased
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before alterations in cell leakage were observed by LDH assay. To examine this further, a 
cell-based assay system that is more sensitive towards mitochondrial toxicants was 
established, whereby cells could be cultured in galactose-containing medium. However, 
results were equivocal, and further work needs to be done in this area. Treatment with 
rifampicin did not increase the toxicity of troglitazone towards HuH-7 cells. Treatment with 
BSO also did not increase the toxicity of troglitazone; instead it protected the cells from 
cellular oxidative stress induced by BSO. Pre-treatment of the cells with paracetamol and 
galactosamine did not enhance the toxicity of troglitazone, but pre-treatment with 
troglitazone enhanced the toxicity of paracetamol and galactosamine.
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Chapter 4: Liquid Chromatography-Mass Spectrometry Investigation of 
Metabolites Linked to Troglitazone-induced Hepatotoxicity
The aim of this chapter was to investigate the feasibility of using a metabolomics 
approach to discriminate troglitazone toxicity and elucidate potential mechanism(s) of 
toxicity based on altered biochemical processes. In this study, metabolomics analysis was 
conducted using liquid chromatography-mass spectrometry (LC-MS), with the 
chromatographic separation performed with an Acquity UPLC™ BEH Cig column. The 
objectives of this study were as follows:
Objective 1: Discrimination of the effect of troglitazone using a metabolomics approach. 
Objective 2: Discrimination of thiazolidinedione (TZD) drugs in terms of hepatotoxicity. 
Objective 3: LC-MS analysis of standard compounds.
Objective 4: Investigation of the effect of non-toxic versus toxic dose of troglitazone. 
Objective 5: Analysis of the dose-response levels of metabolites affected by troglitazone.
4.1 Can metabolomics be used to discriminate the effect of TGZ?
There are numerous published reports of the usefulness of LC-MS analysis in 
answering scientific questions (Wei et al, 2010; Michopoulos et al, 2009; Yang et al, 
2009a; Holcapek et a l, 2008; Lewis et al, 2008). This study was designed to test the 
feasibility of a LC-MS-based metabolomics approach in differentiating cells treated with 
different concentrations of troglitazone.
HuH-7 cells were treated with various concentrations of troglitazone (0 -1 2 0  pM) for 
24 hours and then harvested and processed for LC-MS analysis. Liquid chromatography was 
performed with a reversed-phase gradient over 14 minutes, and the mass spectrometry 
analysis was conducted in the negative ionisation mode (EST). For consistency, all samples 
derived from cell extracts are termed “intracellular samples”, while those samples derived 
from the incubated culture media are termed as “extracellular samples”.
Figure 4.1 shows the total ion current (TIC) chromatograms of the extracellular and 
intracellular samples. The signals are in the form of ions, which represent the mass-to-charge 
ratio (m/z) of the detected metabolites. The TIC plots comprise the summed intensity of the
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entire masses detected at every point in the analysis. Due to their data-rich nature it is 
difficult to make a comparison between conditions and identify differences by looking at the 
TIC plots in isolation. Therefore, multivariate statistical analyses were used to further 
interpret these complex data sets.
Multivariate analysis using partial least square-discriminant analysis (PLS-DA) was 
able to successfully separate intracellular samples derived from cells exposed to differing 
concentrations of troglitazone for 24 hours (Figure 4.2 A). Different concentrations of 
troglitazone treatments can be identified based on the cluster in the scatter plot. As expected, 
technical replicates (LC-MS repeats) clustered closely together, while there was a greater, but 
acceptable, variance between biological replicates (cell sample repeats).
The S-plot shows all the metabolites that were detected across all troglitazone 
concentrations (Figure 4.2 B), and is a useful approach to visualise differentiating 
metabolites. Essentially, metabolites that lie far away from the centre have more significant 
role in driving the separation within the PLS-DA model compared to those located at the 
centre (Bonzo et ah, 2010). As such, metabolites at the top right and bottom left of the ‘S’ are 
selected for further analysis.
Based on the chromatograms, increasing concentration of troglitazone reduced the 
level of a metabolite with the m/z value of 306.0121 (Figure 4.3 A). This information is 
demonstrated clearly when the area under the curve (AUC), which represents integrated ion 
counts, was plotted (Figure 4.3 B). The IC50 value calculated for troglitazone to decrease the 
levels of the metabolite was 19.0 ± 1.1 pM.
Analysis of the extracellular samples from the same experiment by LC-MS is shown 
in Figures 4.4 -  4.5. Again, it was possible to differentiate samples on the basis of their 
treatment by PLS-DA (Figure 4.4 A), and the technical replicates clustered together more 
closely than the biological replicates. In this case, two metabolites that were identified from 
the iS-plot were selected for further analysis (Figure 4.4 B). One metabolite had a m/z value of 
129.0402 and an elution time of 4.94 minutes, while the other metabolite (129.0401 m/z) was 
eluted at 5.20 minutes. Both metabolites were seen to decrease their concentrations with 
increased concentration of troglitazone (Figure 4.5 A). When the levels of the two 
metabolites were plotted using their area under curves (AUC), the IC50 values obtained were
15.6 ± 1.1 and 20.2 ±1.2 pM for the metabolite eluted at 4.94 and 5.20 minutes, respectively
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(Figure 4.5 B). These results suggest that the LC-MS analysis was effective in discriminating 
HuH-7 cells treated with different concentrations of troglitazone.
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Figure 4.1: l otal ion current ( I IC) of (A) intracellular and (B) extracellular samples. HuH-7 
cells were treated with various concentrations of troglitazone (TGZ) for 24 h. The cells were then 
harvested, extracted, and LC-MS analysis was carried out. Chromatography separation was 
performed in reversed-phase gradient of 14 min. while mass spectrometry was conducted in the 
ESI mode.
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Figure 4.2: Multivariate analysis of the LC-MS data obtained from the intracellular samples 
of HuH-7 cells treated with various concentrations of troglitazone for 24 h. (A) Scatter plot of 
PLS-DA analysis, each symbol representing one cell sample. (B) S'-plot of PLS-DA analysis used 
to visualise differentiating metabolites. Each circle in the 5-plot represents a different metabolite 
and the 5-plot shows all the detected metabolites. The highlighted metabolite (306.0121 m/z) has 
the greatest influence on the PLS-DA model and was selected for further analysis. Data shown as 
n = 9 (3 technical repeats x 3 biological repeats).
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Figure 4.3: Further analysis of metabolite 306.0121 m/z. (A) Chromatograms of the metabolite 
when cells were treated with different concentrations of troglitazone. (B) hitegrated ion counts of 
the metabolite represented by the area under the curve (AUC). Increase concentration of 
troglitazone (TGZ) decreased the levels of the observed metabolite. The IC50 value calculated for 
troglitazone to decrease the levels of the metabolite by 50% was 19.0 ± 1.1 pM. Data shown as 
mean ± S.E.M. (n = 3 biological repeats).
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Figure 4.4: Multivariate analysis of the LC-MS data obtained from the extracellular samples 
of HuH-7 cells treated with various concentrations of troglitazone for 24 h. (A) Scatter plot and 
(B) 5'-plot of PLS-DA analysis. The two highlighted metabolites on the upper right quadrant in the 
S-plot represent metabolites with crucial influence on the PLS-DA model. Data shown as n = 9 
(3 technical repeats x 3 biological repeats).
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Figure 4.5: Further analysis of the metabolites highlighted in the iS-plot from the extracellular 
samples. (A) Chromatograms of the two highlighted metabolites (129.0402 m/z eluted at 4.94 min. 
and 129.0401 m/z eluted at 5.20 min.). (B) Integrated ion counts of the observed metabolites. 
Increasing concentration of troglitazone (TGZ) reduced the intensity of both the metabolites. The 
IC50 value of troglitazone by measuring the levels of metabolite eluted at 4.94 min. was 
15.6 ±1.1 gM and 20.2 ± 1.2 gM for the metabolite eluted at 20.2 min. Data shown as 
mean ± S.E.M. (n = 3 biological repeats).
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4.2 Discrimination of TZD class of drugs in terms of hepatotoxicity
Following the positive results obtained in Section 4.1, the next LC-MS analysis was 
performed using samples from cells treated for 24 hours with different TZDs, i.e. 
troglitazone, rosiglitazone, and pioglitazone. The purpose of this evaluation was to examine 
whether a metabolomics approach could discriminate between the known hepatotoxic drug 
(troglitazone) and those drugs with a much lower liability towards hepatotoxicity, i.e. 
rosiglitazone and pioglitazone. In each case, the concentration used was 1 x their respective 
IC50 values, as measured by the MTT assay, ensuring that an equitoxic dose was compared. 
DMSO (0.5%, v/v) was used as the control.
4.2.1 LC-MS analysis: Cells treated with troglitazone, rosiglitazone, and pioglitazone
(intracellular samples)
Figure 4.6 shows the TIC plots of the LC-MS analysis performed in the ESI' mode. 
The TIC plots did not show much difference between the four different types of treatment. 
However, when a PLS-DA analysis was conducted, there was a clear separation between 
intracellular metabolite content of HuH-7 following the different types of treatment 
(Figure 4.7). DMSO-treated samples were separated from the troglitazone- and rosiglitazone- 
treated samples by the first principal component (horizontal axis), and from the pioglitazone- 
treated samples by the second principal component (vertical axis). Troglitazone-treated 
samples appear to be more closely related to the intracellular samples from the rosiglitazone- 
treated HuH-7 cells than pioglitazone-treated samples. These separations imply that there are 
significant differences in the level of metabolites between the treatment groups. However, 
there were too many variables introduced in the PLS-DA analysis (i.e. four different 
treatments), meaning that subsequent data analysis becomes too complicated; in order to 
simplify interpretation, a decision was made to exclude rosiglitazone- and pioglitazone- 
treated samples in the PLS-DA analysis.
The PLS-DA analysis of DMSO versus troglitazone is shown in Figure 4.8 A. The 
results exhibited clear separation between the DMSO- and the troglitazone-treated samples 
by principal component one, indicating that the levels of metabolites present in both samples 
were very distinctive. Ten metabolites that had the most important influence on the PLS-DA 
model in the first component were recorded (Figure 4.8 B). The metabolites were given the 
designation of 1 to 10, according to their contribution to the PLS-DA model, with the suffix 
“I” to represent their origin (intracellular samples).
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Figure 4.6: TIC plots of the intracellular samples of HuH-7 cells treated with DMSO, 
troglitazone (TGZ), rosiglitazone (RGZ), and pioglitazone (PGZ) for 24 h. LC-MS analysis 
was performed with reversed-phase mobile gradient of 14 min. in the ESI' mode.
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Figure 4.7: Untargeted analysis of the intracellular samples of cells treated with various 
TZDs for 24 h. PLS-DA analysis of DMSO vs. troglitazone (TGZ) vs. rosiglitazone (RGZ) vs. 
pioglitazone (PGZ). The LC-MS data was obtained using reversed-phase mobile gradient of 
14 min. in the ESP mode. Data shown as n = 9 (3 technical repeats x 3 biological repeats).________
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Figure 4.8: Untargeted analysis of the intracellular samples of cells treated with various TZDs
for 24 h. PLS-DA analysis of DMSO vs. troglitazone (TGZ) was perfonned to assess the 
differences. (A) Scatter plot and (B) 5-plot of the PLS-DA analysis. The ten most important 
metabolites that influenced the PLS-DA model were labelled as II -  101. The LC-MS data was 
obtained using reversed-phase mobile gradient of 14 min. in the EST mode. Data shown as n = 9 
(3 technical repeats x 3 biological repeats).
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The levels of the ten most important intracellular metabolites to the PLS-DA model 
are plotted in Figure 4.9. The levels of these metabolites from samples treated with 
rosiglitazone and pioglitazone are also displayed for comparison. All the selected metabolites 
exhibited significant differences between troglitazone and DMSO control (compatible with 
the results of the PLS-DA analysis in Figure 4.8 A), with the exception of metabolites II and 
81, which were not statistically significant. When treatment with rosiglitazone was compared 
to the control (DMSO), metabolites 21, 31, 41, 61, and 71 displayed significant reduction while 
metabolites II, 51, 81, 91, and 101 were not significantly different from the control level. 
Comparison between pioglitazone and the control showed that only metabolite 21 and 71 
displayed significant reduction compared to control, while the other eight metabolites were 
not statistically different.
The next target was to find metabolites within these ten that distinguish the 
hepatotoxic troglitazone from the non-hepatotoxie rosiglitazone and pioglitazone (Figure 
4.9). The amount of metabolite 21 was reduced in the samples treated with troglitazone but 
was not statistically significant from cells treated with rosiglitazone and pioglitazone. 
Metabolites 31 and 41 were also reduced in the sample treated with troglitazone but were only 
statistically significant against the pioglitazone samples. Troglitazone treatment caused 
significant increase in metabolite 51 and reduction in metabolite 71 when compared to 
pioglitazone but was similar to the samples treated with rosiglitazone. Treatment with 
troglitazone and rosiglitazone reduced metabolite 61, but showed no significant difference 
from the cells treated with pioglitazone. Metabolite 101 demonstrated significant reduction in 
the troglitazone treatment as compared to the other two types of TZD treatment. On the other 
hand, the levels of metabolite II, 81, and 91 appeared to be similar between the three types of 
TZD treatment. In summary, treatment with troglitazone produced metabolite profiles that 
were distinct from control-, pioglitazone-, or rosiglitazone-treated cells, but were more 
closely related to rosiglitazone-treated cells than pioglitazone.
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Figure 4.9: Levels of the ten most important metabolites (II to 101) that displayed significant 
differences between the DMSO vs. troglitazone treatment in the PLS-DA analysis. The unit 
for elution time was min. The mean ± S.E.M. are shown (n = 3 biological repeats). Data were
analysed using one-way ANOVA followed by Bonferroni post-test (*/?<0.05,
***p < 0.001).
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Figure 4.9 conti Levels of the ten most important metabolites (II to 101) that displayed 
significant differences between the DMSO vs. troglitazone treatment in the PLS-DA analysis.
The unit for elution time was min. The mean ± S.E.M. are shown (n = 3 biological repeats). Data 
were analysed using one-way ANOVA followed by Bonferroni post-test (*/> < 0.05, **p < 0.01, 
0.001).
Metabolites II -  101 were putatively identified based on their m/z values and 
chromatographie profiles. Metabolomics databases sueh as the Human Metabolome Database 
(HMDB), Madison Metabolomies Consortium Database (MMCD), and METLIN Metabolite 
Database were used as reference libraries. Figure 4.10 shows the example of how metabolite 
21 (328.0603 m/z) was identified. A HMDB search provided several putative metabolites 
with similar m/z value as metabolite 21. Mass accuracy tolerance of 40 ppm was set as the 
initial selection criterion. From the list generated by HMDB, reduced glutathione (GSH) had 
the smallest mass accuracy error (~ 6 ppm) and the metabolite was therefore putatively 
identified as GSH. According to the database, metabolite 21 was a GSH adduct with sodium 
[M+Na-2H]‘. Based on the chromatographic profile (Figure 4.11), the parent ion of GSH, 
[M-H]' (» 306.07 m/z) was also detected and it was the major metabolite.
HMDB11616
HMDE00058
HMDB10329
HHDB03601
Adenosine 2',3'-cycllc phosphate 
Cyclic AMP
Dopamine glucuronide 
(S)-Reticuline
C10H12N5O6P
C10H12N5O6P
C14H19N08
C19H23N04
328.045258
[329.052521]
328.045258
[329.052521] 
328,103790 
[329,111053] 
328.155457 
[329,162720]
HMDB01177 (S)-Succinyldihydrolipoamide C12H21N04S2 328,065857[307,091187]
0,015045 M-H [1-]
0,015045 M-H [1-]
0,043488 M-H [1-]
0,095154 M-H [1-]
0,005554 M4-Na-2H [1-]
Figure 4.10: HMDB search result for the identification of metabolite 21. By entering the 
measured m/z into the MS search database, there were 32 hits. Identity was chosen according to the 
smallest mass accuracy error (ppm) with the most plausible explanation of the particular metabolite 
involvement in the process of cell metabolism. The mass accuracy was defined as follows:
Mass accuracy = Theoretical mass (m/z) -  Measured mass (m/z) ^ | q6
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The putative identities of the ten metabolites are tabulated in Table 4.1 while the 
chromatograms and spectra are shown in Supplementary Figure S3. Two metabolites were 
not identified in the HMDB database, 51 and 101. The HMDB displayed several possible 
identities with the same m/z value as metabolite 51 but all exceeded the mass tolerance 
threshold of 40 ppm (Supplementary Figure S4 A). There were several hits below the mass 
accuracy tolerance threshold for metabolite 101, but their identities were not relevant to the 
process of cell metabolism, and hence they can be discounted (Supplementary Figure S4 B). 
Identification based on other databases also did not yield positive results. Metabolites 31 and 
61 were putatively identified as the same metabolite, i.e. mevalonic acid. They have a similar 
m/z value but eluted approximately 0.25 minutes apart (Figures 4.11 C and 4.9 F). However, 
the mass accuracy errors for both were large (~ 40 ppm). Because of the uncertainty of 
putative identifications for metabolites 31, 51, 61, and 101, they were excluded from further 
analysis. Metabolites II and 81 were putatively identified as methyladenine and pyridoxal, 
respectively. Nevertheless, because the levels of these metabolites were not statistically 
different from the DMSO treatment, they were not further investigated.
There were two possible identities for metabolite 41, nicotinuric acid and lactic acid. 
Nicotinuric acid is the major detoxification product of nicotinic acid, a precursor of 
coenzyme NAD^/NADH and NADP^/NADPH, whereas lactic acid is the product of 
anaerobic glycolysis (Mathews et ah, 2000). There were also two possible identities for 
metabolite 71, i.e. malic acid and pyruvic acid. Metabolite 91 was putatively identified as 
acetic acid. Lactic acid, malic acid, and pyruvic acid are all intermediates of glycolysis and 
TCA cycle (Mathews et al, 2000). The results suggest that troglitazone treatment affects the 
glycolysis and TCA cycle, and also may have an effect on coenzyme metabolism and the 
levels of cellular GSH.
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In addition to untargeted analysis of the dataset, targeted analysis was also carried out. 
Troglitazone has been reported to be metabolised to sulphate, quinone, and glucuronide 
derivatives (Tettey et al, 2001; Kostrubsky et al, 2000; Alvarez-Sanchez et al, 2006; Kawai 
et al, 1997; Kassahun et a l, 2001). Based on the chromatograms of the intracellular samples 
(Figures 4.12 A and B), troglitazone sulphate and troglitazone glucuronide (theoretical m/z 
values of 520.1100 and 616.1853, respectively) were not detected. A very small peak with the 
m/z value of 456.1471 and elution time of 9.16 minutes was detected in only the troglitazone- 
treated cells (Figure 4.12 C). This was hypothesised to be troglitazone quinone since the 
measured m/z is very close to the theoretical m/z (456.1481), with only 2 ppm difference. 
However, the level observed was very low (AUC < 1), and hence this identification must be 
treated with some caution (Figure 4.13 A). As a quality control, we also looked for the 
presence of each parent compound within the cellular extracts, demonstrating cell penetration 
by the drugs: Troglitazone, rosiglitazone, and pioglitazone were all detected in the cells 
treated with the respective drugs (Figures 4.12 D -  F). All three TZDs displayed different 
elution times, being 9.55, 5.96, and 6.70 minutes for troglitazone, rosiglitazone, and 
pioglitazone, respectively. The levels of these TZDs observed in the intracellular samples 
were also very small (Figures 4.13 B -  D).
147
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Figure 4.12: Chromatograms of the targeted analysis of TZDs and the metabolites of 
troglitazone metabolism from the LC-MS data performed in the ESI mode (intracellular 
samples). (A) Troglitazone sulphate, (B) troglitazone glucuronide, (C) troglitazone quinone, 
(D) troglitazone (TGZ), (E) rosiglitazone (RGZ), and (F) pioglitazone (PGZ).
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Figure 4.13: Levels of metabolites from the targeted analysis of the intracellular samples.
LC-MS analysis was performed in the ESI' mode. (A) Troglitazone quinone (TGZ-Q),
(B) troglitazone (TGZ), (C) rosiglitazone (RGZ), and (D) pioglitazone (PGZ). The unit for elution 
time was min. The mean ± S.E.M. are shown (n = 3 biological repeats). Data were analysed using 
one-way ANOVA followed by Bonferroni post-test (*/? < 0.05, **p <0.01, ***p < 0.001).
4.2.2 LC-MS analysis: Culture media of cells treated with troglitazone, rosiglitazone,
and pioglitazone (extracellular samples)
LC-MS analysis was also performed on the extracellular samples derived from HuH-7 
cells treated with either the vehicle control (0.5% DMSO) or the three different types of TZD. 
The TICs in the EST mode are shown in Figure 4.14 and the results of the untargeted 
analyses are shown in Figures 4.15 and 4.16. As was seen with the intracellular metabolite 
analysis, PLS-DA analysis showed distinct separation between the four different treatments 
(Figure 4.15). Samples treated with troglitazone were separated from those treated with 
DMSO and pioglitazone by principal component one, while troglitazone was separated from 
rosiglitazone- and pioglitazone-treated samples by principal component two, although the 
separation from pioglitazone was only partial. Pioglitazone-treated samples appeared to be 
more closely related to the DMSO-treated samples than the other two TZDs.
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Figure 4.14: TICs plots of the extracellular samples of HuH-7 cells treated with DMSO, 
troglitazone (TGZ), rosiglitazone (RGZ), and pioglitazone (PGZ) for 24 h. LC-MS analysis 
was performed with reversed-phase mobile gradient of 14 min. in the EST mode.
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Figure 4.15: Untargeted analysis of the extracellular samples of cells treated with various 
TZDs for 24 h. PLS-DA analysis of DMSO vs. troglitazone (TGZ) vs. rosiglitazone (RGZ) vs. 
pioglitazone (PGZ). The LC-MS data was obtained using reversed-phase mobile gradient of 
14 min. in the EST mode. Data shown as n = 9 (3 technical repeats x 3 biological repeats).
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Figure 4.16: Untargeted analysis of the extracellular samples of cells treated with various 
TZDs for 24 h. PLS-DA analysis of DMSO vs. troglitazone (TGZ) was perfonned to assess the 
differences. (A) Scatter plot and (B) S-plot of the PLS-DA analysis. The ten most important 
metabolites that influenced the PLS-DA model were labelled as IE -  lOE. The LC-MS data was 
obtained using reversed-phase mobile gradient of 14 min. in the ESI mode. Data shown as n = 9 
(3 technical repeats x 3 biological repeats).
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Because too many variables complicate the PLS-DA analysis, decreasing the ability to 
identify important metabolites, the analysis was repeated by comparing only DMSO against 
troglitazone extracellular samples. Both treatments were clearly separated by principal 
component one (Figure 4.16 A). The ten most important metabolites that influenced the 
PLS-DA model are shown in Figure 4.14 B. They were also given the designation of 1 to 10, 
plus the letter “E” was added to the end, symbolising their origin from the extracellular pool.
The levels of the ten metabolites are plotted in Figure 4.17, again including the data 
from pioglitazone and rosiglitazone treated cells as well. The levels of metabolite IE -  6E 
were significantly lower in the troglitazone-treated samples compared to the control 
(DMSO-treated), while metabolites 7E -  lOE showed higher levels in the troglitazone 
samples compared to the control, but this was only statistically significant for metabolites 8E 
and lOE. When the samples from rosiglitazone were compared to the control, the levels of 
metabolite IE, 2E, 4E, and 5E were significantly reduced while metabolite 3E and 6E were 
not significantly different. In the pioglitazone-treated samples, metabolite IE, 4E, and 5E 
were decreased compared to the control, while metabolite 2E was not statistically 
significantly different. On the contrary, the levels of metabolite 3E and 6E were higher than 
the control.
Treatment with the three TZDs produced similar levels of metabolite IE but for 
metabolite 2E and 6E, the levels were reduced in the troglitazone-treated samples as 
compared to rosiglitazone and pioglitazone. Metabolite 3E, 4E, and 5E were not statistically 
different between the troglitazone- and rosiglitazone-treated samples but they were 
significantly lower compared to the samples treated with pioglitazone. Metabolites 7E and 9E 
were observed distinctively only in the troglitazone group but were not statistically 
significant. Metabolite 8E and lOE appeared to be part of the component of the culture 
medium, and therefore excluded from further analysis. On this basis, it appears possible to 
separate TZD treatments from each other (and control) on the basis of their extracellular 
samples, and the metabolites responsible for this separation can be identified.
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Figure 4.17: Levels of the ten most important metabolites (IE to lOE) that displayed 
significant differences between the DMSO vs. troglitazone treatment in the PLS-DA analysis.
The unit for elution time was min. The mean ± S.E.M. are shown (n = 3 biological repeats). Data 
were analysed only for the extracellular samples using one-way ANOVA followed by Bonferroni 
post-test (*p < 0.05, **/? < 0.01, ***/? < 0.001). Un-incubated media: Culture media not incubated 
with cells.
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Figure 4.17 cont: Levels of the ten most important metabolites (IE to lOE) that displayed 
significant differences between the DMSO vs. troglitazone treatment in the PLS-DA analysis.
The unit for elution time was min. The mean ± S.E.M. are shown (n = 3 biological repeats). Data 
were analysed only for the extracellular samples using one-way ANOVA followed by Bonferroni 
post-test (*p < 0.05, **p < 0.01, ***/? < 0.001). Un-incubated media: Culture media not incubated 
with cells.___________________________
Table 4.2 shows the putative identities of metabolites IE -  lOE. Metabolites IE and 
2E were both putatively identified as mevalonie acid, even though they were eluted 
approximately 0.37 min. apart. Metabolites 3E and 6E were both identified as nicotinuric 
acid; Metabolite 3E was eluted at 0.82 minutes while metabolite 6E was eluted at 
1.11 minutes. Metabolites 4E and 5E were putatively identified as reduced riboflavin and 
pyruvic acid, respectively. Metabolites 7E and 9E could not be identified. Although there 
were several hits within the mass accuracy tolerance limit, none of the identities were 
relevant in the process of cell metabolism and therefore excluded from further analysis 
(Supplementary Figure S5). The chromatograms and spectra of the ten metabolites are shown 
in Supplementary Figure S6.
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As before, targeted analysis was also performed on the sample set. A small peak 
hypothesised to be troglitazone sulphate was detected at 9.02 minutes (Figure 4.19 A), with 
this identity supported by the fact that this peak was detected only in the troglitazone-treated 
sample. It had an m/z value of 520.1079, which was 4 ppm different from its theoretical m/z 
(520.1100). However, the detection intensity was extremely low and the AUC value was 
unable to be computed by the MarkerLynx software, which means that the robustness of peak 
identification must be considered questionable.
Figure 4.19 B shows a peak with an m/z value of 456.1511 and elution time of 
9.17 minutes. This peak was only observed in the troglitazone-treated samples and the 
un-incubated medium containing troglitazone. Un-incubated medium refers to the culture 
medium prior to incubation with cells. The peak was suspected to be troglitazone quinone, 
based on the m/z value (theoretical m/z for troglitazone-quinone is 456.1481) and also the 
same retention time as observed in the intracellular samples. However, troglitazone quinone 
should not be present in the un-incubated medium, as it should only be generated via 
metabolism of troglitazone. It must thus be considered that this particular metabolites may 
not be troglitazone quinone but some other metabolite with the same m/z value as 
troglitazone quinone (Figure 4.20 A), or that it represents a contamination of the original 
troglitazone source with the quinone metabolite. There was no peak in any of the 
extracellular samples that could be identified as troglitazone glucuronide (Figure 4.19 C).
As expected, troglitazone, rosiglitazone, and pioglitazone were detected in both the 
extracellular samples and un-incubated media (Figures 4.19 D -  F). The levels in the 
un-incubated medium were higher than in the extracellular samples (Figures 4.20 B -  D), 
consistent with cellular uptake of the TZDs during the 24 hours incubation period. The 
elution times for troglitazone, rosiglitazone, and pioglitazone were 9.56, 5.96, and 
6.70 minutes, respeetively, which are similar to those observed in the intracellular samples 
(Figures 4.12 D -F ).
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Figure 4.20 cont.: Levels of metabolites from the targeted analysis of the extracellular 
samples. LC-MS analysis was perfonned in the ESI mode. (A) Troglitazone quinone (TGZ-Q),
(B) troglitazone (TGZ), (C) rosiglitazone (RGZ), and (D) pioglitazone (PGZ). The unit for elution 
time was min. The mean ± S.E.M. are shown (n = 3 biologieal repeats). Data were analysed only 
for the extracellular samples using one-way ANOVA followed by Bonferroni post-test {*p < 0.05, 
**/> < 0.01, ***/> < 0.001). Un-incubated media: Culture media not incubated with cells.
4.3 Confirmation of metabolite identities by comparing the LC-MS profiles of cell 
samples with commercial standard compounds
Studies performed in Section 4.2 suggested that the levels of metabolites related to 
endogenous antioxidant levels, glycolysis, the TCA cycle, and coenzymes were affected by 
troglitazone treatment. The putative metabolite identities were based on reported m/z values 
in databases, and as such require further examination before they can be judged as robust. 
The aim of the following study was to confirm the identities of these metabolites by 
comparing the m/z value and elution time profiles to those of standard compounds.
Standard compounds (1 mM) were subjected to LC-MS analysis together with the 
intracellular and extracellular samples treated with 1 x the IC50 of troglitazone, rosiglitazone.
160
pioglitazone, and DMSO as the control for 24 hours. The LC-MS analysis was performed in 
both ESr and ESI^  modes, as previously described.
The LC-MS profiles of seven standard compounds (GSH, pyruvate, malate, 
oxaloacetate, NAD^, nicotinic acid, and riboflavin) were initially characterised. Although 
oxaloacetate was not one of the metabolites detected in the previous study, it is an 
intermediate of the TCA cycle, a metabolic pathway that was believed to be affected by 
troglitazone. Similarly, NAD"^ , nicotinic acid, and riboflavin were not detected previously but 
they are the coenzymes or precursors of coenzymes that may have been affected by 
troglitazone.
Figures 4.21 and 4.22 show the chromatograms of the seven standard compounds 
obtained in the LC-MS analysis in ESI" and ESI^ modes, respectively. GSH was detected in 
the EST mode but the intensity was low (Figure 4.21 A). The peak in the ESI^ mode was 
even smaller and almost negligible (Figure 4.22 A). Pyruvate, malate, and oxaloacetate were 
detected at reasonable intensity (AUC >50)  with a sharp, single-peak in the EST mode 
(Figures 4.21 B -  C). In the ESI^ mode, pyruvate was not detected while malate and 
oxaloacetate were detected but at lower intensity compared to the EST mode (Figures 4.22 
B -  C). Furthermore, oxaloacetate displayed a pattern of double peaks in the ESI^ mode with 
very close elution times. NAD"^  was not detectable in either mode (Figures 4.21 E and 
4.22 E). Nicotinic acid and riboflavin produced sharp, single-peak chromatograms and the 
intensity was also strong in both modes (Figures 4.21 F and 4.22 F).
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Table 4.3 summarises the LC-MS profiles of the standard compounds. The elution 
times for the standard compounds were approximately the same for both modes of ionisation, 
as would be expected. Unfortunately, for most compounds the retention time was less than 
1 minute, which is close to the void volume of the column (0.55 minutes), and suggests that 
they were not retained efficiently on the column. Mass accuracy for all the compounds was 
below 30 ppm except for malate and oxaloacetate in the ESI^ mode. The mass accuracy for 
malate was 56 ppm while oxaloacetate, which showed a double peaks chromatogram were 
38 ppm for the first peak and 101 ppm for the second peak. The detected intensity 
(represented by the AUC) for these two compounds were, however, extremely low. Since the 
detection intensities for malate and oxaloacetate in the ESI^ mode were low and the mass 
accuracy was quite high, the detection of these compounds can be considered insignificant. 
Overall, the EST mode gave better detection than the ESI^ mode because more compounds 
were detected, and with higher intensity.
Table 4.3: LC-MS profiles of the sitandard compounds
Standard
compounds
ESI
mode
Elution 
time (min.)
Measured 
mass (m/z)
Theoretical 
mass (m/z)
Mass accuracy 
(ppm)
AUC
Glutathione
(GSH)
- 1.225 306.0767 306.0760 2 NC
+ 1.237 308.0939 308.0916 7 NC
Pyruvate - (1839 87.0013 87.0082 8 901
+ ND ND 89.0239 ND ND
Malate - 0.801 133.0150 133.0137 10 1963
+ 0.873 135.0369 135.0293 56 13
Oxaloacetate
(OAA)
- 0.769 130.9963 130.9980 13 168
+ 0.764
0.847
133.0188
133.0002
133.0137 38
101
3
3
NAD"" - ND ND 662.1013 ND ND
+ ND ND 664.1170 ND ND
Nicotinic
acid
- 1.192 122.0210 122.0242 26 1041
+ 1.216 124.0342 124.0399 5 2118
Riboflavin - 5X%9 375.1255 375.1305 13 802
+ 5.698 377.1435 377.1461 7 740
The final injection amount was 10 nmoles/10 pi. NC: Not computed; ND: Not detected.
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After acquiring the measured m/z and elution time for the standard compounds, the 
next step was to assess whether these compounds could be found in detectable quantities in 
the intracellular and extracellular samples treated with the different types of TZDs.
LC-MS analysis of the intracellular samples in the ESI' mode showed that the levels 
of GSH and malate in the troglitazone-treated sample were lower compared to the control 
(DMSO-treated) (Figures 4.23 A and C). Pyruvate was not detected in the troglitazone- 
treated sample (Figure 4.23 B) while riboflavin showed higher level than the control although 
not statistically significant (Figure 4.23 D). Nevertheless, the overall detection levels for both 
pyruvate and riboflavin were very low and can be considered negligible.
The levels of GSH and malate in the rosiglitazone- and pioglitazone-treated samples 
were also significantly lower than the control (Figures 4.23 A and C). Comparison of these 
two metabolites between the three TZD- treatment groups demonstrated that troglitazone- 
treated samples exhibited the lowest levels of GSH and malate, although this was only 
statistically significant in comparison to pioglitazone. Troglitazone quinone and troglitazone 
were detected but the detection intensity was very low and can be considered as artifact 
(Figures 4.23 E and F). Rosiglitazone and pioglitazone were detected in only the 
rosiglitazone- and pioglitazone-treated intracellular samples, respectively (Figures 4.23 G 
and H).
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Figure 4.23: LC-MS analysis in the ESI mode of the intracellular samples. Cells were treated 
with various TZDs at the concentration of Ix their IC50 for 24 hours. DMSO (0.5%) was used as 
the control. Detection of (A) GSH, (B) pyruvate, (C) malate, (D) riboflavin, (E) troglitazone 
quinone (TGZ-Q), (F) troglitazone (TGZ), (G) rosiglitazone (RGZ), and (H) pioglitazone (PGZ). 
The mean ± S.E.M. are shown (n = 3 biological repeats). Data were analysed by one-way ANOVA 
followed by Benferroni post-test (*/? < 0.05, **p < 0.01, and ***/> < 0.001).
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LC-MS analysis of the same intraeellular samples in the ESI'*’ mode only detected 
rosiglitazone and pioglitazone (Figures 4.24). Rosiglitazone was present only in the 
rosiglitazone-treated sample while pioglitazone was present only in the pioglitazone-treated 
sample.
(A) RGZ (elution time 5.8998, m/z 358.1051) (B) PGZ (elution time 6.6166, m/z 357.1239)
DMSO TGZ RGZ
Treatment
PGZ
20
I3
I3
I<
DMSO TGZ RGZ PGZ
Treatment
Figure 4.24: LC-MS analysis in the ESC mode of the intracellular samples. Cells were treated 
with various TZDs at the concentration of Ix their IC50 for 24 hours. DMSO (0.5%) was used as 
the control. Detection of (A) rosiglitazone (RGZ) and (B) pioglitazone (PGZ). The mean ± S.E.M. 
are shown (n = 3 biological repeats). Data were analysed by one-way ANOVA followed by 
Benferroni post-test (*p < 0.05, **p < 0.01, and ***p < 0.001).
Figure 4.25 shows the LC-MS analysis of the extracellular samples in the EST 
mode. GSH was not detected in any of the samples. Samples treated with troglitazone 
exhibited a significant reduction in the level of pyruvate and malate in comparison to the 
control samples (Figures 4.25 A and B). However, the overall detection intensity for malate 
was very low, and hence this conclusion must be treated with some caution. There was no 
significant difference in the detected levels of riboflavin between troglitazone-treated and 
control samples, but again the overall detection intensity was very low (Figure 4.25 C).
The levels of pyruvate in samples treated with rosiglitazone and pioglitazone were 
also significantly lower than the control hut they were higher in comparison to troglitazone- 
treated sample, although there was no statistically significant difference between 
rosiglitazone- and troglitazone-treated samples (Figure 4.25 A).
Troglitazone quinone was detected in the troglitazone-treated extracellular sample 
(Figure 4.25 D). As with the ESF mode, troglitazone quinone was also present in the 
un-incubated medium, which implies that it was either a misidentifieation of a component of 
the medium, or that the troglitazone stock was contaminated with the quinone metabolite: 
Thus, the identity of that particular metabolite as troglitazone quinone is questionable.
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Troglitazone, rosiglitazone, and pioglitazone were detected in the troglitazone-, rosiglitazone, 
and pioglitazone-treated extracellular and un-incubated media samples (Figures 4.25 E -  G). 
Nevertheless, the overall detection intensity for troglitazone was very low.
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Figure 4.25: LC-MS analysis in the ESI mode of the extracellular samples. Cells were treated 
with various TZDs at the coneentration of Ix their IC50 for 24 hours. DMSO (0.5%) was used as 
the control. Detection of (A) pyruvate, (B) malate, (C) riboflavin, (D) troglitazone quinone 
(TGZ-Q), (E) troglitazone (TGZ), (F) rosiglitazone (RGZ), and (G) pioglitazone (PGZ). The 
mean ± S.E.M. are shown (n = 3 biological repeats). Data were analysed by one-way ANOVA 
followed by Benferroni post-test {*p < 0.05, **p < 0.01, and ***p < 0.001). Un-ineubated media: 
Culture media not incubated with cells.
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(G) PGZ (elution time 6.6165, m/z 355.1128)
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Figure 4.25 conti LC-MS analysis in the ESF mode of the extracellular samples. Cells were 
treated with various TZDs at the concentration of Ix their IC50 for 24 hours. DMSO (0.5%) was 
used as the control. Detection of (A) pyruvate (B) malate, (C) riboflavin, (D) troglitazone quinone 
(TGZ-Q), (E) troglitazone (TGZ), (F) rosiglitazone (RGZ), and (G) pioglitazone (PGZ). The 
mean ± S.E.M. are shown (n = 3 biological repeats). Data were analysed by one-way ANOVA 
followed by Benferroni post-test (*p < 0.05, < 0.01, and ***p < 0.001). Un-ineubated media:
Culture media not incubated with cells.
LC-MS analysis in the ESI^ mode was only able to detect riboflavin, rosiglitazone, 
and pioglitazone in the extracellular samples. Although riboflavin was detected, there was no 
difference between all the treatments and the overall detection intensity was very low (Figure
4.26 A). Rosiglitazone and pioglitazone were detected in only the samples treated with 
rosiglitazone and pioglitazone, respectively (Figures 4.26 B and C).
Oxaloacetate, NAD^, and nicotinic acid were not detected in either the intracellular 
or extracellular samples in both ionisation modes. Table 4.4 summarises the metabolites 
detected by LC-MS analysis in the intracellular and extracellular samples, and also the 
LC-MS profiles of the standard compounds.
In summary, the levels of GSH, pyruvate, and malate were reduced in samples 
treated with troglitazone in comparison to the control. Troglitazone quinone, one of the 
metabolites of troglitazone metabolism might also be detected although the identity is not 
confirmed. Troglitazone, rosiglitazone, and pioglitazone were detected in their specific 
treatment group in both intracellular and extracellular samples. The mass accuracy error 
(comparison between the measured m/z and the theoretical m/z value) for rosiglitazone and 
pioglitazone in the ESI^ mode was quite large. LC-MS analysis in the ESF mode produced 
better results for this investigation compared to the analysis in the ESI^ mode, mainly
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because the total number of metabolites detected using the ESI' mode was higher and the 
mass accuracy error was smaller.
(A) Riboflavin (elution time 5.6413, m/z 377.1539) 
4 t
(B) RGZ (elution time 5.8333, m/z 358.0883)
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Figure 4.26: LC-MS analysis in the ESC mode of the extracellular samples. Cells were treated 
with various TZDs at the concentration o f  Ix their IC50 for 24 hours. DMSO (0.5%) was used as 
the control. Detection of (A) riboflavin, (B) rosiglitazone (RGZ), and (C) pioglitazone (PGZ). The 
mean ± S.E.M. are shown (n = 3 biological repeats). Data were analysed by one-way ANOVA 
followed by Benferroni post-test (*p < 0.05, **p < 0.01, and < 0.001). Un-incubated media: 
Culture media not incubated with cells.
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4.4 LC-MS analysis of standard compounds
Results in Section 4.3 suggested that troglitazone affected the levels of cellular GSH 
and intermediates of glycolysis and the TCA cycle. Therefore, a broad range of commercially 
available, pure compounds that are directly or indirectly related to these pathways were 
characterised by LC-MS analysis. The profiles of the standard compounds were then used to 
perform a thorough targeted analysis of cells treated with troglitazone, as discussed in the 
next section. All standard compounds were dissolved in water at the concentration of 1 mM 
and LC-MS analysis was performed in both EST and ESl^ modes.
There was a need to optimise the MS protocol before further experimentation due to 
the MS method not being able to detect all the metabolites of interest (e.g. NAD^ and also at 
reasonable intensity (e.g. GSH), as seen in Section 4.3. The optimum capillary voltage that 
will give the highest possible detection for all the metabolites was investigated. A few chosen 
standard compounds were prepared at 1 mM in 10% aqueous methanol (methanol was used 
to aid ionisation in the MS) and directly infused into the MS at varying capillary voltages.
Figure 4.27 A shows the MS detection of the parent ion in the EST mode. The signal 
intensity is expressed as number of ion counts per scan (counts/scan). Each compound will 
have a different optimum capillary voltage. The capillary voltage used in the former MS 
protocol was 2.7 kV, but at this voltage the detection of some compounds such as NAD"^ , 
oxaloacetate, and GSH had begun to reduce. To mitigate this effect, subsequent experiments 
were undertaken using a capillary voltage for the ESF mode of 2.6 kV.
In the ESr^ mode, detection was optimum at 2.9 kV for majority of the compounds 
except for malate, which was optimum at 3.3 kV (Figure 4.27 B). Detection of pyruvate was 
very low, less than 20 counts/scan regardless of the voltage used. The capillary voltage used 
in the former MS protocol was 3.3 kV but from this experiment, it clearly showed that 2.9 kV 
was the optimum voltage for the detection of most compounds.
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Figure 4.27: The effect of capillary voltage on the intensity of MS detection. The signal 
intensity is expressed as counts/scan. Standard compounds (1 mM in 10% aqueous methanol) 
wered directly infused into the MS (10 nmoles/10 pl/min.) in (A) ESI- and (B) ESE mode._______
Figure 4.28 shows example chromatograms of LC-MS analysis of the standard 
compounds performed under the optimised MS protocol. Notably, GSH was detected at 
higher intensity in comparison to the previous method (Figures 4.28 A and B versus Figures 
4.21 A and 4.22 A). NAD^, which was not detected previously (Figures 4.21 E and 4.22 E), 
was detected in both ESF and ESI^ mode with the optimised MS protocol (Figure 4.28 C and 
D). Pyruvate and malate was detected in the ESF mode but detection intensity was low in the 
ESF  ^mode (Figures 4.28 E -  H). Amino acids such as methionine and phenylalanine were 
detected in both ionisation modes with high detection intensity (Figures 4.28 I -  L). 
Phenylalanine was the only compound that was retained well in the UPLC BEH Cis column 
among these six compounds, exhibiting an elution time of approximately 3.8 minutes. The 
other compounds showed retention times of approximately 1 minute, while the column void 
time was 0.55 minutes.
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Details of the LC-MS profiles of all the tested standard compounds are shown in 
Table 4.5. GSH and OS SO (reduced and oxidised glutathione) were detected in both 
ionisation modes. Intermediates of glycolysis and TCA cycles (e.g. glucose 6-phosphate, 
pyruvate, lactate, citrate, a-ketoglutarate, fumarate, malate, and oxaloacetate) were also 
detected in both the EST and ESI^ modes except for oxaloacetate and lactate, which were 
only detected in the EST mode. Although pyruvate, a-ketoglutarate, and fumarate were 
detected in the ESl^ mode, the detection intensities were very low and can be considered 
negligible. The majority of the glycolysis and TCA cycle intermediates were not retained 
very well in the UPLC BEH Cis column. The elution time ranged between 0.7 -  1.4 minutes.
ATP was eluted at two separate times in both ionisation modes, namely 1.1 minutes 
and 3.6 minutes, with the former being the major peak. Coenzymes and related compounds 
(NAD^, NADH, NADP^, NADPH, nicotinamide, nicotinic acid, nicotinuric acid, riboflavin, 
and pyridoxal) were detected in both the EST and ESf^ modes. NADH displayed double­
peaks in the EST mode (3.6 and 3.7 minutes retention time), with peaks being of similar 
intensity. On the other hand, in the ESI^ mode, NADH was detected as two different ions, i.e. 
666.12 and 665.10 m/z. The former ion was the major detectable metabolite with an elution 
time of 3.6 minutes, while the minor metabolite was eluted at 1.9 minutes. NADPH was also 
detected in two different forms, i.e. 744.08 and 745.07 m/z in the EST mode and 746.08 and 
747.09 m/z in the ESf^ mode, with the lower mass ion being the major form. The elution time 
for the two different ion forms of NADPH was similar, i.e. approximately 3.6 minutes. In 
general, the compounds related to coenzymes were retained better with the UPLC BEH Cig 
column in comparison to the glycolysis and TCA cycle intermediates. The retention times for 
the eoenzymes and related compounds were between 1.0 -  5.6 minutes, compared to a void 
time of approximately 0.55 minutes.
Tryptophan, valine, methionine, phenylalanine, and leucine were detected at 
reasonable detection intensities in both ionisation modes and they also showed good retention 
with the UPLC BEH Cig column. The shortest retention time was approximately 0.9 minutes 
(valine) and the longest retention time was 4.4 minutes (tryptophan).
Overall, LC-MS analysis for the 27 standard compounds in the EST mode, generally, 
gave an improved detection than in the ESI^ mode with regard to the detection intensity was 
higher; exceptions included nicotinamide, nicotinic acid, nicotinuric acid, and riboflavin, 
which exhibited higher detection intensities in the ESI^ than the EST mode.
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When the elution time of the standard compounds obtained in Table 4.5 was 
compared to the elution time of the metabolites detected in the intracellular and extracellular 
samples in Section 4.3, there were slight discrepancies noted. For example, in the EST mode, 
pyruvate the standard compound was eluted at 0.88 minutes. (Table 4.5), but in the 
intracellular and extracellular samples, the elution time was 0.77 and 0.80 minutes, 
respectively (Figures 4.23 B and 4.25 A). Similarly, with malate the standard compound was 
eluted at 0.87 minutes (Table 4.5), but in the intracellular and extracellular samples, the 
elution time was detected at 0.80 and 0.72 minutes, respectively (Figures 4.23 C and 4.25 B). 
Preparation of samples in different matrices may have an effect on the LC-MS analysis, 
especially the retention time, which could explain these discrepancies. The standard 
compounds were dissolved in water while the intraeellular samples were prepared in PBS and 
the extracellular samples were in culture medium. Furthermore, the de-proteinisation and 
freeze-drying process undertaken during preparation of the intraeellular and extracellular 
samples might also have had an effect on the LC-MS profile.
Therefore, the LC-MS profiles of standard compounds dissolved in water, culture 
medium, and PBS were investigated. The standard compounds were also subjeet to extraction 
and freeze-drying process similar to those used for the intracellular and extracellular samples: 
This extraction process consisted of addition of acetonitrile to the dissolved standard 
compounds in the ratio of 1:1 (v/v), vortexing (30 seconds), incubation (4°C, 30 minutes), 
vortex (30 seconds), and centrifugation (10,000 x g, 4°C, 10 minutes). The supernatants were 
freeze-dried and the dried solids were re-suspended in water prior to LC-MS analysis in the 
ESF mode. The final concentration of the standard compounds was 50 pM and the injection 
volume used for LC-MS analysis was 10 pi, which was equivalent to 500 pmoles of the 
standard compounds loaded onto the column.
Figure 4.29 shows the chromatograms of malate and GSH dissolved in different 
solutions/matrices. Malate that was prepared in culture medium produced multiple peaks, 
while the same compound prepared in water and PBS exhibited only a single peak (Figure
4.27 A). The detection intensity also varied between different matrices. GSH prepared in the 
culture medium was not detected, and the detection intensity of GSH prepared in PBS was 
lower than in water (Figure 4.29 B). The complete profiles of the standard compounds are 
tabulated in Table 4.6. Overall, standard compounds prepared in water gave better deteetion
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intensity with single peaks whereas majority of the standard compounds prepared in the 
culture medium and PBS exhibited multiple peaks.
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Figure 4.29: Chromatograms of (A) malate and (B) GSH prepared in different matrices.
Standard compounds were dissolved in water, culture medium, or PBS and subjected to 
de-proteinisation and freeze-drying process. The dried samples were re-suspended in water prior to 
LC-MS analysis in the ESI" mode. Standard compounds were prepared as a mixture of 50 pM and 
injected at the volume of 10 pi, i.e. 500 pmoles.
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4.5 Effect of solvent on the detection of troglitazone
It was difficult to detect the presence of troglitazone and its metabolites in the 
intracellular and extracellular samples. It was suspected that the solvent used during the 
sample preparation process affects the detection of troglitazone. Hence, troglitazone was 
prepared at various concentrations in either water or 50% aqueous acetonitrile. These samples 
were then subjected to the extraction protocols used for the preparation of intracellular and 
extracellular samples for LC-MS analysis. The final concentrations of troglitazone were 
0, 0.5, 1.2, 2.5, 5, 7.5, 10, 12, and 15 pM in either water or 50% aqueous acetonitrile. DMSO 
(0.25%) was used as the control.
Re-suspending troglitazone in 50% aqueous acetonitrile after the extraction protocol 
enabled detection at concentrations as low as 0.5 pM (Figures 4.30 A and B). On the other 
hand, troglitazone re-suspended in water was only detectable at 5 pM and above (Figures 
4.30 C and D). Re-suspension of troglitazone in 50% aqueous acetonitrile also gave better 
detection intensity compared to re-suspension in water (Figure 4.31). The elution time for 
troglitazone re-suspended in 50% aqueous acetonitrile was slightly higher than those 
re-suspended in water (Figure 4.32 A). The measured m/z values for troglitazone were 
similar in all four methods of preparations (Figure 4.32 B). The mass tolerances were all 
within the acceptable range and did not show much variation (Figure 4.32 C). Therefore, 
re-suspending troglitazone in 50% aqueous acetonitrile gave better detection regardless of 
whether it was initially prepared in water or 50% aqueous acetonitrile.
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(A) Diluted in H^ O & re-suspended in 50% ACN (B) Diiuted & re-suspended in 50% ACN
10001000
800800
Z 600
400400
200 -200
0.5 1.2 2.50.5 1.2 2.5 7.5 7.5
(C)
TGZ (pM)
Diluted & re-suspended in H2 O
■5 40
< 20
(D)
TGZ (pM)
Diluted in 50% ACN & re-suspended in H2 O
TGZ (pM) TGZ (pM)
Figure 4.31: Detection intensities of troglitazone prepared by various methods. (A) Diluted in 
water and re-suspended in 50% aqueous acetonitrile, (B) diluted and re-suspended in 50% aqueous 
acetonitrile, (C) diluted and re-suspended in water, and (D) diluted in 50% aqueous acetonitrile and 
re-suspended in water. LC-MS analysis was performed in ESP mode with 10 pi injection. Data of 
two replicates are shown._______________________________________________________
(A) Elution time (B) Measured m/z
9.60-
□□
9.58 □  □I
□□□□■B 9.56
m  9.54
1.52-
440.160-
440.158-
N 440.156-
■g 440.154-
<8 440.152-
Oo°
440.150
440.148
440.146-
TGZ (pM)
Mass tolerance
(c)
I □□
8
1 QD(
sm
'oO
TGZ (pM)
O  Diluted and re-suspended in H2 O 
•  Diluted in ACN and re-suspended in H2 O
□  Diluted in H2 O and re-suspended in ACN 
■  Diluted and re-suspended in ACN
Figure 4.32: LC-MS profiles of troglitazone in the ESI' mode, prepared in various methods.
(A) Elution time, (B) measured m/z values, and (C) mass tolerance. The injection volume was 
10 pi. Data shown as each measured value from various concentrations of troglitazone.
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4.6 Effect of non-toxic versus toxic levels of troglitazone on HuH-7 cells
The following investigation was aimed at evaluating the effect of troglitazone on 
HuH-7 cells when used at a non-toxic level (O.lx IC50). Similar to previous experiments, cells 
were treated with troglitazone for 24 hours but at 2.4 pM compared to the previously used 
24 pM. DMSO (0.5%) was used as the control. Following the exposure period, cells were 
harvested, extracted with acetonitrile (1:1, v/v), freeze-dried, re-suspended in water, and 
finally LC-MS analysis was conducted on both the intracellular and extracellular samples in 
the EST and ESf^ mode. Using the data obtained in Table 4.6 as a reference, metabolites of 
interest in the intracellular and extracellular samples were sought.
4.6.1 LC-MS analysis: Cells treated with 2.4 pM (non-toxic) and 24 pM (toxic) of
troglitazone (intracellular samples)
A total of 14 metabolites were detected from the intracellular samples in the EST 
mode (Figure 4.33). The identities were established by comparison of the m/z value and 
elution time with those of the standard compounds in Table 4.6, as previously described. 
Cells exposed to the toxic concentration of troglitazone showed a reduction in the level of 
GSH, compared to the non-toxic concentration, where the GSH level was not significantly 
different from control (Figure 4.33 A). The levels of malate were also reduced when cells 
were treated at both the toxic and non-toxic concentration of troglitazone in comparison to 
the control. Interestingly, the levels of malate were also significantly different between the 
toxic and non-toxic concentration of troglitazone, suggesting a concentration-dependent 
effect (Figure 4.33 B). Pyruvate was detected in the intracellular samples but the amount 
detected was very low and, hence, considered negligible (Figure 4.33 C). Lactate did not 
show any significant pattern between the treatments (Figure 4.33 D). ATP was not detected 
but the levels of ADP were observed to be the highest in cells treated with 2.4 pM of 
troglitazone, followed by the control and almost zero in the cells treated with 24 pM of 
troglitazone (Figure 4.33 E). Cells treated with 24 pM of troglitazone demonstrated almost 
3-fold higher AMP level as compared to the control and cells treated with 2.4 pM of 
troglitazone (Figure 4.33 F).
Riboflavin was detected in the intracellular samples in the ESP mode but the amount 
detected was very low (Figure 4.33 G). Phenylalanine was present in all the treatments at 
almost similar amount (Figure 4.33 H). Other detected amino acids were glutamine, 
tryptophan, leucine, and valine but the levels of these four metabolites were also very low
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and with high error, and hence no robust conclusions can be drawn (Figures 4.33 I -  L). As 
expected, troglitazone and troglitazone quinone were also detected in treated samples, but not 
control, and were higher in cells treated with the higher concentration of troglitazone (Figures 
4.33 M -N ).
Out of the 14 metabolites detected in the intracellular samples using LC-MS analysis 
in the ESI" mode, there were significant difference in the levels of GSH, malate, ADP, AMP, 
troglitazone, and troglitazone quinone in cells treated with 2.4 versus 24 pM of troglitazone. 
Lactate and phenylalanine were not significantly different between the treatments while the 
remaining detected metabolites were detected at very low levels and can be assumed 
negligible in the intracellular samples.
(A) GSH (elution time 1.1354 min., 306.0736 m/z)
C 200
DMSO 2.4 pM 
Treatment
24 pM
(C) Pyruvate (eiution time 0.9046 min., 87.0079 m/z)
0 .6 t
DMSO 2.4 pM 
Treatment
24 pM
(B) Maiate (eiution time 0.7734 min., 133.0125 m/z)
120 t
DMSO 2.4 pM
Treatment
24 pM
(D) Lactate (elution time 0.9174 min., 89.0236 m/z)
Ë
3
I
C3
S
< 20
DMSO 24 pM
Treatment
Figure 4.33: LC-MS analysis in the ESI mode of the intracellular samples treated with 2.4 vs. 
24 pM of troglitazone for 24 h. Treated eells were harvested, extracted with acetonitrile, freeze- 
dried, and re-suspended in water prior to LC-MS analysis. DMSO (0.5%) was used as the control. 
Detection of (A) GSH, (B) malate, (C) pyruvate, (D) lactate, (E) ADP, (F) AMP, (G) riboflavin, 
(H) phenylalanine (Phe), (I) glutamine (Gin), (J) tryptophan (Trp), (K) leucine (Leu), (L) valine 
(Val), (M) troglitazone (TGZ), and (N) troglitazone-quinone (TGZ-Q). The mean± S.E.M are 
shown (n = 3 biological repeats). Data were analysed by one-way ANOVA followed by Bonferroni 
post-test (*p < 0.05, **p < 0.01, ***p < 0.001).
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(E) ADP (elution time 0.8585 min., 426.0193 m/z)
DMSO 2.4 pM 
T reatment
24 pM
(G) Ribofiavin (elution time 5.6241 min., 375.1306 m/z) 
0.15:
L. 0.05
0.00
2.4 pM 
Treatment
24 pM
(I) Gin (eiution time 0.6974 min., 145.0601 m/z)
5t----------------------------------------------------------------------------------
DMSO 2.4 pM 
Treatment
24 pM
(F)
160
AMP (elution time 1.1247, 346.0545 m/z)
0) 120
DMSO 2.4 pM 
Treatment
24 pM
(H) Phe (eiution time 3.7431 min., 164.0681 m/z) 
50:
[f 30
DMSO 2.4 pM 
Treatment
24 pM
(J) Trp (eiution time 4.4893 min., 203.0774 m/z)
15:----------------------------------------------------------------------------------
10
DMSO 2.4 pM 
Treatment
24 pM
Figure 4.33: LC-MS analysis in the ESF mode of the intracellular samples treated with 2.4 vs. 
24 pM of troglitazone for 24 h. Treated cells were harvested, extracted with acetonitrile, freeze- 
dried, and re-suspended in water prior to LC-MS analysis. DMSO (0.5%) was used as the control. 
Detection of (A) GSH, (B) malate, (C) pyruvate, (D) lactate, (E) ADP, (F) AMP, (G) riboflavin, 
(H) phenylalanine (Phe), (I) glutamine (Gin), (J) tryptophan (Trp), (K) leucine (Leu), (L) valine 
(Val), (M) troglitazone (TGZ), and (N) troglitazone-quinone (TGZ-Q). The mean ± S.E.M are 
shown (n = 3 biological repeats). Data were analysed by one-way ANOVA followed by Bonferroni 
post-test (*p < 0.05, **p < 0.01, ***p < 0.001).
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(K) Leu (elution time 1.7057 min., 130.0851 m/z)
O.IOt
«  0.06
0.00
DMSO 2.4 pM 
Treatment
24 pM
(M) TGZ (eiution time 9.4705 min., 440.1528 m/z)
50t
DMSO 2.4 pM 
Treatment
24 pM
(L) Vai (eiution time 0.8791 min., 116.0703 m/z)
0.020
0) 0.015
^  0.010
0.005
0.000
DMSO 2.4 pM 
Treatment
24 pM
TGZ-Q (eiution time 9.0644 min., 456.1451 m/z)
DMSO 2.4 pM 
T reatment
24 pM
Figure 4.33 conti LC-MS analysis in the ESF mode of the intracellular samples treated with
2.4 vs. 24 pM of troglitazone for 24 h. Treated cells were harvested, extracted with acetonitrile, 
freeze-dried, and re-suspended in water prior to LC-MS analysis. DMSO (0.5%) was used as the 
control. Detection of (A) GSH, (B) malate, (C) pyruvate, (D) lactate, (E) ADP, (F) AMP, 
(G) riboflavin, (H) phenylalanine (Phe), (I) glutamine (Gin), (J) tryptophan (Trp), (K) leucine 
(Leu), (L) valine (Val), (M) troglitazone (TGZ), and (N) troglitazone-quinone (TGZ-Q). The 
mean ± S.E.M are shown (n = 3 biological repeats). Data were analysed by one-way ANOVA 
followed by Bonferroni post-test (*p < 0.05, **p < 0.01, ***p < 0.001).
LC-MS analysis of the intracellular samples in the ESI^ mode detected GSH, AMP, 
valine, and phenylalanine (Figure 4.34). GSH levels in the samples treated with 24 pM 
troglitazone were significantly reduced (Figure 4.34 A), similar to the trend observed in the 
ESP mode (Figure 4.33 A). However, the detection level for GSH in the ESI^ was lower than 
in the ESF mode. For AMP, valine, and phenylalanine, the amount detected was very low and 
can be considered not present in the intracellular samples (Figures 4.34 B -  D). Overall, the 
ESI^ mode gave lower levels of detection for the same metabolites from the same samples 
than was observed in the EST mode.
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Figure 4.34: LC-MS analysis in the ESC mode of the intracellular samples treated with 2.4
vs. 24 pM of troglitazone for 24 h. Treated cells were harvested, extracted with acetonitrile, 
freeze-dried, and re-suspended in water prior to LC-MS analysis. DMSO (0.5%) was used as the 
control. Detection of (A) GSH, (B) malate, (C) pyruvate, (D) lactate, (E) ADP, (F) AMP, 
(G) riboflavin, (H) phenylalanine (Phe), (I) glutamine (Gin), (J) tryptophan (Trp), (K) leucine 
(Leu), (L) valine (Val), (M) troglitazone (TGZ), and (N) troglitazone-quinone (TGZ-Q). The 
mean i  S.E.M are shown (n = 3 biological repeats). Data were analysed by one-way ANOVA 
followed by Bonferroni post-test (*p < 0.05, **p < 0.01, ***p < 0.001).
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4.6.2 LC-MS analysis: Culture media of cells treated 2.4 pM (uou-toxic) and 24 pM
(toxic) of troglitazone (extracellular samples)
In the extracellular samples, a total of 11 metabolites were detected using the ESF 
mode (Figure 4.35). Cells exposed to troglitazone showed increased levels of lactate, with
2.4 pM troglitazone-exposed cells containing approximately 3.5 times higher levels than 
24 pM troglitazone-exposed cells and nearly 14 times greater than the control (Figure
4.35 A). Lactate was not detected in the un-incubated media (culture medium controls) of all 
the treatments. Pyruvate was found to display two apparent peaks, which was about 
0.2 minutes apart. Both pyruvates (eluted at 0.71 and 0.91 minutes) showed similar pattern. 
The highest level was detected in the extracellular samples of cells treated with 2.4 pM 
troglitazone and the lowest in the control (Figures 4.35 B -  C). The level of pyruvate in 
24 pM troglitazone was not statistically different from the other treatments. Pyruvate was 
also present in the un-incubated media of all treatments, but this is expected as the culture 
medium formulation contained pyruvate.
Both 2.4 and 24 pM of troglitazone treatments increased the level of phenylalanine in 
the medium, compared to the control samples (Figure 4.35 D). Several other amino acids 
such as leucine, methionine, valine, and glutamine also exhibited a similar trend, with very 
low levels in the control samples and statistically higher levels in samples treated with 
troglitazone (Figures 4.35 E -  H). On the other hand, tryptophan did not show any statistical 
difference between the treatments (Figure 4.35 I). The amino acids detected in the 
extracellular samples were also detected in the un-incubated media because the culture 
medium formulation contained phenylalanine, leucine, methionine, valine, and tryptophan; in 
addition, it was further supplemented with 1% of non-essential amino acids and 2% of 
L-glutamine.
Riboflavin was detected in the extracellular and un-incubated media samples, but the 
amount detected was low and not considered a robust signal (Figure 4.35 J). Troglitazone 
quinone was detected in the extracellular samples of cells treated with troglitazone, but not in 
control samples. Troglitazone quinone was also detected in the un-incubated medium (Figure
4.35 K). Troglitazone was not detected in the extracellular samples but was observed in the 
un-incubated media controls of the troglitazone treatment although the overall detection 
amount was extremely low (Figure 4.35 L).
195
(A) Lactate (elution time 1.1172 min., 89.0235 m/z)
DMSO 2.4 nM 
T reatment
24 nM
(C) Pyruvate (elution time 0.9050 min., 87.0085 m/z)
DMSO 2.4 ^M 
T reatment
24 ^M
(E) Leu (eiution time 1.7336 min., 130.0850 m/z)
«  300
■5 200
*
2.4 (iM 
T reatment
(B) Pyruvate (elution time 0.7114 min., 87.0069 m/z)
100- 200:
80- 0) 150
BÉBI t3
"  60-
(U »•D
C g  100
3
(U 40-2 £
< <
5020- H  0
0 -  H  H 0 ^ 0
DMSO 2.4 nM 
T reatment
24 nM
(D) Phe (elution time 3.7181 min., 164.0650 m/z) 
800:
0) 600
2.4 pM 
T reatment
24 nM
|F) Met (elution time 1.0901 min., 148.0422 m/z)
24 nM
Extracellular samples □ Un-incubated media
2.4 ^M 
T reatment
24 pM
Figure 4.35: LC-MS analysis in the ESF mode of the extracellular samples treated with 2.4 vs. 
24 pM of troglitazone for 24 h. Treated cells were harvested, extracted with acetonitrile, freeze- 
dried, and re-suspended in water prior to LC-MS analysis. DMSO (0.5%) was used as the control. 
Detection of (A) lactate, (B) and (C) pyruvate, (D) phenylalanine (Phe), (E) leucine (Leu), 
(F) methionine (Met), (G) valine (Val), (H) glutamine (Gin), (I) tryptophan (Trp), (J) ribofiavin, 
(K) troglitazone-quinone (TGZ-Q), and (L) troglitazone (TGZ). The mean ± S.E.M are shown 
(n = 3 biological repeats). Data were analysed by one-way ANOVA followed by Bonferroni post­
test (*p < 0.05, **p < 0.01, ***p < 0.001). Un-incubated media: Culture media not incubated with 
cells.
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Figure 4.35 cont. : LC-MS analysis in the ESI mode of the extracellular samples treated with
2.4 vs. 24 pM of troglitazone for 24 h. Treated cells were harvested, extracted with acetonitrile, 
freeze-dried, and re-suspended in water prior to LC-MS analysis. DMSO (0.5%) was used as the 
control. Detection of (A) lactate, (B) and (C) pyruvate, (D) phenylalanine (Phe), (E) leucine (Leu), 
(F) methionine (Met), (G) valine (Val), (H) glutamine (Gin), (I) tryptophan (Trp), (J) riboflavin, 
(K) troglitazone-quinone (TGZ-Q), and (L) troglitazone (TGZ). The mean ± S.E.M are shown 
(n = 3 biological repeats). Data were analysed by one-way ANOVA followed by Bonferroni post­
test {*p < 0.05, **p < 0.01, ***p < 0.001). Un-incubated media; Culture media not incubated with 
cells.
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LC-MS analysis in the ESI^ mode of the same extracellular samples detected 
phenylalanine, leucine, methionine, valine, tryptophan, and riboflavin (Figure 4.36). The 
levels of these amino acids did not show statistical difference between treatments (Figures
4.36 A, B, C, and E) except for valine, which was higher in the control in comparison to the 
samples treated with 24 pM of troglitazone (Figure 4.36 D). All the amino acids detected in 
the extracellular samples were also present in the un-incubated media controls at almost 
similar amount, indicating that they are part of the component of the culture media. 
Riboflavin was detected but the detection amount was very low and was not considered 
further (Figure 4.36 F).
Overall, there were significant difference in the levels of lactate and pyruvate in the 
extracellular samples of cells treated with troglitazone. The levels of phenylalanine, leucine, 
methionine, valine, and glutamine also appear to be different in the troglitazone treated 
samples but there is discrepancy between the results obtained in the EST versus ESI^ mode, 
which will be discussed later. Riboflavin and troglitazone were detected, but only at very low 
levels that were not worthy of further examination. Overall, LC-MS analysis of the 
extracellular samples in the EST mode gave better detection than in the ESI^ mode as it was 
able to detect double the number of metabolites (12 metabolites versus 6 metabolites).
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Figure 4.36: LC-MS analysis in the ESC mode of the extracellular samples treated with 2.4
vs. 24 pM of troglitazone for 24 h. Treated cells were harvested, extracted with acetonitrile, 
freeze-dried, and re-suspended in water prior to LC-MS analysis. DMSO (0.5%) was used as the 
control. Detection of (A) phenylalanine (Phe), (B) leucine (Leu), (C) methionine (Met), (D) valine 
(Val), (E) glutamine (Gin), and (F) riboflavin. The mean ± S.E.M are shown (n = 3 biological 
repeats). Data were analysed by one-way ANOVA followed by Bonferroni post-test (*/? < 0.05, 
**p < 0.01, ***p < 0.001). Un-incubated media: Culture media not incubated with cells.
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4.7 Dose-response levels of metabolites affected by troglitazone
The dose-response levels of metabolites affected by troglitazone treatment were 
investigated by LC-MS analysis. Cells were exposed to troglitazone at various concentrations 
for 24 hours. In contrast to all the previous experimental designs, cells were cultured in 2% 
FBS; a low concentration of FBS was used because this is part of an extended time period 
exposure experiment (although the results are not reported in this thesis) and FBS was 
required to prevent the cells from dying or entering into the resting (Go) phase. After the 
24 hours treatment period, cells were harvested and processed and the intracellular samples 
analysed by LC-MS in the ESF mode.
Figure 4.37 shows a sample of one of the metabolites detected after 24 hours of 
treatment with troglitazone. The levels of malate decreased with an increasing concentration 
of troglitazone, demonstrating a clear concentration-response relationship. The highest dose 
of troglitazone used in this experiment was 100 pM and as more cells became non-viable, the 
level of metabolites such as malate was expected to decrease as well as a direct result of the 
decreased viable cell number. To eliminate this confounding factor, data analysis should only 
take into account the dose at which troglitazone did not affect the viability of the cells. Figure
4.38 shows a dose-response curve of the same experimental design but assayed by the MTT 
assay. The percentage of viability was not affected below 5 pM of troglitazone (E. Mercer, 
2011, pers. comm.). Therefore, for subsequent data analysis, only concentrations of 5 pM and 
below were used, reflecting 100% viability by the MTT assay.
LC-MS analysis detected GSH, lactate, malate, phenylalanine, AMP, and tryptophan, 
after 24 hours of treatment with troglitazone (Figure 4.39). Two metabolites (306.0788 and 
306.0789 m/z) were detected for GSH (Figures 4.39 A and B) eluting at 1.22 and
1.09 minutes, and both have mass differences of 9 ppm from the theoretical mass. The levels 
of GSH, lactate, malate, and phenylalanine were decreased even with treatment as low as 
5 pM of troglitazone (Figures 4.39 A -  E). The levels of AMP were not affected by 
troglitazone (Figure 4.39 F) and although tryptophan was detected, the detection intensity 
was very low and almost negligible (Figure 4.39 G).
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Figure 4.37: The levels of malate detected via LC-MS analysis in the ESI mode. HuH-7 cells 
were treated with various concentrations of troglitazone for 24 h and then harvested, processed and 
the intracellular samples were subjected to LC-MS analysis. DMSO (0.5%) was used as the control 
and the treatment media contained 2% of FBS. The mean ± S.E.M. are shown (n = 3 biological 
repeats). Data were analysed by non-linear regression and one-way ANOVA followed by 
Benferroni post-test (*/? < 0.05, **p < 0.01, and ***p < 0.001).
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Figure 4.38: The dose-response curves of HuH-7 cells treated with various concentrations of 
troglitazone for 24 h. Cell viability was assessed by the MTT assay. DMSO (0.5%) was used as 
the control and the treatment media contained 2% of FBS. The mean ± S.E.M. are shown (n = 3 
biological repeats). Data were analysed by non-linear regression and one-way ANOVA followed 
by Benferroni post-test (*/? < 0.05, **/? < 0.01, and ***p < 0.001).
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Figure 4.39: Levels of intracellular metabolites detected by LC-MS analysis of HuH-7 cells 
treated with troglitazone for 24 h. (A -  B) GSH, (C) lactate, (D) malate, (E) phenylalanine (Phe),
(F) AMP, and (G) tryptophane (Trp). Treatment media contained 2% of FBS. The mean ± S.E.M. 
are shown (n = 3 biological repeats). Data were analysed by non-linear regression and one-way 
ANOVA followed by Benferroni post-test {*p < 0.05, **p < 0.01, and ***p < 0.001).
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The concentration of troglitazone required to decrease the levels of the detected 
metabolites by 50% (IC50) were calculated by non-linear regression from the treatment dose 
of 0 -  5 gM. The IC50 values for GSH, lactate, malate, and phenylalanine range from 2.2 -
3.9 pM (Table 4.7). Because AMP was not affected by troglitazone treatment and the 
concentration of tryptophan can be considered as negligible, the IC50 values for these two 
metabolites were not determined.
Table 4.7: The concentration of troglitazone required to decrease the levels of 
metabolites by 50% (IC5 0)
Metabolites IC5 0
24-h treatment
GSH 3.9 ±0.6
3.8 ±0.7
Lactate 3.0 ± 0.7
Malate 3.0 ±0.9
Phenylalanine 2.2 ± 0.3
ADP ND
Glutamate ND
IC50 values were calculated by non-linear regression. LC-MS analysis was performed in the ESP 
mode using the intracellular samples. HuH-7 cells were treated with troglitazone at various 
concentrations for 24 h. The mean ± S.E.M. are shown (n = 3 biological repeats). ND: not determined.
4.8 Discussion
Metabolomics is a comprehensive analysis directed to identify and quantify all 
metabolites in a given biological system (Weckwerth and Fiehn, 2002), and utilises 
sophisticated analytical technologies and statistical and multi-variant methods for information 
extraction and data interpretation (Roessner and Bowne, 2009). In this chapter, the feasibility 
of a metabolomics approach using LC-MS analysis to discriminate troglitazone toxicity was 
demonstrated. Both untargeted and targeted metabolomics approaches were used; an 
untargeted metabolomics approach takes into account as many measured metabolites as 
possible and compares between samples without bias. The experimental design, including the 
sample preparation method and choice of instrument determines the number and chemical 
composition of the studied metabolites. On the other hand, targeted metabolomics approach 
look at a specific list of metabolites, focusing on the metabolic pathway(s) of interest. 
Targeted metabolomics approaches are typically driven by a hypothesis whereas untargeted 
metabolomics approach are often hypothesis-generating (Patti et al, 2012).
The untargeted LC-MS analysis of the intracellular and extracellular samples of cells 
treated with different concentrations of troglitazone for 24 hours revealed three metabolites
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which levels decreased with troglitazone treatment (Figures 4.3 B and 4.5 B). When the 
changes of these metabolites were evaluated, all three metabolites exhibited decrement in a 
dose-dependent manner, with IC50 values calculated to be between 15.6 -  20.2 pM. The IC50 
values obtained from LC-MS analysis were in agreement with the IC50 value obtained from 
the MTT assay (i.e. approximately 22.1 pM), suggesting that there were 50% changes in the 
levels of these endogenous metabolites and cell viability induced by troglitazone at the 
concentrations between 15.6 -  22.1 pM.
In another untargeted LC-MS analysis (Section 4.2), cells were treated with different 
TZDs for 24 hours at 0.1 x their respective IC50 values, as measured by the MTT assay. This 
concentration was chosen to evaluate whether LC-MS analysis was able to discriminate the 
toxicity between the three TZD drugs as previously described with the MTT assay. Results 
showed that LC-MS analysis was able to separate the different treatments based on the global 
metabolite profiles in the intracellular and extracellular extracts. Treatment with troglitazone 
and rosiglitazone showed more differences compared to the control while pioglitazone 
produced almost similar metabolites with the control (Figures 4.7 and 4.15). Between the 
three TZDs, the metabolite profile of troglitazone was more closely related to rosiglitazone 
than pioglitazone. Identification of the metabolites that separate troglitazone-treated cells 
from control samples using only on the m/z value was a difficult task. Not all metabolites 
were detected as the parent ion; for example, metabolite 21, which was later putatively 
identified as GSH (Table 4.1). GSH has a theoretical m/z value of 306.0760 but the detected 
m/z value was 328.0603. This was because GSH formed an adduct with sodium, increasing 
its apparent m/z value. Ionisation techniques such as electrospray (ESI) are able to form not 
only single adduct ions but sometimes sets of multiple adducts and the common adducts 
include sodium and ammonium (Kind and Fiehn, 2010), which may be considered a 
disadvantage as this complicates downstream analysis. In addition, electrospray can also 
produce singly or multiple charge ions (Taylor, 2005), further confounding robust analysis.
In LC-MS experiments, each detected peak in a chromatogram corresponds to a 
detected ion with a unique m/z value and a unique retention time, which represents a 
metabolite. However, some metabolites may produce more than one peak (Patti et ah, 2012). 
For example, metabolite 31 and 61 from the intracellular samples were putatively identified as 
nicotinuric acid (Table 4.1). They both exhibited very similar m/z values but were eluted at 
two different times, i.e. 5.08 versus 4.83 minutes, respectively, which was approximately 
0.25 minutes apart. Similarly, metabolites IE and 2E (mevalonic acid) and metabolites 3E
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and 6E (nicotinuric acid) from the extracellular samples also have very similar m/z values but 
were eluted at 0.37 and 0.30 minutes apart, respectively (Table 4.2). Deviation of retention 
times in LC-MS experiments can be the consequence of column degradation, sample 
carryover, a small fluctuation in room temperature, mobile phase pH, and other variations 
(Patti et a l, 2012).
The ten most important metabolites in the intracellular samples that separate 
troglitazone-treated cells from the control samples in the untargeted LC-MS analsyis were 
putatively identified as methyladenine, GSH, mevalonic acid, nicotinuric acid, lactic acid, 
malic acid, pyruvic acid, pyridoxal and acetic acid (Table 4.1). In the extracellular samples, 
mevalonic acid, nicotinuric acid, reduced riboflavin, pyruvic acid, and lactic acid were 
putatively identified (Table 4.2). It should be noted that not all metabolites were identified, 
and these unidentified metabolites require further analysis. However, from these results, it 
can be hypothesised that troglitazone affects both glycolysis and the TCA cycle, as indicated 
by the detection of lactic pyruvic acid, acid, malic acid, acetic acid. Troglitazone can also be 
seen to affect the oxidative state of the cells, as indicated by the decreased levels of 
intracellular GSH. Other metabolic pathways that were suspected to be affected by 
troglitazone treatment include cholesterol synthesis (mevalonic acid), DNA repair 
(methyladenine), nicotinamide synthesis (nicotinuric acid), activity of flavin reductase 
(reduced riboflavin), and the precursor of pyridoxal phosphate (pyridoxal), which is an active 
form of vitamin Be. The putative identifications were then confirmed by comparing the 
profiles (m/z value and retention time) obtained in the treated samples to that of standard 
compounds. The focus for this investigation was only on metabolites related to glycolysis and 
the TCA cycle, oxidative state, nicotinamide synthesis, metabolites related to the 
NAD^/NADH and NADP^/NADPH coenzymes, and riboflavin.
LC-MS analysis of the standard compounds was able to detect all the tested 
compounds. Fragments of ATP, i.e. ADP and AMP were also detected. Some compounds 
were observed to be eluted at two different times while others were detected as two different 
ions with different m/z values (Table 4.5). ATP was eluted at two different times, i.e. 
approximately 1.17 and 3.60 minutes. Majority of ATP was detected in the former elution 
time, which is an indication that ATP is not well retained by the UPLC BEH Cig column. 
NADH was also detected with two different elution times (in the EST mode), i.e. 3.62 and 
3.73 minutes. Both showed similar detection intensities (same AUC levels). This was 
probably because of experimental drift since the elution time was not very far apart. On the
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Other hand, in the ESI^ mode, NADH appears to be detected as two different ions with 
different m/z values, 666.1299 and 664.1042 m/z. The former was the major ion and eluted at 
3.63 minutes while the minor ion was eluted at 1.90 minutes. NADPH was also detected as 
two different ions in both ionisation modes, i.e. 744.0776 and 745.0727 in the EST and 
746.0825 and 747.0923 in the ESI^. These ions were eluted at the same time, approximately 
3.62 minutes and the lower m/z ion appears to be the major ion.
LC-MS analysis of the standard compounds also discovered that matrix effects affect 
the chromatographic separation and MS detection (Table 4.6). The same standard compound 
prepared in different matrices such as water, culture medium, and PBS displayed different 
retention times, peak shape, and detection intensities (Figure 4.29 and Table 4.6). Matrix 
effect is a phenomenon when co-eluting matrix with compound(s) of interest, and alters the 
ionisation efficiency of the electrospray interface. This is probably due to competition 
between the compound of interest and the matrix components for access to the droplet 
surface, which is necessary for transfer into the gas phase. This competition may effectively 
decrease (ion suppression) or increase (ion enhancement) the efficiency of ionisation of the 
desired compound. Therefore, the efficiency of compounds to form ions is very much 
dependent on the matrix entering the electrospray ion source. The chemical nature of a 
compound also has significant effect on the degree of matrix effects. The most polar 
compounds have been found to have been the most subject to ion suppression, while 
non-polar metabolites are only weakly subject to ion suppression (Taylor, 2005). The degree 
of matrix effects can be assessed by post-extraction addition or post-column infusion. 
Post-extraction addition method compares the difference in response of a compound in neat 
solution to the response of a compound spiked into a blank matrix Sample (Figure 4.41). The 
post-column infusion method delivers a constant amount of compound into the ion source of 
a mass spectrometer and when a blank matrix sample is injected into the LC, any eluting 
compounds fi*om the column that causes a variation in response of the infused compound is 
considered as a suppression or enhancement of the infused compound (Figure 4.40) (Taylor, 
2005; Van Eeckhaut et al, 2009).
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Figure 4.40: Schematic overview of methods used to assess matrix effects. (A) Post-extraction 
spiked method and (B) post-column infusion method. The dashed line represents signals of 
standard compounds and the full line is obtained when blank matrix sample is included in the 
LC-MS analysis. A clear reduction is observed indicating ion suppression. Adapted from Van 
Eeckhaut et al. (2009).
Matrix effects have also been reported to result in retention time drift and 
chromatographic tailing (Ghosh et al, 2012), as observed in this study. Moreover, standard 
compounds prepared in culture medium were observed not only to display retention time drift 
but also multiple peaks with lower detection intensity whereas standard compounds prepared 
in water exhibited an almost “perfect” peak with high detection intensity (Figure 4.29). The 
culture medium contains many components, any one of which could act to elicit ion 
suppression for the compound of interest.
The only setback of the investigation in this chapter is that most of the compounds of 
interest were not well retained using UPLC BEH Cis column. The retention time observed for 
majority of the metabolites was less than 1 minute. This is because the metabolites of interest 
were all polar metabolites and reversed-phase chromatography retained the most non-polar 
metabolites while eluting first the most polar metabolites (Dejaegher and Vander, 2010; Latif 
and Sarker, 2012). However, several publications have reported the separation and 
quantification of metabolites related to glycolysis and the TCA cycle using a reversed-phase
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gradient. Ross and Dalluge (2009) employed a Phenomenex Aqua Cig column with mobile 
phase consisting of 0.1% aqueous formic acid and 0.1% formic acid in acetonitrile. The 
retention time for the metabolites was reported to be acceptable; for example, the retention 
time for pyruvate was approximately 3.5 minutes for a total run time of 7 minutes (Ross and 
Dalluge, 2009). However, the peak width was broad, but symmetrical. It took at least 1 
minute to completely elute pyruvate, with other metabolites taking at least 0.5 minutes. This 
was probably because the liquid chromatography flow rate was low, i.e. 0.2 ml/min. If the 
flow rate was increased, the peak width would be narrower but this will probably cause less 
retention. In another study that also utilised a Cig-type of column (Synergi Hydro-RP) with a 
reversed-phase gradient that aimed to simultaneous identify and quantify a large number of 
highly polar intracellular metabolites from the glycolysis, pentose phosphate pathway, and 
TCA cycle, tributylamine, an ion pair reagent was used. The hydrocarbon chain of the ion 
pairing reagent imparts hydrophobicity when paired with the metabolites, so that the ion pair 
can be retained on the reversed phase column. Stronger retention was observed when the 
concentration of tributylamine was increased (Luo et al, 2007). However, past experience in 
the laboratory found that tributylamine is a very “sticky” compound that leaves traces in both 
the liquid chromatography and mass spectrometer interfaces, which cannot be removed 
without difficulty. It seems that ion pairing application using tributylamine is more feasible 
when there is an instrument that is designated specifically for ion-pairing application. Yang et 
al (2008) proposed labelling with aniline in a single 30 minutes reversed-phase LC-MS 
analysis. The rationale is that by introducing a hydrophobic moiety into hydrophilic 
molecule, hydrophobicity is increased, facilitating reversed-phase separation and mass 
spectrometry detection (Yang et a l, 2008). It appears that simultaneous analysis of all the 
intermediates involved in central carbon and energy metabolism is a challenging analytical 
problem. Several different LC-MS techniques are probably needed to quantify all the 
metabolites.
Nevertheless, after obtaining the profiles of the standard compounds, LC-MS analysis 
allowed to identify which metabolties had been affected by troglitazone treatment. The 
metabolomics approach shifted fi*om an untargeted analysis to a targeted analysis because 
there is now a list of specific metabolites fi’om specific biochemical pathways to measure and 
the experiments are driven by the hypothesis that troglitazone affects the glycolysis and the 
TCA cycle, oxidative state, and metabolites related to the coenzymes NAD^/NADH and 
NADP^/NADPH. Results in Section 4.3, 4.6, and 4.7 revealed that 24 hours of troglitazone
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treatment consistently decreased the levels of intracellular GSH (Figures 4.23 A, 4.33 A, 4.34 
A, 4.39 A and B) and malate (Figures 4.23 C. 4.33 B, 4.39 D), which suggests that 
troglitazone affected the oxidative state of the cells and the TCA cycle, respectively. In 
addition, the levels of ADP and AMP were increased in comparison to the control (Figures 
4.33 E and F), although ATP was not detected. ADP and AMP levels will concomitantly 
increase when there is a fall in ATP level, an indicator of disruption in ATP recycling process 
(Champe et al., 2008; Mathews et al., 2000). Troglitazone has been reported to cause 
oxidative stress and mitochondrial dysfunction (Yokoi, 2010; Smith, 2003; Masubuchi, 2006; 
Chojkier, 2005), and the findings in this study (altered intracellular concentrations of GSH, 
malate, ADP, and AMP) could also explain those effects via basic biochemical processes. 
Reactive oxygen species (ROS) are formed continuously as byproducts of aerobic 
metabolism while GSH in the cells functions as an antioxidant, detoxifying ROS. When the 
level of GSH is depleted, effective removal of excess ROS is halted and oxidative stress may 
occur (Champe et ah, 2008). The TCA cycle takes place in the mitochondria and malate is an 
intermediate of the TCA cycle. Mitochondrial dysfunction will interrupt the TCA cycle 
pathway, decreasing the production of the intermediates, which may ultimately decrease ATP 
production (Champe et al, 2008; Mathews et al, 2000).
Intracellular lactate and phenylalanine were also detected but no definitive conclusion 
can be drawn for these two metabolites. Troglitazone up to 24 pM was observed to have no 
significant effect on both lactate and phenylalanine (Figures 4.33 D and H) but in another set 
of experiment, for the same duration of exposure time (24 hours), 5 pM of troglitazone 
decreased the levels of both metabolites in comparison to the control (Figures 4.39 C and E). 
On the contrary, the levels of extracellular lactate were increased after 24 hours treatment 
with troglitazone at 2.4 pM and to a lesser extent at 24 pM in comparison to the control 
(Figure 4.35 A), which implies that troglitazone caused an increased in lactate production, 
and this further contradicts the intracellular lactate results, in which troglitazone was found to 
either decrease (Figure 4.39 C) or has no effect (Figure 4.33 D) on lactate production. Hence, 
as no clear concentration-dependent effect exists, these results should be treated with caution 
until further experiments are undertaken to deconvolute the findings.
Pyruvate is another metabolite that exhibited conflicting results. In the extracellular 
samples, the levels of pyruvate appears to be higher in the control compared to troglitazone- 
treated samples (24 pM) (Figure 4.25 A), but in another set of experiment, the levels in the 
control were lower compared to the treated samples (2.4 and 24 pM) (Figures 4.35 B and C)
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although not statistically significant versus the 24 pM. The former result is suggests that cells 
treated with troglitazone were absorbing more pyruvate fi*om the culture medium while the 
latter result implies that pyruvate was not absorbed into the cells as much as the control cells. 
Pyruvate in the intracellular sample was detected at very low levels and can be considered 
negligible (Figures 4.23 B and 4.33 C).
The levels of extracellular amino acids (phenylalanine, leucine, methionine, valine, 
and glutamine) were low in the control and higher in cells treated with 2.4 and 24 pM 
troglitazone (Figures 4.35 D -  H). This result can be interpreted as troglitazone-treated cells 
were taking in less amino acids fi-om the culture medium than the control cells. However, 
when LC-MS analysis was conducted in the ESI^ mode, no significant difference between the 
treatments were observed even though the same samples were used for the analysis (Figures
4.36 A -  D). The discrepancy could be because, generally, LC-MS analysis in the ESI^ mode 
produced lower detection intensities than the ESF mode and hence differences may be 
obscured by the resultant increase in signal-noise background. Leucine, valine, and glutamine 
were also detected in the intracellular samples but the levels were very low and can be 
considered negligible (Figures 4.33 I, K, L). Tryptophan levels in the extracellular samples 
showed no significant difference between treatments (Figures 4.35 J and 4.36 E) and the 
levels detected in the intracellular samples can be considered negligible (Figures 4.33 J and
4.39 G). Further experiments are needed to confirm the findings whether troglitazone affected 
cells intake of amino acids and pyruvate and also on lactate production.
Troglitazone quinone was the only metabolite of troglitazone metabolism that was 
detected (Figures 4.33 N (intracellular); 4.20 A, 4.25 D, 4.35 K (extracellular)). However, 
troglitazone quinone was also detected in the culture medium controls (un-incubated media). 
Troglitazone quinone is a product of troglitazone metabolism and it should not be present in 
samples not incubated with cells that have the enzymes to metabolise troglitazone. The 
measured m/z value is the same as the theoretical value but because there is no commercially 
available standard compound for troglitazone quinone, comparison using the retention time 
was not possible. Nonetheless, the metabolite suspected to be troglitazone quinone was only 
observed in troglitazone-treated samples and not in the control or other TZD-treated samples. 
The possible explanation is that the troglitazone used in this study may contain a low 
percentage of troglitazone quinone, as the purity of the product is only > 98%, according to 
the product information sheet (Cayman Chemical Company, 2012). The detection intensity of
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troglitazone quinone was however, quite low, which probably reflects the low drug 
metabolising capacity of HuH-7 cells.
In the study on the effect of organic solvent on LC-MS detection intensity of 
troglitazone, the detection intensity was higher when the final solution contains 50% aqueous 
acetonitrile (Figures 4.31 A and B). This is probably due to the solubility of troglitazone. 
Troglitazone is soluble in organic solvents and sparingly in aqueous solution. To maximise 
solubility in aqueous solutions, it is recommended that troglitazone should first be dissolved 
in DMSO and then diluted with aqueous solution (Cayman Chemical Company, 2012). 
Therefore, samples that contained more organic solvent increase the solubility of troglitazone 
and thus, increase the detection of troglitazone.
Perhaps the most interesting finding in this study is that LC-MS analysis was able to 
detect changes elicited by troglitazone at very low concentrations. The levels of intracellular 
GSH (Figures 4.37 A and B, 4.38 A), malate (Figures 4.28 B, 4.74 D, 4.38 C), and ADP 
(Figures 4.28 E and 4.38 E) were significantly decreased with treatment of not more than 
5 pM troglitazone. While it is possible that these changes are the result of a positive 
adaptation to troglitazone exposure, this is unlikely because, as described above, these 
changes can all be linked to known toxic effects of troglitazone at higher doses. This, 
therefore, leads to the conclusion that LC-MS analysis is more sensitive to toxic damage of 
troglitazone, and was able to detect signature of biochemical alteration at concentration 
where the MTT assay (a traditional toxicity assay) was still detecting 100% cell viability. 
However, further experimentation is required to examine if these changes are causally linked 
to the observed cell toxicity, such as the use of an increased number of concentrations over 
the chronic dosing period.
To sum it up, results from this chapter showed that LC-MS is a sensitive tool in 
assessing biochemical changes that might lead to toxicity. In addition, troglitazone decreased 
the intracellular antioxidant, as indicated by low GSH and also affected the TCA cycle 
intermediate (malate) and the process of energy generation (higher levels of ADP and AMP).
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Chapter 5: LC-MS Analysis using Luna NH2 Column
LC-MS analysis using the UPLC BEH Cig column was able to detect several 
metabolites of the glycolytic and TCA cycle that were affected by troglitazone in both the 
intracellular and extracellular samples of HuH-7 cells (Chapter 4). However, most of the 
metabolites were eluted at approximately 1 minute, i.e. close to the void time, meaning that 
the robustness of the detection can be questioned.
In this chapter, the main aim was to improve the LC-MS analysis by improving the 
liquid chromatography separation and retention for polar metabolites. Hydrophilic liquid 
chromatography (HILIC) with a Luna NH2 column has been previously reported to separate 
polar metabolites formed within glycolysis, TCA cycle, and energy production, such as 
pyruvate, malate, fumarate, succinate, ATP, ADP, AMP, NAD^, NADP^, NADH, and 
NADPH (Yang et al, 2009a; Lewis et al, 2008). Therefore, the Luna NH2 column was 
chosen for the liquid chromatography separation in this study. The specific objectives of this 
study were as follows:
Objective 1: Evaluation of the detection potential of LC-MS analysis using Luna NH2 
column.
Objective 2 : Optimisation of liquid chromatography flow rate.
Objective 3: Optimisation of mass spectrometry capillary voltage.
Objective 4: Evaluation of the effect of acetonitrile on peak shape and broadness.
Objective 5: Evaluation of the effect of column conditioning on detection intensity. 
Objective 6: Optimisation of liquid chromatography mobile phase to increase detection.
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5.1 Assessing the retention of polar metabolites on Luna NH2 column
The purpose of this experiment was to test the capability of Luna NH2 column in 
separating polar metabolites from a relatively simple mixture. Mixtures of purchased, 
standard compounds were prepared at concentration of 200 pM in water or 20% (v/v) 
aqueous acetonitrile. Liquid chromatography was conducted using a HILIC gradient with a 
flow rate of 0.3 ml/min, using a mobile phase of (A) 20 mM ammonium acetate with 0.05% 
(v/v) ammonium hydroxide in 5% (v/v) of aqueous acetonitrile, pH 8.5 and (B) acetonitrile. 
The mass spectrometry protocols were similar to the protocols used for the UPLC BEH Cig 
column.
Figures 5.1 -  5.4 show the chromatograms of the detected standard compounds in the 
ESF mode. A total of 14 compounds were detected: All the examined amino acids 
(glutamine, glutamate, tryptophan, valine, methionine, phenylalanine, and leucine) were 
detected and the retention time was between 3 - 5  minutes (Figures 5.1 -  5.2); lactate, was 
detected with a retention time of 9.51 minutes (Figure 5.2 D), but other intermediates of 
glycolysis and the TCA cycle were not detected; nicotinamide, nicotinic acid, nicotinuric 
acid, and pyridoxal were detected with retention times of 1.15, 10.37, 9.55, and 7.60 minutes, 
respectively (Figure 5.3); GSH was eluted at 12.78 minutes (Figure 5.4 A) while riboflavin 
displayed a broad peak with elution time of 1.59 minutes (Figure 5.4 B). In general, 
compounds dissolved in water produced higher detection intensities compared to when 
20% (v/v) aqueous acetonitrile was used as a solvent. For example, the peak area (AUC) for 
glutamine was 1746 when dissolved in water, but only 998 when dissolved in 20% (v/v) 
aqueous acetonitrile. The summary of the LC-MS profiles of the standard compounds are 
tabulated in Table 5.1.
In the ESI^ mode, a more limited set of compounds was detected, compared to 
detection in the ESF mode (Figures 5.5 -  5.7): All the amino acids were detected except for 
glutamine (Figures 5.5 -  5.6); none of the glycolysis and TCA cycle intermediates was 
detected; nicotinamide, nicotinic acid, nicotinuric acid, GSH, and ribofiavin were also 
detected (Figures 5.6 -  5.7); importantly, NAD^ was detected in the ESI^ mode, which was 
not detected in the ESF mode (Figure 5.7 D). Therefore, a total of 12 metabolites were 
detected in the ESI^ mode (Table 5.1). In this ionisation mode, only compounds dissolved in 
water was detected, with no detection of compounds dissolved in 20% (v/v) aqueous 
acetonitrile.
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These results show that Luna NH2 column was able to effectively separate and 
produce better retention for polar compounds than the UPLC BEH Cig column, although not 
all the compounds of interest were detected.
5.2 Optimisation of the experimental protocols
Results in Section 5.1 showed that the Luna NH% column produced better retention for 
polar compounds than the UPLC BEH Cig column, but not all the compounds were detected. 
The next sets of experiments were conducted to optimise the experimental protocols.
5.2.1 Optimisation of liquid chromatography flow rate
The first optimisation experiment undertaken was to find the best flow rate for the 
liquid chromatography. Since most of the amino acids were detected, they were used as 
model compounds for this study. Glutamine, tryptophan, valine, methionine, phenylalanine, 
and leucine were prepared as a 200 pM mixture in water, and subjected to LC-MS analysis 
with the flow rate ranging from 0.1 to 0.4 ml/min: The highest flow rate was chosen based on 
the recommendation of the column manufacturer to keep the backpressures below 3,500 psi 
(maximum 5,000 psi). Other conditions of the LC-MS analysis were similar to the protocols 
used in Section 5.1, with the exception that the mobile phase consisted of (A) 5 mM 
ammonium acetate with 0.05% (v/v) ammonium hydroxide in 5% (v/v) aqueous acetonitrile, 
pH 8.5. The amount of ammonium acetate was reduced compared to previous experiments to 
limit contamination on the mass spectrometry sampling cone, which could reduce detection 
intensities.
Figure 5.8 shows the chromatograms of glutamine detected with varying flow rates. 
An analysis of the chromatograms shows that lower flow rate produced sharper peaks. In 
addition, higher flow rate also reduced the detection intensities (Figures 5.9 B and D) and, as 
expected, increased the retention time (Figures 5.9 A and C). LC-MS analysis in the ESI^ 
mode only detected the compounds at flow rates between 0.1 to 0.25 ml/min. (Figure 5.8 B). 
In general, chromatogram peaks were broader in ESI^ detection mode compared to EST 
detection mode.
Further work was continued with a flow rate of 0.15 ml/min. as this provided the 
optimal compromise between detection intensity and peak shape.
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Figure 5.8: Chromatograms of glutamine detected at varying liquid chromatography flow 
rates. Glutamine, one of the five amino acids combined as a 200 pM mixture in water was 
subjected to LC-MS analysis in (A) ESf and (B) ESC modes with HILIC gradient of 35 min. and 
injection volume of 10 pi, i.e. 2 nmoles of glutamine.
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Figure 5.9: The effect of different flow rates on the elution time and detection intensity of 
valine, methionine, phenylalanine, leucine, glutamine, and tryptophan. Standard compounds 
were prepared as a mixture of 200 pM in water. LC-MS analysis was performed in (A and B) ESf 
and (C and D) ESI  ^modes with HILIC gradient of 35 min. and varying flow rates. The injection 
volume was 10 pi, i.e. 2 nmoles. Data shown as mean ± S.E.M (n = 2 technical repeats).
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5.2.2 Optimisation of the mass spectrometry capillary voltage
The second optimisation experiment was to find the optimum capillary voltage that 
would enable detection of all the compounds of interest. This experiment was conducted 
previously (Section 4.4) but with a limited number of compounds, i.e. pyruvate, malate, 
oxaloacetate, GSH, NAD"^ , nicotinic acid, and riboflavin. In this experiment, an increased 
number of compounds were used, a total of 28 compounds prepared at a concentration of 
250 pM in 50% (v/v) aqueous acetonitrile were directly infused (10 pl/min.) into the QToF 
Premier mass spectrometer at varying voltages in the EST and ESI^ ionisation modes. The 
final injection amount for each compound was 2.5 nmoles. Acetonitrile was added to the 
samples because it is a volatile organic solvent that provides an optimal environment for 
electrospray ionisation.
Figure 5.10 shows the results of the mass spectrometry detection in the EST mode: 
The majority of compounds displayed the highest detection at around 2.6 kV. This result was 
similar to the findings in Section 4.4, in which the optimum capillary voltage for EST mode 
was 2.6 kV. Another observation was that compounds from the glycolytic and TCA cycle 
were detected in two forms, i.e. -COOH (protonated) or -COO’ (deprotonated), with the 
former being the major form. NADH and NADPH were also detected in two forms, 
depending whether the phosphate group was protonated or deprotonated, while ATP was 
detected as both the parent compound and fragmented into ADP and AMP.
In the ESŸ mode, 3.2 kV was found to be the optimum voltage for the detection of 
majority of the compounds (Figure 5.11), compared with 2.9 kV used in Chapter 4. The 
detection intensity in the ESI^ mode was lower than in the EST mode, especially for NADH, 
NADP^, NADPH, ATP, ADP, and AMP, in which the detection were less than 
20 counts/scan. Nevertheless, 3.2 kV detected the highest signal in comparison to other 
capillary voltages. Hence, 2.6 and 3.2 kV were selected as the optimum capillary voltage for 
the EST and ESI^ modes, respectively, and used in all the subsequent experiments.
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Figure 5.10: The effect of capillary voltage on the detection intensity in the ESF mode.
Standard compounds were prepared as 250 pM mixtures in 50% aqueous acetonitrile. Samples 
were directly infused into the QToF Premier at the amount of 2.5 nmoles (10 pFmin.).
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Figure 5.11: The effect of capillary voltage on the detection intensity in the ESI^ mode. 
Standard compounds were prepared as 250 pM mixtures in 50% aqueous acetonitrile. Samples 
were directly infused into the QToF Premier at the amount of 2.5 nmoles (10 pl/min.).
228
5.2.3 Effect of acetonitrile on peak shape and broadness
The effect of acetonitrile concentration on peak shape and broadness was investigated. 
Amino acids were again used as model compounds: Leucine, methionine, tryptophan, 
glutamine, and glutamate were prepared as a 200 pM mixture in various concentrations of 
aqueous acetonitrile. The mixtures were then subjected to LC-MS analysis in the EST 
ionisation mode with a 35 minutes HILIC gradient. The injection volume was 10 pl/sample, 
i.e. 2 nmoles/sample.
Figures 5.12 -  5.13 show the chromatograms of the five amino acids. A higher 
percentage of acetonitrile in the samples produced a sharper peak. The intensity of the 
detection, represented by the peak area (AUC) was, however, not affected by acetonitrile 
(Figure 5.14).
The effect of acetonitrile on polar compounds related to energy production was also 
evaluated. Lactate, oxaloacetate, nicotinuric acid, NAD\ and NADH were used as examples 
of the polar compounds. All the compounds were detected except for oxaloacetate 
(Figure 5.15 B). However, only nicotinuric acid and NAD^ were detected at reasonable 
intensity, i.e. with peak area (AUC) above 50 (Figure 5.17). In contrast, lactate and NADH 
were detected only at very low levels. The major form of NADH was detected as 
663.1091 m/z. Acetonitrile did not improve the peak shape or detection potential of the polar 
compounds. Nevertheless, it should be noted that some compounds were not detected at a 
high percentage of acetonitrile such as in the case of NAD^ and NADH (Figures 5.15 D and 
5.16).
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Figure 5.13: The effect of acetonitrile on peak shape and broadness of amino acids (II).
Chromatograms of glutamate (Glu) from LC-MS analysis of amino acid mixtures (200 pM) 
prepared in various concentrations of aqueous acetonitrile conducted in the ESf mode with HILIC 
gradient of 35 min., 0.15 ml/min. flow rate, and 10 pi injection, i.e. 2 nmoles.
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Figure 5.14: Peak area of the chromatograms of (A) leucine, (B) methionine, (C) tryptophan, 
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5.2.4 Improving detection intensity by column conditioning
In Figure 5.14 and Figure 5.17, it was observed that the detection intensity of the 
second run (replicate 2) was always higher than the first run (replicate 1), which suggests that 
the Luna NH2 column might need to be conditioned in order to produce a stable detection 
result. Figure 5.18 shows the detection intensities of leucine, methionine, tryptophan, 
glutamine, and glutamate after the column was conditioned with 13 repetitions of a 
3 5-minutes run of the amino acid mixture at a very concentrated level (2 mM), providing a 
final injected amount of 20 nmoles. It was observed that the detection intensity begun to be 
consistent after the fourth run. A repeat of the same experiment using a column that had been 
stored in the storage solution (i.e. isopropanol) also showed that the detection intensity of the 
five amino was stabilised.
These results indicate that a new column needs to be conditioned with the 
compounds/metabolites/analytes of interest for a consistent detection result. Among the 
23 standard compounds used as a mixture (200 pM) to condition the column, only 
10 compounds were detected (Figure 5.19); and among these 10 detected compounds, 6 
showed that column conditioning improved the consistency of the detection intensity (valine, 
phenyalanine, NAD^, riboflavin, GSH, and nicotinuric acid; Figures 5.19 A -  F). Reduction 
of the detection intensity in the last five runs was suspected to be caused by build-up on the 
sampling cone that reduced sensitivity. The other detected compounds (nicotinic acid, lactate, 
and NADH) did not show clear improvement after the conditioning but the detection intensity 
fluctuated less as compared to the beginning of the run (Figures 5.19 G -  1). Nicotinamide 
was detected at low levels and no improvement was observed after column conditioning 
(Figure 5.19 J).
The column was also conditioned with a cell extract. Leucine, glutamine, glutamate, 
valine, and GSH were the only detectable metabolites even though the cell extract used was 
harvested from a whole T75 flask, i.e. more concentrated in terms of number of cells than the 
usual one well used in Chapter 4. The conditioning did not a show a distinct improvement in 
the consistency of the detection intensity (Figure 5.20).
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Figure 5.18: Conditioning of Luna NH2 column with amino acids. Peak area (AUC) of 
(A) leucine, (B) methionine, (C) tryptophan, (D) glutamine, and (E) glutamate. Samples were 
prepared as a mixture of 2 mM and LC-MS analysis was performed in the ESP mode with HILIC 
gradient of 35 min., 0.15 ml/min. flow rate, and 10 pi injection, i.e. 20 nmoles.
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Figure 5.19: Conditioning of Luna NH2 column with polar compounds. A total of 23 
compounds were analysed by LC-MS but only 10 were detected. The highlighted box shows the 
detection intensity that was stabled after column conditioning. Samples were prepared as a mixture 
(200 pM) and LC-MS analysis was performed in the EST mode with HILIC gradient of 35 min., 
0.15 ml/min. flow rate, and 10 pi injection, i.e. 2 nmoles._______________________________
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Figure 5.20: Conditioning of Luna NH2 column with cell extract. (A) Leucine, (B) glutamine, 
(C) glutamate, (D) valine, and (E) GSH were the only detected metabolites. Cell samples from a 
T75 flask were harvested, extracted, and subjected to LC-MS in the ESI" mode. A HILIC gradient 
of 35 min., 0.15 ml/min. flow rate, and 10 pi injection were used.
5.2.5 Effect of mobile phase on LC-MS detection
The main metabolites of interest in this chapter were the intermediates of glycolysis 
and the TCA cycle, but the results obtained so far showed that these metabolites were not 
detected, either in cell extracts or using standard compounds. Thus, the type of mobile phase 
used was reconsidered. Malate was used as an example for the optimisation procedure.
Direct infusion of malate (prepared at 1 mM in the buffer used as mobile phase A, i.e. 
ammonium acetate with 0.05% (v/v) ammonium hydroxide in 95/5 (v/v) water/acetonitrile, 
pH 8.5) into the QToF Premier at a flow rate of 10 pl/min (i.e. 10 nmoles of malate) showed 
that it was detected in the EST mode but not in the ESI^ mode (Figure 5.21). Malate was 
detected as 132.98 m/z, although the buffer alone also contained an ion with approximately
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the same m/z value as malate: Samples containing malate were distinguishable as the 
detection intensity was very much higher compared to the buffer (1,620 versus 99,900 ion 
counts). However, when LC-MS analysis in the ESF mode was performed, the 
chromatograms between the malate and the buffer solution were indistinguishable (Figure 
5.22).
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Figure 5.21: Spectrum of malate obtained from direct infusion. (A) Malate was detected in the 
ESI mode as 132.98 m/z. An ion with the same m/z value as malate was also detected in the buffer 
solution. (B) Malate was not detected in the ESC mode. Malate was prepared at 1 mM in the buffer 
used as mobile phase A and directly infused into the QToF Premier at a flow rate of 10 pl/min. 
(10 nmoles of malate).
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Figure 5.22: Comparison of the chromatograms between malate and the buffer used as 
mobile phase A. Malate was prepared at 1 mM in buffer and subjected to LC-MS in the ESF mode 
with a HILIC gradient of 80 min., 0.15 ml/min. flow rate, and 10 pi injection (10 nmoles of 
malate).
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An acidic mobile phase was used to evaluate the effect of pH on malate detection. 
Figure 5.23 demonstrates that pH 8.5 was better than pH 4.0 for the detection of malate, 
although the peak was extremely broad and detection intensity was low. Increasing the 
injection concentration by 10-fold, i.e. from 10 nmoles to 100 nmoles, did not increase the 
detection intensity of malate (Figure 5.24).
In order to improve the detection of malate, LC-MS analysis using HILIC separation 
was compared to reversed-phase chromatography. The reversed-phase gradient did not 
improve the deteetion of malate (Figure 5.25). The chromatogram of malate was similar to 
the water blank except for a small peak at the beginning of the run. If the small peak was 
malate, it would suggest that malate was not retained using a reverse-phase gradient. 
However, in a HILIC gradient, at least malate was detected as an extremely broad peak.
The effect of ammonium acetate concentration on malate detection was also 
evaluated. Reducing the coneentration of ammonium acetate in the mobile phase did not 
improve the detection of malate (Figure 5.26 A). However, lower concentrations of 
ammonium acetate did reduce background noise. Glutamine, was also examined, and showed 
that lower coneentrations of ammonium acetate produced a sharper peak, higher deteetion 
intensity, and a reduced background noise level (Figure 5.26 B). After eonducting all these 
investigations, malate was still not detected with appropriate peak and it was decided that 
Luna NH2 column could not be used to address the research question in this study.
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Figure 5.23: The effect of basic vs. acidic mobile phase on malate detection. Chromatograms of
malate obtained from LC-MS analysis in the ESf mode using HILIC gradient of 60 min.,
0.15 ml/min. flow rate, and 10 pi injection (100 nmoles of malate).
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Figure 5.26: LC-MS analysis using different concentrations of ammonium acetate in the 
mobile phase. (A) Chromatograms of malate and (B) glutamine (Gin) obtained from LC-MS 
analysis in the ESf mode with HILIC gradient of 12 min., 0.15 ml/min. flow rate, and 10 gl 
injection, i.e. 10 qmoles.
5.3 Discussion
The main aim of performing LC-MS analysis using the Luna NH] column was to 
improve the chromatographic separation of metabolites from the glycolytic and TCA cycle, 
such as glucose-6-phosphate, pyruvate, lactate, citrate, a-ketoglutarate, succinate, fumarate, 
malate, and oxaloacetate. These metabolites are polar molecules, and reversed-phase 
chromatography was shown to be ineffective in retaining these metabolites (Chapter 4). 
Reversed-phase chromatography uses a non-polar stationary phase and a more polar eluting 
solvent (mobile phase). The result of this approach is that most polar metabolites are eluted 
first, followed by most non-polar metabolites, and this can lead to issues of non-retention for
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polar metabolites (Dejaegher and Vander, 2010; Latif and Barker, 2012). Normal-phase 
chromatography is essentially the opposite of reversed-phase chromatography, meaning that 
polar metabolites should be efficiently retained by the column. However, normal-phase 
chromatography uses a non-aqueous solvent as the mobile phase, such as heptane, hexane, 
pentane, and cyclohexane, meaning that hydrophilic metabolites may have poor solubility 
(Dejaegher and Vander, 2010). Hence, normal-phase chromatography is best suited for 
separation of lipophilic compounds, long-chain alkane derivatives, or when the analysed 
compound is sparingly soluble in aqueous conditions (Latif and Barker, 2012). 
Chromatographic separation of polar (hydrophilic) metabolites is more suitable with 
hydrophilic interaction liquid chromatography (HILIC). HILIC is characterised by the use of 
a hydrophilic stationary phase and an aqueous-polar organic solvent mobile phase, meaning 
that the elution order is similar to normal-phase chromatography, improving retention of 
polar metabolites (Dejaegher and Vander, 2010). However, the non-aqueous mobile phase 
used in normal-phase chromatography is replaced with a mobile phase containing a high 
content of water-miscible organic solvent, typically acetonitrile in water or volatile buffer 
(Cubbon et al, 2010). Buch a mobile phase resolves the insolubility problem encountered in 
normal-phase chromatography with hydrophilic metabolites. Furthermore, at least 3% water 
is required in the mobile phase. This is the minimal amount to sufficiently hydrate the 
stationary phase because in HILIC application, a fraction of the mobile phase becomes an 
integral part of the stationary phase, creating a water-enriched liquid layer within the 
stationary phase that is important in the retention mechanism of HILIC (Dejaegher and 
Vander, 2010).
In this chapter, HILIC was undertaken using a Luna NH2 column. This column was 
chosen because researchers such as Yang et ah (2009), Bajad et a l (2006), and Lewis et a l 
(2008) have reported their success in using this column to separate and quantify metabolites 
from the glycolysis, TCA cycle, and intermediates related to energy production such as ATP, 
ADP, AMP, NAD% NADH, NADP\ and NADPH,.
The experimental set up used was based closely on the method described by Yang 
et al. (2009), although further optimisation of some important parameters was conducted. 
High flow rates enable shorter run times and thus higher throughput, provided that the 
column can withstand the high backpressure and resolution is not compromised. Based on the 
optimisation results, a lower flow rate was observed to produce higher detection intensity 
(Figure 5.9 B and D). This could be explained by the relation between the droplet size and
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electrospray ionisation process. Low flow rate forms smaller droplets, which have a larger 
surface area, increasing the prospect of target analytes to be ionised in the electrospray 
process in comparison to co-eluting matrix at a given time. When the total surface area of the 
droplets increases, competition between target analyte and matrix components also decreases, 
enabling more target analytes to be ionised and thus, increasing the detection signal (Kloepfer 
et al, 2005; Van de Steene et al, 2006). The findings presented here are also in agreement 
with the review work of Pitt (2009), where low flow rates (0.05 to 0.2 ml/min.) was 
suggested to improve sensitivity (Pitt, 2009).
The main advantage of HILIC is the ability to retain polar compounds, but with the 
drawback being that peak shapes are often distorted in comparison to reversed-phase 
chromatography (Yang et al, 2009b). Peak broadening, distortion, and even fragmentation 
occurs when the properties of the mobile phase differ from the samples diluent (Loeser and 
Drumm, 2006). It is well established that the samples should be dissolved in a solvent that is 
similar to the mobile phase or in a weaker eluent than the mobile phase (Ruta et al, 2010). In 
reversed-phase chromatography (Chapter 4), the mobile phase was water and samples were 
prepared in water, so peak spreading was not evident. However, in HILIC, the mobile phase 
was predominantly acetonitrile (organic solvent). Unsurprisingly, samples dissolved in 100% 
water showed prominent peak broadening, and this is consistent with the work of Ruta et al. 
(2010), who suggested that more than 10% water in the sample diluent should be avoided to 
maintain sharp peaks. This need for water in the sample diluent must be balanced against the 
fact that most of the metabolites of interest in this study were polar metabolites, meaning that 
a high proportion of organic solvent might cause precipitation or lack of solubility. 
Experiments in this chapter were able to provide optimal conditions that retained peak 
intensity, while minimising peak spread.
The Luna NH2 column was also conditioned with all the standard compounds of 
interest and the cell extracts with the intention of obtaining a stable detection. Conditioning 
the column essentially saturates the column with the compounds of interest, and enabled a 
more consistent detection, especially with amino acids (Figures 5.18 -  5.19). It was 
postulated that there were certain “spots” in a new column that bind strongly to the 
compounds, reducing elution. When these “spots” had been filled, a more consistent 
detection was achieved. Column conditioning demonstrated a clear improvement in detection 
intensity for the majority of compounds, with the exception of nicotinic acid, lactate, and 
NADH (Figures 5.19 G -  I). The detection intensity for these compounds was much lower
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than the other compounds examined (AUC not more than 800), even though the sample 
loading amount (2 nmoles) was considered high for LC-MS analysis, which suggests that 
there might be another factor that is limiting the detection of the compounds. The particular 
set of experiments also showed that the detection intensity reduced after the 25* run, 
indieating that LC-MS analysis with Luna NH2 column is only usable up to 25* run, equating 
to approximately 15 hours run time. Whereas the column was able to clearly identify 
metabolites from a standard mixture, most of the metabolites of interest were not detected in 
the cell extracts, suggesting that this column may be unsuitable for the separation and 
quantification of glycolysis and TCA cycle intermediates in real experiments under the initial 
HILIC conditions.
In an attempt to mitigate this problem, the mobile phase used was evaluated. The 
mobile phase composition plays an important role in the separation and detection of analytes. 
It has to be an appropriate eluent for chromatographic separation and also suitable for 
electrospray ionisation (Blasco and Pico, 2007; Constantopoulos et al, 1999). The best pH 
for the mobile phase is dependent on the chemistry of the column, mobile phase constituents, 
and the analytes of interest. For this application, using the Luna NH2 column with ammonium 
acetate as the aqueous mobile phase, a basic pH (pH 8.5) was found to be more suitable than 
an acidic pH (pH 4.5) (Figure 5.23). Similar observations using a Luna NH2 column have 
been documented, with a basic pH producing better detection for compounds such as malate, 
a-ketoglutarate, tryptophan, glutamate, valine, phenylalanine, ADP, AMP, NAD\ NADH, 
NADP^, and riboflavin (Bajad et al, 2006). Bajad et a l (2006) also compared the 
performance of the column between HILIC and reversed-phased chromatography. HILIC 
produced better detection for majority of the compounds, which is in agreement with the 
results in this study (Figure 5.25).
Low concentration of ammonium acetate may lead to poor peak shape and efficiency, 
while too high a concentration might result in suppression of analyte signal (Garcia, 2005). 
Such suppression could be due to increased ionisation of the matrix/contaminant, thus 
reducing signal-to-noise ratio of the analyte. Suppression of analyte ion could also be due to 
the massive presence of charged components of the mobile phase that hampers analyte 
ionisation, as shown by (Fiers et a l, 2012). As a general rule, the concentration of the mobile 
phase should be at the minimum required for a satisfactory chromatography (Pitt, 2009). 
Figure 5.26 B shows that 1 mM ammonium acetate produced higher detection intensity for 
glutamine, in comparison to 5 mM ammonium acetate. However, 1 mM ammonium acetate
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was insufficient for the ionisation of malate (Figure 5.26 A), demonstrating that there is no 
“one size fits all” method in LC-MS analysis. Bajad et al. (2009) has demonstrated that the 
performance efficiency of different chromatography conditions varies according to the 
metabolites of interest and Yang et al. (2009) used a combination of different platforms 
(LC-MS and GC-MS) to determine 39 targeted metabolites involved in the central carbon 
metabolism of Methylobacterium extorquens AMi.
After these further optimisation processes, LC-MS analysis using the Luna NHa 
column still did not efficiently detect metabolites from glycolysis and the TCA cycle. There 
are published reports of the same column being used to separate and quantify the same 
metabolites of interest from biological samples (Bajad et al, 2006; Lewis et al, 2008; Yang 
et al, 2009a), but none were detected in this study, not even high concentration of standard 
compounds. The only plausible explanation is that different mass spectrometry instruments 
were employed. A quadrupole time-of-flight (QToF) mass analyser was used in this study 
whereas a triple quadrupole mass analyser was used by others (Bajad et al, 2006; Lewis et 
al, 2008; Yang et a l, 2009a).
A triple quadrupole instrument has three sets of quadrupoles aligned in series (Figure 
5.27 A). Each set of quadrupole consists of four metal rods, assembled parallel to each other 
with equal distance (Figure 5.27 B). Each pair of opposing rods is connected electrically, and 
an equal but opposite DC voltage superimposed with a radio frequency (RF) AC voltage is 
applied to each pair of rods. As the movement of ions through a magnetic or electrical field is 
affected by their mass-to-charge ratio (m/z), only ions with a certain m/z reach the detector 
for a given ratio of voltages. Other ions have unstable trajectories and will collide with the 
rods, become neutralised, and fail to reach the detector (Ho et al, 2003). In a triple 
quadrupole system, the first (Qi) and third (Qg) quadrupoles serve as mass filter while the 
middle quadrupole (q2) is employed as a collision cell. The analyte ion of interest (precursor 
ion) is mass-selected in Qi and allowed to pass through to q2, where the precursor ion collides 
with collision gas. q2 is an RF-only quadrupole that does not filter mass. Fragments of the 
precursor ion are passed through to Q3 where they may be filtered or scanned (Ho et a l, 
2003; Pitt, 2009). Triple quadrupole system is the instrument-of-choice for targeted and 
quantitative analyses, largely because in selected-reaction monitoring (SRM) mode, the 
analyser has the advantage of specificity (Couchman and Morgan, 2011; Becker et a l, 2012; 
Himmelsbach, 2012). Only pairs of target precursor ions and the unique fragment ions
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combination will be detected, enabling accurate identification of the target species (Pitt, 
2009).
(A)
Source
Collision Gas
(B)
Source Detector
Q I Q2 Q3
Figure 5.27: Schematic diagram of a triple quadrupole mass analyser. (A) Operation of a 
single quadrupole mass analyser. The ion (M"^ ) travels from the source through the four metal rods 
in a unique oscillating pattern and reaches the detector. (B) A triple quadrupole mass analyser. It 
consists of three sets of quadrupoles aligned in series. The first (Qi) and third (Q3) quadrupoles are 
mass spectrometers while the middle quadrupole (Q2) is a collision cell. Reproduced from Ho et al. 
(2003).
In a QToF mass analyser, the final quadrupole of a triple quadrupole mass analyser is 
replaced with a time-of-flight (ToF) analyser and an additional RF quadrupole (Qo) is added 
to provide collisional damping. Therefore, the instrument consists of three quadrupoles, Qo, 
Qi, and q2 , followed by a reflecting ToF mass analyser with orthogonal injection of ions 
(Figure 5.28) (Chemushevieh et al, 2001). A ToF analyser operates by accelerating ions 
through a high voltage, with the velocity of the ions dependent on their m/z values (Pitt, 
2009). A QToF can work in single mass spectrometry (MS) or tandem MS (MS/MS) 
operation modes. In a single MS operation mode, Qi operates in band pass mode and the 
analysis is performed on the high end ToF analyser. For MS/MS operation mode, precursor 
ion is selected in Qi, collision-induced dissociation occurs in q2, and the mass analysis of the 
fragments ions is performed in the ToF analyser (Blasco and Pico, 2007). The QToF analyser 
yields high sensitivity, mass resolution, and mass accuracy. However, the instrument is often 
considered to be suitable only for qualitative analysis, even though nothing stands against its
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use for quantitative applications (Himmelsbach, 2012). Nevertheless, the specificity of triple 
quadrupole instrument is an added advantage over QToF instrument for targeted analysis.
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Figure 5.27: Schematic diagram of a quadrupole time-of-flight (QToF) mass analyser. Ions 
are sampled from the source into the Qo and Q%. Qo is an additional quadrupole used for collision 
cooling and focusing the ion entering the instrument. Qo and Q] operate in the RF-only mode. Ions 
leaving the RF quadrupoles are re-accelearated and travelled through a flight of tube to reach the 
detector. Reproduced from Chemushevieh et al. (2001).
Overall, LC-MS analysis with the Luna NH] column was ineffective in accomplishing 
the aim of this chapter, i.e. to separate and quantify metabolites from the glyeolysis and TCA 
cyeles. Nonetheless, the eolumn can be used to separate and analyse amino acids.
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Chapter 6: LC-MS Analysis using Synergi PoIar-RP Column
The aim of this chapter was to improve the chromatographic separation for polar 
metabolites; in particular, intermediates of glycolysis and the TCA cycle that might be 
affeeted by troglitazone. A Synergi Polar-RP column was used to accomplish the aim, based 
on published reports of its utilisation to quantitate similar metabolites of interest (e.g. 
pyruvate, lactate, succinate, and malate) from complex biological samples (Lewis et al, 
2008; Wei et al, 2010). The specific objectives of this study were as follows:
Objective 1: Determination of the coneentration of ammonium acetate used as aqueous 
mobile phase.
Objective 2; Determination of the optimal type of chromatography for separation of polar 
metabolites (HILIC versus reversed-phase).
Objective 3: Determination of the optimal pH for the aqueous mobile phase.
Objective 4: Optimisation of the sample preparation protocol.
6.1 Optimisation of ammonium acetate concentration, the aqueous mobile phase
Ammonium acetate is a popular buffer in mass spectrometry due to its volatility and 
compatibility with mass spectrometry detectors (Pitt, 2009). Buffers used in mass 
spectrometry analysis should be volatile because non-volatile buffers will damage and clog 
the LC-MS interface (Waters, 2006). The salt concentration affects analyte ionisation 
response (Constantopoulos et al, 1999), and the concentration of ammonium acetate has 
been shown to affect LC-MS results, as observed in Section 5.2.5: Ammonium acetate 
concentrations that are too low will be insufficient for ion ionisation, while too high a 
concentration is likely to cause ion suppression. The following experiment was carried out to 
determine the best concentration of ammonium aeetate to be used with a Synergi Polar-RP 
column for the detection of polar metabolites, especially the intermediates of glycolysis and 
the TCA cycle.
HILIC LC-MS analysis as described by Wei et al. (2010) and Lewis et al. (2008), 
with modification, was conducted. The total run time was 35 minutes, with a flow rate of 
0.15 ml/min. The tested concentrations of ammonium acetate were I, 5, and 20 mM, adjusted
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to pH 5.6. Purchased, standard compounds were prepared as mixtures of 50 pM in 0%, 50%, 
and 80% of acetonitrile. The injection volume was 10 pi, equivalent to 500 pmoles/sample.
The amino acids glutamine, leucine, methionine, phenylalanine, tryptophan, valine, 
and glutamate were suitably detected with all concentrations of ammonium acetate in both 
eleetrospray modes (Figures 6 .1 - 6.7). The retention time for these compounds was between 
4.8 -  6.0 minutes except for glutamate, which eluted between 8.9-10.8  minutes, depending 
on the concentration of ammonium acetate. Different concentrations of ammonium acetate do 
not seem to have a prominent effect on the retention of glutamine, leucine, methionine, 
phenylalanine, tryptophan, and valine, as it varied for only approximately 0.2 minutes in each 
case. The void time for the Synergi Polar-RP column was approximately 1.6 minutes for 
samples prepared in 100% water, and inereased with acetonitrile concentration to 
approximately 1.8 minutes for samples prepared in 80% aqueous acetonitrile.
The detection intensity for all the amino acids was good, with values of the peak area 
(AUC) generally more than 100 for a loading amount of 500 pmoles/sample in 10 pi. The 
concentration of ammonium aeetate does not appear to have drastic effect on the detection 
intensity of the amino acids. However, for compounds that exhibited lower detection 
intensity, e.g. glutamate, it was clear that higher coneentration of ammonium acetate 
produced a sharper peak (ESF mode) and increased the detection intensity (ESl^ mode) 
(Figure 6.7). Finally, samples containing higher percentages of acetonitrile produced only a 
single, elean and sharp peak while a higher concentration of water in the samples caused 
multiple peaks with the first peak eluted during or close to the void time.
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For the intermediates of glycolysis and the TCA cycle, pyruvate and lactate were 
detected only in the EST mode while malate was detected only in the ESI^ mode 
(Figures 6.8 -  6.10). These compounds showed better detection with a higher concentration 
of ammonium acetate, either due to a sharper peak (for malate and lactate) or higher detection 
intensity (for pyruvate). In addition, the retention time decreased with increasing 
concentration of ammonium acetate: The retention time of lactate reduced from 
approximately 7.5 minutes to 6.8 minutes and 6.1 minutes with 1 mM, 5 mM, and 20 mM 
ammonium acetate, respectively. The retention time for malate was 8.3, 7.7, and 6.8 minutes 
for 1, 5, and 20 mM ammonium acetate, respectively. The retention time for pyruvate was 
difficult to determine accurately as peaks were distorted or appear as multiple peaks. Citrate, 
a-ketoglutarate, succinate, fumarate, oxaloacetate, and G6P were not detected in both 
ionisation modes (data not shown).
NAD^ and NADH were detected with sharper and less distorted peak shape in the 
ESr^ mode compared to the EST mode (Figures 6.11 -  6.12). A higher concentration of 
ammonium acetate increased the detection intensity of NAD^, which was undetecable with 
1 mM ammonium acetate. For both compounds, higher concentrations of ammonium acetate 
sharpened the peak and reduced the retention time. The ESI^ mode also provided better 
detection for nicotinamide, nicotinic acid, and nicotinuric acid than the EST mode (Figures 
6.13 -  6.15). In the EST mode, the peaks of these compounds were distorted and split into 
multiples whereas the peaks observed in the ESI^ mode were sharp. Similar to previous 
observations, an increase of ammonium acetate concentration produced sharper peaks and 
reduced the retention time. Nicotinamide was not retained very well with the Synergi 
Polar-RP column. The elution time was about 2.0 minutes and the peak was broad, compared 
to a void time of 1.6 -  1.8 minutes. NADP^ and NADPH were not detected (data not shown).
ADP was detected only in the ESI^ mode, while GSH was detected in both ionisation 
modes (Figures 6.16 -  6.17). A higher concentration of ammonium acetate increased the 
detection intensity for ADP and improved the peak shape for both of the compounds. 
Riboflavin was not retained with the Synergi Polar-RP column. The elution time was 
approximately 2.2 minutes, which is close to the void time and considered not retained by the 
column (Figure 6.18). Pyridoxal showed better detection in the ESI^ mode compared to the 
EST mode and was the only compound in which an increased concentration of ammonium 
acetate resulted in a diminished detection quality, producing a broad and flat peak (Figure 
6.19). ATP, AMP, and GSSG were not detected (data not shown).
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Overall, increasing the concentration of ammonium acetate in the aqueous mobile 
phase produced sharper peaks for the majority of the compounds, and for some compounds it 
also increased the detection intensity. Based upon these preliminary experiments, 20 mM 
ammonium acetate was chosen as the mobile phase for all the subsequent experiments.
6.2 Chromatographic optimisation: HILIC versus reversed-phase chromatography
The Synergi Polar-RP column displayed better chromatography separation for polar 
metabolites, judged as increased retention time, compared to the UPLC BEH Cis column. 
However, not all the compounds of interest were detected. For example, a large group of the 
compounds from the glycolysis and TCA pathways, such as citrate, a-ketoglutarate, 
succinate, fumarate, oxaloacetate, and G6P, were not detected. In addition, NADP\ NADPH, 
ATP, AMP, and GSSG were also not detected in the LC-MS analysis using the Synergi 
Polar-RP column.
The following experiment was conducted to test whether reversed-phase 
chromatography would increase the number of detected metabolites/compounds, without 
compromising the retention time. The same protocol as in Section 6.1 was carried out except 
that a reversed-phase gradient was used (elution starting with high aqueous mobile phase, i.e. 
ammonium acetate buffer).
Examples of chromatograms from four standard compounds are shown in 
Figures 6.20 -  6.21. Glutamine and NAD^ were detected in both ionisation modes but had 
poor retention in reversed-phase chromatography with the Synergi Polar-RP column. 
Pyruvate was detected in the EST but not in the ESI^ mode, and also showed poor retention. 
GSSG, which was not detected using HILIC application (Section 6.1) was retained in this 
reversed-phase gradient (elution time approximately 24.3 minutes) and detected in both 
ionisation modes.
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Table 6.1 summarises the retention times and detection intensities of all the standard 
compounds examined under each chromatography condition. GSSG, nicotinamide, and 
riboflavin were the only compounds that exhibited longer retention in reversed-phased 
chromatography as compared to HILIC. a-Ketoglutarate, fumarate, and oxaloacetate were 
compounds that were detected in reversed-phase chromatography but not in HILIC. 
However, the retention time for these compounds was poor and detection intensity was very 
low. All the other detected compounds displayed less retention in reversed-phase 
chromatography than in HILIC.
A closer inspection of Table 6.1 reveals that there were differences between the 
retention time obtained in the EST and ESI^ ionisation mode, within the same type of 
chromatographic separation. For example, LC-MS analysis of glutamine using HILIC 
recorded the retention time as 5.81 minutes in the ESI" mode whereas in the ESI^ mode, 
retention time was 5.53 minutes. Differences were also observed for leucine, methionine, 
phenylalanine, tryptophan, valine, glutamate, nicotinamide, nicotinic acid, and riboflavin. In 
reversed-phase chromatography, the retention time obtained from LC-MS analysis in the ESI" 
and ESr^ mode were quite similar, with differences of less than 0.1 minutes in all cases 
except methionine (0.9 minutes).
In summary, reversed-phase chromatography produced lower retention for the 
majority of the compounds, and was still unable to detect several compounds (citrate, 
succinate, G6P, NADP , NADPH, ATP, and AMP). However, reversed-phase 
chromatography was able to detect a-ketoglutarate, fumarate, and OAA, which were not 
detected in HILIC, although the retention was poor and detection intensity was low. Based 
upon these results, a reversed-phase gradient was not considered suitable to be used with the 
Synergi Polar-RP column for the separation and detection of the compounds of interest.
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Table 6.1: Comparison of the retention and detection intensity between HILIC and reversed-phase 
chromatography of Synergi Polar-RP column
Standard compounds EST mode ESL mode
Reversed-
phase
HILIC Reversed-
phase
HILIC
Glutamine
ESI': 145.0612 m/z 
ESC: 147.0770 m/z
Elution time (min.) 
AUC
1.89
62
5.81
1396
Peak 1 
#1.88  
13
Peak 2 
#5.32  
8
5.53
495
Leucine
ESI': 130.0868 m/z 
ESC: 132.1025 m/z
Elution time (min.) 
AUC
2.43
107
4.82
1610
Peak 1 
#2.42  
57
Peak 2 
#5.32  
12
5.42
334
Methionine
ESI': 148.0432 m/z 
ESC: 150.0589 m/z
Elution time (min.) 
AUC
2.31
67
5.06
1255
3.19
936
11.57 
12620 (very 
broad peak)
Phenylalanine
ESI': 164.0712 m/z 
ESC: 166.0868 m/z
Elution time (min.) 
AUC
3.54
119
5.04
2501
3.51
127
5.50
264
Tryptophan
ESI’: 203.0821 m/z 
EST: 205.0977 m/z
Elution time (min.) 
AUC
5.35
157
5.15
1307
5.32
64
5.51
566
Valine
ESI': 116.0712 m/z 
ESC: 118.0868 m/z
Elution time (min.) 
AUC
2.05
58
5.05
885
Peak 1 
#2.05  
18
Peak 2 
#5.32  
4
5.53
558
Glutamate
ESI': 146.0453 m/z 
ESL: 148.0610 m/z
Elution time (min.) 
AUC
2.30
61
&95
118
2.27
20
9.14
7
Pyruvate
ESF: 87.0082 m/z 
EST: 89.02390 m/z
Elution time (min.) 
AUC
2 j #
20
Peak 1 
#4.09  
135
Peak 2 
#6.05  
296
ND ND
Citrate
EST: 191.0192 m/z 
ESC: 193.0348 m/z
Elution time (min.) 
AUC
ND ND ND ND
a-ketoglutarate
ESI'; 144.0137 m/z 
ESC: 147.0293 m/z
Elution time (min.) 
AUC
* 1.98 
5
ND ND ND
Succinate
ESI': 117.0188 m/z 
EST: 119.0344 m/z
Elution time (min.) 
AUC
ND ND ND ND
Fumarate
ESI': 115.0031 m/z 
ESC: 117.0188 m/z
Elution time (min.) 
AUC
* 1.95 
16
ND ND ND
Malate
ESI': 133.0137 m/z 
ESC: 135.0293 m/z
Elution time (min.) 
AUC
ND ND 3.54
11
6.79
345
Oxaloacetate
(OAA)
ESI': 130.9980 m/z 
ESC: 133.0137 m/z
Elution time (min.) 
AUC
* 1.97 
4
ND ND ND
Lactate
EST: 89.0239 m/z 
ESC: 91.0395 m/z
Elution time (min.) 
AUC
2.50
30
6.13
300
ND ND
* Detected in the anion form:
a-ketoglutarate ('OOCCOCH2 CH2 COO'): 142.9980 m/z 
Fumarate ('OOCCHCHCOO'): 112.9875 m/z 
Oxaloacetate (OOCCOCH2 COO): 128.9824 m/z
# Multiple peaks detected.
Data from samples prepared in 100% water were used for the reversed-phase and samples prepared in 80% acetonitrile for the 
aqueous normal-phase chromatography. Injection amount was 500 pmoles/10 pi.
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Table 6.1 conti Comparison of the retention and detection intensity between HILIC and reversed-phase 
chromatography of Synergi Polar-RP column
Standard compounds ESF mode ESL mode
Reversed-
phase
HILIC Reversed-
phase
HILIC
Glucose
6-phosphate
ESI': 259.0219 m/z 
ESC: 261.0375 m/z
Elution time (min.) 
AUC
ND ND ND ND
NAD+
ESI’: 662.1013 m/z 
ESL: 664.1170 m/z
Elution time (min.) 
AUC
3.00
65
9.39
127
2.94
181
9.45
408
NADH
EST: 663.1091 m/z 
ESL: 665.1248 m/z
Elution time (min.) 
AUC
3.02
5
9.44
6
2.94
19
9.43
39
NADP+
ESI': 743.0755 m/z 
E Sf: 745.0911 m/z
Elution time (min.) 
AUC
ND ND ND ND
NADPH
ESI': 744.0833 m/z 
ESC: 746.0989 m/z
Elution time (min.) 
AUC
ND ND ND ND
Nicotinamide
ESI': 121.0402 m/z 
ESC: 123.0558 m/z
Elution time (min.) 
AUC
ND 5.72
146
4.30
512
2.06
9108
Nicotinic acid
ESI’: 122.0242 m/z 
ESC: 124.0399 m/z
Elution time (min.) 
AUC
3.69
102
6.23
934
3.69
236
6.45
1224
Nicotinuric acid
ESI': 179.0457 m/z 
EST: 181.0613 m/z
Elution time (min.) 
AUC
3.59
49
6.63
329
3.56
81
6.79
458
ATP
ESI': 505.9878 m/z 
E Sf: 508.0036 m/z
Elution time (min.) 
AUC
ND ND ND ND
ADP
ESI': 426.0216 m/z 
E S f  : 428.0372 m/z
Elution time (min.) 
AUC
ND ND 2.94
6
9.46
16
AMP
EST: 346.0553 m/z 
EST: 348.0709 m/z
Elution time (min.) 
AUC
ND ND ND ND
GSH
ESI': 306.0760 m/z 
EST: 308.0916 m/z
Elution time (min.) 
AUC
2.49
42
9.24
70
2.43
98
9.23
61
GSSG
ESI': 611.1441 m/z 
ESL: 613.1598 m/z
Elution time (min.) 
AUC
24.32
50
ND 24.27
145
ND
Riboflavin
ESI : 375.1305 m/z 
ESL: 377.1461 m/z
Elution time (min.) 
AUC
6.72
86
2.24
196
6.70
505
1.91
10945
Pyridoxal
ESI': 166.0504 m/z 
EST: 168.0661 m/z
Elution time (min.) 
AUC
Peak 1 
#3.25 
135
Peak 2 
#5.20  
19
Peak 1 
#5.00  
20
Peak 2 
#7.26  
31
3.20
162
ND
* Detected in the anion form:
a-ketoglutarate (OOCCOCH2 CH2 COO): 142.9980 m/z 
Fumarate ('OOCCHCHCOO'): 112.9875 m/z 
Oxaloacetate ('OOCCOCH2 COO'): 128.9824 m/z
# Multiple peaks detected.
Data from samples prepared in 100% water were used for the reversed-phase and samples prepared in 80% acetonitrile for the 
aqueous normal-phase chromatography. Injection amount was 500 pmoles/10 pi.
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6.3 Optimisation of mobile phase pH
The concentration of ammonium acetate and chromatographic approach to be used 
with the Synergi Polar-RP column have been optimised but a large number of polar 
metabolites (e.g. citrate, succinate, G6P, NADP+, NADPH, ATP, and AMP) were not 
detected. In an attempt to further increase the efficiency of LC-MS analysis, different mobile 
phase pHs were tested.
LC-MS analysis in the ESI^ mode was conducted as previously, i.e. with a HILIC 
gradient and 20 mM ammonium acetate as the aqueous mobile phase. The pH of the aqueous 
mobile phase was adjusted to 3.0, 4.5, 5.6, and 7.5. Pyruvate was used as model compound 
and prepared at a concentration of 5 mM in 80% acetonitrile, giving a final injection amount 
of 50 nmoles in 10 pi.
Pyruvate can exist in two forms depending on the pH, as an acid (CH3COCOOH) or 
anion (CH3COCOO ). LC-MS analysis detected a very low level of pyruvate in the acid form 
(89.0239 m/z) (Figure 6.22), but none in the anion form (88.0004 m/z), regardless of the pH 
used (data not shown). Pyruvate can also interact with sodium, and this was detected at 
111.0058 m/z (Figure 6.23). Both, the acid and sodium forms of pyruvate were poorly 
retained by the column, with retention times of approximately 1.9 minutes, compared to a 
void time of 1.8 minutes. Pyruvate was detected predominantly as ammonium adduct 
(CH3COCOO + N H /,  106.0504 m/z) and ammonia adduct (CH3COCOO+NH3, 105.0426 
m/z) (Figures 6.24 -  6.25).
The detection intensity of pyruvate (acid form) was not affected by the pH of the 
aqueous mobile phase (Figure 6.26 A). In contrast, the sodium adduct showed a slight 
increment in detection intensity as pH increased from 3.0 to 4.0 but at higher pH level, the 
detection intensity was unaffected (Figure 2.26 B). Increasing the pH of ammonium acetate 
produced higher detection intensities for the ammonium and ammonia adducts of pyruvate 
(Figures 6.26 C -  D), but had no effect on the retention time of pyruvate in the form of acid 
and sodium adduct (Figures 2.26 A -  B). At higher pH condition of the aqueous mobile 
phase, the retention for ammonium and ammonia adducts increased (Figures 2.26 C -  D).
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Figure 6.26: The effect of mobile phase pH on detection intensity and elution time of 
pyruvate. Pyruvate was detected in the (A) acid form, (B) sodium adduct, (C) ammonium adduct, 
and (D) ammonia adduct. LC-MS analysis was performed in the ESI^ mode with a 35 min. HILIC 
gradient. Flow rate: 0.15 ml/min, injection amount: 50 nmoles/10 pi. Data shown as n = 1.
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The results indicate that higher pH level increased the detection intensity of pyruvate 
in the form of ammonium and ammonia adducts. However, pH 7.5 was not a suitable pH 
condition for the Synergi Polar-RP column as it was too near to the recommended highest pH 
for the column. Based upon this limitation, the best choice would be pH 5.6; however, this is 
the pH originally used in Section 6.1 (Figures 6.1 -  6.19) where many of the compounds of 
interest were not detected. Lowering pH to 4.0 was therefore further examined for its 
potential to detect all the compounds of interest.
Table 6.2 shows the profiles of the compounds from LC-MS analysis with pH 4.0 of 
20 mM ammonium acetate. Each compound (50 pM) was prepared in 80% acetonitrile and 
injected on individual LC-MS runs at the amount of 500 pmoles in 10 pi. All the amino acids 
were detected (except for leucine). In addition, the detected intensity, represented by the 
AUC at pH 4.0 was higher (Table 6.2) than at pH 5.6 (Table 6.1).
Most of the glycolysis and TCA cycle intermediates can exist either in the acid or 
anion form, as previously described for pyruvate. At pH 4.0, a-ketoglutarate, succinate, and 
lactate were detected in the acid form (-COOH) in both ESF and ESl^ modes. However, in 
the ESl  ^ mode, the observed retention time for a-ketoglutarate and succinate were poor, 
being approximately 2.1 minutes. Pyruvate and fumarate in the acid form were detected only 
in the ESF mode while oxaloacetate was detected in the acid form only in the ESl^ mode. The 
anion form (-C 00 ) of the glycolysis and TCA cycle intermediates was detected for 
a-ketoglutarate in the ESF mode and succinate in the ESl^ mode, but both displayed poor 
retention times of 2.1 and 2.3 minutes, respectively. Pyruvate was also detected as 
ammonium and ammonia adducts in the ESl^ mode. Glucose 6-phosphate was detected only 
in the form of the ammonium adduct in the ESl^ mode, but with a poor retention time of 2.1 
minutes. The only compound detected in the form of sodium adduct was succinate (in the 
ESF^  mode), but the detection intensity was low. At pH 4.0, compounds from the glycolysis 
and TCA cycle intermediates were observed mainly in the form of an acid. Although most of 
the glycolysis and TCA cycle intermediates were detected at pH 4.0, citrate was still not 
detected, and malate, which was detected in the ESl^ mode at pH 5.6 became undetected at 
pH 4.0 in both ionisation modes.
NAD^ and NADH exhibited good retention times (approximately 6.5 minutes) at 
pH 4.0, but the detection intensity was low. Neither NADP^ nor NADPH was detected. 
Nicotinamide was detected only in the ESl^ mode but not well retained, with an elution time
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of 2.1 minutes. Nicotinic acid and nicotinuric acid were detected in both ionisation modes 
with retention times of approximately 5.2 and 5.8 minutes. Altering the pH of the aqueous 
mobile phase from 5.6 to 4.0 increased the detection intensity of nicotinamide, nicotinic acid, 
and nicotinuric acid, but reduced the detection intensity ofNAD^ and NADH.
At pH 4.0, ATP, ADP, AMP, and GSSG were not detected. GSH was detected in both 
ionisation modes with retention time of approximately 6.6 minutes. Riboflavin was also 
detected in both ionisation modes but showed poor retention, the elution time was 
approximately 2.3 minutes. Pyridoxal was detected but multiple peaks were observed in both 
ionisation modes.
There were differences in the retention times obtained between the EST and ESl^ 
modes, but in most cases this was less than 0.15 minutes. For the case of a-ketoglutarate, 
succinate, and lactate, the difference in retention times were larger, presumably due to the 
broad nature of the peaks, or poor retention times of the chromatographic separation in that 
particular ionisation mode.
In summary, 20 mM ammonium acetate at pH 4.0 enabled the detection of more 
compounds as compared to pH 5.6, especially for the intermediates of glycolysis and TCA 
cycle. These conditions will be used for all the subsequent experiments.
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Table 6.2: Profiles of standard compounds detected by LC-MS analysis with pH 4.0 ammonium acetate
Compounds ESI mode ESC mode
Form (theoretical 
m/z+ 0 .1 )
AUC Elution 
time (min.)
Form (theoretical 
m/z + 0 .1 )
AUC Elution 
time (min.)
Glutamine 145.0613 1885 5.90 147.0770 1311 5.79
Leucine 132.1025 ND 132.1025 ND
Methionine 148.0432 417 5.53 150.0589 3080 5.46
Phenylalanine 164.0712 3435 5.53 166.0868 6134 5jg
Tryptophan 203.0821 2240 5.36 205.0977 3238 5.35
Valine 116.0712 1830 5.62 118.0868 1526 5.46
Glutamate 146.0453 32 6.61 148.0610 18 6.70
Pyruvate 87.0082 (COOH) 1053 5.06 89.0239 (COOH) ND
86.0004 (COO ) ND 88.0160 (COO) ND
104.0348 (+NH 4+) ND 106.0504 (+NH4I 35 6.49
103.0269 (+NH 3) ND 105.0426 (+NH 3) 41 6.53
108.9902 (+Na) ND 111.0058 (+Na) ND
Citrate 191.0192 (3C00H) ND 193.0348 (3C00H) ND
187.9957(30 0 0 ) ND 190.0114(3000) ND
242.0988 (+ 3NH4t) ND 244.1145 (+3NH4^ ND
239.0753 (+ 3 NH3) ND 241.0910 (+ 3 NH3) ND
256.9650 (+ 3Na) ND 258.9807 (+ 3Na) ND
a-ketoglutarate 145.0137 (2C00H) 64 &63 147.0293 (2C00H) 47 2.09
142.9980 (2C00 ) 1 0 2.09 145.0137 (2C00 ) ND
179.0668 (+ 2NH4^ ND 181.0824 (+ 2 NH4I ND
177.0511 (+ 2 NH3) ND 179.0668 (+ 2 NH3) ND
188.9776 (+2Na) ND 190.9932 (+2Na) ND
Succinate 117.0188 (2C00H) 1324 5.92 119.0344 (2C00H) 1443 2.05
115.0031 (2 C 0 0 ) ND 117.0188(2000) 2 1 2.34
151.0719 (+2NH4^ ND 153.0875 (+ 2 NH4'] ND
149.0562 (+ 2 NH3) ND 151.0719 (+ 2 NH3) ND
160.9827 (+2Na) ND 162.9983 (+ 2Na) 7 6.48
Fumarate 115.0031 (2C00H) 17 6.60 117.0188 (2C00H) ND
112.9875(20 0 0 ) ND 115.0031 (2000) ND
149.0562 (+ 2 NH4I ND 151.0719 (+2NH4’^ ND
147.0406 (+ 2 NH3) ND 149.0562 (+ 2 NH3) ND
158.9670 (+2Na) ND 160.9827 (+ 2Na) ND
+ NH/: Ammonium adduct; + NH3: Ammonia adduct; + Na: Sodium adduct.
COOH: Acid form of glycolysis and TCA cycle intermediates; COO': Anion form of glycolysis and TCA cycle intermediates. 
H2P2O7: Acid form of the phosphate group in cofactors; HP2O7' and?2 0 7 '^: Anion form of the phosphate group in cofactors. 
H4P3O10, H3P2O7, and H2PO4: Acid form of the phosphate group in ATP, ADP, and AMP, respeetively; P3 0 io% P2 0 7 '^, and 
P0 4 '^: Anion form of the phosphate group in ATP, ADP, and AMP, respectively. ND: Not detected.
Each compound was prepared as an individual sample in 80% acetonitrile. LC-MS analysis was performed in the ESL mode 
with a 35 min. HILIC gradient. Flow rate: 0.15 ml/min, injection amount: 500 pmoles in 10 pi.
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Table 6.2 cont.'. Profiles of standard compounds detected by LC-MS analysis with pH 4.0 ammonium acetate
Compounds ESI mode ESC mode
Form (theoretical 
m/z + 0.1)
AUC Elution 
time (min.)
Form (theoretical 
m/z + 0.1)
AUC Elution 
time (min.)
Malate 133.0137 (2C00H) ND 135.0293 (2C00H) ND
130.9980 (2C00 ) ND 133.0137 (2C 00 ) ND
167.0668 (+ 2NH4^ ND 169.0824 (+ 2 NH4I ND
165.0511 (+ 2 NH3) ND 167.0558 (+ 2 NH3) ND
176.9776 (+ 2Na) ND 178.9932 (+2Na) ND
Oxaloacetate 130.9980 (2C00H) ND 133.0137 (2C00H) 18 6.49
(OAA) 128.9824 (2C00 ) ND 130.9988 (2C00 ) ND
165.0511 (+2NH4^ ND 167.0668 (+ 2 NH4+) ND
153.0355 (+ 2 NH3) ND 165.0511 (+ 2 NH3) ND
174.9619 (+2Na) ND 176.9776 (+ 2Na) ND
Lactate 89.0239 (COOH) 3207 4.81 91.0395 (COOH) 3 6.55
88.0160 (COO ) ND 90.0317 (COO ) ND
106.0504 (+NH 4^ ND 108.0661 (+NH 4+) ND
105.0426 (+ NH3) ND 107.0582 (+NH 3) ND
111.0058 (+Na) ND 113.0215 (+Na) ND
Glucose 259.0219 (H2PO4) ND 261.0375 (H2PO4) ND
6 -phosphate 258.0141 (HPO4-) ND 260.0297 (HPO4 ) ND
257.0062 (P04h ND 259.0219 (P04^‘) ND
293.0750 (+ 2 NH4I ND 295.0906 (+ 2 NH4") 359 2.05
291.0593 (+ 2 NH3) ND 293.0750 (+ 2 NH3) ND
302.9858 (+ 2Na) ND 305.0014 (+2Na) ND
NAD+ 662.1013 (HP2O7 ) 40 6.53 664.1170 (HP2O7-) 8 6.49
661.0935 (P2O / ) ND 663.1091 (P207'^‘) ND
663.1091 (H2P2O7) 1 0 6.53 665.1248 (H2P2O7) 2 6A8
697.1622 (+2NH4^ ND 699.1779 (+ 2NH4^ ND
695.1466 (+ 2 NH3) ND 697.1622 (+ 2 NH3) ND
707.0730 (+ 2Na) ND 709.0887 (+ 2Na) ND
+ NH/; Ammonium adduct; + NH3: Ammonia adduct; + Na: Sodium adduct.
COOH: Acid form of glycolysis and TCA cycle intermediates; COO : Anion form of glycolysis and TCA cycle intermediates. 
H2P2O7: Acid form of the phosphate group in co factors; HP2O7' andP2 0 7 '^: Anion form of the phosphate group in cofactors. 
H4P3O10, H3P2O7, and H2PO4: Acid form of the phosphate group in ATP, ADP, and AMP, respectively; P3 0 ,o \ P2 0 7 '^, and 
PO/': Anion form of the phosphate group in ATP, ADP, and AMP, respectively.
ND: Not deteeted.
Eaeh compound was prepared as an individual sample in 80% acetonitrile. LC-MS analysis was performed in the ESL mode 
with a 35 min. HILIC gradient. Flow rate: 0.15 ml/min, injeetion amount: 500 pmoles in 10 pi.
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Table 6.2 cont.\ Profiles of standard compounds detected by LC-MS analysis with pH 4.0 ammonium acetate
Compounds EST mode ESU mode
Form (theoretical 
m/z + 0 .1 )
AUC Elution 
time (min.)
Form (theoretical 
m/z + 0 .1 )
AUC Elution 
time (min.)
NADH 663.1091 (HP2O7 ) ND 665.1248 (HP2O7 ) ND
664.1170 (P207'^') ND 665.1326 (P2O7 " ) ND
662.1013 (H2P2O7) 1 0 6.54 664.1170 (H2P2O7) ND
698.1700 (+ 2 NH4") ND 700.1857 (+2NH4^ ND
696.1544 (+ 2 NH3) ND 698.1700 (+ 2 NH3) ND
708.0808 (+ 2Na) ND 710.0965 (+2Na) ND
NADP+ 742.0676 
(HP2O7 & H 2PO4)
ND 745.0833
(HP2O7 & H 2PO4)
ND
741.0598
(P207^-&H2P04)
ND 753.0755
(P207^-&H2P04)
ND
743.0755
(H2P2O7 & H 2PO4)
ND 745.0911
(H2P2O7 & H 2PO4)
ND
739.0442 
(P207^ & P 0 / ')
ND 741.0598
(P207^-&P04^)
ND
740.0520 
(HP2O7 & P 0 4 -^)
ND 742.0676
(HP2O7-& P O 4")
ND
811.1817 (+4NH4^ ND 813.1973 (+ 4 NH4I ND
807.1504 (+ 4 NH3) ND 809.1660 (+ 4 NH3) ND
83Î.ÔÔ32 (+ 4Na) ND 833.0189 (+4Na) ND
NADPH 743.0755
(HP2O7' & H2PO4)
ND 745.0911
(HP2O7' & H2PO4)
ND
742.0676 
(P2 0 7  ^ & H 2PO4)
ND 744.0833
(P207^-&H2P04)
ND
744.0833
(H2P2O7 & H 2PO4)
ND 746.0989
(H2P2O7 & H 2PO4)
ND
740.0520
(P207^-&P04^-)
ND 742.0676
(P207^ & P 0 4 ^
ND
741.0598 
(HP2O7- & P0 4 *^)
ND 743.0755 
(HP2O7 & P 0 4 -^)
ND
812.1895 (+4NH4^ ND 814.2051 (+ 4 NH4I ND
808.1582 (+ 4 NH3) ND 810.1738 (+ 4 NH3) ND
832.0111 (+4Na) ND 834.0267 (+ 4Na) ND
Nicotinamide 121.0402 ND 123.0558 21041 2.06
Nicotinic acid 122.0242 2875 5.16 124.0399 9188 532
Nicotinuric acid 179.0457 2780 5.79 181.0613 6687 5.87
+ NH/: Ammonium adduct; + NH3: Ammonia adduct; + Na: Sodium adduct.
COOH: Acid form of glycolysis and TCA cycle intermediates; COO*: Anion form of glycolysis and TCA cycle intermediates. 
H2P2O7: Aeid form of the phosphate group in cofaetors; HP2O7' andP2 0 7 "^: Anion form of the phosphate group in eofaetors. 
H4P3O10, H3P2O7, and H2PO4: Aeid form of the phosphate group in ATP, ADP, and AMP, respectively; P3 0 io"*, P2 0 7 '^> aud 
P0 4 *^: Anion form of the phosphate group in ATP, ADP, and AMP, respectively.
ND: Not detected.
Eaeh compound was prepared as an individual sample in 80% acetonitrile. LC-MS analysis was performed in the ESL mode 
with a 35 min. HILIC gradient. Flow rate: 0.15 ml/min, injection amount: 500 pmoles in 10 pi.
286
Table 6.2 contr. Profiles of standard compounds detected by LC-MS analysis with pH 4.0 ammonium acetate
Compounds ESI mode ESU mode
Form (theoretical 
m/z + 0 .1 )
AUC Elution 
time (min.)
Form  (theoretical 
m/z + 0 .1 )
AUC Elution 
time (min.)
ATP 505.9878 (H4P3O10) ND 508.0036 (H4P3O10) ND
501.9566 (P3O10"-) ND 503.9723 (P3O10" ) ND
574.0941 (+4NH4^ ND 576.1098 (+4NH4^ ND
570.0628 (+ 4 NH3) ND 572.0785 (+ 4 NH3) ND
593.9157 (+4Na) ND 595.9314 (+4Na) ND
ADP 426.0216 (H3P2O7) ND 428.0373 (H3P2O7) ND
422.9981 (P2O7") ND 425.0138 (P2O7" ) ND
477.1012 (+3NH4^ ND 479.1169 (+3NH4^ ND
474.0778 (+ 3 NH3) ND 476.0934 (+ 3 NH3) ND
491.9674 (+3Na) ND 493.9831 (+3Na) ND
AMP 346.0553 (H2PO4) ND 348.0709 (H2PO4) ND
344.0396 (P04^‘) ND 346.0553 (P04^‘) ND
3801084 (+2NH4^ ND 382.1240 (+ 2 NH4I ND
578.0927 (+ 2 NH3) ND 380.1084 (+ 2 NH3) ND
390.0192 (+2Na) ND 392.0348 (+ 2Na) ND
GSH 306.0760 89 6.59 308.0916 2 2 6.74
GSSG 611.1441 ND 613.1598 ND
Riboflavin 375.1305 1495 233 377.1461 9593 2.41
Pyridoxal 166.0504 8182
4388
238
451
2 . 6 6
4.65
6.48
636
168.0661 33549
539
2.34
6.77
+ NH/: Ammonium adduct; + NH3: Ammonia adduct; + Na: Sodium adduct.
COOH: Acid form of glycolysis and TCA cycle intermediates; COO': Anion form of glycolysis and TCA cycle intermediates. 
H2P2O7: Acid form of the phosphate group in cofactors; HP2O7" and P2 0 7 '^: Anion form of the phosphate group in cofactors. 
H4P3O10, H3P2O7, and H2PO4: Acid form of the phosphate group in ATP, ADP, and AMP, respeetively; P3 0 io% P2 0 7 '^, and 
PO/': Anion form of the phosphate group in ATP, ADP, and AMP, respectively.
ND: Not deteeted.
Each compound was prepared as an individual sample in 80% acetonitrile. LC-MS analysis was performed in the ESC mode 
with a 35 min. HILIC gradient. Flow rate: 0.15 mPmin, injection amount: 500 pmoles in 10 pi.
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6.4 Optimisation o f the sample preparation protocol
One of the problems encountered in the LC-MS analysis was that the level of 
metabolites detected within cell samples was very low, even when these cell samples had 
been spiked with pure compounds. It is possible that metabolites from the cells were being 
lost during the extraction procedure, and hence an alternate extraction protocol was 
examined. The following experiment was conducted to evaluate whether the process of 
extraction with 50% acetonitrile and concentration by freeze-drying led to loss of the 
metabolites.
Glutamine was used as a model compound because it was easily detected in the 
LC-MS analysis. Glutamine was prepared with/without the extraction and/or freeze-drying 
processes, with a final concentration of glutamine of 5 pM in 0%, 50%, and 80% acetonitrile. 
50 pmoles of glutamine in 10 pi was then subjected to LC-MS analysis in the ESI  ^mode.
Figure 6.27 shows the detection intensity of glutamine following different preparation 
methods. In general, the detection intensity of samples containing acetonitrile was higher than 
those without. In addition, sample preparation processes that involved extraction and ffeeze- 
drying reduced the detection intensity, especially for samples that contained water and 50% 
acetonitrile. Freeze-drying alone also reduced the detection intensity to a certain degree, but 
this was only apparent for samples prepared in water and when the final injection amount was 
high, i.e. at 250 nmoles in 50 pi (Figure 6.27 B). These results indicate that (1) samples 
re-suspended in acetonitrile produced a higher detection intensity and (2) the currently used 
sample preparation process that include extraction and freeze-drying led to some loss of 
metabolites, and a better method needs to be developed.
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(A)
ü
<
60
40
20
No extraction, no freeze-drying With extraction, with freeze-drying No extraction, with freeze-drying
(B) 250
200
Ü 150 
<
100
50
0
No extraction, no freeze-drying With extraction, with freeze-drying No extraction, with freeze-drying
□  0%ACN □  50% ACN 80% ACN
Figure 6.27: The effect of extraction and freeze-drying on detection intensity. (A) LC-MS 
injection amount of 50 nmoles in 10 |il and (B) 250 mnoles in 50 pi. Glutamine was prepared 
with/without the extraction and freeze-drying process and reconstituted to 5 pM in 0%, 50%, and 
80% acetonitrile prior to LC-MS analysis in the ESr mode with a 35 min. HILIC gradient and flow 
rate of 0.15 ml/min. Data shown as single run.
The extraction process could not be omitted because it is essential to remove other 
components of the cells such as lipids and proteins from the metabolites for good LC-MS 
analytical results (Particle Sciences, 2009). Hence, the objective of the next experiment was 
to set up a new sample preparation method that did not involve freeze-drying, since the 
previous experiment supports the hypothesis that this significantly contributes to loss of 
metabolites during sample preparation. Glutamine was prepared in PBS, and acetonitrile 
added (1:1, v/v) to represent the extraction process. The final concentration of glutamine was 
5 pM in 50% acetonitrile, and 50 pmoles of glutamine was subjected to LC-MS analysis in 
the ESI”^ mode. PBS was used because it was the buffer used during the cell harvesting 
process. As controls, the extracted glutamine was also freeze-dried and re-suspended in 0%, 
50%, and 80% acetonitrile prior to LC-MS analysis. In addition, to check whether the 
addition of acetonitrile during the extraction process caused precipitation of polar
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metabolites, the sequence of extraction and concentration was reversed. Glutamine was 
prepared in PBS, ffeeze-dried, and then re-suspended/extracted with 50% or 80% acetonitrile 
before LC-MS analysis.
Out of the six different sample preparation methods, glutamine was detected only in 
three samples, (1) extraction and freeze-drying, with re-suspension in 50% acetonitrile 
(condition 2), (2) extraction with 50% acetonitrile but without freeze-drying (condition 4), 
and (3) freeze-drying and re-suspensionin 50% acetonitrile (condition 5) (Figure 6.28). It 
appears that glutamine was only detected in samples containing 50% acetonitrile. However, 
the detection intensity for all three was very low. When the injection amount was increased to 
150 and 250 pmoles by increasing the injection volume to 30 and 50 pi, respectively, 
glutamine became undetected in all conditions (Figure 6.29). This was unexpected because in 
the previous LC-MS analysis (Figure 6.27), glutamine prepared with the same method 
(extraction and freeze-drying), plus re-suspension in 80% acetonitrile, injection at 50 and 
250 pmoles produced detection with peak area (AUC) of approximately 40 and 200, 
respectively.
The only difference to the previous finding was that PBS was used as the dissolving 
solution in this experiment whereas water was used previously. The results obtained indicate 
that PBS may have an effect on the detection intensity and a further experiment was carried 
out to compare the detection intensity of glutamine dissolved in water versus PBS. 
Acetonitrile was added to both samples (1:1, v/v) and 50 pmoles of glutamine was subjected 
to LC-MS analysis with injection volume of 10 pi. Glutamine prepared in PBS was not 
detected although glutamine prepared in water was detected (Figure 6.30), indicating that 
samples containing PBS reduced the detection intensity. Based on the above findings, it was 
decided that the freeze-drying process should be omitted from the sample preparation method 
and replaced PBS with ice-cold water during cell-harvesting to prevent reduced detection of 
the metabolites. Details of the optimised protocol have been documented in Section 2.2.3.1.2.
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M ethod  2^100%  w ater^B lank
2011_09_16_Q05 Sm [Mn. 2x3) Gin: 1 4 7 .0 7 7 0  ± 5 0  ppm ; Injection: 5 0  p m o les
Condition 1: Blank
2 00 4 00 6 00 8 00 1000 12 00 14 00 16 00 18 00 2000  22 00 24 00 2600  28 00 3000  32 00 34 00
2011 09 16 006Sm(Mn.2x3) 1 TOF MS ES+
147 077 5DPPM
lirfvr.. "
Condition 1: 5 [jM Gin
2 00 4 00 6 00 8 00 10 00 12 00 14 00 16 00 18 00 2000  22 00 24 00 26 00 28 00 30 00 32 00 34 00
20t1_09_16_007 Sm(Mn.2x3) 1 TOP MS ES*
147 077 50PPM
Condition 2: Blank■ f a i l l i 11
2.00 4 00 6 00 8 00 10 00 12 00 14 00 16 00 18.00 20.00 22 00 24 00 26 00 28 00 3000  32.00 34 00
2011_09_16_006 Sm (Mn. 2x3) 1 TOP MS E S-
6 23 147 077 50PPM
80 9494 50
Area. Heignr
Condition 2: 5 |j M Gin
2 00 4 00 6 00 8.00 10 00 12.00 14.00 16 00 18.00 20 00 22 00 24 00 26 00 28.00 3000  32 00 34.00
2011 09 16 009 Sm (Mn, 2x3) 1 TOP MS ES*
147 077 50PPM
Condition 3: Blank
2 00 4 00 6.00 8 00 1000 12 00 14,00 16 00 18.00 2000  22.00 24 00 26.00 2800  30.00 3200  34.00
2011 09 16^010 Sm(Mn. 2x3) 1 TOP MS ES*
147 077 50PPM
Condition 3: 5 pM Gin
2.00 4 00 6 00 8 00 10 00 12.00 14 00 16 00 18.00 2000  22 00 24.00 26 00 28.00 3000  32 00 34.00
M ethod  1_50%  A CN ^Blank 
2011_09_16_003 Sm (Mn. 2x3) Gin: 1 4 7 .0 7 7 0  ± 5 0  ppm ; Injection: 5 0  pm o les
Condition 4: Blank
2 00 4 00 6 00 8 00 10 00 12 00 14 00 16 00 18 00 2000 2200  24 00 26 00 28 00 30 00 32 00 34 00
2011_09_16_004 Sm(Mn.2x3) 1 TOP MS ES*
147 077 50PPM
Condition 4: 5 pM Gin
2 00 4 00 6 00 8 00 10 OD 12 00 14 00 16 00 18 00 20 00 22 00 24 00 26 00 28 00 30 00 32 00 34 .00
2011 09 16_011 Sm (Mn. 2x3) 1 TOP MS ES+
147 077 50PPM
Condition 5; Blank
2 00 4 00 6 DO 8 00 10 00 12 DO 14 00 16 00 18 00 20 00 22 00 24 00 26 00 28 00 30 00 32 00 34 .00
20n_09  16.012 Sm (Mn. 2x3) 1 TOP MS ES*
147 077 505PM
Condition 5; 5 |jM Gin
2.00 4 00 6 00 8 00 10 00 12 00 14 00 16 .00 18 00 20 00 22 00 24 00 26 00
2011_09_16.013 Sm (Mn, 2x3)
30 00 32.00 34.00
1 TOP MS ES* 
147 077 5DPPM
Condition 6: Blank
iM'pi IM
2.00 4 00 6 00 8 00 10 00 12.00 14 00 16.00 18 00 20 00 22 00 24 00 26 00 28 00 30 00 32.00 34 00
2011 09 16 014 Sm(Mn.2x3) 1 TOP MS ES*
147 077 SOPPM
Condition 6: 5 |j M Gin
2 00 4 00 6 00 8.00 10 00 12 00 14 00 16 00 16.00 20 00 22 00 24 00 26 00 26 00 30 00 32 00 34 00
Figure 6.28: Detection of 5 jiM glutamine using different sample preparation methods.
Condition 1: Glutamine was dissolved in PBS, extracted with acetonitrile (1:1, v/v), freeze-dried, 
reconstituted with water prior to LC-MS analysis. Condition 2 and 3 were similar to condition 1 
except that the sample was reconstituted with 50% and 80% acetonitrile, respectively. Condition 4; 
Glutamine was dissolved in PBS, extracted with acetonitrile (1:1, v/v), and subjected to LC-MS 
analysis. Condition 5 and 6: Glutamine was dissolved in PBS, freeze-dried, and reconstituted with 
50% and 80% acetonitrile, respectively before subjecting to LC-MS analysis. LC-MS analysis was 
conducted in the ESC mode with a 35 min. HILIC gradient. The flow rate was 0.15 ml/min. and the 
injection amount was 50 pmoles in 10 pi.
LT)CO g %
CL eu • >o00 o  oLO 0 0
T 5.zz .t: *z tn
"g "g "g ;  
5 5 5 y
to
5 y
a o
Q .
Q .CLOin in
o
N-
;JS
00
<U 'O
in
©£ ^C GO
in in
o
o D£
292
W at€ r_ B la n k  1
2011_09_19_002 Sm (Mn. 2x3) G in  ( 1 4 7 .0 7 7 0  ± 2 0  ppm ); In jec tion : 5 0  p m o le s
147 077 20PPM
Water blank
2-00 4 00 6 00
20n^09_19^QCM Sm (Mn. 2x3)
3 00 ID 00 12 00 14 00 16 00 18 00 20 00 22 00 3 00 26 00 28.00 30 00 32 00 34 00
1 TOP MS ES* 
147 077 20PPM
2 00 4 00 6 00
2011_09_19_003 Sm (Mn. 2x3)
3 00 10 OO 12 00 14 00 16 00 16.00 20 C
Sample in water
22 00 24 00 26 00 28 00 30 00 32 00 34 00
1 TOF MS ES* 
147.077 20PPM
PBS blank
2.00 4 00 6 00
2011_09_19_OQ5 Sm (Mn. 2x3)
3.00 10 00 12 00 14.00 16 00 18.00 20 00 22 00 24 00 26 00 28.00 30 00 32 00 34 00
1 TOF MS ES* 
147 077 20PPM
Sample in PBS
2.00 4 00 6 00 8 00 10.00 12 00 14 00 16 00 18 00 20 00 22 00 24 00 26 00 28 00 30 00 32.00 34 00
Figure 6.30: The effect of PBS on detection. Glutamine was dissolved in water versus PRS, 
extracted with acetonitrile (1:1, v/v), and subjected to LC-MS analysis in the E S r mode with a 
35 min. aqueous normal-phase gradient. Flow rate: 0.15 ml/min., injection amount: 50 pmoles in 
10 pi.
6.5 Discussion
A suitable LC-MS procedure needs to be established before the investigation of a 
biological effect can be carried, ensuring distortion or obscurity of data is avoided. The 
Synergi Polar-RP column was used in this chapter for LC-MS analysis. The column can be 
used with a HILIC gradient (Wei et al,  2010) or a reversed-phase gradient (Lewis et al,  
2008; Bajad et al,  2006). The present study revealed that the majority of the metabolites 
tested were better retained with a HILIC gradient as compared to a reversed-phase gradient 
(Table 6.1).
The retention time of the metabolites obtained from HILIC chromatography 
(Figures 6.1 -  6.19) was in line with the results reported by Wei et al  (2010). For example, 
using exactly the same mobile phase as Wei et al (2010), i.e. 5 mM ammonium acetate in 
5/95 (v/v) acetonitrile/water with pH 5.6 as the aqueous mobile phase and acetonitrile as the 
organic mobile phase, the retention time for lactate in the EST mode (Figure 6.9) was 
approximately 6.97 minutes while the reported retention by Wei et al  (2010) was 
6.91 minutes. Nicotinic acid was reported at 6.92 minutes while the observed retention time
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in this study was approximately 6.99 minutes (Figure 6.14). However, a closer inspection of 
the retention times observed in this study (Table 6.1 and 6.2) shows that there were 
differences between retention times in the EST and ESI  ^ mode for certain metabolites. As 
these should theoretically be identical, this is most likely due to inter-day technical variation, 
rather than biological variance. In addition, another contributing factor is certainly distorted 
or broad peaks, which complicates the determination of exact retention times. Figure 6.31 
shows example of distorted and broad peak bands with peak width of approximately 
0.6 minutes. The exact elution time was difficult to be determined in peaks that were broad or 
distorted. Nevertheless, the Synergi Polar-RP column produced peak bands that were 
generally sharper in terms of higher peak height and narrower peak width than the Luna NH2 
column (Chapter 5) although not as sharp as the BEH Cig column (Chapter 4).
(A) 2011_ 04J 3_010 S m  (M n . 2x3)
IO O t
ESI 5. æ
145.0593 
931.52
1.68 5.16
130.0840 i 64.0Ê65i 
58^  399.93 j  ^
I I [ I I V l ' l j 4  J U  I I I I I I I
2011_06_20_020 Sm (Mn. 2x3)
IOOt
E sr 5.51
1ÜS.0531 
448.S3
■ j ' j ' i U l  I I I I 1 U J  J , l l l  I J
2.00 4.00 6.00 8.00 10.00
(B) 2011„ 04J 3J 11 S m ( M n .2x3)
3.00 «-S3
126,1028146.0621 
19.45 71.79^
---
"  J I "  J M I ‘ ‘
lOOn
ESI 145.0^
1111.19
2.00 4.00 6.00 8,00 10.00
J i >«. '111 PI'fT.'M l- f f  W f
2.00 d.OO 6.00 8.00 10.00
2011_OS_20_021 Sm (Mn. 2x3)
IOOt
Esr
2,11
123.05330.^
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188.0646
494.60
H  I "  '  I " ’ I I I I I I I I
2.00 4.00
r~T iiT  11 > i S H f ¥ f  I' f  S ' i'i ’f  n  'H
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Figure 6.31: Peak shapes that affect the determination of the exact retention time.
Chromatograms of glutamine in (A) 50% acetonitrile and (B) 80% acetonitrile. Compound that 
exhibited distorted or broad peak bands showed retention times that are slightly different in the 
ESr compared to the ESC mode.
Chromatographic retention of eompounds is infiueneed by several factors, including 
the stationary phase, characteristics of the metabolite (analyte), organic solvent, buffer 
coneentration, mobile phase pH, and column temperature (Guo and Gaiki, 2011; Hao et al,  
2008; Guo and Gaiki, 2005; Dong and Huang, 2007; Vikingsson et al,  2008). A HILIC 
stationary phase is typieally a bare silica or silica derivatised with different polar functional 
groups. The functional groups can be neutral (e.g amide, cyano, diol, and eyclodextrin).
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charged (e.g. amino, imidazole, and triazole), or zwitterionie (e.g. sulphobetaine) (Guo and 
Gaiki, 2011).
Metabolites (analytes) can be classified into aeidie, neutral, zwitterionie, and basic 
categories (Storton et al,  2010). The predominant meehanism of retention in HILIC is based 
on liquid-liquid partitioning between the bulk eluent and a water-rieh layer that is partially 
immobilised on the surface of the stationary phase. However, adsorption, ion-exchange, 
hydrogen-bonding, hydrophobic and hydrophilic interactions between analytes and the 
stationary phase are also involved (Guo and Gaiki, 2011; Naidong, 2003; MeCalley, 2010).
Besides the ehemistry of the metabolite (analyte) and stationary phase, the eluting 
strength of the mobile phase is another important parameter for ehromatographie retention. A 
mobile phase eontent of less than 50% water increases the retention of hydrophilie 
metabolites, while higher water percentages (v/v) rapidly decreases retention of hydrophilic 
metabolites on HILIC eolumns (Dong and Huang, 2007). A higher content of organic solvent 
in the mobile phase has been shown to increase the retention of polar metabolites (Guo et al,  
2007; Guo and Gaiki, 2005). This provides a possible explanation for the unretained and 
distorted peaks seen in samples prepared in 100% water as compared to samples that 
contained 80% aqueous acetonitrile, whieh showed sharper, narrower width, and well 
retained peak bands (Figures 6.1 -  6.6). The unretained peak was probably caused by the 
present of water (from the sample) that swept through the eolumn and eluted the metabolites 
before they have a ehance to bind with the stationary phase. Furthermore, sample diluent 
influenees peak shape, and it should be similar to the initial mobile phase condition to 
minimise its impaet (Grumbaeh et al,  2004). In HILIC, the sample should be dissolved in a 
high organic solvent so that it is compatible with the high-organic starting mobile phase, but 
this will cause solubility problems for the target metabolites here, as they are generally polar 
in nature. Grumbaeh et al  (2004) showed that peak shape was improved as aqueous content 
of the sample diluent decreases but when aqueous eontent is completely removed, wide peaks 
were observed and suggested a mixture of 72:25 (v/v) acetonitrile-methanol as the best 
compromise between solubility and peak shape.
The buffer eoncentration of the aqueous mobile phase also has an effect on 
chromatographic retention. A higher concentration of ammonium aeetate was observed to 
reduce retention (Figures 6.7, 6.9 -  6.12, 6.14 -  6.17). Cazenava-Gassiolt et al  (2009) 
reported that increasing coneentrations of ammonium aeetate reduced retention times and
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postulated that the ammonium aeetate infiueneed retention by deactivation of active silanols 
groups in the stationary phase and to a lesser extent, formed ion-pairing interactions between 
analyte and additive (i.e. ammonium acetate). A separate study conducted to investigate the 
retention behaviour of small polar compounds in HILIC chromatography showed that the 
effect of ammonium acetate concentration was dependent on the type of stationary phase and 
eharacteristies of the tested compounds (Guo and Gaiki, 2005; Guo et al,  2007). Salicylic 
acid and aspirin exhibited inereased retention on TSKgel Amide-80, HILIC Silica, and 
ZIC-HILIC columns when the eoncentration of ammonium acetate was increased, but 
decreased retention on a YMC-Pack NH2 column. In contrast, cytosine displayed inereased 
retention on all four stationary phases with increasing eoneentration of ammonium aeetate. 
The retention observed in the amino eolumn was postulated to be as a result of ion-exehange 
effeets between the positively eharged stationary phase and negatively eharged test 
eompounds (aeids). A higher ammonium acetate coneentration inereased the eluting strength 
of the mobile phase, leading to decreased retention on the amino stationary phase. In 
ZIC-HILIC column, retention was due to electrostatie interactions between the negatively 
charged sulphonate groups on the sulphobetaine phase and negatively charged acids, but 
higher ammonium acetate coneentrations weakened the electrostatic repulsion leading to 
stronger retention. It should be noted that for eystosine, the retention might be related to 
hydrophilic partitioning rather than speeifie interaetions between the stationary phase and test 
eompound (eystosine), as inereased retention was observed when different functional groups 
of stationary phase were used. A further study by the same group concluded that buffer 
eoncentrations had a greater effeet on compound retention with eharged stationary phases as 
compared to less charge stationary phases.
Higher concentrations of ammonium acetate were also found to improve peak shape 
in this study, e.g. for lactate, malate, N A D \ and NADH (Figures 6.9 -  6.12), whieh is 
consistent with the published literature. Low buffer coneentration (10 mM or below) has been 
shown to eause severe fronting for positively charged analytes and tailing for negatively 
charged analytes. This can be removed by inereasing the buffer eoncentration to 100 mM, 
whieh resulted in improved peak symmetry, although no improvement was observed beyond 
100 mM (Risley and Pack, 2006). In another study, higher eoncentrations of ammonium 
acetate in the mobile phase (methanol) improved peak shapes, produeing symmetrical and 
well-defined peaks for compounds that have strong peak tailing (Cazenave-Gassiot et al.
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2009). In this study, pyridoxal (in the ESI  ^mode) was the only metabolite that has worsened 
peak shape when the concentration of ammonium aeetate was increased.
Mobile phase pH is also an important factor in chromatography experiments. Many 
studies have been condueted to evaluate the effects of mobile phase pH on chromatography, 
and all demonstrate that it affects the retention and seleetivity of HILIC separation in a 
metabolite- and stationary phase-dependent manner (Ali et al,  2007; Vikingsson et al,  2008; 
Guo and Gaiki, 2005). Mobile phase pH can affect the charge state of both the analytes and 
stationary phase. Generally, charged analytes are more hydrophilic than their neutral forms, 
inereasing retention times in HILIC where the predominant retention meehanism is liquid- 
liquid partitioning (Guo and Gaiki, 2011). However, changing the pH may shift this 
mechanism towards interactions between the analytes and the stationary phase (Dong and 
Huang, 2007). For example, when the mobile phase pH is high, ion-exehange effect 
contribute signifieantly to the overall retention of aspirin in an amino column, but when the 
mobile phase is acidic, aspirin would be protonated and become less hydrophilic, the ion- 
exchange effect no longer exist, leading to decrease in retention (Guo and Gaiki, 2005). 
Similarly, the charge state of the stationary phase ean also be affected by mobile phase pH, 
resulting in significant effects on the retention and selectivity of HILIC because of ion- 
exchange or eleetrostatic (attraction or repulsion) interactions between the eharged stationary 
phase and charged analytes (Guo and Gaiki, 2011).
Column temperature also has a signifieant effeet on retention, not only in HILIC but 
in all liquid chromatography. Temperature affects the solubility and diffiisivity of metabolites 
(analytes) and the viseosity of the mobile phase, whieh then affects retention, eolumn back 
pressure and efficiency, and the stationary phase properties (Dong and Huang, 2007; Hao et 
al,  2008). The effeet of column temperature on chromatography has been studied and 
reviewed by many researehers, e.g. Guo and Gaiki (2005), Gou et al  (2007), Dong and 
Huang (2007), Hao et al  (2008), and Guo and Gaiki (2011). Changes in retention and 
seleetivity of the separation have been observed when the temperature was altered and the 
effeet was dependent on the nature of the metabolites, analyte-stationary phase interaetions, 
type of mobile phase and its pH. In a study conducted by Guo et al  (2007), it was coneluded 
that eolumn temperature had less impaet on retention eompared to the effect of organic 
solvent content and buffer coneentration in HILIC, and henee this was not a variable that was 
examined in the present study.
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Factors that affect chromatography also have an impaet on mass spectrometry 
detection intensity, such as the pH and concentration of buffer. In this study, by altering the 
pH of the mobile phase from 5.6 to 4.0, more glyeolytic and TCA cycle intermediate 
metabolites were deteeted and they were detected in the form of the aeid (-COOH) (Section 
6.3). When the mobile phase pH is lowered, there are more protons (H )^ available for the 
protonation of the metabolites (analytes), thus the metabolites (analytes) are deteeted in the 
form of -COOH. When the pH is increased, the metabolites are more prone to be 
deprotonated (-C 00 ), and with the addition of mass speetrometry ionisation effeet in the 
ESf  ^mode, there would be a tendeney for adduct formation. This is a possible explanation 
for pyruvate, whieh was deteeted predominantly as adduets with ammonium and ammonia in 
the ESI  ^ mode and the deteetion intensity increased with higher pH mobile phase (Figure 
6.26).
When the eoncentration of ammonium aeetate used as the aqueous portion of the 
mobile phase was increased from 1 mM to 5 mM or 20 mM, the detection intensit}  ^increased 
for some metabolites such as NAD^ and ADP in the ESI** mode (Figures 6.11, and 6.16) and 
pyruvate in the ESI' mode (Figure 6.8). This was probably because ammonium acetate 
influenced the ionisation of the metabolites in the mass spectrometer, thus improving the 
detection of the metabolites. Ammonium acetate functions in a similar manner to formic acid, 
which is added to the mobile phase in reversed-phase chromatography to improve ionisation 
effieieney (Gareia et al,  2002; Gareia, 2005; Wu et al,  2004). Furthermore, a higher organic 
solvent content in the mobile phase can improves electrospray ionisation efficiency in mass 
spectrometry, thus inereasing the detection signals (Pitt, 2009).
Although addition of ammonium acetate can suppress unwanted signals or selectively 
enhance the signals of metabolites of interest, the simultaneous presenee of more than one 
component in the ion source ean cause eompetition in the ionisation process. Such 
competition may lead to ion suppression, leading to redueed detection intensity. Buffer is also 
a souree of ion suppression and the coneentration should be kept to the minimum required for 
a satisfactory chromatographic separation (Pitt, 2009). Ion suppression could be a possible 
reason for the redueed deteetion intensity for some metabolites with 20 mM ammonium 
aeetate as compared to 5 mM ammonium acetate, such as the case of glutamate, N A D \ and 
GSH (Figures 6.7, 6.11, and 6.17).
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Besides buffer as the souree of ion suppression, the content of the sample itself is also 
a possible source of ion suppression. When a sample causes ion suppression, this is usually 
refers to as a matrix effect. Matrix effects is a collective term for all the effects that corrupt 
the quantification of a metabolite of interest and are eaused by other substanees present in the 
sample (Buscher et al,  2009). It has erucial impact on the detection intensity of LC-MS 
analysis. The presence of co-eluting substanees with the metabolite of interest alters the 
ionisation and efficiency of the electrospray interface, causing the response of a metabolite of 
interest to differ in a biological matrix from a standard solution (Taylor, 2005). Matrix effects 
are generally directly related to insufficient sample clean-up (Van et al,  2009), with many 
studies examing possible permutations in this process(Sana et al,  2008; Madalinski et al,  
2008; Kay et al,  2008; Wu et al ,  2008). In this study, the reduetion of detection intensity 
observed in Figures 6.28 -  6.30 was due to the present of salts from PBS. PBS was used to 
re-suspend cells during eell-harvesting because of its isotonie properties but appeared to have 
undesirable effeet on LC-MS analysis (Section 6.4). This is consistent with a separate study 
that demonstrated that water or water/ethanol used as the perfusion medium instead of 
Ringer’s solution reduced salt eontent and limited ion suppression (Lanekmans et al,  2008). 
Thus, replacing PBS with ice-cold water was a suitable ehoice. There was also reduction in 
the detection intensity of samples prepared with freeze-drying (Figure 5.27), indieating that 
certain compounds might have been degraded in the proeess. Therefore, the freeze-drying 
process was also omitted from the sample preparation procedure.
After all the optimisation procedures were completed in this study, 22 out of 28 pure 
standard eompounds tested were detected on the Synergi Polar-RP eolumn at the amount of 
500 pmoles. The compounds that were not detected were citrate, malate, NADP^, NADPH, 
ATP (including ADP and AMP), and GSSG. Based on the work by Wei et al. (2010), 
NADP^, NADPH, ATP, ADP, AMP, and GSSG were chromatographically separated using 
an Atlantis T3 OBD column instead of Synergi Polar-RP eolumn. For eitrate and malate, 
although the loaded amount of the eompounds used in this study were very much higher than 
the deteetion limit (LOD) reported by Wei et al  (2010) but different MS instrument was 
employed for the LC-MS analysis. A QToF analyser was used in this study whereas a triple 
quadrupole analyser has been used by other groups (Bajad et al,  2006; Wei et al,  2010; 
Lewis et al,  2008). A QToF-MS is generally considered to me more suitable for an 
untargeted metabolomics approaeh due to its full-scan sensitivity over a wide mass range, 
high resolving power, and fast response. However, a triple quadrupole-MS is generally used
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for targeted quantification due to its advantage of specificity (Ens and Standing, 2005; 
Chemushevich et al,  2001). With a triple quadrupole mass spectrometer, the mass of a 
precursor ion is selected in the first quadrupole, fragmentation of the precursor ion is induced 
in the second quadrupole, and the last quadrupole filters the desired fragment of produet ion. 
This results in the deteetion of a speeifie pair of preeursor and produet ions with a specific 
m/z value (Shi et al,  2012).
In summary, ehromatographie separation using a Synergi Polar-RP eolumn with 
20 mM ammonium acetate in 5/95 (v/v) acetonitrile/water, pH 4.0 as the aqueous mobile 
phase and acetonitrile as the organic mobile phase provided the best option for the detection 
of the majority of the metabolites of interest. In addition, sample preparation procedure 
without the freeze-drying proeess or the use of PBS reduced the possibility of ion suppression 
and enabled detection of the metabolites.
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Chapter 7: Effects of Troglitazone on HuH-7 Cells Analysed by LC-MS
using Synergi Polar-RP Column
After optimising the experimental protocols for LC-MS analysis using the Synergi 
Polar-RP column as described in Chapter 6, the effects of troglitazone on HuH-7 eells were 
investigated. The purpose of this investigation was to evaluate the response of HuH-7 eells 
towards 24-hour treatment with troglitazone ( 1 - 2 4  pM). In Chapter 4, a non-targeted 
metabolomics approach was used to diseriminate troglitazone toxicity; in this chapter a 
targeted metabolomies approach is used to examine the effects of troglitazone on glycolysis, 
TCA cycle, and energy generation previously deseribed (Chapter 4). To aehieve this, a set of 
target metabolites were assessed, i.e. metabolites associated with energy generation 
pathways, in particular the glycolysis and TCA cycle intermediates.
The effeets of troglitazone on HuH-7 cells were examined using samples from 
intracellular cell extracts; metabolite identities were determined putatively using their 
theoretical mass (m/z value) with an error of 40 ppm. These identities were then eonfirmed 
hy eomparison of the putatively identified metabolites with the profiles of eommercial 
standard compounds, based on the m/z value and retention time. Profiles of the standard 
compounds were attained from LC-MS analysis of spiked water blank and spiked untreated 
cell extracts. Spiked samples were prepared by the addition of a mixture of standard 
compounds (28 compounds in total) to water blank and untreated cell extracts, which were 
then subjected to similar extraction protocols and LC-MS analysis as the cells treated with 
troglitazone. The final concentration of the spiked samples was 5 pM, and the injeeted 
amount for LC-MS analysis was 50 pmoles in a volume of 10 pi.
The speeifie objeetives of this study were as follows:
Objective 1: Evaluation and quantification of the ehanges of metabolites level in HuH-7 
eells treated with troglitazone.
Objective 2: Elucidation of the relationship between the metabolome of HuH-7 cells treated 
with troglitazone and toxicity.
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7.1 LC-MS analysis of the effects of troglitazone on HuH-7 cells
Glutamate a n d  slu tam ine
Figures 7.1 A and C show the effeets of troglitazone on intracellular glutamate, which 
was detected with an approximate elution time of 10.5 minutes in both the ESF and ESI  ^
ionisation modes. The levels of intracellular glutamate were found to decrease when the dose 
of troglitazone was increased. The dose-response eurves for glutamate in the EST and ESf  ^
modes have IC50 values of 5.48 ± 0.98 pM and 8.72 ± 1.50 pM, respectively. These IC50 
values are not statistieally significantly different, as would be expected given that the same 
metabolite is being measured in both cases. A eomposite value can thus be generated, being 
7.00 ±1.25 pM.
The spiked blank and spiked untreated cell extract showed an increment in the levels 
of glutamate in both the EST and ESI  ^ ionisation modes, although this was not statistically 
significant compared to their respeetive unspiked pair (Figures 7.1 B and D). The spiking 
process (addition of 5 pM glutamate) caused an increment of only about 1 0 -2 0  AUC value 
in the ESF mode. In the ESI  ^mode, the increment was less visible than in the ESF mode. The 
deteetion intensity of glutamate in the ESI  ^mode was lower in eomparison to the ESF mode. 
These data suggest that the intracellular levels of glutamate are already fairly high, meaning 
that the spiking procedure did not inerease them by much.
Glutamine was deteeted in both EST and ESI  ^ modes with an elution time of 
approximately 7.3 minutes. Troglitazone treatment did not affect the levels of intraeellular 
glutamine deteeted under either mode (Figures 7.1 E and G).
The spiked blank showed a higher glutamine level eompared to the unspiked blank in 
the ESF and ESI  ^modes, but again this was not statistieally signifieant (Figures 7.1 F and H). 
The spiked untreated cells also showed higher glutamine level than the unspiked cell extract 
although the increment appears to be less prominent in eomparison to the increment observed 
in the spiked blank sample. This was probably because eells eontained high level of 
intraeellular glutamine and the spiking with 5 pM of glutamine detected an inerement of only 
40 -  50 AUC values in the ESF and 1 0 -2 0  AUC values in the ESI  ^mode.
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Glutamate: m/z value = 146.0453 ± 40 ppm (ESI ) and elution tim e % 10.65 min.
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Figure 7.1: The effect of 24-h treatment with troglitazone on intracellular levels of glutamate 
and glutamine. Dose-response curves for glutamate and glutamine and their standard compounds 
profiles (A, B, E, and F) ESI and (C, D, G, and H) EST modes. Treated HuH-7 cells were 
processed for LC-MS analysis with flow rate of 0.15 ml/min. and injection volume of 10 pi. The 
final injected amount of glutamate was 50 pmoles. Data shown as mean ± S.E.M. (n > 3 biological 
repeats) and were analysed by non-linear regression and one-way ANOVA followed by Bonferroni 
post-test (*p < 0.05, **/> < 0.05, ***p < 0.05).
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Methionine, leucine, phenylalanine, tryptoyhan, and valine
Methionine, leucine, phenylalanine, tryptophan, and valine were also detected, with 
the approximate elution times of 5.9, 5.7, 5.8, 5.7, and 5.9 minutes, respectively 
(Figures 7.2 -  7.4). The detection intensity for methionine was very low in the ESI  ^ mode, 
with an AUC value below 10 (data not shown), and therefore further analysis of methionine 
in the ESI  ^mode was excluded. Troglitazone did not appear to have any effect on the levels 
of these five intracellular metabolites.
Blank samples spiked with methionine, leueine, phenylalanine, tryptophan, and valine 
exhibited higher levels of the metabolites compared to the unspiked blank samples although 
the increase was not always statistically significant. Untreated cell extracts spiked with the 
standard amino acids also showed differences from their unspiked pairs. The increment in the 
spiked untreated cell extracts was less apparent when the unspiked cell extracts contained 
high level of the metabolites or when the overall detection intensity for the particular 
metabolites was low.
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Figure 7.2: The effect of 24-h treatment with troglitazone on intracellular levels of 
methionine. (A) Dose-response curve for methionine and (B) profile of methionine standard 
compound in the ESF mode. Treated HuH-7 cells were processed for LC-MS analysis with flow 
rate of 0.15 ml/min. and injection volume of 10 jil. The final injected amount of methionine was 
50 pmoles. Data shown as mean ± S.E.M. (n > 3 biological repeats) and were analysed hy non­
linear regression and one-way ANOVA followed hy Bonferroni post-test (*/? < 0.05, **p < 0.05, 
***p < 0.05).
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Leucine: m/z value = 130.0868 ± 40 ppm (ESI ) and elution time % 5.72 min.
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Figure 7.3: The effect of 24-h treatment with troglitazone on intracellular levels of leucine 
and phenylalanine. Dose-response curves for leucine and phenylalanine and their standard 
compounds profiles in the (A, B, E, and F) ESI and (C, D, G, and H) ESF modes. Treated HuH-7 
cells were processed for LC-MS analysis with flow rate of 0.15 ml/min. and injection volume of 
10 pi. The final injected amount of standard compounds was 50 pmoles. Data shown as 
mean ± S.E.M. (n > 3 biological repeats) and were analysed by non-linear regression and one-way 
ANOVA followed by Bonferroni post-test (*p < 0.05, **/> < 0.05, ***/? < 0.05).
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Tryptophan m /z value = 203.0821 ± 40 ppm (ESI ) and elution time «  5.72 min.
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Figure 7.4: The effect of 24-h treatment with troglitazone on intracellular levels of 
tryptophan and valine. Dose-response curves for tryptophan and valine and their standard 
compounds profiles in the (A, B, E, and F) ESF and (C, D, G, and H) E Sr modes. Treated HuH-7 
cells were processed for LC-MS analysis with flow rate of 0.15 ml/min. and injection volume of 
10 pi. The final injected amount of standard compounds was 50 pmoles. Data shown as 
mean ± S.E.M. (n > 3 biological repeats) and were analysed by non-linear regression and one-way 
ANOVA followed by Bonferroni post-test {*p < 0.05, < 0.05, ***p < 0.05).
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Lactate
Among all the intermediates of glycolysis and the TCA cycle examined, lactate was 
the only metabolite detected in the intracellular samples. It was detected in the EST mode and 
eluted at approximately 7.0 minutes. However, the levels of lactate were not affected by 
troglitazone (Figure 7.5 A).
There was a clear increment of lactate levels in the spiked blank and spiked untreated 
cell extract samples in comparison to their respective unspiked counterpart even though not 
statistically significant (Figures 7.5 B).
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Figure 7.5: The effect of 24-h treatment with troglitazone on intracellular levels of lactate.
(A) Dose-response curve for lactate and (B) profile of lactate standard compound in the EST mode. 
Treated HuH-7 cells were processed for LC-MS analysis with flow rate of 0.15 ml/min. and 
injection volume of 10 pi. The final injected amount of lactate was 50 pmoles. Data shown as 
mean ± S.E.M. (n > 3 biological repeats) and were analysed by non-linear regression and one-way 
ANOVA followed by Bonferroni post-test (*/> < 0.05, **p < 0.05, ***p < 0.05).
GSH
Figure 7.6 shows the intracellular GSH levels in response to troglitazone treatment. 
GSH was detected in the EST mode at approximately 10.6 minutes and 10.3 minutes in the 
ESI  ^mode, with this difference being due to the broad nature of the peaks, with peak widths 
of approximately 0.5 -  0.7 minutes. Treatment of HuH-7 cells with troglitazone decreased the 
levels of intracellular GSH significantly. The IC5 0  value was detennined to be 
2.57 ± 0.24 pM in the EST mode and 5.79 ± 2.38 pM in the ESI  ^mode, giving a combined 
IC5 0  value of 3.14 ± 1.12 pM.
The addition of pure GSH (5 pM) to the blank and untreated cell extract showed a 
small increase in the levels of GSH, an increment of approximately 5 AUC value from the 
unspiked samples. However, the increase was not significantly different statistically, which
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presumably reflects the known large amounts of intraeellular GSH usually present within 
liver cells (approximately 5 mM).
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Figure 7.6: The effect of 24-h treatment with troglitazone on intracellular levels of GSH.
Dose-response curves for GSH and profiles of GSH standard compound in the (A and B) ESI' and 
(C and D) ESfl modes. Treated HuH-7 cells were processed for LC-MS analysis with flow rate of 
0.15 ml/min. and injection volume of 10 pi. The final injected amount of GSH was 50 pmoles. 
Data shown as mean ± S.E.M. (n > 3 biological repeats) and were analysed by non-linear 
regression and one-way ANOVA followed by Bonferroni post-test (*/? < 0.05, **/? < 0.05, 
***/?< 0.05).__________________________________________________________________
Nicotinamide
Another metabolite that was affected by 24-hour treatment with troglitazone was 
nicotinamide. Nicotinamide was detected only in the ESI^ mode, but it was not very well 
retained by the Synergi Polar-RP column, with an elution time of only 2.1 minutes, compared 
to a void time of 1.8 minutes. The levels of intracellular nicotinamide were observed to 
decrease with increasing dose of troglitazone (Figure 7.7 A), resulting in an IC50 value 
calculated of 9.40 ± 1.91 pM.
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The addition of standard nicotinamide compound to the blank and untreated cell 
extract exhibited a significant increase in the levels of detected nicotinamide in comparison to 
the unspiked samples (Figure 7.7 B).
Nicotinamide: m /z value = 123.0558 ± 40 ppm (ESF) and elution time «  2.10 min
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Figure 7.7: The effect of 24-h treatment with troglitazone on intracellular levels of 
nicotinamide. (A) Dose-response curve for nicotinamide and (B) profile of nicotinamide standard 
compound in the EST mode. Treated HuH-7 cells were processed for LC-MS analysis with flow 
rate of 0.15 ml/min. and injection volume of 10 pi. The final injected amount of nicotinamide was 
50 pmoles. Data shown as mean ± S.E.M. (n > 3 biological repeats) and were analysed by 
non-linear regression and one-way ANOVA followed by Bonferroni post-test (*p < 0.05, 
**p < 0.05, ***/? < 0.05).
Nicotinic acid, nicotinuric acid, riboflavin, pyridoxal, and NAD^ were also examined, 
but were only detected in the spiked samples (Figures 7.8 and 7.9). They were detected in 
both the EST and ESI^ modes except for NAD^, which was detected only in the ESI^ mode. 
The elution times for nicotinic acid, nicotinuric acid, pyridoxal, and NAD^ were 
approximately 7.0 (EST) and 6.4 (ESI^); 7.7 (EST) and 7.3 (ESI^); 6.5 (EST) and 6.1 minutes 
(ESI^); and 11.1 minutes (ESI^), respectively. Differences in the elution time between the 
EST and ESI^ modes were due to broad peak width. The Synergi Polar-RP column exhibited 
less retention for riboflavin, with an elution of 2.7 minutes.
As stated above, nicotinic acid, nicotinuric acid, riboflavin, pyridoxal, and NAD^ 
were only detected in the spiked blanks and spiked untreated cell extracts, with none or very 
low levels in the unspiked samples. As such, this suggests that there were very low levels of 
these metabolites in the intracellular cell extracts, meaning it was not feasible to analyse the 
effect of troglitazone on these five metabolites further.
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Figure 7.8: Profiles of nicotinic acid, nicotinuric acid, riboflavin, and pyridoxal standard 
compounds. Water blank and untreated cell extracts were spiked with (A) nicotinic acid, 
(B) nicotinuric acid, (C) riboflavin, and (D) pyridoxal and processed for LC-MS analysis with flow 
rate of 0.15 ml/min. and injection volume of 10 pi. The final injected amount of standard 
compounds was 50 pmoles. Data shown as mean ± S.E.M. (n > 3 biological repeats) and were 
analysed by non-linear regression and one-way ANOVA followed by Bonferroni post-test 
{*p < 0.05, **p < 0.05, ***/? < 0.05).
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Figure 7.9: Profile of NAD^ pyridoxal standard compounds. Water blank and untreated cell 
extracts were spiked with NAD'  ^and processed for LC-MS analysis with flow rate of 0.15 ml/min. 
and injection volume of 10 pi. The final injected amount of NAD^ was 50 pmoles. Data shown as 
mean ± S.E.M. (n > 3 biological repeats) and were analysed by non-linear regression and one-way 
ANOVA followed by Bonferroni post-test (*/> < 0.05, **/? < 0.05, ***/? < 0.05).
In summary, a total of 15 metabolites were detected by LC-MS analysis using the 
Synergi Polar-RP column. Nicotinic acid, nicotinuric acid, riboflavin, pyridoxal, and NAD^ 
were only detected in the spiked samples and the intracellular levels of these metabolites 
were too low to be analysed for the effect of troglitazone. Treatment of HuH-7 cells with 
troglitazone for 24 hours did not have any apparent effect on the intracellular levels of 
glutamine, leucine, phenylalanine, tryptophan, valine, methionine, and lactate. However, this 
treatment caused a reduction in the intracellular levels of glutamate, GSH, and nicotinamide.
7.2 Reproducibility and quality control
Paracetamol and reserpine were used as the quality controls to monitor the 
performance and reproducibility of the LC-MS analysis. LC-MS analysis of paracetamol and 
reserpine was performed in the beginning, middle, and end of each set of runs. Eigure 7.10 
shows an example of the chromatograms of paracetamol and reserpine in the EST and ESI^ 
modes. Paracetamol was not well retained with the Synergi Polar-RP column, with an elution 
time of approximately 2.0 minutes (Eigures 7.10 A and B), compared to a void time of 
1.8 minutes. Reserpine demonstrated better retention with the column (approximately 
6.7 minutes) but in the ESI^ mode, the peak was split into two (Figures 7.10 C and D).
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Figure 7.11 shows the reproducibility of paracetamol and reserpine in terms of peak 
area, retention time, detected mass and mass error. Each column within the graph represents 
inter-day variation while the symbols within each column refer to between runs variation. 
Some variations of the detection intensity, retention time, and detected mass value were 
observed between different day’s results. The variation between runs was however less 
evident. The detection of paracetamol and reserpine for all experiments was within the 
40 ppm mass error, demonstrating reproducibility.
7.3 Discussion
The aim of this chapter was to investigate the effect of troglitazone on HuH-7 cells by 
LC-MS analysis using a Synergi Polar-RP column, which showed retention for the 
metabolites of interest. The results of this study revealed that intracellular levels of glutamate, 
GSH, and nicotinamide decreased when the cells were treated with increasing concentration 
of troglitazone. However, the levels of glutamine, leucine, phenylalanine, tryptophan, valine, 
methionine, and lactate were not affected by troglitazone. To explain these effects, there is a 
need to understand the normal metabolic pathways within HuH-7 cells.
Most cells rely on glucose as the fuel source and produce energy (ATP) via 
glycolysis, the TCA cycle, and oxidative phosphorylation. In comparison, the production of 
energy through the glycolytic pathway is restricted to anaerobic conditions (Salway, 2004). 
However, highly proliferative cells such as cancer cells tend to have a higher reliance on 
glucose metabolism via the glycolytic pathway to generate energy even when oxygen is 
plentiful, a condition termed as “the Warburg effect” or aerobic glycolysis (Vander Heiden et 
al, 2009). HuH-7 cells are liver-like cells that originate from a liver tumour (Nakabayashi et 
a l, 1982) and therefore, the cells energy metabolism is expected to be predominantly via 
aerobic glycolysis. It was originally hypothesised that cancer cells have defective 
mitochondria, which impairs aerobic respiration, and the cells have to rely on anaerobic 
glycolytic metabolism (converting pyruvate to lactate) for the production of ATP (Vander 
Heiden et a l, 2009; Lunt and Vander Heiden, 2011). However, subsequent work showed that 
impairment of mitochondrial function is not the case in all cancer cells and damaged 
oxidative phosphorylation cannot be the sole cause for the reliance on anaerobic glycolysis 
(Vander Heiden et a l, 2009; Pantin et a l, 2006; Moreno-Sanchez et a l, 2007). There must 
be another explanation to why cancer cells turn to aerobic glycolysis, but this is as yet 
undetermined.
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Figure 7.11: Inter-day and inter-run variation of paracetamol and reserpine. (A) Detection 
intensity in the ESI' and (B) ESr modes; (C) retention time in the ESP and (D) ESŸ modes; 
(E) detected mass in the ESP and (F) ESI  ^modes; and (G) mass error in the ESP and (H) ESI  ^
modes. Each column within the graph shows inter-day variation and each symbol within the 
column shows inter-run variation.
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The glycolytic pathway is an inefficient method to yield ATP (Salway, 2004), but it 
can generate ATP at a faster rate than oxidative phosphorylation (Pfeiffer et a l, 2001). Lunt 
and Vander Heiden (2011) suggest that the major function of aerobic glycolysis is to maintain 
high levels of glycolytic intermediates to support biosynthesis of macromolecules for cell 
proliferation, while glutamine metabolism is important for the production of energy. In 
agreement with this suggestion is the observation that interfering with the conversion of 
pyruvate to lactate by knocking down lactate dehydrogenase A levels has been shown to 
restrict the ability of tumours cells to grow beyond small lesions (Fantin et a l, 2006).
Glutamine has long been known as an important source of fuel in cancer cells for 
energy generation. Reitzer et a l (1979) demonstrated that only 4 -  5% of glucose-derived 
carbon entered the TCA cycle, compared to approximately 80% of glucose being metabolised 
through glycolysis to lactate in HeLa cells. When the cells were cultured in fiuctose instead 
of glucose, they still grew exponentially, but the glycolytic activity was nearly 900 times 
lower with undetectable levels of glycolytic intermediates in the cells. Fructose-derived 
carbon was channelled almost entirely through the pentose phosphate cycle, with little or no 
energy generation resulting from its metabolism, which implies that there must be other 
sources of energy. The next most abundant carbon compound present in culture medium after 
sugars is glutamine. Reitzer et a l (1979) also observed that glutamine utilisation was very 
significant in HeLa cells. Even in the presence of glucose, glutamine contributed towards 
approximately 65% of energy production while in the presence of fructose rather than 
glucose, this rose to almost 99.9% of energy production.
Glutamine in cells is converted to glutamate by glutaminase, which yields ammonium 
as a byproduct (Routh et a l, 2002; Mathews et a l, 2000). Glutamate is then converted to 
a-ketoglutarate, by either transamination or deamination. Transamination is catalysed by 
alanine aminotransferase (ALT), which is present in both the cytosol and mitochondria, and 
utilises pyruvate as a eo-substrate and produces both a-ketoglutarate and alanine as products. 
Alanine may then further undergo transamination reactions and serve as a precursor for 
protein production. Alternatively, deamination of glutamate can be catalysed by 
mitochondrial glutamate dehydrogenase (GDH), releasing ammonium (Routh et a l, 2002; 
Coates et a l, 2002). a-Ketoglutarate is an intermediate in the TCA cycle, with other 
intermediates being suecinyl-CoA, succinate, fumarate, malate, oxaloaeetate, citrate, and 
isocitrate. Figures 7.12 and 7.13 show the metabolic pathways in normal and cancer cells.
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Figure 7.12: Metabolic pathways in normal cells. Glucose is the major substrate for energy and 
new cell mass. It is metabolised in the cytosol to pyruvate via glycolysis and then oxidised in the 
TCA cycle to generate a large amount of ATP through oxidative phosphorylation. Pyruvate can 
also be reduced to lactate under anaerobic conditions. Glutamine is a substrate for anaplerotic 
reactions. It is hydrolysed to glutamate by glutaminase, yielding ammonium as a byproduct. 
Glutamate is metabolised to a-ketoglutarate via either deamination, which is catalysed by 
glutamate dehydrogenase (GDH), or through transamination, which is catalysed by alanine 
aminotransaminase (ALT). The deamination process produces ammonium as a byproduct while 
transamination converts pyruvate to alanine during the process. a-Ketoglutarate that is produced 
from glutamate then enters the TCA cycle. Malate, an intermediated of the TCA cycle is a 
cataplerotic substrate that can exit the mitochondria and is converted to pyruvate by malic enzyme 
(NADP^-dependent malate dehydrogenase) in the cytosol, during the process reduces NADP^ to 
NADPH. Pyruvate then re-enters the TCA cycle or is reduced to lactate. Besides malate, citrate is 
also another cataplerotic substrate. It can leave the TCA cycle to be used as a precursor for 
biosynthesis of macromolecules or is converted back to pyruvate in the cytosol. The pentose 
phosphate pathway main function is to provide substrates for nucleotide synthesis and NADPH. 
NADPH is the “reducing power” requires for biosynthesis and reduction of GSSG to GSH. GSH 
can also be synthesised from glutamate as GSH is a tripeptide made up of glycine, cysteine, and 
glutamate. Based on Lunt and Vander Heiden, (2011); Dang et al, (2012); Champe et al. (2008); 
Nelson and Cox (2008).
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Figure 7.13: Metabolic pathways in cancer cells. Most rapidly dividing cells rely on the 
reduction of pyruvate to lactate for energy generation regardless of oxygen availability, thus, there 
is less pyruvate that enters the TCA cycle. In order to balance the pool of TCA cycle intermediates, 
there is an increase of anaplerotic reactions, i.e. the conversion of glutamine glutamate 
a-ketoglutarate via glutamate dehydrogenase (GDH) activity at the expense of alanine 
aminotransferase (ALT). Export of citrate from the TCA cycle to the cytosol is also increased to 
provide the carbon skeleton for the biosynthesis of macromolecules. The pentose phosphate 
pathway also supports biosynthesis by providing NADPH and precursors for nucleotide synthesis. 
Cataplerosis of malate to pyruvate is an alternative pathway to provide NADPH. Overall, lactate 
production and glutamine metabolism are the pathways to produce energy in cancer cells while 
glucose is used mainly for the biosynthesis. Based on Lunt and Vander Heiden, (2011); Dang et al, 
(2012); Champe et al. (2008); Nelson and Cox (2008).
Malate can exit the mitochondria into the cytosol, where it is converted by 
cytoplasmic malic enzyme (NADP^-dependent malate dehydrogenase) to pyruvate (Lunt and 
Vander Heiden, 2011). This process is different from the NAD^-dependent oxidisation of 
cytosolic malate to oxaloaeetate by malate dehydrogenase, which can subsequently be 
converted to phosphoenolpyruvate and then to glucose for gluconeogenesis (Owen et a l, 
2002). The conversion of malate to pyruvate via malic enzyme also reduces NADP^ to 
NADPH, which can be a significant source of NADPH (Lunt and Vander Heiden, 2011; 
DeBerardinis et a l, 2007). The fate of the pyruvate is either the production of lactate or 
re-entering the TCA cycle via conversion to acetyl-CoA or oxaloaeetate (Reitzer et a l, 1979; 
Lunt and Vander Heiden, 2011; Mathews et a l, 2000; Champe et a l, 2008).
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Consistent with the findings presented in this chapter, troglitazone has been 
previously shown to regulate the metabolism of glutamine (Routh et a l, 2002; Coates et a l, 
2002; Oliver et a l, 2010): Routh et a l (2002) demonstrated that troglitazone reduced 
glutamine uptake in rat mesangial cells, in a dose-dependent manner, and that the conversion 
of glutamate to a-ketoglutarate via alanine formation and ALT activity were decreased, but 
ammonium formation and GDH activity remained unchanged. The glutamine nitrogens were 
thus released predominantly as ammonium in troglitazone-treated cells. In another study, 
using renal tubule-derived Madin-Darby canine kidney (MDCK) cells, troglitazone did not 
reduce glutamine uptake but alanine formation was decreased while ammonium formation 
increased, again indicating that conversion of glutamate to a-ketoglutarate favoured the 
GDH-mediated process in the presence of troglitazone (Coates et a l, 2002). Oliver et a l 
(2 0 1 0 ) also showed that troglitazone enhanced ammonium production, but without increasing 
glutamine utilisation. The studies of Routh et a l (2002), Coates et a l (2002), and Oliver et 
al (2 0 1 0 ) provided evidence that troglitazone treatment results in increased utilisation of the 
deamination pathway for the conversion of glutamate to a-ketoglutarate. The studies also 
indirectly implied that troglitazone did not increase the utilisation of glutamine, which is in 
line with the results of the present study, i.e. the level of intracellular glutamine was 
unaffected by troglitazone (Figures 7.1 E and G).
Troglitazone has also been reported to decrease intracellular content of glutamate 
(Oliver et a l, 2010), consistent with the finding observed in this study (Figures 7.1 A and C). 
The decreased in glutamate levels can be explained by the anaplerotic and cataplerotic 
reactions in the TCA cycle. Anaplerosis replenish the pools of TCA cycle intermediates while 
cataplerosis removes the intermediates to prevent excess accumulation in the mitochondrial 
matrix (Owen et a l, 2002). The hydration of glutamate to a-ketoglutarate is an example of an 
anaplerotic reaction, whereas the efflux of malate from the mitochondria to the cytosol is an 
example of cataplerosis. Other metabolites that are involved in anaplerosis and cataplerosis 
are shown in Figures 7.14 and 7.15. The cataplerosis of malate will cause a deficit in the TCA 
cycle intermediates pool, with malate re-entering the TCA cycle via pyruvate to balance the 
TCA cycle intermediates pool. However, troglitazone has been reported to block this 
re-entering, leading to more glutamate being “pulled” into the TCA cycle via GDH to 
compensate for the deficit, which ultimately reduced the intracellular glutamate level. When 
intramitochondrial pyruvate in the form of methyl pyruvate was provided to cells treated with
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troglitazone, the glutamate metabolism via GDH was reduced and there was elevated 
glutamate metabolism via ALT to control levels (Oliver et a l, 2010).
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Figure 7.14: Substrates for anaplerosis. Anaplerosis is the entry of substrates into the TCA cycle 
to replenish the shortage of intermediates. Pyruvate can be converted to oxaloaeetate by pyruvate 
carboxylate (PC) while various amino acids can enter the TCA cycle via pyruvate, acetyl-Co A, 
a-ketoglutarate, succinyl-CoA, fumarate, and oxaloaeetate. Adapted from Owen et al (2012); 
Champe et al. (2008); Mathews et a l (2000).
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Figure 7.15: Products for cataplerosis. The efflux of TCA cycle intennediates is known as 
cataplerosis. Citrate can be used for biosynthesis of macromolecules. a-Ketoglutarate and 
oxaloaeetate can be used to generate amino acids. Malate can be used to generate pyruvate or for 
gluconeogenesis. Adapted from Owen et al (2012); Champe et al (2008); Mathews et al (2000).
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Besides the effect on pyruvate, glutamine, glutamate, ammonium, and alanine 
production, troglitazone has been shown to increase the utilisation of glucose in astrocytes 
(Dello et a l, 2003) and renal cells (Coates et a l, 2002). Troglitazone was also observed to 
increase lactate production (Oliver et a l, 2010; Coates et a l, 2002; Oliver et a l, 2008; 
Welboume et a l, 2004; Welboume et a l, 2004). In this study, glucose was not included as a 
targeted metabolite and the results on lactate was equivocal, as such, further work in this area 
would be of interest to confirm the findings in a robust manner.
The increase in lactate production observed by other researchers was accompanied 
with spontaneous cellular acidosis, which could be a contributing factor for toxicity. For 
example, troglitazone has been shown to impair the acid extrusion ability of renal cells in 
responding to both the exogenous N H / acid and endogenous lactic acid loads (Coates et a l, 
2002). Further studies employing LLC-PKi-F^ cells, a renal proximal tubule-like cell line 
that is pH-sensitive, showed that troglitazone induced cellular acidosis in a dose-dependent 
manner and this was the result of Na’^ ./H^  exchanger-mediated acid extrusion inhibition 
(Welboume et a l, 2004). The cellular acidosis was associated with a glutamine-dependent 
increase of ammonium production and decreased alanine formation. The resultant shift from 
alanine to ammoniagenesis was associated with reduced ALT activity (Welboume et a l, 
2004; Coates et a l, 2002). A more detailed investigation on the mechanistic of cellular 
acidosis by Oliver et a l (2008) revealed that the troglitazone-induced acidosis was due to 
activation of Extracellular Signal-Response Kinase and mitochondrial depolarisation; it was, 
thus, proposed that the mitochondrial Complex I proton pumping was coupled to 
mitochondrial glutamate uptake and oxidation to ammonium. The reduction of cytosolic pH 
was suggested as a factor that “pushes” the conversion of glutamate to a-ketoglutarate via 
GDH instead of the transamination and alanine production, in order to restore the acid-base 
balance. Hence, the regulation of anaplerosis by troglitazone was dependent upon a “pull” 
(TCA cycle intermediates deficit) and “push” (cytosolic acidosis) mechanisms (Oliver et a l, 
2010).
In this study (Figures 7.6 A and C), troglitazone was also seen to decrease 
intracellular GSH levels. The loss of viable cells would likewise decrease the overall GSH 
levels and therefore, care must be taken to avoid exaggerated interpretations. Based on the 
MTT assay, cells treated with 5 pM of troglitazone were still 100% viable (Figures 3.16 and 
3.17) and thus, decrement of intracellular GSH levels at low concentration of troglitazone 
treatment can be considered independent of cell death. However, at high concentration, the
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loss in numbers of viable cells could contribute to the decrement of GSH levels. Similarly, 
the changes of other metabolites levels must also be interpreted in the same manner, in which 
the decreased levels observed could be attributed to less number of viable cells. Troglitazone- 
induced oxidative stress is not something new. A multiparameter flow cytometric assessment 
of Novikoff rat hepatoma (NISI) showed that troglitazone reduced cell viability and 
intracellular GSH content, while increasing membrane peroxidation and superoxide 
generation accompanied by a decrease in mitochondrial membrane potential (Narayanan et 
al, 2003). GSH is a tripeptide-thiol (y-glutamylcysteinylglycine) with antioxidant properties. 
Regeneration of GSH from its oxidised form (GSSH) is catalysed by glutathione reductase 
with NADPH as a source of reducing electrons (Champe et a l, 2008). NADPH functions as 
the body’s biochemical reductant and it is produced in the pentose phosphate pathway 
through the reduction of NADP^. For every molecule of glucose-6-phosphate that enters the 
pentose phosphate pathway, one molecule of carbon dioxide and two molecules of NADPH 
are produced (Salway, 2004; Champe et a l, 2008). Another pathway that provides NADPH 
is the conversion of cytosol malate to pyruvate, catalysed by the NADP^-dependent malate 
dehydrogenase (Lunt and Vander Heiden, 2011; DeBerardinis et a l, 2007). A decrease in 
intracellular levels of reduced glutathione (GSH) levels could be due to (1) a decrease in the 
activity of pentose phosphate pathway or (2) a decrease in the cataplerotic conversion of 
malate to pyruvate. Interference of both pathways would reduce the level of NADPH, and as 
this is necessary for the regeneration of GSH from GSSG, GSH levels would also remain 
depleted. Alternatively, (3) decreased availability of GSH precursor could also reduce the 
levels of intracellular GSH. It should be noted that as one of the component peptides of GSH 
is glutamate (Champe et a l, 2008), levels of which we observed to reduce in HuH-7 cells 
following troglitazone treatment (Figure 7.1 A). Such as decrease would also mean that fewer 
precursors for the synthesis of GSH would be present, further adding to the decreased 
regenerative capacity of this system.
Finally, we also observed a decrease in nicotinamide levels in troglitazone-treated 
HuH-7 cells (Figure 7.7 A). Nicotinamide is the precursor for the production of NAD^ and 
NADP^ (Champe et a l, 2008; Mathews et a l, 2000), and is immediately metabolised to these 
products upon entry into the cell (Depeint et a l, 2006). The reduced forms of NAD^ and 
NADP^ are NADH and NADPH, respectively (Salway, 2004; Champe et a l, 2008; Mathews 
et a l, 2000). NADPH is the “reducing power” in biological systems that protects against 
oxidative stress, and also functions as a hydrogen donor in drug metabolism (cytochrome
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P450), fatty acids, cholesterol, and amino acids synthesis (Salway, 2004; Champe et a l, 
2008; Mathews et a l, 2000). A decrease in levels of nicotinamide would potentially 
destabilise this system, thus increasing oxidative stress, due to the link between NADPH and 
the conversion of GSSG to GSH.
In summary, LC-MS analysis using the Synergi Polar-RP column detected reduced 
levels of glutamate, GSH, and nicotinamide in cells treated with troglitazone. It is proposed 
that troglitazone affects the anaplerotic conversion of glutamate to a-ketoglutarate, which 
could be linked to decreased NADPH and GSH generation and therefore increased levels of 
oxidative stress.
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Chapter 8: Conclusions
8.1 Conclusions
The detection of potential toxic liability early in the drug discovery/development 
pipeline is a central challenge in modem pharmaceuticals. The mantra “fail early, fail cheap” 
is certainly tme, with the majority of a dmgs development costs occurring during pre-clinical, 
and especially, clinical testing. Given the size of current compound libraries, plus the ability 
of medicinal chemistry to further alter these building blocks, it can be seen that the number of 
new chemical entities entering the drug pipeline is seldom limiting. Instead, it is imperative to 
identify which of these thousands of chemicals has a good chance of progressing all the way 
through to a successful market launch. In addition, once on the market, the risk of dmg 
restriction or withdrawal through unexpected adverse effects must be mitigated.
The TZD class of chemicals are an ideal group to examine this issue as there is both a
1 • V1 1 • * 1 • • 1 1 r*r* , r*» i  .4range of compounds wim uuiermg cnnicai aaverse eiieci proiiies, ana compounas tnat were 
withdrawn from the market due to toxic liabilities that were undetected through the standard 
development programme. Within this project, the use of a metabolomics approach to 
differentiate between troglitazone, withdrawn through idiosyncratic hepatotoxicity, and the 
safer TZDs pioglitazone and rosiglitazone was examined. The eventual aim was to 
understand if such approaches may help us to avoid similar mistakes in the future.
Troglitazone was the most toxic TZD in comparison to rosiglitazone and pioglitazone, 
as measured by a standard toxicity test, the MTT assays (Figure 3.16). The IC50 values for 
troglitazone, rosiglitazone, and pioglitazone were 25.9 ± 1.8, > 168.9 ± 30.0, and 
> 79.4 ± 13.5 pM, respectively (Table 3.3), which are consistent with the literature (Liao et 
ah, 2010; Haskins et a l, 2001; Rachek et a l, 2009). In addition to the MTT assay, a second 
toxicity assay (LDH leakage assay) was also used; comparison of the IC50 values obtained 
with the MTT versus LDH assays, i.e. 25.9 ± 1.8 versus > 42.7 ± 3.6 pM (Figure 3.17), 
suggests that troglitazone affected the reductive capacity of mitochondria (MTT assay) at a 
lower level of troglitazone than that required from the cells to rupture and release their 
intracellular contents (LDH assay). This conclusion is in accordance with reports indicating 
that troglitazone causes mitochondrial disruption, leading to mitochondrial permeability 
transition and cell death (Tirmenstein et a l, 2002; Shishido et a l, 2003; Nadanaciva et a l, 
2007; Masubuchi et a l, 2006; Bova et a l, 2005; Haskins et a l, 2001). It should, however, be
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noted that in both cases the derived IC50 values are high, being orders of magnitude higher 
than the affinity of the TZDs for their cellular target, PPARy, which is in the range of 40 -  
200 nM (Reginato and Lazar, 1999). Such data may not, therefore, necessarily inform initial 
“stop-go” decisions on a chemical, as it might be felt that there a sufficient margin-of- 
exposure could be achieved in vivo. The O.lx IC50 concentration of troglitazone, based on the 
MTT assay, was used for subsequent investigations. This value is of particular relevance for 
two reasons: Firstly, it approximates the plasma levels in human subjects treated with 
troglitazone (Loi et a l, 1999a; Owen et a l, 2002). Secondly, it is at a level where no overt 
toxicity is seen in vitro (via either MTT or LDH assay), and hence might be considered 
“safe”.
Co-incubation and pre-incubation experiments (Sections 3.3 and 3.4) were undertaken 
to examine the potential role of biological systems previously identified as being important in 
troglitazone toxicity. Such experiments not only examine molecular mechanism in a targeted 
manner, but might also shed light on the idios>Ticratic aetiology of troglitazone toxicity and 
highlighting predisposing factors known to vary amongst the general population. 
Troglitazone toxicity was not enhanced when the cells were exposed to rifampicin, BSO, 
paracetamol, or galactosamine. This suggests that the toxicity of troglitazone (measured by 
decreased cell viability using the MTT assay) is not affected by troglitazone bio-activation, 
reduced antioxidant levels, or interaction with other hepatotoxicants in the cell-based assay 
system evaluated.
Having demonstrated that several potential predisposing factors had no major impact 
on our test system, the converse question was asked: Does troglitazone exposure at sub-toxic 
doses predispose an individual to the toxicity of other chemicals? Pre-incubating cells with 
troglitazone enhanced the toxicity of paracetamol and galactosamine (Figures 3.10 and 3.11), 
which presumably reflects a depletion of cellular defences from the initial troglitazone insult; 
while this insult may not have been sufficient to produce overt toxicity, as demonstrated by 
LC-MS, it was able to significantly deplete cellular GSH levels, for example. Interestingly, 
troglitazone exposure was found to protect HuH-7 cells from BSO-induced oxidative stress 
(Figure 3.9). This protective effect was not a TZD class effect as rosiglitazone and 
pioglitazone were unable to protect the cells against BSO effect (Figure 3.13), and it is 
postulated to be an antioxidant effect due to the troglitazone molecular structure that contains 
an a-tocopherol moiety, potentially giving it a vitamin E-like antioxidant property (Crawford 
et a l, 1999; Inoue et a l, 1997; Aoun et a l, 2003; Garg et a l, 2000).
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After the initial investigation using the MTT assay to measure toxicity and 
characterise the model cell system, a metabolomics approach employing LC-MS analysis was 
conducted. LC-MS analysis was performed using three different HPLC columns in this study, 
namely UPLC BEH Cig, Luna NH2, and Synergi Polar-RP. A reversed-phase gradient was 
used for the LC-MS analysis with the UPLC BEH Cig column (Chapter 4). The method 
enabled detection of all the standard compounds, including fi*agments of ATP (ADP and 
AMP) (Table 8.1). The shape of the peak bands produced was good, i.e. with high peak 
height and narrow peak width (e.g. Figure 4.28). The overall peak width was less than 
0.3 minutes. However, the UPLC BEH Cig column was unable to retain majority of the 
compounds of interest. The retention time observed for most of the compounds was within 
1 minute while the column void time was approximately 0.55 minutes (Table 8.1). All the 
compounds of interest in this study were polar, and poor retention of polar compounds in 
reversed-phase chromatography is common since the concept of reversed-phase 
chromatography is to elute the most polar compounds first and the most non-polar 
compounds last (Dejaegher and Vander, 2010; Latif and Sarker, 2012). Several researchers 
have tried to improve the retention of polar compounds in reversed-phase chromatography: 
Application of a low flow rate, i.e. 0.2 ml/min. showed that the intermediates of glycolysis 
were well retained in a total 7 minutes run, although the peak widths were generally large 
(0.5 minutes) but symmetrical (Ross and Dalluge, 2009). Another method was to employ 
tributylamine, a volatile ion pairing reagent. The hydrocarbon chains of tributylamine 
contribute to the hydrophobicity when paired with polar compounds, enabling retention in the 
reversed-phase column (Luo et a l, 2007). Inserting a hydrophobic moiety onto hydrophilic 
molecule, e.g. by aniline-labelling, can also facilitate reversed-phase separation of polar 
compounds in reversed-phase chromatography (Yang et a l, 2008). Even though reversed- 
phase chromatography with the application of UPLC BEH Cig column in this study showed 
poor retention for the majority of the compounds of interest, nevertheless, there were several 
compounds that were well retained on the UPLC BEH Cig column, such as GSSG, NADH, 
NADPH, nicotinuric acid, riboflavin, tryptophan, and phenylalanine. The retention times for 
these compounds were between 2.0 -  5.6 minutes (Table 8.1). Due to the acidic mobile 
phase, most of the compounds, especially those related to the TCA cycle intermediates were 
detected in the protonated form. MS detection in the EST ionisation mode produced higher 
detection intensity (represented by the peak area, AUC) in comparison to the BSI^ mode 
(Table 8.1). In addition, lactate and oxaloaeetate were only detected in the EST mode and not
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in the ESI^ mode. Nicotinamide is the only exception, and showed higher detection intensity 
in the ESI^ than the ESI' mode.
The second column used for this study was Luna NH2 (Chapter 5). LC-MS analysis 
utilising the Luna NH2 column was conducted with a HfLIC gradient. The retention time for 
all the tested amino acids, lactate, NAD^, NADH, nicotinamide, nicotinic acid, nicotinuric 
acid, and GSH was increased compared to the retention time obtained with the UPLC BEH 
C18 column (Table 8.1). Riboflavin was the only compound that was not retained as well as 
on the UPLC BEH Cig column. It can be concluded that the poor retention of polar 
compounds observed in reversed-phase chromatography has been solved using HILIC with 
Luna NH2 column, even though only 15 out of the 30 compounds of interest were detected 
using this method. The peak bands were, however, broad and sometimes distorted (e.g. 
Figures 5.12 -  5.13 and 5.15 -  5.16). In terms of the detection intensity, the overall AUC 
values for the detected standard compounds were more than 100, but it must be noted that the 
concentration of compounds tested was high (between 2 - 2 0  nmoles in 10 pi). Nicotinamide 
was the only compound that displayed low detection intensity although a reasonably high 
concentration was used for the analysis (2 nmoles in 10 pi). Nevertheless, LC-MS analysis 
with the cell extracts was only able to detect glutamine, glutamate, leucine, valine, and GSH. 
Metabolites that were previously detected in the cell extract samples using reversed-phase 
chromatography, such as lactate and phenylalanine, were not detected in this LC-MS analysis 
utilising Luna NH2 column. Other researchers have reported successful separation and 
quantification of metabolites from glycolysis and the TCA cycle using Luna NH2 column 
(Bajad et a l, 2006; Lewis et a l, 2008; Yang et a l, 2009a). The main difference was because 
other researchers employed a triple quadrupole instrument, which has the advantage of 
increased specificity for targeted and quantitative analysis (Couchman and Morgan, 2011; 
Becker et a l, 2012; Himmelsbach, 2012) whereas in this study, a quadrupole time-of-flight 
(QToF) was used, which is an instrument often considered to be suitable for qualitative and 
untargeted analysis (Himmelsbach, 2012). Although the Luna NH2 column only detected a 
limited number of compounds of interest, it was efficient for amino acids separation and 
quantification.
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The final column employed for the LC-MS analysis was a Synergi Polar-RP column 
(Chapter 6). A HILIC gradient was also conducted with this column. LC-MS analysis using 
this method enabled detection of all the tested amino acids, a majority of the glycolysis and 
the TCA cycle intermediates, NAD^, NADH, nicotinamide, nicotinic acid, nicotinuric acid, 
GSH, riboflavin, and pyridoxal (Table 8.1). The Synergi Polar-RP column exhibited good 
retention for the detected compounds. The overall retention time was between 5 - 7  minutes, 
with the exception of a few compounds that were eluted at around 2 minutes (column void 
time was approximately 1.8 minutes). The peak bands produced were not as sharp or as 
narrow as the peaks obtained in reversed-phase chromatography using UPLC BEH Cig 
column, although they were not as broad as those acquired with Luna NH2 column. Lactate 
displayed different retention time in the EST and ESI^ mode (Table 8.1), although this was 
most likely an artifact caused by the broad peak in the EST mode. Meanwhile, 
a-ketoglutarate and succinate also appeared to exhibit different retention time in different 
ionisation modes, due to poor retention within the column, reducing robustness of the derived 
retention time. All the tested amino acids were detected in both ionisation modes with high 
detection intensity (AUC value above 100), except for glutamate. All the tested compounds 
fi'om the glycolysis and TCA cycle intermediates were detected either in the EST, E S l\ or 
both ionisation modes, except for citrate and malate, which were not detected in either 
ionisation modes. The majority of the compounds were detected in the protonated form 
although pyruvate was detected as the ammonium and ammonia adducts, while glucose 
6-phosphate was detected as the ammonium adduct in the ESI^ mode (Table 6.2). The 
detection intensity for the compounds from the glycolysis and TCA cycle intermediates 
varies, some were high (AUC values above 100) and some were at acceptable values (AUC 
values around 50) while others were low (AUC values less than 20) such as fumarate in the 
EST mode and oxaloaeetate and lactate in the ES A mode (Table 8.1). Other compounds of 
interest, such as NAD”^ and NADH, were detected at quite low intensity, but for the same 
amount of sample used (500 pmoles in 10 pi), the detection intensity for nicotinamide, 
nicotinic acid, nicotinuric acid, riboflavin, and pyridoxal was high. Pyridoxal exhibited 
multiple peaks. GSH exhibited a higher detection intensity in the EST than in the ESI^ mode. 
The total number of compounds detected using the Synergi Polar-RP column was more than 
the total number detected with Luna NH% column (22 versus 15 compounds). However, there 
were still compounds such as citrate, malate, NADP^, NADPH, ATP, ADP, AMP, and 
GSSG, which were not detected using the Synergi Polar-RP column although other studies 
that utilised the same column were able to detect them (Wei et al., 2010; Lewis et a l, 2008;
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Bajad et a l, 2006). The reason for those compounds not being detected in this study is most 
likely the same as for the Luna NH2 column, i.e. other researchers used a triple quadrupole 
mass analyser, which has the advantage of specificity for targeted analysis over QToF 
analyser (Couchman and Morgan, 2011; Becker et a l, 2012; Himmelsbach, 2012; 
Chemushevich et a l, 2001).
The overall conclusions from the LC-MS method development process are (1) buffer 
concentration, mobile phase pH, and sample diluent affect greatly the chromatographic 
separation (peak shape and retention) and the mass spectrometry detection (intensity and 
detection form), as shown here and previously by Guo and Gaiki (2011), Cazenave-Gassiot et 
al (2009), Guo et a l (2007), Dong and Huang (2007), Risley and Pack (2006), Guo et aï. 
(2005), and Grumbach et a l (2004), and therefore, have to be optimised according to the 
target analytes. (2) A majority of the glycolysis and TCA cycle intermediates were detected 
in the protonated form (-COOH) but this is dependent on the pH of the mobile phase. (3) 
Nicotinamide is only detected in the ESI^ mode. It is not detected in the EST mode or 
detection is at extremely low intensity. On the other hand, lactate is better detected in the EST 
mode and almost undetectable in the ESI^ mode. (4) Riboflavin showed better retention in 
reversed-phase chromatography compared to HILIC. (5) PBS in the sample matrix is a source 
of ion suppression, which corrupts the quantification of the metabolites of interest, especially 
in HILIC chromatography. Table 8.2 shows the “best” LC-MS results for specific standard 
compounds.
330
Table 8.2: The “best” LC-MS results for specific standard compounds
Compounds Column Chromatographic gradient MS ionisation
Glutamine Synergi Polar-RP HILIC type A Esr
Glutamate Synergi Polar-RP HILIC type A EST
Leucine Synergi Polar-RP HILIC type A EST
Methionine Synergi Polar-RP HILIC type A EST
Phenylalanine Synergi Polar-RP HILIC type A EST
Tryptophan Synergi Polar-RP HILIC type A EST
Valine Synergi Polar-RP HILIC type A EST
Pyruvate Synergi Polar-RP HILIC type A EST
Citrate NC NC NC
a-Ketoglutarate Synergi Polar-RP HILIC type A EST
Succinate Synergi Polar-RP HILIC type A EST
Fumarate NC NC NC
Malate Synergi Polar-RP HILIC type B ESI*
Oxaloaeetate (QAA) NC NC NC
Lactate Synergi Polar-RP HILIC type A EST
G6P NC NC NC
NAD* Synergi Polar-RP HILIC type B ESI*
NADH UPLC BEH C,g RP type C EST
NADP* NC NC NC
NADPH UPLC BEH Ci8 RP type C EST
Nicotinamide NC NC ESI*
Nicotinic acid Synergi Polar-RP HILIC type A EST
Nicotinuric acid Synergi Polar-RP HILIC type A EST
ATP UPLC BEH Cig RP type C EST
ADP Synergi Polar-RP HILIC type B ESI*
AMP NC NC NC
GSH Synergi Polar-RP HILIC type A EST
GSSG UPLC BEH Cig RP type C EST
Riboflavin UPLC BEH Cig RP type C EST
Pyridoxal NC NC NC
Criteria based on good retention with column, high MS detection intensity, and peak bands that are sharp and narrow. 
HILIC type A: 20 mM ammonium acetate in water/acetonitrile (95/5, v/v), pH 4.00 and acetonitrile.
HILIC type B: 20 mM ammonium acetate in water/acetonitrile (95/5, v/v), pH 5.60 and acetonitrile.
RP type B: 0.1% aqueous formic acid and 0.1% formic acid in methanol.
NC: Not conclusive
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The effects of troglitazone on HuH-7 cells were evaluated by LC-MS analysis in 
Chapter 4 and 7. Initially, an untargeted approach was conducted to identify metabolites that 
were affected by troglitazone treatment. Subsequently, after discovering that troglitazone has 
an impact on metabolites involved in glycolysis and the TCA cycle pathway, a targeted 
analysis was conducted to determine the effects of troglitazone specifically on intermediates 
of glycolysis, the TCA cycle, and energy production. LC-MS analysis was able to detect 
changes elicited by troglitazone at concentrations where no overt toxicity was observed by 
either the MTT or LDH assays. For example, cells treated with 5 pM troglitazone showed a 
50% reduction in the levels of intracellular malate, glutamate, and GSH (Figures 4.39 D, 7.1 
A, and 7.6 A) but at this treatment concentration, MTT and LDH assays were detecting 100% 
cell viability (Figures 3.16 and 3.17). Even at concentrations that did show some impact on 
classical toxicity assays, the LC-MS approach was more sensitive. For example, at 
approximately 10 pM troglitazone, intracellular levels of nicotinamide were decreased by 
50% (Figure 7.7) while MTT and LDH assays detected about 10% and 0% reduction in cell 
viability, respectively (Figures 3.16 and 3.17). These results clearly demonstrate that LC-MS 
is a more sensitive tool for the detection of cellular changes in response to chemical challenge 
than the conventional MTT and LDH assays. However, there are several caveats to this 
statement. First, LC-MS analysis is not a straightforward method and is considerably more 
time consuming / expensive than either MTT or LDH; second, not all metabolites from a 
biological sample can be measured with a single LC-MS analysis, mainly because biological 
samples consist of a complex mixture of metabolites and the solubility and polarity of the 
metabolites affect the chromatographic separation and mass spectrometry detection. Many 
researchers have used a combination of different stationary phases, mass analysers (triple 
quadrupole, QToF, ion traps), and chromatography platforms (LC-MS, GC-MS) with the aim 
of measuring all the metabolites from a biological sample (Wei et a l, 2010; Kim et #7,2011; 
Bajad et a l, 2006; Pandher et a l, 2009; Yang et a l, 2009a; Lewis et a l, 2008; Buscher et a l, 
2009); third, the changes observed may reflect an adaptation to chemical challenge, and as 
such may be toxicologically silent, or possibly even beneficial. To address this, it is important 
to examine both low doses and known (high) toxic doses, as undertaken here, as this allows 
changes to be put into the context of overt toxicity, an approach in toxicogenomics known as 
phenotypic anchoring (Luo et a l, 2005). Indeed, such an approach may provide important 
information on potential mechanism of toxicity for chemicals. Despite these caveats, once the 
experimental protocol has been developed and optimised, LC-MS is definitely a feasible and 
sensitive method for the study of drug effects at low doses.
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As mentioned above, the use of metabolomics approaches may inform the mechanism 
of toxicity for a chemical, identifying biological pathways affected by chemical insult. 
Troglitazone toxicity is probably one of the most well studied examples of drug-induced 
hepatotoxicity yet the exact mechanism is still unclear (Yokoi, 2010), and hence 
metabolomics was employed to analyse the response of metabolome to sub-toxic and toxic 
concentration of troglitazone. Several mechanisms have been proposed to explain the 
mechanism of troglitazone toxicity, including the formation of toxic metabolites, oxidative 
stress, mitochondrial dysfunction, and inhibition of bile salt transporters leading to 
cholestasis (Smith, 2003; Chojkier, 2005; Masubuchi, 2006; Yokoi, 2010). However, it is not 
clear if these effects are symptoms of toxicity, rather than the causative effect, and this is 
where low dose studies are helpful. A combination of reversed-phase and HILIC-based 
LC-MS analysis revealed that troglitazone decreased intracellular levels of glutamate, malate, 
GSH, and nicotinamide while increasing the levels of intracellular ADP and AMP (Sections 
4.6, 4.7, and 7.1). The levels of intracellular glutamine, leucine, phenylalanine, tryptophan, 
valine, methionine, and lactate were unaffected by troglitazone (Section 7.1). Based on these 
results, a model for troglitazone toxicity is proposed.
Figure 8.1 shows a hypothetical mechanism of troglitazone toxicity generated from 
this study. Decreased levels of intracellular glutamate may interfere indirectly with the TCA 
cycle as glutamate is an anaplerotic substrate (Owen et a l, 2002), and this would lead to 
decreased intermediates of TCA cycle such as malate and the production of ATP. In addition, 
decreased levels of glutamate may also affect the biosynthesis of GSH, as GSH is synthesised 
from cysteine, glutamic acid, and glycine (Champe et a l, 2008). GSH is required to provide 
cellular defence against oxidative stress, and such depletion would leave the cell more 
susceptible to toxic insult. It should be noted that GSH can also be generated from the 
reduction of GSSG by the enzyme glutathione reductase; however, this process requires the 
“reducing power” from NADPH (Champe et a l, 2008; Salway, 2004). NADPH is generated 
from the pentose phosphate pathway (Champe et a l, 2008; Salway, 2004) and the conversion 
of cytosolic malate to pyruvate also yields a significant amount of NADPH (Lunt and Vander 
Heiden, 2011; DeBerardinis et a l, 2007). Finally, decreased levels of intracellular 
nicotinamide, a precursor of NADPH (Depeint et a l, 2006), may also reduce the availability 
of NADPH and eventually decreased the levels of GSH. Within this study, metabolite 
profiles consistent with many of these effects were seen, lending weight to the hypothesis that 
troglitazone has an impact on both energy production within the cell and GSH levels. The
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changes in the levels of these metabolites could underlie the reported mitochondrial 
dysfunction and oxidative stress in cells treated with troglitazone.
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Figure 8.1: Hypothetical mechanism of troglitazone toxicity. Cells treated with troglitazone 
have decreased levels of intracellular glutamate but the glutamine levels are unaffected (Figure 
7.1). It is postulated that troglitazone inhibits glutaminase that converts glutamine to glutamate. 
Troglitazone also decreased the levels of intracellular malate (Figures 4.23 B, 4.33 B, and 4.39 D) 
and this could be because of decreased glutamate levels, as glutamate is an anaplerotic substrate 
that can be converted to a-ketoglutarate and enters the TCA cycle (Owen et al, 2002). Treatment 
with troglitazone increased the levels of ADP and AMP (Figures 4.33 E and F), probably due to the 
intermption of the TCA cycle to generate ATP. Malate in the TCA cycle can be converted to 
oxaloaeetate or exported out of the mitochondria into the cytosol as a cataplerotic product. The 
cytosolic malate is then converted to pyruvate, catalysed by malic enzyme (Lunt and Vander 
Heiden, 2011), and subsequently to lactate or re-enters the mitochondria as oxaloaeetate or 
acetyl-CoA (Champe et al, 2008). However, troglitazone is known to block the re-entry of 
pyruvate into the mitochondria (Oliver et al, 2010) and this may cause further deficit in the 
balance of TCA intennediates. Decreased availability of intramitochondrial pyruvate could be the 
reason for cells treated with troglitazone to favour the conversion of glutamate to a-ketoglutarate 
via the GDH pathway instead of ALT pathway (Coates et al, 2002; Routh et al, 2002; Oliver et 
al., 2010). Troglitazone also decreased intracellular GSH levels (Figures 4.23 A, 4.33 A, 4.39 A 
and B, and 7.6) and this could be linked to decreased levels of glutamate, malate, and nicotinamide. 
GSH is a tripeptide of glycine, cysteine, and glutamate (Champe et al,  2008) and the biosynthesis 
of GSH is affected by decreased levels of glutamate. GSH can also be generated from the reduction 
of GSSG, which requires NADPH that is generated mainly in the pentose phosphate pathway 
(Champe et al, 2008; Salway, 2004) but the conversion of cytosolic malate to pyruvate may also 
contribute to the pool of NADPH (Lunt and Vander Heiden, 2011; DeBerardinis et al, 2007). 
Furthennore, troglitazone decreases the levels of nicotinamide (Figure 7.7), a precursor of 
NADPH. T: Increased levels; Decreased levels; =: Unchanged levels.
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Although troglitazone was observed to decrease the levels of intracellular glutamate 
in this study, it did not affect the levels of glutamine (Figures 7.1), which at first appears 
counter-intuitive. However, this finding is consistent with other studies, which demonstrated 
that intracellular glutamine levels were not affected by troglitazone, and that troglitazone 
does not increase glutamine uptake (Oliver et ah, 2010; Coates et a l, 2002; Routh et a l, 
2002), therefore indirectly ruling out that that decreased glutamate levels are due to lower 
glutamine levels. Given these findings it is tempting to speculate that this effect reflects either 
an inhibition of the enzyme glutaminase, which converts glutamine to glutamate, and/or 
increased utilisation of glutamate by other reactions, such as increased conversion of 
glutamate to a-ketoglutarate.
Troglitazone has been reported to inhibit the delivery of pyruvate into the 
mitochondria and thus limit pyruvate’s contribution to the TCA cycle (Oliver et a l, 2010). 
Due to the limited availability of intramitochondrial pyruvate, there may be an imbalance in 
the TCA cycle, which probably leads to the decreased of malate levels (4.23 C, 4.33 B, and 
4.39 D) and/or increases the conversion of glutamate to a-ketoglutarate to compensate the 
deficit. The levels of other amino acids, specifically methionine, leucine, phenylalanine, 
tryptophan, and valine, were unaffected by troglitazone (Figure 7.2 -  7.3), suggesting that 
these anaplerotic substrates were not used to compensate the deficit of the TCA cycle 
intermediates.
Troglitazone has also been shown to favour the conversion of glutamate to 
a-ketoglutarate via glutamate dehydrogenase (GDH) pathway, rather than the alanine 
aminotransferase (ALT) pathway (Oliver et a l, 2010; Coates et a l, 2002; Routh et a l, 2002; 
Welboume et a l, 2004). This could be a consequence of the limited availability of 
intramitrochondrial pymvate, since the ALT pathway is a transamination process that 
requires pymvate but intramitochondrial pymvate is not available, therefore, glutamate is 
converted to a-ketoglutarate via the deamination process catalysed by GDH. When highly 
permeable methyl ester of pymvate was provided to restore the intramitochondrial pymvate 
availability, there was reduced glutamate metabolism via GDH and elevated glutamate 
metabolism via ALT (Oliver et a l, 2010). Taken together, these data add significantly to the 
knowledge of troglitazone toxicity, helping to intercalate several previous observations on 
discrete effects of troglitazone into a single, overall mechanisms of toxicity. As such, this
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demonstrates the significant potential impact of metabolomics approaches for delineating 
mechanism.
In this study, the intracellular levels of lactate were not affected by troglitazone 
(Figure 7.5), suggesting that lactate production was not used by the cell to compensate for the 
reduced TCA flux. However, other studies have reported increased lactate production, and 
hence this area requires further clarification (Oliver et a l, 2010; Oliver et a l, 2008; Coates et 
a l, 2002; Welboume et a l, 2004).
The main function of TCA cycle is to oxidise the fuel molecule acetyl-CoA to NADH 
and FADH2, which are energy-rich reduced coenzymes that subsequently undergo the 
coupling process of electron transport and oxidative phosphorylation to generate ATP 
(Champe et a l, 2008). Increased levels of intracellular ADP and AMP were observed in this 
study (Figures 4.33 E and F), which may be an indication of decreased ATP recycling 
process, and this would be consistent with the dismption of the TCA cycle by troglitazone. 
Moreover, troglitazone has been reported to be a potent inhibitor of Complexes II + III, IV, 
and V of the electron transport chain (Nadanaciva et a l, 2007), which means that even if the 
TCA cycle is functioning properly and NADH and FADH2 are generated, troglitazone 
inhibits the final pathway to generate ATP, i.e. the coupling of oxidative phosphorylation and 
electron transport.
In terms of oxidative stress and troglitazone toxicity, an attractive hypothetical 
mechanism of toxicity can be generated fi*om the levels of GSH, glutamate, malate, and 
nicotinamide detected in this study. Troglitazone at 10 pM has been reported to increase 
intracellular superoxide generation (Narayanan et a l, 2003), which reflects insufficient GSH 
to neutralise the superoxide. This is consistent with the observation in this study, in which 
troglitazone decreased the levels of intracellular GSH (Figures 4.23 A, 4.33 A, 4.39 A and B, 
and 7.6). The decreased GSH levels could be due to lower GSH synthesis and/or increased 
GSH oxidation to GSSG. As mentioned earlier, decreased glutamate levels may be related to 
lower GSH synthesis while decreased malate and nicotinamide levels, may have an effect on 
NADPH that is responsible for the reduction of GSSG to GSH.
Even though LC-MS analysis revealed that troglitazone decreased intracellular GSH 
levels, at a non-toxic concentration (2.4 pM) troglitazone was also shown to protect cells 
against BSO-induced oxidative stress (Figure 3.9). BSO is an inhibitor of y-glutamylcysteine 
synthetase (y-GCS), one of the two enzymes involved in the synthesis of GSH (Griffith,
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1982). It seems counterintuitive that troglitazone can act as both an antioxidant and also 
induce oxidative stress: Nevertheless, troglitazone has been previously demonstrated to 
exhibit antioxidant activity, and thus this effect must be treated as real (Inoue et ah, 1997; 
Garg et al, 2000). A possible explanation is hormesis, i.e. an agent at low dose induces 
beneficial effects through cellular adaptation, whereas at high dose, toxic effects are observed 
(Mattson, 2008). Based on the dose-response curves for glutamate, nicotinamide, GSH, and 
malate, at 2.4 pM troglitazone, the levels of intracellular glutamate and nicotinamide were 
not significantly different from control (Figures 7.1 and 7.7), GSH was decreased but not 
statistically significant (Figure 7.6), and only malate was significantly decreased in 
comparison to the control (Figures 4.39 D and 4.33 B). These results indicate that 
troglitazone has not exerted its toxic effect at 2.4 pM and probably any changes observed 
were adaptive rather than directly linked to the toxicity observed at higher doses.
Taking all these information into account, the use of a metabolomics approach has 
added significant information to the understanding of the mechanism of toxicity for 
troglitazone in relation to metabolome levels. It is suggested that troglitazone interrupts the 
proper function of TCA cycle by affecting the anaplerotic and cataplerotic balance of the 
TCA cycle, while oxidative stress and reduced energy levels appear to be a secondary 
consequence of these effects.
8.2 Future work
Whilst this study has provides some information regarding the effect of troglitazone 
on endogenous metabolites levels, there are still many unanswered questions.
(1) Glycolysis, TCA cycle, pentose phosphate pathway, and energy generation 
involve multiple steps with numerous intermediates. What are the effects of troglitazone on 
all these intermediates? The current study was only able to detect a limited number of those 
intermediates. Performing targeted LC-MS analysis using a triple quadrupole mass analyser 
might increase the numbers of metabolites detected, if not all, which are involved in the 
central carbon metabolism since triple quadrupole mass analyser has the advantage of 
specificity for targeted and quantitative analysis. However, it should be noted that the amount 
of cells harvested for the LC-MS analysis may need to be increased or concentrated because 
levels of intracellular or extracellular metabolites may be too low for detection.
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(2) Troglitazone appears to decrease the levels of intracellular glutamate, malate, 
nicotinamide, and pyruvate, and this ultimately leads to troglitazone-induced cytotoxicity. 
Therefore, can the cells be rescued by providing extra glutamate, malate, methyl ester 
pyruvate, nicotinamide, and NADPH to prevent disruption of mitochondrial activity and the 
occurrence of oxidative stress?
(3) Troglitazone decreases the intracellular levels of glutamate but did not affect the 
levels of intracellular glutamine. What is the cause that decreases glutamate levels? One 
hypothesis is that troglitazone inhibits glutaminase, the enzyme that is responsible for the 
conversion of glutamine to glutamate.
(4) The levels of GSH are decreased in troglitazone-treated cells but how about the 
ratio in relation to GSSG? Commercially available kits can be used to quantify the ratio of 
GSH/GSSG or via LC-MS analysis. Similarly, the levels of glucose and lactate can also be 
quantified via commercial detection kits or LC-MS analysis.
(5) Several studies have shown that troglitazone induced cellular acidosis (Coates et 
al, 2002; Welboume et a l, 2004; Oliver et a l, 2008; Oliver et al, 2010). Investigating the 
intracellular pH levels in relation to the intracellular metabolite levels will give a better 
understanding on the mechanism of troglitazone toxicity.
(6) Finally, in the untargeted metabolomics approach in Section 4.2.1, mevalonic 
acid was putatively identified as one of the metabolites which levels were decreased by 
troglitazone treatment (Table 4.1). Mevalonic acid is an intermediate in HMG Co A reductase 
pathway, which is involved in cholesterol synthesis. Mevalonic acid was excluded from the 
current study but the results imply that troglitazone may also affect cholesterol synthesis 
pathway.
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